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Abstract
This thesis will describe attempts to use suitably substituted 2-imidazolines in 
Diels-Alder reactions. In order to synthesise these target 2-imidazolines a new and reliable 
method for the synthesis of 2-alkyl and 2-alkenyl-2-imidazolines has been developed. 
Metallation at C(2a) of l-ferf-butyloxycarbonyl-2-methyl-2-imidazoline, followed by 
reaction with a range of electrophiles and deprotection with TFA reliably afforded N(l)- 
unsubstituted 2-substituted 2-imidazolines; P- or Se-electrophiles led to 2-alkenyl-2- 
imidazolines via W ads worth-Emmons reaction or selenoxide elimination.
In an attempt to prepare N-butadienyl-2-imidazolines via the reaction of 2-alkyl-2- 
imidazolines and a,p-unsaturated aldehydes or ketones, tetrahydroimidazo[ 1,2-a]pyridines 
have been synthesised via conjugate addition of the heterocycle N(l) nitrogen atom 
followed by enamine-aldol condensation at C(2a).
2-Imidazolines reacted with p-ketoesters to give tetrahydroimidazo[ 1,2-ti]pyridin- 
5-ones. It has also been shown that 2-imidazolines undergo conjugate additions with other 
unsaturated compounds with electron withdrawing groups.
Whilst examining the reactions of 2-alkyl-2-imidazolines with alkyne diesters, a 
new annulation was uncovered that is based on N(l) conjugate addition followed by 
C(2a)-acylation. The reaction of 2-imidazolines with dialkyl acetylenedicafboxylate 
afforded tetrahydropyrrolo[ 1,2-<z] imidazole-5,6-diones.
None of the 2-imidazolines synthesised that contained diene functionalities 
underwent either intra or intermolecular Diels-Alder reactions.
Abbreviations used in the Thesis
AIBN (X^a'-Azozsobutyronitrile
n-BuLi n-Butyllithium
sec-BuLi sec-Butyllithium
Boc rerr-Butoxycarbonyl
Bn Benzyl
Cbz Benzyloxycarbonyl
m-CPBA meto-Chloroperbenzoic acid
DBU l,8-Diazabicyclo[5.4.0]undec-7-ene
DCC 1,3-Dicyclohexylcarbodiimide
DMF jVJV-Dimethylformamide
DMSO Dimethylsulfoxide
LDA Lithium diisopropylamide
Ph Phenyl
TBDMS tezt-Butyldimethylsilyl
TFA Trifluoroacetic acid
THF Tetrahydrofuran
TMEDA Tetramethylethylenediamine
TMS Trimethylsilyl
Tr Trityl
Ts p-T oluenesulfony 1
Z Benzyloxycarbonyl
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Chapter 1 
1.0 Introduction
As organic chemists attempt syntheses of increasingly complex molecules, the need 
for efficient, mild, and selective functional group transformation and elaboration becomes 
even more apparent. The ability of heterocycles to act as vehicles to assist in meeting these 
requirements is not a new idea,1 and this concept has been generally accepted for synthesis. 
The introduction and rapid acceptance of dithianes,2 dihydroxazines,3 isoxazoles,4 2- 
oxazolines5 and other heterocycles as versatile tools for the synthetic chemist results 
predominantly from their ability 1) to remain inert to a variety of commonly used reagents, 
2) to act as a platform on which to perform a desired transformation efficiently and under 
mild conditions, and 3) to be available for further modification via mild or neutral 
"releasing" conditions. These properties, commonly identified with latent functionality, 
provide a flexibility which is both rare and valuable to the chemist involved in synthesis,
2-Imidazolines (1.1), although well known compounds, are newcomers to this elite 
group of molecules. It was of great interest to us to use 2-imidazolines in our synthetic 
methodology.
n  ,
NU ,N—R
R2 1-1
The 2-imidazoline ring has long been recognised as having potential by interesting 
biological and synthetically useful properties.6 This introduction has been restricted to the 
synthetic utility of the 2-imidazoline system as a template in the synthesis of other organic 
molecules and to its involvement in annulation reactions. No attempt has been made to 
survey preparations of 2-imidazolines; these are many and well documented.7
1
1.1 2-Imidazolines
The 2-imidazoline (or 4,5-dihydroimidazole) nucleus (1.1) has a numbering system derived 
from the imidazoles (1.2) (Scheme 1.1).
4n 5 , 7 = \ 6 ,
aN V r
R2 1-1 R2 1.2
Scheme 1.1
The nitrogen atom connected to the two adjacent ring atoms via single bonds is 
assigned position 1. The second nitrogen atom in the 5-membered ring is therefore 
assigned position 3, and is connected to C(2) by a double bond and to C(4) by a single 
bond.
1.2 Biological activity of 2-imidazolines
The nitrogen atoms of the 2-imidazoline ring are arranged in the form of a cyclic 
amidine and therefore constitute nitrogen analogues of carboxylic acids.8 Amidines and 
hence 2-imidazolines possess pharmaceutical properties6 and have been the subject of 
many studies in the search for drugs to be used in both man and domestic animals.
Nature uses a 2-imidazoline in 5,10-methenyl-5,6,7,8-tetrahydrofolate (1.3),9 one of 
the tetrahydrofolate family of coenzymes, which plays an important role in one-carbon 
transfers in purine biosynthesis. It is required for the insertion of C(8) and indirectly for the 
insertion of C(2) into the purine ring. An enzyme, 5,10-methenyl-5,6,7,8-tetrahydrofolate 
hydrolase catalyses the hydrolysis of 5,10-methenyl-5,6,7,8-tetrahydrofolate to N10-formyl- 
5,6,7,8-tetrahydrofolate10 which then acts as a donor and effects formylation of the amino 
function on compound (1.4). The reaction of (1.5) is catalysed by the enzyme 10-fonnyl-
SjôjTjS-tetrahydrofolaterS-amino-l-ribosyM-imidazole-carboxamide-S'-phosphate 
transformylase and lies on the pathway for biosynthesis of the purine nucleotides (1.6) 
(Scheme 1.2).11
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Scheme 1.2
Many 2-imidazolines substituted in the 2-position by either alkyl, aryl or even 
arylalkyl groups show pharmacological activity. 2-Benzyl-2-imidazoline (1.7), known as 
Priscol, is an important vasodilator and is used in the treatment of peripheral circulatory 
disorders.12 Replacement of the phenyl group by a naphthyl group reverses the effects, so 
that Pivine (1.8) is a potent vasoconstrictor.13 Phentolamine (1.9) is also used for the 
treatment of circulatory disorders, and blocks the pressor action of noradrenaline and 
adrenaline.14 Structural modification of these drugs led to the discovery of clonidine (1.10), 
a molecule that is used for the treatment of hypertension (Scheme 1.3).15
3
n
N <s/N H
Ph
1.8
f ~ \
Ph—N
NH
1.9 1.101.7
Scheme 1.3
Other 2-imidazolines have properties and uses in the control of cardiac arrhythmias. 
Antazoline (1.11) has the properties of an antihistamine drug and also possesses local 
anaesthetic and anticholinergic properties.16 Structural modification of antazoline led to the 
discovery of compounds (1.12) and (1.13) that have antifibrillatory effects on aconitine- 
induced cardiac arrhythmias (Scheme 1.4).17
f ~ \
NLx JsIH
Ph—N
Cl
NH
1.131.12
Scheme 1.4
Ph 
1.11
Structurally more complex 2-imidazolines such as (1.14), which contains two 2- 
phenyl-2-imidazolines linked through a meta urea bridge, has found use in the treatment of 
babesiasis in domestic animals18 whereas (1.15) has been shown to be active against 
transplantable leukemia L1210 (Scheme 1.5).19
NH
NHCONI
1.14
1.15
Scheme 1.5
A number of other simpler compounds have shown biological activities. The 2- 
amino-4-aryl-2-imidazolines (1.16) have been reported to have antihypertensive activity 
and several members of that series also exhibited central nervous system activity through 
prevention of reserpine-induced ptosis.20 2-(Methoxycarbonylamino)-4-phenyl-2- 
imidazolines (1.17), on the other hand, demonstrated an antidepressant profile.21 A recent 
report documented that compound (1.18) has been shown to be a potent cholesterol 
acyltransferase inhibitor and antihypercholesterolemic agent (Scheme 1.6).22
X v =
N.x JMHT
NH
1.181.17
CN
Scheme 1.6
It is not only the 2-substituted 2-imidazolines that are biologically active. N- 
Substituted 2-imidazolines have also been shown to exhibit biological activity. Compounds 
(1.19a) and (1.19b) were reported to inhibit a  and (J-adrenergic receptors (Scheme 1.7).23
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1.19a n=1 
1.19b n=2
Scheme 1.7
The biological activity shown by a large number of 2-imidazolines and the ease of 
their synthesis explains the extensive use of the imidazoline ring in synthetic organic 
chemistry.
1.3 2-Imidazolines: Tools to synthetically useful compounds
1.3.1 Carboxylic acids
The labile nature of the a-hydrogen atoms in 2-substituted 2-imidazolines was 
recognised early24 and was utilised by Jones et al. in reports of C(2a) metallation of 2- 
alkyl-2-imidazolines.25 This property proved valuable because it allowed the synthesis of 
more elaborate 2-imidazolines.
The simple N-benzyl-2-methyl-2-imidazoline (1.20) may be metallated with n- 
butyllithium at -78°C and treated with alkyl halides to afford the elaborated imidazolines 
(1.21) in excellent yields. Acidic hydrolysis afforded the homologated carboxylic acids. A 
second metallation followed by addition of alkyl halide furnished the 2- 
dialkylmethylimidazolines (1.22) which were likewise hydrolysed with aqueous H2SO4 to 
give the disubstituted carboxylic acids (Scheme 1.8).26,25
n  , n
,N—CH,Ph i) n-BuLi, R X .N—OH^Ph iii) h 3 0 +
1.20
R’CHaCOzH
R1 1.21
ii) n-BuLi, RZX
R 1^ R 2 1 ,2 2
Scheme 1.8
1.3.2 Ketones from 2-imidazolines
1 -Benzyl-2-alkyl or 2-dialkylmethyl-2-imidazolines can be used to synthesise 
ketones efficiently.27 2-Imidazolines (1.22) can be easily and quantitively converted into 
the more electrophilic methiodide salts (1.23) by reaction with methyl iodide (neat, 2 
equiv.). Grignard reagents (3 equiv. in THF) can be added to these salts to produce the 
presumed 2,2-disubstituted imidazolidines (1.24) which were not isolated but instead were 
decomposed on mild acidic work up (2M hydrochloric acid at 0°C). The ketones were 
obtained in good yields on simple extraction with diethyl ether (Scheme 1.9). This method 
gave satisfactory results with primary organomagnesium halides and alkyl lithiums; 
secondary organomagnesium reagents added slowly and gave low yields.
7
n
N<x /N —CH2Ph
R 1.22
R3COCHR1R2
i) Mel
2M MCI
n
Me— ,N—CH2Ph
+
R2 1.23
ii) R3M
n
Me—Nx_ / N—CH2Ph 
^ R3
1.24
Scheme 1.9
133 Aldehydes
A mild methodology to transform 2-imidazolines to aldehydes has also been 
developed recently.28 The aldehyde was obtained in a “one-pot” three step sequence 
(Scheme 1.10). Imidazoline (1.25) was N-permethylated using excess of methyl iodide and 
the resulting imidazolinium derivative was in turn reduced with sodium borohydride. The 
aminal was obtained and without isolation was converted to the aldehyde (1.26) using 
0.5M HC1.
/NH i) 4 eq. Mel, BaO E tN 02,130°C
S 02Ph
ii) NaBH4, EtOH, 0-5°C
iii) HCI (0.5 M)
U / h
 i-
Me
-N.
S 0 2Ph
1.26
Scheme 1.10
An alternative synthetic methodology was also reported for the conversion of 2- 
imidazolines to aldehydes.29 The 2-substituted-2-imidazolines (1.27) were reduced to the 2-
8
substituted imidazolidines with Na in ethanol. It was found that the best results were 
obtained when the reduction was performed at 0-5°C using 2.5 equiv. of sodium. The 2- 
substituted imidazolidines were then subjected to acidic cleavage in aqueous oxalic acid. 
The aldehydes derived from the hydrolysis were isolated after distillation in good yields 
(Scheme 1.11).
O
Nr NH ■ A h +  w - w *
R
1.27
Scheme 1.11
1.3.4 2,3-Diaimnoesters, acids and amino alcohols
Optically active 2-imidazolines (1.28) have been synthesised by stereoselective 
aldol-type reaction of N-sulfonylimines with ethyl isocyanoacetate catalysed by a gold (I) 
complex having a chiral ferrocenyl phosphine ligand (1.29).30
RHC=NTs +  CNCH2C02Et
Me2SAuCI
Hoisr
kNH;
1.33 C02H
22-56%
1.29
R
MeOH, aq. NaOHNR
TsHN
1.32
33% HBr/AcOH 
Phenol
Fk  , jP 0 2Et
r~ \
Ts' nx^ > n
1.28
con. HCI/EtOH
R
TsHN
1.30
,\X»'
J
kNH2 
C02Et 
UAIH4
kNHo
TsHN'
1.31 CH2OH
Scheme 1.12
The 2-imidazolines (1.28) could easily be ring opened to produce a variety of 
synthetically useful compounds.31 The 2,3-diamino ester (1.30) was obtained from the 
chiral imidazoline by treatment with conc. HCI in ethanol. Reduction of the ester produced 
the chiral amino alcohol (1.31). Hydrolysis of the ester followed by removal of the tosyl 
group in a refluxing solution of HBr/AcOH in the presence of phenol afforded the free 2,3- 
diamino acid (1.33).
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1.3.5 Synthesis of P-hydroxy-Oramino acids
The use of 2-imidazolines as templates has been extended even further to the 
synthesis of p-hydroxy-a-amino acids.32 Imidazolines (1.34) reacted with aldehydes in 
dimethylformamide to give the corresponding products by an aldol type reaction (Scheme 
1.13).
n  . .
N^x /N H  i>r c h o  , ,N H  ii) PhSO-ÆI | R ~ C H —c h — C O gH
I DMF i") HCI. 110=0 H O  N H 2
Z H N  Z H N
OK i.3 6
1'34 R= Me, Et, Ph R- Me, El, Ph
Scheme 1.13
Hydrolysis of the benzenesulfonyl derivatives of (1.35) with 1M HCI at 110°C gave 
the P-hydroxy-a-amino acids (1.36) in 5:1 ratio of threo and erythro forms.
1.3.6 Chiral Diamines
Imidazolines have also been used as intermediates in the conversion of diols to 
diamines.33 Enantiomerically enriched diols (1.37) were converted into the cyclic sulphates 
(1,38), The sulfates (1.38) reacted with the amidines (1.39) in DME to give the zwitterionic 
intermediates (1.40) which underwent cyclisation to afford the imidazolines (1.41) in a 
stereocontrolled sequence. Acétylation of (1.41) followed by hydrolysis in refluxing aq. 
HBr/AcOH afforded the enantiomerically pure diamines (1.42) (Scheme 1.14).
OH R1 R2
,1.R' ') S0CI2
HO
1.37
ii) RuCI3, N al0 4
R1 R2
H y
N <yN H  
i  1.41
i) AcCI, Et3N
ii) HB./AcOH
ÈIH2
r 2
H,N 1.42
0 ^ / 0  1.38
o ' ^ ^ o
i
R1
H2N X
0 S 0 3'
-R2
H2K  X
39
r
HN
1.40
Scheme 1.14
The ready availability of enantiomerically pure diols34 coupled with the versatile 
electrophilic behaviour of the derived cyclic sulfates35 provided an efficient route to chiral 
1,2-diamines.
1.3.7 Amidoamines
Hydrolysis of N-unsubstituted 2-imidazolines requires rather harsh conditions, such 
as concentrated acids and elevated temperatures.36 E. Korshin et al. have discovered that 
N-benzoylated 2-imidazolines (1.43) can be easily hydrolysed when boiled for 3 hours in 
aqueous acetone, to give amido amines (1.44).37 The replacement of the benzoyl group by 
the p-nitrobenzoyl group had an incredible effect. The hydrolysis occurred at 10°C in 
aqueous acetone (Scheme 1.15).
12
/  \  R 1
r  »n  an nH«nonHo ni J,A r x .N J  °  aq . CH3 COCH3
r1 / Y d  1.-
R1 = p-N 02 C6 H4, Ph
O
.43 1.44
Scheme 1.15 
1.3.6 Imidazoles from 2-imidazolines
The dehydrogenation of 2-imidazolines to imidazoles (1.45) has recently attracted a lot of 
attention. An efficient method for this conversion using commercially available Pd-C has 
been reported (Scheme 16).38
R2 R2
C ~ > i h  — — » r j , .
Y  toluene,
i i  re,lux i i  1..45
Scheme 1.16
The 2-substituted or 2,4-disubstituted-2-imidazolines were heated to reflux in toluene in 
the presence of 10% Pd/C to give the corresponding imidazoles (1.45) in good yields.
1.4 2-Imidazolines as synthetic intermediates
1.4.1 As nucleophilic transfer reagents
The 2-imidazoline subunit was utilised as a nucleophilic carbon reagent in order to 
mimic biological processes mediated by the tetrahydrofolate coenzymes.39 The simple 1- 
benzyl-2-imidazoline (1.46) was metallated with w-butyllithium in THF at -78C and the 2- 
lithio derivative was treated with a variety of aldehydes to give 2-(l-hydroxyalkyl)-2- 
imidazolines (1.47) in 60-70% yield. Oxidation of the resulting alcohols (Mn02, OH2Ol2) 
produced the corresponding 2-( 1 -oxoalkyl)-2-imidazolines (1.48). An alternative approach 
to these 2-acyl-2-imidazolines was via the direct acylation of the lithio derivative of (1.46) 
with carboxylic acids ethyl esters. Ketones (1.48) were treated with organometallic 
reagents to give tertiary alcohols (1.49) in moderate to good yields (34-92%). These 
alcohols were also obtained via direct reaction of the lithio derivative of imidazoline (1.46) 
with ketones in slightly lower yields.
Compounds (1.49) collapsed to the corresponding ketones (1.50) upon heating in 
chloroform containing a catalytic amount of conc. hydrochloric acid. It was suggested that 
the reaction proceeds via protonation of the amidine at N(3) and elimination to give the 
ketone and the imidazolinium ylide (1.52; R=H) that then protonates at C(2). In support of 
this proposal, treatment of the tertiary alcohols (1.49) with an excess of methyl iodide led 
to the urystalline 1-benzyl-3-methyl-2-imidazolinium iodide, presumably via the ylide 
(1.52), where R=Me, and a mother liquor that contained the desired ketones (1.50) 
(Scheme 1.17).
n
Ns ^ / N ^ CH2Ph
n-BuLi
1.46
R1CHO
60-71%
n-BuLi, R1C 0 2Et
41-67%
. t X
1) Mel
2) NuH 
58-89%
n
N ^ /N -
R 'OH
M n02  
53-67%
CH2Ph 
1.47
n
N' V ' N''CH,Ph
R1 / X)
12I
1.48
Nu
1.51 Nu=0, EtO, EtS,
PhCHgNH, BuNH
R ^N v^/M ^cH jR h
1.52 r = h ,  Me
,JL,
1.50
Scheme 1.17
n-Buü
R1COR2
35-50%
n
R2M , N" ^ / N ^ C H 2P h  
46-89%
il.
R"
"OH 1-49
CHCI3  trace H+
52-94%
Ketone (1.48), R1=Ph, was treated with an excess of iodomethane and the salt was 
reacted with nucleophiles to afford benzoic acid (NaOH), ethyl ester (EtOH reflux), ethyl 
thioester (EtSH, THF reflux) and benzyl or butyl amides (PI1CH2NH2 or BUNH2, THF 
reflux). In all the above cases the 2-imidazoline proved to be a good nucleophilic Ci- 
transfer reagent and a useful leaving group.
1.4.2 As reagents
It is known that alcohols can be converted to alkyl halides with a number of 
reagents. Japanese researchers have developed an imidazoline reagent40 that transforms 
alcohols to alkyl halides. 2-Chloro-1,3-dimethylimidazolinium chloride (1.53) was found 
to be an extremely useful reagent. Chloroalkanes (1.54) were obtained from alcohols by
15
reaction with (1.53) in the presence of triethylamine (1 equiv.) in good yields (Scheme 
1.18).
+ n
RCH2OH +  M er^N' V ' N''M e  1eqEt3N -  RCH2CI
Q | I CH2CI2
ci 1.53 1.54
Scheme 1.18
When the same reaction was carried out in the presence of carboxylic acids the 
acylated alcohols (1.55) were obtained (Scheme 1.19).
R’CHaOH +  M r ^ O S f c  " R’CHaOCOR2
Scheme 1.19
Vinylogous acid chlorides (1.56) were also efficiently synthesised under the same 
conditions when diketones were used as starting materials (Scheme 1.20).
f t  f t  - t /  V  1 eq Et3N 9* f t
+  Mec f - Y  M e  c h 2c ,2  r i A ^ A r 2  
Cl 1.53 1.56
Scheme 1.20
This imidazoline reagent (1.53) was shown to have the ability to oxidise secondary 
alcohols to ketones (1.57) in the presence of 2 equiv. of triethylamine when 1 equiv. of 
DMSO was used as co-additive. The ketones were obtained in good yields (71-92%) 
(Scheme 1.21).
? H +Ny/ 2 eq Et3N r ft
R ^ R :  +  Mec r Y  Me ' S T  R R2
Cl 1.53 1.57
Scheme 1.21
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Aromatic aldehydes were also obtained from benzyl alcohols in moderate yields of 
47-63%, when the reaction was carried out in the presence of hexamethylenetetramine, in 
place of DMSO, followed by the hydrolysis of an intermediate with 50% aqueous acetic 
acid. DMSO was found to give a mixture of chlorinated (major) and oxidised products 
(minor).
A Lossen-type rearrangement was observed when (1.53) was reacted with 
hydroxamic acids (Scheme 1.22) to produce isocyanates (1.58). Urea derivatives (1.59) 
were obtained in good to moderate yields by trapping the intermediate isocyanates (1.58) 
with primary amines. The use of either alcohols or thiols in place of amines afforded 
carbamates (1.60) or thiocarbamates (1.61) (Scheme 1.22).
,1 . nNHOH ci T Me
Cl
i H „
R1— N -C —SR4 
O
1.61
r 4s h
2 eq Et3N 
CH2Cl2
R— N =C =0 R3OH
1.58
-N- 
1.60
R1— —C—OR3
r 2nh2
H
R1— N -C —NHR2
t i 1.59
Scheme 1.22
1.4.3 As metallation directing groups
The presence of the two nitrogen atoms in the imidazoline ring appealed to 
researchers that investigated the ability of the imidazoline ring to act as a metallation 
directing group. Studies of the metallation characteristics of 2-arylimidazolines and of their
17
heteroaromatic analogues have been reported. Houlihan and Parrino reported ortho (and N- 
1) lithiation in 2-phenyl-2-imidazoline to afford (1.62), and lithiation of the methyl group 
(and of N-l) in 2-(2-methylphenyl)-2-imidazoline to give (1.63) (Scheme 1.23).41
nNU JMLi NLi
1.631.62
Scheme 1.23
The ortho lithiated imidazoline (1.62), generated with 3 equiv. of /i-butyllithium in hexane 
at 50°C, reacted with methyl 4-chlorobenzoate to form 5-(4-chlorophenyl)-2,3-dihydro-5//- 
imidazo[2,l-a]isoindol-5-ol (1.64) in 60% yield (Scheme 1.24).
ISU .NLi RCOgMo
R = -Cl
OH
1.64
Scheme 1.24
When the dilithio derivative (1.63) formed from 2-(2-methylphenyl)-2-imidazoline was 
reacted with methyl 4-chlorobenzoate at 50°C, the compound (1.65) was isolated, 
incorporating two molecules of the ester. In contrast, the ‘simple* acylation product (1.66) 
was produced when the reaction was performed at -25°C (Scheme 1.25).
r~\
1.63
RCO2M8 
50 °C
1.65
RCO2M6
-25 °C
1.66
Scheme 1.25
The 2-imidazoline moiety has also been studied as a director of 3-metallation in 
heteroaromatic rings such as pyrroles, furans and thiophenes (Scheme 1.26).42 The dilithio 
intermediate (1.67) was generated using n-butyllithium (2.2 equiv.) in either THF or DME 
at -78°C for 2 hours. A high level of metallation was achieved after that period, and the 
intermediate (1.67) was reacted with a range of electrophiles leading to the 2,3- 
disubstituted heterocycles (1.68). In cases where excess butyllithium was added 5- 
substitution was also observed.
r~ \
N ^ N L i R+
Li
' 0 . „
X = S, O, NMe
= /  1.68
R= D, SMe, C(OH)Ph2, 
CH(OH)Ph, TMS
Scheme 1.26
These metallations directed by 2-imidazolines presumably occur via an initial 
complex formation between the directing group and the incoming metallation agent, with 
Subsequent delivery of the metal to an adjacent orf/zo-position (Figure 1.1).
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1.4.4 2-Imidazolines as spin labels
An elegant route to a series of useful biological probes and paramagnetic ligands in 
coordination compounds was developed by Russian researchers.43. The reaction of a- 
hydroxylamino oxime (1.69) with aldehydes in an ethanolic solution led to the 
corresponding 3-imidazoline-3-oxides (1.70) (Scheme 1.28). Oxidation with PdOz in 
chloroform afforded 4#-imidazole-1,3-dioxides (1.71). Further oxidation with Pd02 in 
methanol led to nitronylnitroxy radicals (1.73). When the oxidation was performed in 
ethanol saturated with ammonia, compound (1.72) was obtained containing an amino 
group at the carbon atom a  to the nitroxyl group. The conjugation with the double bond at 
the C(2) position favours addition of methanol and am m o n ia  at C(4). In the reaction of 477- 
imidazole dioxide (1.71) with excess phenyllithium the addition of only one molecule was 
observed; this addition occurred preferentially at the arylnitrone group and gave the 
nitronylnitroxyl radical (1.74) on subsequent oxidation (Scheme 1.28).44 This reaction 
route correlates with the ability of the alkylnitrone to be metallated at the C(2) position thus 
preventing the phenyllithium from adding at the C(2) position.
Ar
RCHO
HQNH N \OH
1.69
Ar
OMe
0 - ' N< y N'v0  
R 1.73
HO
Y > ° -
R 1.70
PdOg/CHCIg
_ 0 " N<Y/N ^ 0
Ar
+
R
PdOa/MeOH
i) PhLi
ii) P d 0 2
r H
Ar
Ph
PdOg/NHg
0 / N n S / N
x r ' N ' Y ' ^ o .
R
1.74
Scheme 1.28
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1.5 2-Imidazolines as mimics
1.5.1 2-Imidazoline azaprostanoids
The doubly nucleophilic character of 2-methyl-2-imidazoline has been utilised for
(1.75) with w-butyllithium at 20°C and bromo-orthoester (1.76) to give imidazoline (1.77), 
followed by a second C-alkylation with 1-iodoheptane afforded the orthoester (1.78). 
Conversion of the orthoester to the methyl ester with H2S04-Me0 H and then K2CO3 
provided the first analogues (1.79) of the primary prostaglandins to contain the 2- 
imidazoline moiety (Scheme 1.29 ).
the synthesis of 2-imidazoline azaprostanoids.45 N-Alkylation of 2-methyl-2-imidazoline
ii) Br(CH2),
iii) n-BuLi,-78°C
iv) l(CH2 )6 CH3
y) MeOH, H2 SO 4  N
(Ch^JeCHg
1.79 1.78
Scheme 1.29
1.5.2 2-Imidazoline analogues of the Kainoid family
In an effort to mimic the anthelmintic and insecticidal activities of “kainoid” (1.80) 
with compounds of simpler structure and much easier accessibility, O’Sullivan et al. 
synthesised functionalised imidazolines (1.83a), (1.83b) and (1.83c) (Scheme 1.30).46
Me02 
+H3N
C02Me 
NHPh
i) RC(OMe) 3
ii) Na2 C0 3
1.81
HO-
HN. """•hi.
Me'1.80
MeOgC^  COglVIo
N^s^N—Ph 
R 1.82
iii) HCI/HgO 
HOgC^  ^ — COpH
1.83a R= H 
1 83b R= Me 
1 83c R= Bu
—Ph
R
Scheme 1.30
The condensation reactions of the diamine salt (1.81) with orthoesters were 
performed under acidic conditions and imidazolines (1.82) were obtained in moderate 
yields. After hydrolysis of the esters, the desired diacids (1.83) were isolated.
The diamine salt (1.81) was used because it was found that the free base was 
unstable and underwent a facile ring closure to form the butyrolactam (1.84) (Scheme 
1.31).
MeOi COgMa
+H3N NHPh 
1.81
MeOOC .NHPh
neutralisation
HN
Scheme 1.31
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These cyclic glutamate analogues (1.83a-c) showed no anthelmintic or insecticidal 
activity despite the fact that the glutamic acid subunit in these imidazolines is held by the 
planar imidazoline ring in a conformation similar to that found in the crystal structure of 
kainic acid.
1.5.3 2-Imidazolines as C-protected p-enamino acid derivatives
The imidazoline heterocycle has been employed as the masked carboxyl functionality 
in the synthesis of C-protected P-enamino acids47 which are potential precursors to P- 
amino acids.
The 1 -benzyl-2-alkyl-2-imidazolines (1.85) were treated with 1.25 equiv. of n- 
butyllithium in THF at -78°C. The lithiated imidazolines (1.86) were then reacted with 
nitriles to give the anionic intermediate (1.87) after short reaction times (2-5 h). After 
quenching with saturated aqueous NH4CI, the intermediates (1.87) evolved to the single 
reaction products (1.88) that were isolated in the P-tautomeric form, due to the additional 
stabilisation resulting from delocalisation and the possibility of intramolecular hydrogen 
bonding (Scheme 1.32). The configuration of the double bond was confirmed as Z by 
n.0 .e. experiments.
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Scheme 1.32
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N^x /N - ■CH2Ph
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1.5.4 Imidazolines as pseudopeptides
The imidazoline ring contains an amidine that has similar resonance structures to 
those of the parent amide bond and may be viewed as a mimic of many of the features of 
the amide bond. The similarities include the presence of two heteroatoms, similar 
configuration of double bonds, similar hydrogen bonding possibilities and similar steric 
properties. On the other hand the basicity of an amidine is much greater than that of an 
amide, a property that retards hydrolysis under the conditions likely to prevail in biological 
systems. Jones et al. capitalised on these advantages and similarities to the amide bond and
synthesised 2-imidazolines as pseudopeptides (Scheme 1.33).48
Me
ZHN
indole-3-CH
1.89
H2N
H2N t ; 0 2Me 
1.90
Bu
 F. O  2 M e
l< s / fJ L _  N<x  .NH
ZHN^^CH2-3-indole
1.91
Bu
 f..««CO-Asp-Phe-NH2
N<x/NH < '»)-vi)
H2N*'"'^cH2-3-indole
1.93a
Bu
TnuftCOg Me 
B o c ^ NN j^ N * "
ZHN4"'^Q H 2-3-indole
1.92a
Bu Pu
^ L .v C O -A s p -P h e -N H 2 y— ^ " « C 0 2M e
N<s /N H  iü). vi) Boc/ N X ^ :'N
HgN CH2-3-indole 
1.93b
ZHN CH2-3-indole 
1.92b
ii)
i) MeOH, reflux, (80%), ii) BoczO, NaHCOg aq. THF, column chromatography to separate (1.92a) and
(1.92b) (41 and 43%); iii) 0.1 M LiOH (100%); iv) pentafluorophenol, DCC, EtOAc, (86%); then H-Asp- 
Phe-NH2, Et3N, DMF, (97 and 62%) v) H2, 50 psi, Pd(OH)2 on C, MeOH (98%); vi) TEA (84%).
Scheme 133
The S-methylthioimidate salt (1.89) was treated directly with the homochiral R- 
diaminoester (1.90) to give the protected pseudopeptide (1.91) as inseparable mixture of 
diastereoisomers. After protection of the amidine ring as the terf-butyloxycarbonyl amide 
chromatographic separation of the two diastereoisomers (1.92a) and (1.92b) was achieved. 
Basic hydrolysis at the C-terminus, followed by activation as the pentafluorophenyl ester 
and coupling with Asp-Phe-NH2 afforded the separate protected pseudotetrapeptide 
diasteroisomers. Deprotection by hydrogenolysis and trifluoroacetic acid treatment 
afforded the separate pseudopeptide isomers (1.93a) and (1.93b) as trifluoroactate salts.
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Unfortunately these compounds showed minimal binding activity when tested 
against the rodent CCK-A and CCK-B.
1.6 2-Imidazolines in annulations
1.6.1 Guanidine units from 2-imidazolines
The nucleophilic character exhibited by 2-imidazolines has been explored by a 
number of chemists that have used this molecule in ring forming reactions. Compounds 
containing the guanidine unit are of considerable biological interest due to the hydrogen- 
bond mediated interactions of guanidinium ions with phosphate-containing biomolecules49 
and to their large range of biological activities, including hypotensive and adrenergic 
neuron-blocking effects.50 The synthesis of acylguanidines from suitable 2-amino-2- 
imidazolines has been the subject of a number of reports. 2-Amino-2-imidazoline (1.94),
for example reacted directly with ethyl acrylate to give exclusively the product (1.95) 
(Scheme 1.34).51
The other possible regioisomeric product (1.97) was prepared by ring closure of 
suitably 2-substituted-2-imidazoline (1.96a) (Scheme 1.35). This was achieved by refluxing 
in mineral acid. The guanidinium ion is sufficiently nucleophilic to react with the 
protonated carboxylic acid group. In the case of the N-methyl-2-imidazoline (1.96b), 
compound (1.98) was obtained (Scheme 1.35).52
CH2=CHC02Et HN
NH2
1.94
Scheme 134
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aq. H2SO4
Me*
1.98or
COgH
HN
1.97
1.96a, R = H 
1.96b, R = Me
Scheme 1.35
The N(l)-methyl derivative (1.99) reacted similarly to give compound (1.100) 
(Scheme 1.36).53
r ~ \
N' ^ / N" M e  CH2=CHCQ2Et
NH-
1.99
n
M e"N\ / N'
V,.100
Scheme 1.36
2-Methylamino-2-imidazoline (1.101) on the other hand gave only the acyl 
guanidine (1.102) in refluxing ethyl acrylate. However when the reaction was carried out in 
ethanol at 5°C, it afforded 61% of (1.102) accompanied by a 21% yield of compound
(1.103) (Scheme 1.37).52
n
N<yNH
NHMe
CH2=CHC02Et
n
N .\  ,N.
5°C
MeN
1.101
CH2=CHC02Et
78°C
T 1.103
1.102
Scheme 137
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Compound (1.105), prepared from the reaction of 2-methylthio-2-imidazoline
(1.104) and y-ammobutyronitrile, underwent cyclisation to form the imine (1.106) which 
was hydrolysed to give (1.97). Conversion of the acid (1.107) to the methyl ester resulted 
in a spontaneous alternative cyclisation to give pyrroline (1.108) (Scheme 1.38).52 The 
formation of the five membered pyrroline ring in (1.108) appears to be more favourable 
than the seven membered ring fused to the imidazoline.
ISU .NHT
H2N(CH2)2CN /  \  H2N(CH2)3C 0 2H J
------------------- N<<zNH  ► N^s^NH
SMe HNx / s^ / CQ2H
1.104 1.107
HN
1.106
HN
1.97
Scheme 1,38
These imidazo[ 1,2-a]pyrimidine molecules can be regarded as analogous to many 
of the nucleotides.
In a similar way chiral 2-imidazolines have been employed as starting materials in 
the synthesis of chiral bicyclic guanidines (Scheme 1.39).54
kU\H
NH
NH-Tr
S
H NH-Tr
SMe
1.110
DMF
120°C
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>111
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Scheme 139
Thiourea (1.109) was transformed with 2 equiv. of methyl iodide in methanol into 
the isothiouronium iodide (1.110), which was then heated in DMF at 120°C to produce 
bicyclic guanidine (1.111).
1.6.2 Synthesis of pyrimidones
The double nucleophilic character of 2-amino-2-imidazolines has been used by 
other researchers in order to synthesise heterocyclic molecules. 2-Anilino-2-imidazolines 
(1.112a) when treated with P-ketoesters produced tetrahydroimidazopyrimid-7-ones 
(1.113).55 In particular 2-(2-amino-anilino)-2-imidazoline (1.112b) reacted with ethyl 
benzoylacetate to give compound (1.114) as an intermediate which eliminated one 
molecule of water spontaneously to give benzimidazole derivative (1.115) (Scheme 1.40).54
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These 2-anilino-2-imidazolines (1.116) also reacted with propiolate esters to give 
pyrimidones (1.117) of the opposite regiochemistry (Scheme 1.41).52
/ \ 
N>x .NH R —= —C 0 2Et
NH
fltC y ,116 1.117
Scheme 1.41
1.6.3 Reaction of 2-aminomethyl-2-imidazolines with double electrophiles
The ability of 2-aminomethyl-2-imidazolines to act as binucleophiles has been 
explored even further by Korshin et al.56 The reaction of 2-arylaminomethyl-2- 
imidazolines (1.118) with oxalyl chloride in the presence of 2 equiv of triethylamine gave 
hexahydro-5,6-dioxoimidazo[l,2-a]pyrazines (1.119), while the reaction with phosgene
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under the same conditions resulted in 5-oxo-5/f-tetrahydroiniidazo[ 1,2-a]imidazole (1.120) 
in 60% yield. A possible acylation reaction at the highly nucleophilic N(l) atom of the 
imidazoline ring takes place first followed by cyclisation to afford the compounds (1.119) 
and (1.120). Imidazoline (1.118) also reacted with methylbromoacetate to give the bicyclic 
compound (1.121) in 27% yield (Scheme 1.42).
diamides of phosphinic acids in the presence of triethylamine afforded (1.122) in only 24% 
yield and the bicyclic diamidophosphinates (1.123) (Scheme 1.43) in 58 and 70% yields, 
respectively.
/ \
coci.(COCI)2
BrCHgCC^Me
Et3N
1.119
Ar
1.120
Ar 1.121
Scheme 1.42
The reactions of these 2-arylaminomethyl-2-imidazolines with MeOP(0 )Cl2 and
MeP(0)CI2
2 equiv Et3N
P(N 2 Et)2
2 equiv Et3N
Ar
Scheme 1.43
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1.6.4 Triazinones
In a similar fashion to the 2-amino-2-imidazolines, 2-hydrazino-2-imidazoline 
hydroidides (1.124) reacted with dimethyl acetylenedicarboxylate in methanol in the 
presence of triethylamine to give the l,2,4-triazin-5-ones (1.125) (Scheme 1.44).57
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n Y n " r
HN- nh2 
R= H, Me 
1.124
CO2CH3
CO2CH3
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Scheme 1.44
1.6.5 Triazine derivatives from 2-imidazolines
2-Methyl-2-imidazolines bearing a hydrogen or a methyl group at the amidine 
nitrogen have been shown to react smoothly with 2 equivalents of methyl isothiocyanate in
anhydrous DMF, yielding condensed 1,3,5-triazine derivatives (1.126 ) (Scheme 1.45)
CH3N=C=S
58
n
/N ^ r 1
R1= H, Me
PhN=C=S 
R1 = H
n  Hy v Ph
1.127
1 n  
H a C 'Y  J
T
1.126
Scheme 1.45
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Phenyl isothiocyanate on the other hand reacted to give only the N-thiocarbamyl 
derivatives (1.127) but did not proceed to form the cycloadduct. This reaction appears to 
depend on the R group of the isothiocyanate.
1.6.6 Imidazo [2,1-6] thiazinones and imidazo [2,1 -b\thiazolones
Imidazoline (1.128) reacted with chloroacetic acid and 3-bromopropanoic acid in 
acetic acid and sodium acetate to give the 2-substituted sulfanyl derivatives (1.129) and 
(1.131) which were cyclised by polyphosphoric acid to give imidazo[2,1 -6]thiazolones 
(1.130) and imidazo[2,l-6][l,3]thiazinone (1.132) (Scheme 1.46).59 Imidazoline-2-thiol 
(1.128) also reacted with dimethyl acetylenedicarboxylate (Scheme 1.46) to give the 
bicyclic compound (1.133).60 The sulfur atom added to the triple bond followed by 
cyclisation of the NH group onto the non-conjugated ester to give the isolated product.
N -v N H  CICHR2C 0 2H |y ^ |^|_| BrChkCHgCC^H  ^ v m h
SH
1.128
AcOH
1.131
HaCOaCC^CCOaCHg PPA
PPA
R R R 1 R R R
1.133 CHC02Me
Scheme 1.46
1.6.7 2,4,6-Trisubstituted pyrimidines from 2-imidazolines
C-Alkyl and C-arylpyrimidines were synthesised by a rearrangment of 4- 
functionalised 2-imidazoline derivatives.61 4-(l-Chloroalkyl)-2-imidazoline derivatives 
(1.134) were treated with 2 equiv. of NaH and underwent intramolecular alkylation to give 
aziridino[ 1,2-c]-2-imidazolines (1.135). These aziridine derivatives were subsequently 
treated with 1 equiv. of NaH in dimethylformamide which resulted in a base induced p- 
eliminative ring expansion to the dihydropyrimidines (1.136). Air oxidation of (1.136) 
produces the aromatic pyrimidines (1.137) (Scheme 1.47).
1.134
" h r *N < s >
R3 1.135
2 eg. NaH
NaH
1.137
air oxidation
N_
1.136
Scheme 1.47
1.6.8 Homochiral piperidines from 2-imidazolines
The chiral enaminoester (1.138) has been reported by Jones et al. to undergo a 
conjugate addition to pent-l-enone to give the imidazoline adducts (1.139).62 Reduction of 
imidazoline (1.139) with diborane followed by H2SO4 work up afforded the 
octahydroimidazopyridines (1.140) as a single enantiomer. Further reduction of the aminal,
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with NaBHgCN at pH 3, and hydrogenolysis of the benzylic C-N bond (% , Pd-C, MeOH) 
produced a single enantiomer of the volatile ^-substituted piperidines which were isolated 
as their N-tosyl derivatives (1.141) (Scheme 1.48). The other enantiomer of the 
enaminoester (1.138) led to piperidines of the opposite stereochemistry.
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NH i) RCOCH=CH2
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iii) NaBHgCN, pH=3 p h H  ^ .N,
1.141
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Scheme 1.48
Other annulations involving imidazoline enaminoesters of the type (1.138) will be 
referred to during the discussion of our own studies.
1.7 2-Imidazolines in cycloaddition reactions
1.7.1 Imidazolines in 2+2 cycloadditions
2-Imidazolines have been involved in the synthesis of azapenams. An earlier 
attempt to synthesise azapenams from the reaction of azidoketene with 2-imidazolines was 
not successful.63 Azapenams were detected as intermediates, but not isolated. Recent 
reports of the photolytic reaction of ch rom ium  carbene complexes (1.142) with
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imidazolines (1.143) have shown that the synthesis of azapenams is possible (Scheme 
1.49).*
CbzCbz
1.142 1.143 1.144
H21  Pd/C 
MeOH, Et3N
H2, Pd/C, 
THF ^
1 .1  equiv. cam phor 
sulfonic acid
NH
1.1451.146
Scheme 1.49
Protection of the imidazoline NH group was deemed essential to prevent its 
reaction with the photogenerated ketene, so the easily removed Cbz group was appended to 
the imidazoline. In all cases a single diastereoisomer of the Cbz protected azapenams 
(1.144) was detected. Removal of the Cbz group by hydrogenolysis at 45 psi in methanol 
and triethylamine occurred in 4 min and produced azapenams (1.145). When the 
deprotection of the Cbz-azapenams was carried out under acidic conditions, 
hexahydrodiazepinones (1.146) were produced (Scheme 1.49).
1.7.2 Homochiral imidazolines in 1,3-dipolar cycloadditions
Optically active 2-imidazolines (1.147) have also been employed as templates for 
the synthesis of chiral pyrrolidines by using the 1,3-dipolar cycloaddition reaction.65
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N-Alkylation of 1 -benzyl-4-phenyl-2-imidazoline (1.147) with bromoesters and 
addition of DBU to these quaternary salts generates the azomethine ylides (1.148). Ylides 
(1.148) were shown to undergo diastereoseleetive 1*3 dipolar cycloaddition with a variety 
of electron-deficient electrophiles to afford hexahydropyrrolo[ 1,2-a] imidazole 
cycloadducts (1.149) as single enantiomers, and generating three of the five bonds of the 
new pyrrolidine ring in one-pot. Further reduction with NaBHsCN followed by 
hydrogenolysis, led to the formation of optically active pyrrolidines (1.150) (Scheme 1.50). 
The 4-phenyl substituent provides facial selectivity in the cycloaddition and facilitates the 
removal of the templating atoms. The other imidazoline enantiomer produced pyrrolidines 
of the opposite stereochemistry.
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1.8 Strategy
1.8.1 The Diels-Alder approach to the target molecules
The original aim of this project was to extend the idea of employing 2-imidazolines
alkaloids such as lycoricidine (1.151) and narciclasine (1.152), compounds that have 
attracted considerable interest due to their range of biological effects and antitumour
Aloperine 1.154 
Scheme 1.51
One possible way to access these compounds could be by designing imidazoline templates 
that could undergo either inter or intramolecular Diels-Alder reactions.
The Diels-Alder reaction was chosen as a possible method for the synthesis of the 
hydroquinolines because it accomplishes the union of a 4jc electron system with a 2n
as templates in order to synthesise the optically active hydroquinoline unit found in many
activity.66 Pumiliotoxin C (1.153) is an alkaloid, produced by poison frogs native to South 
and Central America,67 that also contains the hydroquinoline moiety. Aloperine (1.154) has 
been isolated from seeds and leaves of Sophora alopecuroides Z,.68 These plants have been
long used in the treatment of inflammation in traditional Chinese medicine (Scheme 1.51).
kOH Me
OH
I N  à
H H H
X O
X= H lycoricidine 1.151 
X= OH narciclasine 1.152
Pumilioxin 1.153
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electron system creating two new carbon-carbon bonds, a six-membered ring and up to four 
contiguous stereocentres in one efficient step.69 The Diels-Alder cycloaddition is indeed a 
most productive process because it involves a simple summation of the reaction partners; 
all the atoms that constitute the diene and the dienophilic components are expressed in the 
[4+2] cycloaddition, and none are wasted.
Even more substantial structural changes can be brought about when the Diels- 
Alder reaction is intramolecular, where the probability is enhanced that the diene and 
dienophile will react with each other. When the reactive components are themselves cyclic 
and/or have ring substituents, complex multicyclic arrays such as those contained in drugs 
and natural products, can be constructed in a single step (Scheme 1.52).70
Scheme 1.52
Those advantages and the fact that the Diels-Alder reaction offers a good control of 
the sterochemistry of the final products led us to investigate this approach to the synthesis 
of those molecules.
1.8.2 The intermolecular Diels-Alder approach
Retrosynthetic analysis of a target hydroquinoline such as (1.155) (retrosynthetic 
analysis 1) reveals that an intermolecular Diels-Alder reaction between the electron-rich 
imidazoline (1.158) and the electron-deficient methyl acrylate would lead to cyclohexene 
(1.157). Ring closure could be forced by addition of a base to give the tricycle (1.156). 
Reduction of the carbonyl group and cleavage of the imidazoline will provide the target 
molecule (1.155). The presence of the double bond could be used for further manipulation.
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The original imidazoline (1.158) should be available in principle by reaction of a ring 
nitrogen atom with 2-butenal.
n
1.155 1.156
N>x /N
r~\
NK .NH
fT
x o c
.AX
1.157
V
1.158 J
R XOC '
Retrosynthetic analysis 1
1.8.3 The intramolecular Diels-Alder approach
Another possible route to the target hydroquinolines could be from 2-imidazoline 
templates designed to undergo intramolecular Diels-Alder reactions. Retrosynthetic
analysis suggests two possible templates (retrosynthetic analyses 2 and 3).
1.156 1.159
v
1.1601.161
Retrosynthetic analysis 2
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As can be seen from retrosynthetic analysis 2, the imidazoline (1.159) contains an 
electron-rich diene attached to the ring nitrogen, and the dienophile at the C(2) position. 
Disconnection of the dienamine (LI 59) reveals that it could in principle be formed from 2 
butenal and 2-(but-3-enyl)-2-imidazoline (1.160) which would be synthesised from 
N,C(2a) dianion (1.161) and 3-bromopropene.
A different disconnection reveals that an isomeric target molecule (1.162) could 
also be synthesised from an imidazoline (1.163) which contains a diene at the C(2) position 
and the dienophile now attached at N(l). The enamine could be synthesised from 
imidazoline nucleophile (1.164) and a suitable partner; use of methyl propiolate or ethyl 
acetoacetate would provide an electron withdrawing dienophile substituent, for example. 
The second disconnection shows that the diene could be introduced by generation of the 
N,C(2a) dianion (1.161) and 5-bromopenta-l ,3-diene.
1.162
nNx .N-
1.161
Br-
V
1.163
n
Nx ,N_ ‘CO2M©
or
CH3COCHCO2CH3
1.164
Retrosynthetic analysis 3
In both cases the analysis leads to a doubly nucleophilic synthon (1.161) which is 
the key for the synthesis of the proposed imidazoline templates. This synthon is equivalent 
to the 2-methyl-2-imidazoline reagent, which is a commercially available material.
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Chapter 2 
2.0 Discussion
2.1 A new protocol for the synthesis of 2-substituted-2-imidazolines
2.1.1 Studies on 2-imidazoline dianions
In considering assembly of the target Diels-Alder templates of dienamine (1.159) or 
enamine (1.163), it was felt that enamines would be unstable under lithiation conditions. It 
was therefore decided that the enamine functionality should be introduced at a later stage. 
C(2a)-alkylation had to be completed first which implied that N(l)-protection could be 
necessary in order to prepare those target molecules, unless a different method for their 
synthesis was devised.
If the double anion that was suggested as the key synthon (1.161) for the synthesis 
of the target imidazoline could actually be generated, the least stable anion at the C(2a) 
position would be expected to react first with the electrophile to give the C(2)-substituted
2-imidazoline. If this methodology proved successful there would be no need for an N(l) 
protecting group, therefore the synthesis of the target imidazoline templates would become 
shorter.
Dianions derived from C(2a)-disubstituted chiral 2-imidazolines (2.1.1) have been 
reported to undergo diastereoselective alkylation in the presence of 1.1 equiv. of alkyl 
halides to afford the corresponding quaternary substituted imidazolines (2.1.2) in good
1.161
Scheme 2.1.1
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yields (Scheme 2.1.2).71 These presumed dianions benefit from the extra stabilisation 
provided by the aryl substituent.
i) n-BuLi, THF, -25°CN -  NH N ^ N H  
R:
R
ii) R2 X, -5-0°C
R
R R
2 .1.1 2.1.2
Scheme 2.1.2
On the other hand, earlier efforts in our group to create the dimetallated species 
(1.161) from 2-methyl-2-imidazoline with 2.2 equiv. of w-butyllithium in THF at -78°C,
bromide afforded only the N-benzylated-2-methyl-2-imidazoline.45 In contrast to this, when 
we attempted to form the dianion (1.161) by double deprotonation of 2-methyl-2- 
imidazoline (2.1.3) with 2.0 equiv. of /z-butyllithium in tetrahydrofuran at 0°C, quenching 
with 1.0 equiv. of 3-bromopropene did afford the desired C-allylated compound (2.1.4) but 
only in a 10% yield (Scheme 2.1.3).
Scheme 2.1.3
Despite efforts to optimise the yield by pre-drying the 2-methyl-2-imidazoline 
(2.1.3) in a vacuum oven over phosphorous pentoxide, compound (2.1.4) could not be
water solubility. The presence of a phenyl ring at the C(2<x)-position does indeed appear to
had failed to demonstrate formation of a dianion. Quenching with 1.1 equiv. of benzyl
ii) 1 equiv. CH2=CHCH2 Br, 0°C
2.1.3 2.1.4
obtained in more than 10% yield. No unchanged starting material was recovered due to its
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stabilise the anion more than in the case of 2-methyl-2-imidazoline, which could explain 
the difference in yield.
It was not clear at this point whether complete formation of the dianion (1.161) had 
been achieved. In order to understand whether the dianion formation was possible, the 
question of the C- versus N-lithiation behaviour was addressed in more detail. When 1.0 
equiv. of n-butyllithium was added to 2-methyl-2-imidazoline at 0°C, a yellow solution of 
the anion was produced and on quenching with 1.1 equiv. of 3-bromopropene the N-prop-
3-enyl-2-methyl-2-imidazoline (2.1.5) was obtained in 44% yield, along with 10% of the 
diallylated compound (2.1.6). This result confirms that the NH is the most acidic site on 
the molecule and that this is the first proton that is abstracted (Scheme 2.1.4).
n
N 'X / N H  i) n-BuLi, THF, 0°C N<s /N
ii) CH2 =CHCH2Br
2.1.5
Scheme 2.1.4
A different experiment was carried out to investigate whether the N(l) and C(2) 
doubly alkylated species can be formed. 2 Equiv. of n-butyllithium were added to a 
solution of 2-methyl-2-imidazoline in THF at 0°C and to the yellow suspension formed 
was added 2.2 equiv. of 3-bromopropene. The disubstituted 2-imidazoline (2.1.6) was 
obtained in 45% yield (Scheme 2.1.5).
J  \ i) 2 . 2  eq. n-BuLi. 0 °C '  '
/NH ----------------------------------
ii) 2 .2 eq. CH2=CHCH2Br
2.1.6
Scheme 2.1.5
It is not clear whether the NH and C(2oc) protons are abstracted together or 
sequentially. In the latter case N-alkylation would be followed by C-deprotonation by the 
excess base, and then C-alkylation. The yellow suspension observed when the 2 equiv. of
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«-butyllithium added is possibly an indication (yellow solution formed when 1 equiv. of n- 
butyllithium was added) that the dianion is actually formed. The negative charge in the 
mono-anions is delocalised in the imidazoline ring in both cases (Scheme 2.1.6).
? -
Scheme 2.1.6
Similar experiments were carried out with 2-benzyl-2-imidazoline (2.1.7). 2 Equiv. 
of M-butyllithium were added to a solution of 2-benzyl-2-imidazoline in THF at 20°C and 
2.2 equiv. of 3-bromopropene was added to the white suspension that was formed at 0°C. 
The dialkylated product (2.1.8) was obtained in 91% yield (Scheme 2.1.7). This difference 
in yields is an indication of the difference in the stability and reactivity of the two dianions.
r \
ISLx JSIH
2.1.8
i) 2.2 eq. n-BuLi, 0°C
ii) 2.2 eq. CH2=CHCH2Br
Ph"
2.1.7
Scheme 2.1.7
When 2-benzyl-2-imidazoline was treated with 2.1 equiv. of /i-butyllithium at 20°C 
followed by 1.0 equiv. of 3-bromopropene produced a mixture of diallylated, N-allylated 
and C(2)-alkylated compounds was produced. Although this experiment was carried out 
under different conditions to those described by Langlois, it proves that C(2)-substituted 
imidazolines could be obtained. In any case, we can conclude that efficient N,C(2cx)- 
dianion formation and reaction is limited to the 2-aryl cases, where extra delocalisation is 
available.
It is evident therefore that this approach to the C(2)-alkylated imidazolines is not 
very useful for the 2-methyl substrate, and a good imidazoline N(l) protecting group that
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could be easily removed at a later stage, was required in order to synthesise the proposed 
imidazoline templates.
2.1.2 N-Benzyl protected 2-imidazoline,s
An alternative approach to the synthesis of 2-substituted 2-imidazolines involved 
the utilisation of l -benzyl-2-methyl-2-imidazoline (2.1.9) as a starting material. It has been 
reported earlier by our group that l -benzyl-2-methyl-2-imidazoline can be metallated at the 
C(2a)-position by treatment with n-butyllithium (1 equiv.) in tetrahydrofuran to afford, 
after addition of an alkyl halide, the 2-substituted N-benzyl-2-imidazoline (2.1.10).72 
Débenzylation of the N-benzyl-2-imidazoline (2.1.10) with sodium in liquid 
ammonia/ethanol has also been reported to give the 2-substituted 2-imidazoline (2.1.11) 
(Scheme 2.1.8).45
2.1.9
.Ph i) n-BuLi
ii) Br(CH2 )6
Ph
iii) Na-NH3  (I), EtOH
2.1.11
Scheme 2.1.8
This already existing methodology was an attractive one for the synthesis of 2- 
substituted-2-imidazolines that contained the required diene and dienophile fimctionalites 
at the C(2)-position.
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1 -Benzyl-2-methyl-2-imidazoline (2.1.9) was easily synthesised (Scheme 2.1.9).
Ph rPhNH OEt
+
‘NH2
2.1.12 2.1.13
Ph
2.1.9 I 
Scheme 2.1.9
Ethyl acetimidate hydrochloride (2.1.13) was prepared by addition of acetyl 
chloride (1 equiv.) to ethanol (2 equiv.) followed by treatment with dry acetonitrile at 5°C.
solid in 32% yield. N-Alkylation of an excess of 1,2-diaminoethane with benzyl chloride at 
gentle reflux afforded a crude product from which N-benzyl-1,2-diaminoethane (2.1.12) 
was isolated after distillation as a colourless liquid in 72% yield. N-Benzyl-1,2- 
diaminoethane and ethyl acetimidate hydrochloride were heated at reflux for 3 h under 
nitrogen to afford after work up, the l -benzyl-2-methyl-2-imidazoline (2.1.9) as a 
colourless liquid in 70 % yield.
1 -Benzyl-2-methyl-2-imidazoline (2.1.9) was lithiated with zz-butyllithium in THF 
at -78°C and the orange anion was quenched with 1.1 equiv. of 3-bromopropene to give 1- 
benzyl-2-(but-3-enyl)-2-imidazoline (2.1.14) after work up and chromatography, as a 
colourless liquid (72%) (Scheme 12).
Storage at 0°C for 12 h and addition of dry diethyl ether afforded the imidate salt as a white
n
N ^ s / N ^ ^ P h  i) n-B uü, THF, -78°C N < S / N \ / P h
| ii) CH2 =CHCH2Br
2-1.9 2.1.14
Scheme 2.1.10
When methyl 4-bromobut-2-enoate was used as the electrophile the reaction did not 
produce the expected compound (2.1.15) (Scheme 2.1.11). This target imidazoline was 
selected because it would have contained an electron-deficient dienophile at C(2), which is 
important in Diels-Alder reactions.
n  n
N x X z N ^ / P h  i) n-BuLi _ N s \ , N ^ ^ , P h
ii) BrCH2 CH=CHC02Me
\ / ^ ^ C 0 2 M e
2.1.15
Scheme 2.1.11
NMR spectroscopy showed traces of the desired product but purification and 
isolation of the pure material proved difficult. The presence of three electrophilic centres 
on methyl 4-bromobut-2-enoate and its ability to act as a proton source could be 
responsible for the poor reaction.The lithiated 2-imidazoline has the choice of attacking the 
ester carbonyl, the bromide or the conugated double bond.
1 -Benzyl-2-(but-3-enyl)-2-imidazoline (2.1.14) was subjected to the Birch 
reduction conditions using 8 equiv. of sodium in liquid ammonia/ethanol as described in 
the literature73 which resulted in unidentified products without any of the desired material 
being isolated. When the amount of sodium was reduced to 2.6 equiv., an inseparable 3:2 
mixture of the unsaturated 2-(but-3-enyl)-2-imidazoline (2.1.4) and the saturated 2-butyl-2- 
imidazoline (2.1.16) was obtained in 31 % yield (Scheme 2.1.12). The saturated compound 
is probably produced via an intramolecular electron transfer from the benzene ring to the 
double bond of the side chain. Only when the amount of sodium was reduced to 1.95 equiv. 
was the desired 2-(but-3-enyl)-2-imidazoline (2.1.4) obtained but unfortunately in a
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disappointing 21% yield (Scheme 2.1.12). Attempts to optimise the yield proved 
unsuccessful.
2.6 equiv. Na/liq NH
+
(31%)
2.1.14 2.1.4
1.95 equiv. Na/liq NH;
(21%)
2.1.4
Scheme 2.1.12
In order to understand whether it is the presence of the double bond in the side 
chain that interferes with the débenzylation or whether the débenzylation is not generally 
useful, 1 -benzyl-2-butyl-2-imidazoline was prepared. 1 -Benzyl-2-methyl-2-imidazoline
(2.1.9) was lithiated using zz-butyllithium in THF at-78°C and C-alkylation was carried out 
by addition of 1.1 equiv of 1-iodopropane to produce compound (2.1.17) in 96% yield 
(Scheme 2.1.13). Imidazoline (2.1.17) was subjected to a Birch reduction using 2.5 equiv. 
of sodium in liquid ammonia/ethanol to give a yellow oil which solidified after column 
chromatography. 1H, 13C and DEPT NMR spectroscopy suggest it may be compound
(2.1.18) (Scheme 2.1.13). Although mass spectroscopy showed that the molecular ion of
(2.1.18) was present (M* 218), high resolution mass spectroscopy (which was done a few 
months later) suggested that facile oxidation back to the starting material (2.1.14) may have 
taken place upon standing.
n
Y
2.1.9
i) n-BuLi, -78°C PhPh
2.1.17
2.5 equiv. Na/liq NH
2.1.18
Scheme 2.1.13
It is evident from these results that the benzyl group is not the ideal protecting 
group and another more general N(l)-protection should be found.
2.1.3 2-Alkyl-2-imidazolines
During our search for a better N-protecting group for 2-imidazolines we were aware 
of a report from our group that silyl-protected imidazolines had been found to be unstable 
and moisture sensitive, and that C-lithiation and alkylation of these compounds did not 
occur cleanly.73 The use of the ter/-butyloxycarbonyl (Boc) group as 2-imidazoline N- 
protection, has been reported for pseudopeptide imidazolines74 and for 2-imidazolines used 
in chromium mediated 2+2 cycloaddition reactions,75 but had not been reported as an 
imidazoline protecting group in lithiation reactions, so its application seemed attractive.
l-ter/-Butyloxycarbonyl-2-methyl-2-imidazoline (2.1.19) was easily prepared from 
the commercially available 2-methyl-2-imidazoline (2.1.3) and di-ferf-butyl dicarbonate in 
the presence of triethylamine in dichloromethane at 20°C, and was isolated as a colourless 
low melting solid in 72% yield after distillation (Scheme 2.1.14). The compound is stable 
and can be stored at room temperature for long periods of time.
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n Et3N/Boc20
T CHgClg
2.1.3 2.1.19
Scheme 2.1.14
In an initial attempt to form the anion, l-ter/-butyloxycarbonyl-2-methyl-2- 
imidazoline (2.1.19) was treated at -78°C in dry THF with 1.1 equiv. of /z-butyllithium to
overnight did not produce the desired C(2a)-alkylated compound. The same procedure was 
repeated with lithium diisopropylamide (LDA) as base and a brown solution was again 
produced but no product was isolated after quenching with 3-bromopropene. In both cases 
starting material was recovered. The brown colour could suggest aggregation of the base 
which may inhibit anion formation.
The effect of a stronger base was investigated in the hope that this would facilitate 
the anion formation. 1 -Boc-2-methyl-2-imidazoline was treated at -78°C in dry THF with
1.1 equiv. of sec-butyllithium. A bright yellow solution was obtained which was 
maintained at this temperature for 20 min. The 2-lithiomethyl-1 -Boc-2-imidazoline 
(2.1.20) may be stabilised by interaction with the carbamate carbonyl forming a six- 
membered intermediate (Scheme 2.1.15).76 3-Bromopropene was then added and the 
reaction mixture was allowed to warm to 20°C overnight, as it was found that shorter times 
resulted in lower yields. Aqueous work up, followed by purification using column 
chromatography on silica gel produced the desired 1 -Boc-2-(but-3-enyl)-2-imidazoline 
(2.1.21a) as a colourless oil in 82% yield (Scheme 2.1.15). 3-Bromopropene was the first 
electrophile to be used because the resulting product would be useful for another part of the
The same brown colour seen previously when w-butyllithium or LDA were used as 
bases, was observed on some occasions with seobutyllithium. Addition of
give a brown solution. Quenching with 1.2 equiv. of 3-bromopropene and stirring
project.
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tetramethylethanediamine (TMEDA) solved the problem. TMEDA proved to be an 
essential additive in this reaction because it leads to higher yields. Presumably the TMEDA 
deaggregates the sec-butyllithium producing the monomeric species and hence 
strengthening the base.
In order to investigate the scope and limitations of the Boc moiety as a replacement 
for the benzyl group in imidazoline N-protection, it was decided to prepare a number of 2- 
substituted-2-imidazolines using the chemistry described in Scheme 2.1.15.
Scheme 2.1.15
Metallation of l-Boc-2-methyl-2-imidazoline in the usual way (sec-butyllithium, 
THF/TMEDA, -78°C) was followed by addition of alkyl halides (3-bromoprop-l-ene, 1- 
iodopropane, 4-bromobut-1 -ene, benzyl bromide, 2-(phenyl)benzyl bromide, furfuryl
(Table 2.1.1). Furfuryl chloride was prepared from furfuryl alchohol, pyridine and thionyl
probably due to the poor quality of the bromide. When pure bromide was obtained by
sec-BuLi
TMEDA
2.1.19 2.1.20
R X
2 .1.22
TFA r~\
chloride, l-bromohexa-2,4-diene and 5-bromopenta-1,3-diene) to afford after work up and
purification the l -Boc-2-alkyl-2-imidazolines (2.1.21a-h), respectively in good yields
chloride using the method described by W. Kimer.77 l-Bromohexa-2,4-diene was 
synthesised from commercial hexa-2,4-dien-l-ol and phosporous tribromide.78 The 
reaction with l -bromohexa-2,4-diene initially produced the desired product in low yield
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careful distillation the yield of (2.1.21g) increased significantly. 5-Bromopenta-1,3-diene 
was made from commercial penta-1,4-dien-3-ol and phosphorous tribromide using the 
method described by Prévost and Bidon.79 The alkylation reaction proceeded well and the 
desired compound was obtained in 60% yield. Imidazolines (2.1.2If), (2.1.21g) and 
(2.1.21h) all contain diene functionalities that could potentially undergo intermolecular or 
intramolecular Diels-Alder reactions.
When methyl 4-bromobut-2-enoate and 3-chloroprop-1 -yne were used as 
electrophiles no reaction was observed. In the case of 3-chloroprop-1 -yne the reaction 
mixture turned brown when the chloride was added and starting material was recovered. It 
is possible that the chloride polymerises under the strongly basic reaction conditions.
Table 2.1.1
compound R1 yield
2.1.21a CH2CH=CH2 82%
2.1.21b CH2CH2CH3 86%
2.1.21c CH2CH2CH=CH2 64%
2.1.21d CH2Ph 92%
2.1.21c CH2(2-Ph)Ph 81%
2.1.211 CH2Furyl 71%
2.1.21g CH2CH=CHCH=CHCH3 81%
2.1.21h CH2CH=CHCH=CH2 70%
Deprotection of the 2-alkyl-1 -ferf-butyloxycarbonyl-2-imidazolines was achieved 
with excess of neat trifluoroacetic acid (Scheme 2.1.15). The Boc group is cleaved within 
20 min. under these conditions. When the reaction was completed the trifluoroacetic acid 
was removed under reduced  pressure and the imidazoline trifluoroacetate salt was
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dissolved in dichloromethane. The free imidazolines were liberated by washing the organic 
layer with a 10% solution of aqueous NaOH (Table 2.1.2).
Table 2.1.2
compound R1 Yield
2.1.4 CH2CH=CH2 82%
2.1.15 CH2CH2CH3 87%
2.1.22a CH2Ph 73%
2.1.22b CH2(2-Ph)Ph 87%
2.1.22c CI^Furyl 65%
2.1.22d CH2CH=CHCH=CHCH3 67%
Imidazolines (2.1.22a), (2.1.22b) and (2.1.22c) were synthesised because of the 
reported hypoglycemic activity exhibited by 2-imidazoline derivatives with bulky aryl and 
heterocyclic groups located at a distance of two carbon units from position 2 in the 
imidazoline ring.80 Compounds (2.1.22c) and (2.1.22d) contain diene functionalities at 
C(2) and are precursors to the proposed templates for intramolecular Diels-Alder reactions.
A small amount of the dialkylated imidazoline (2.1.23a) was isolated when excess 
(1.3 equiv.) of seobutyllithium was added to 1 -Boc-2-methyl-2-imidazoline (2.1.19), 
followed by 3-bromopropene. In order to exploit this result and to test whether formation 
of C(2a)-dialkylated 2-imidazolines can be achieved in one pot, a reaction was carried out 
with 1 -Boc-2-methyl-2-imidazoline using 2.2 equiv. of sec-butyllithium under the usual 
conditions followed by quenching with 2.2 equiv. of 3-bromopropene. The reaction 
produced the dialkylated compound (2.1.23a) in 22% yield and the monoalkylated product 
(2.1.21a) in 56% yield. The overall yield for the dialkylated imidazoline (2.1.23a) was 
increased when it was synthesised in two steps from the 2-methyl compound, by
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metallation of (2.1.21a) with sec-butyllithium in THF/TMEDA at-78°C and quenching 
with freshly distilled 3-bromopropene (Scheme 2.1.16).
N Boc
2.1.21
r \  n
i) sec-BuLi/TMEDA TFA N>x/ NH
ii) R X
'R 1 R2 / f l1
2.1.23 2.1.24X
Boc
Scheme 2.1.16
Compound (2.1.23c) was prepared in the same way from (2.1.21a) and benzyl 
bromide. Imidazoline (2.1.23b) was again synthesised from (2.1.21b) and 3-bromopropene 
in good yield over two steps. Attempts to introduce a third group onto C(2a) in imidazoline 
(2.1.23a) failed. Presumably the C(2a) position is now too hindered and the electrophile 
cannot approach. Table 2.1.3 shows the dialkylated 1 -Boc-2-imidazolines (2.1.23a-c).
Table 2.13
compound R1 R2 Yield
2.1.23a CH2CH=CH2 c h 2c h = c h 2 22% one pot
2.1.23a CH2CH=CH2 c h 2c h = c h 2 84%
2.1.23b c h 2c h 2c h = c h 2 c h 2c h = c h 2 87%
2.1.23c c h 2c h = c h 2 CH2Ph 76%
Deprotection of the 2-(a-dialkyl)-l-/e^butyloxycarbonyl-2-imidazolines (2.1.23a- 
c) with trifluoroacetic acid followed by washing with a 10% w/v solution of aqueous 
NaOH affords the C(2a)-dialkylated-2-imidazolines (2.1.24a-c) (Table 2.1.4).
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Table 2.1.4
compound R1 R2 Yield
2.1.24a CH2CH=CH2 c h 2c h = c h 2 67%
2.1.24b c h 2c h = c h 2 c h 2c h 2c h = c h 2 81%
2.1.24c c h 2c h = c h 2 CH2Ph 67%
The Boc group thus provides a general and robust solution to the N-protection of 2- 
imidazolines during lithiation-alkylation studies.
2.1.4 Synthesis of 2-(2-oxoalkyl)-2-imidazolines
The varied biological activities shown by many 2-imidazolines and the possible 
uses of the 1 -Boc-2-lithiomethyl-2-imidazoline in carbon-carbon forming processes led us 
to explore the C-acylation which would provide a route to the synthesis of 2-(2-oxoalkyl)- 
2-imidazolines. 2-(2-oxoalkyl)-2-imidazolines have been synthesised by treatment of 
ketene N,0-acetals, or imino esters derived from benzoyl, and ester-substituted 
acetonitriles, with 1.2-diamines (Scheme 2.1.17).81
H2bL
AiCOCH2- ^ NHHCI +  
OEt
2.1.26
n
HM .NH
H2N
2.1.27 
Scheme 2.1.17
T
2.1.28
Related compounds had been previously made in our group by reaction of C(2a)- 
metallated 1 -benzyl-2-imidazolines with carboxylic acid esters, but the N-benzyl group was
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never removed (Scheme 2.1.18).82 These compounds were assigned to exist as their imino-
enol tautomer (2.1.29b). An X-ray structure in this series, however was unable to locate the 
exchangeable hydrogen atom.
The use of the Boc group as 2-imidazoline N-protection should allow the synthesis
such compounds. In an initial attempt to synthesise these compounds, the reaction of 1- 
Boc-2-lithiomethyl-2-imidazoline with propenoyl chloride was investigated. This produces 
a yellow polymeric material due to the extreme reactivity of propenoyl chloride, which 
appears to undergo polymerisation under the reaction conditions. In order to circumvent 
this problem the reaction was repeated and this time the 1 -Boc-2-lithiomethyl-2- 
imidazoline was quenched with methyl propenoate to afford the desired 2-(2-oxoalkyl)-2- 
imidazoline (2.1.30c) in 42% yield (Scheme 2.1.19). It is possible that the presence of the 
double bond in methyl propenoate could be responsible for the low yield obtained. On the 
other hand the reaction of l-Boc-2-methyl-2-imidazoline with ethyl acetate and methyl 
benzoate proceeded smoothly to give compounds (2,1.30a) and (2,1,30b) in 72% and 64% 
yield respectively as white crystalline solids (Scheme 2.1.19).
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Scheme 2.1.18
of 2-(2-oxoalkyl)-2-imidazolines with no N-substituent and provide an alternative route to
i) seoBuLi/TMEDA
Boc ii) R C 0 2Me
2.1.30s R=Me 
2.1.30b R=Ph 
2.1.30c R=CH=CH
iii) TFA
n
NH
2.1.31a R=Me 
2.1.31b R=Ph
Scheme 2.1.19
It appears that these compounds (2.1.30a-c) exist in their enaminoketone form 
based on evidence from IR, and 13C NMR spectra. Both compounds displayed in their 
I.R. spectra (KBr discs) sharp bands corresponding to a hydrogen bonded NH (3253 and 
3245 cm'1) and carbonyl stretching bands at around 1600 cm"1 characteristic of a 
vmylogous amide. The NMR spectra exhibited a one proton vinyl resonance and a 
broad one proton signal (NH) at 9.5 ppm typical of hydrogen bonded NH. The 13C NMR 
spectra showed signals at 186.3 and 195.6 ppm which correspond to two carbonyl groups.
To support these conclusions a crystal structure was obtained on compound 
(2.1.30b), which was recrystallised from hexane-methanol, and confirmed the proposed 
structure (Figure 2.1.1). For x-ray bond lengths and angles of compound (2.1.30b) see 
appendix.
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Figure 2.1.1
It can be seen from the crystal structure that the compound exists in its enamine 
form with one vinyl hydrogen and an NH. Intramolecular hydrogen bonding is indicated by 
the proximity (1.94 Â) of the NH and keto carbonyl. This sets the enamine with the bulky 
phenyl and Boc groups anti to each other. The spectral data obtained are very similar to the
1-benzyl compounds (2.1.29) and the structures formely assigned as enol-imines should 
probably be revised to the enamino-ketones tautomers.82
Deprotection of (2.1.30a) and (2.1.30b) using acidic conditions (TFA) proceeded 
smoothly to give the desired products (2.1.31a) and (2.1.31b) in 81% and 89% yields, 
respectively. They also exist in their enamine form (Scheme 2.1.19) based on the evidence 
from !H and 13C NMR spectroscopy. Hydrogen bonding between the carbonyl oxygen and 
an NH is also present.
2.1.5 Synthesis of 2-alkenyl-2-imidazolines
We wished to extend this work to produce 2-alkenyl-2-imidazolines in order to 
examine their potential as acceptors in conjugate additions,83 and as dienes and dienophiles 
in Diels-Alder reactions. They were also of interest to us because of their reported
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biological activities, e.g. anthelmintic84 or hypoglycemic.85 It was anticipated that the 
incorporation of a heteroatom at the a-carbon of 1 -Boc-2-methyl-2-imidazoline would 
provide a good route to the desired 2-alkenyl-2-imidazolines. Other methods used for the 
synthesis of 2-alkenyl-2-imidazolines were long and the conditions used were rather harsh 
(high temperatures).86
1 -Boc-2-Methyl-2-imidazoline (2.1.19) was treated with 1.1 equiv of sec- 
butyllithium followed by diethyl chlorophosphate (1.1 equiv.) and quenching with water 
afforded phosphonate (2.1.32) in 50% yield. The pure compound was isolated after column 
chromatography along with some unidentified impurities. Attempts to improve the yield 
and quality of (2.1.32) proved unsuccessful. The phosphonylated compound (2.1.32) was 
then lithiated with 1.1 equiv. of seobutyllithium and the phosphonate salt produced was 
quenched at -78°C with butanal, 2-butenal and benzaldehyde. After allowing the reaction 
to warm up to 25°C overnight, the 2-alkenyl-1 -Boc-2-imidazolines (2.l.33a-c) were 
isolated after column chromatography on silica gel in 67%, 65% and 66% yield (Scheme 
2.1.20). Benzaldehyde and 2-butenal gave only the E  alkenes whereas when butanal was 
the carbonyl component both E  and Z isomers were obtained initially in a 2:1 ratio. The Z 
isomer slowly converts to the thermodynamically more stable E  isomer upon standing at 
25°C for a few days. The preparation of 2-alkenyl-1 -Boc-2-imidazolines (2.1.33a-c) was 
also carried out in one pot from 1 -Boc-2-methyl-2-imidazoline (2.1.19), thus making the 
synthesis even shorter. sec-Butyllithium (1.1. equiv.) was added to 1 -Boc-2-methyl-2- 
imidazoline (2.1.19) followed by addition of diethyl chlorophosphate at -78°C and the 
reaction mixture was stirred at that temperature for Ih. A further 1.1 equiv. of sec- 
butylithium was injected at 78°C and the orange anion produced was quenched with 
freshly distilled aldehydes. Work up and column chromatography afforded the desired 
compounds (2.1.330a-c) in comparable overall yields (33%, 32% and 40%) to the two-step 
sequence.
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Scheme 2.1.20
When deprotection of (2.1.33a), (2.1.33b) and (2.1.33c) with trifluoroacetic acid 
was followed by chromatogaphy on silica gel the reactions failed to produce the desired 
products (2.1.34a), (2.1.34b) and (2.1.34c), respectively. Aqueous work up also led to 
decomposition of the material and was therefore avoided. It is suspected that one mode of 
decomposition is addition of water taking place on the column followed by a retro-aldol 
reaction possibly via the the “retro-ene” pathway drawn in Scheme 2.1.21, as has been 
suggested earlier,87 although this is not proven.
n / \HNX v^N
R R
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Scheme 2.1.21
This problem was overcome by carrying out the chromatography on alumina 
(activation grade ID) eluting with 3:97 v/v isopropylamine:ethyl acetate. The basic 
conditions that were used to carry out the column are also sufficient to liberate the free
in 82%, 64% and 91% yield respectively. 2-(Pent-1 -enyl)-2-imidazoline (2.1.34a) is 
extremely hygroscopic and appears to be decomposing at room temperature. 2-(2- 
Phenylethenyl)-2-imidazoline (2.1.34c) appears to be the most stable. The conjugation 
through the phenyl group presumably provides extra stability.
A second approach to 2-alkenyl-2-imidazolines was also investigated. It was 
anticipated that the insertion of a sulfur or selenium atom at the a-carbon atom of l-Boc-2- 
methyl-2-imidazoline, followed by C-alkylation, selenium or sulfur oxidation and 
elimination would produce the desired 2-alkenyl-2-imidazolines. This approach had been 
unsuccessful in the N-benzyl series.
The reaction of the 2-lithiomethyl-l-Boc-2-imidazoline (2.1.19) with diphenyl 
disulfide produced both monosulfenated and disulfenated products (2.1.36) and (2.1.37) in 
38% and 28% yield, respectively (Scheme 2.1.22). The monosulfenated imidazoline was 
deprotected using the usual conditions (TFA) to give (2.1.37), which is a compound that 
has been tested for activity in mice against the nematode Nemotosproides dubiusP
imidazoline from the trifluoroacetate salt. The desired products (2.1.34a-c) were obtained
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2.1.37
Consistent with this result, the reaction of the 2-methyl-1 -Boc-2-imidazoline
(2.1.19) with diphenyl diselenide produced phenylselenenomethyl derivative (2.1.38) in 
52% yield and diselenenated product (2.1.39) in 8% yield (Scheme 2.1.23). The 
disubstituted products could be formed because the insertion of one heteroatom makes the 
a  carbon more acidic and proton exchange between the 2-lithiomethyl compound and the 
monosubstitution product allows a second substitution to compete.
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The ability of selenium to stabilise adjacent negative charges and the weakness of 
the Se-C bond, as well as the ease with which selenides undergo oxidation to selenoxides 
with subsequent facile selenoxide ^-elim ination (often at room temperature or below), 
compared to the more vigorous conditions required for sulfoxide elimination (often at 
reflux in toluene), directed our attention towards the monoselenenated compound (2.1.38) 
as our starting material for the synthesis of 2-alkenyl-2-imidazolines.
Insertion of an alkyl group onto (2.1.38) at the a-carbon was easily achieved. 
Lithiation of (2.1.38) in the usual way (sec-BuLi, THF/TMEDA, -78°C) gave the 
lithio(phenylselenenomethyl)-2-imidazoline; addition of an alkyl halide (benzyl bromide,
1-iodopropane and 3-bromopropene) produced compounds (2.1.40a-c) in good yields
(79%, 80%, 90%) (Scheme 2.1.23). The NMR spectra of all these compounds (2.1.40a- 
c) show a CH signal which appears to exist as a broad singlet rather than a triplet or double 
doublet.
Oxidation of compound (2.1.40a) was attempted with 3-chloroperbenzoic acid in 
dichloromethane at 0°C, in order to generate a selenoxide and hence achieve selenoxide 
elimination. This produced only starting material and some unidentified impurities.
Instead deprotection (removal of the Boc group) with neat trifluoroacetic acid 
produced the 2-imidazolines (2.1.41a), (2.1.41b) and (2.1.41c) in 71%, 91%, and 80% 
yield, respectively (Scheme 2.1.23). Oxidation with 3-chloroperbenzoic acid in 
dichloromethane at 0°C followed by column chromatography on alumina now produced 
the desired 2-alkenyl-2-imidazolines (2.1.42a-c) in 90%, 92% and 92% yield, respectively 
(Scheme 2.1.23), presumably via selenoxide formation and spontaneous elimination. 
Aqueous work up and chromatography on silica gel were again avoided to prevent 
hydrolysis of these compounds.
When we attempted to introduced a second alkyl group onto imidazoline (2.1.40c) 
by treatment with 1.1. equiv of sec-butyllithium followed by addition of 3-bromopropene, 
the dialkylated imidazoline (2.1.24a) was obtained in 60% yield (Scheme 2.1.24). No trace 
of the expected product (2.1.43) was observed. A transmetallation reaction of the selenide 
must have occurred. The resulting lithioalkylimidazoline (2.1.44) was then trapped with 3- 
bromoprop-1 -ene to give the observed compound (2.1.24a). Such transmetallation 
reactions of selenides have been reported in the literature.88
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Scheme 2.1.24
This concluded our survey of the reactivity of 1 -Boc-2-methyl-2-imidazoline in 
lithiation reactions.
2.2 Reactions of 2-imidazolines with double electrophiles
2.2.1 Synthesis of tetrahydroimidazo [1,2-s]pyridines
A new and reliable protocol has been developed for the synthesis of 2-substituted 2- 
imidazolines that contain a diene or a potential dienophile at the C(2)-position for the 
proposed Diels-Alder reactions. A method to introduce a diene onto the nitrogen centre 
was needed in order to synthesise the target template (1.159) which was expected to 
undergo intramolecular Diels-Alder reaction. This system, if it were to undergo Diels- 
Alder reaction could, after cleavage of the imidazoline template, provide the 
tetrahydroquinoline moiety.
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It was anticipated that 2-(but-3-enyl)-2-imidazoline (2.1.4) when heated with 2- 
butenal in toluene at reflux, under Dean-Stark conditions for water removal, would provide 
the dienamine (1.159).
N>x ,NH
2.1.4
Toluene
Reflux
*
|SL\
2.2.1
1.159 
Scheme 2.2.1
A reaction was indeed observed but no trace of the expected compound was 
isolated. The only product that was isolated was the tetrahydroimidazo[l,2-o]pyridine 
(2.2.1) in 36% yield.
^ J L  r y
Toluene
Reflux
2.1.4
Scheme 2.2.2
The structure of bicycle (2.2.1) is supported by and 13C NMR spectra; for 
example there are signals consistent with the C=CH (doublet of doublets) and NCH 
fragments, that would not be present in alternative isomers arising from the reaction of
(2.1.4) with but-2-enal with the opposite regiochemistry that would contain two alkenic 
signals and no NCH signal.
The most likely mechanism for the formation of the annulation products (2.2.5) is 
conjugate addition of the imidazoline NH to the aldehyde double bond, followed by an 
enamine-aldol reaction of C(2tx) as a nucleophile, with dehydration (Scheme 2.2.3).
O f T ^  r2
2.2.2 2.2.3
2.2.5
-H20 HN
OH
2.2.4b
Scheme 2.2 J
The opposite order of bond formation could not be ruled out at this stage, although 
results reported later in this thesis support initial conjugate addition by the nitrogen atom. It 
is possible that the enamine does a nucleophilic attack on the carbonyl group to initiate the 
annulation but dehydration would have to occur at this stage to allow subsequent N(l) 
addition on the double bond. It seems unlikely that the reaction proceeds via the latter 
route.
The reaction can be rationalised if we consider the terms “hard” and “soft” acids 
and bases. The 2-alkyl-2-imidazolines are soft bases as the lone pair of electron is 
delocalised between the two nitrogen atoms (Scheme 2.2.4). a,P-Unsaturated carbonyl 
compounds have a hard electrophilic centre at the carbonyl carbon and a soft electrophilic 
centre at the P-carbon. Soft bases such as imidazolines react with soft electrophiles in a 
Michael-type addition.
O
NLv .NH
soft nucleophile 
delocalised 8 -
hard electrophile 
localised 8+
soft electrophile 
delocalised 84-
Scheme 2.2.4
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Due to the pharmaceutical activities displayed by many heteropolycyclic 
compounds, it was of interest to us to investigate the applicability of the observed reaction. 
It was therefore repeated with a range of 2-alkyl-2-imidazolines, namely 2-butyl, 2-(but-3- 
enyl), 2-(2-phenylethyl), 2-[2-(2-phenyl)phenylethyl] and 2-benzyl-2-imidazolines. The ot,P 
-unsaturated aldehydes were 2-butenal, pent-2-enal and 3-phenylprop-2-enal. The same 
annulation reaction was observed in all cases to afford tetrahydroimidazopyridines (2.2.5; 
R2=H) (Table 2.2.1). 3-Phenylprop-2-enal reacted with 2-(but-3-enyl)-2-imidazoline to 
some extent to give the tetrahydroimidazo[l,2-o]pyridines (2.2.5b) in only 13% yield. The 
bulky phenyl group could be held responsible for the low yield by hindering the approach 
of the 2-imidazoline to the double bond.
2-Benzyl-2-imidazoline reacted with but-2-enal under the same conditions to 
produce a 2:1 mixture of the tetrahydroimidazo[ 1,2-a]pyridines (2.2.51) and the alcohol 
(2.2.6a) in 46% yield (Scheme 2.2.5). Some of the pure alcohol was isolated after careful 
chromatography in 37% yield. The stereochemistry of alochol (2.2.6a) has not been 
determined. The tetrahydroimidazo[ 1,2-a]pyridine (2.2.51) was isolated after extended 
reflux in toluene in 33% yield. Although compound (2.2.51) appeared to be pure by and 
13C NMR spectroscopy, mass spectroscopy showed a higher molecular weight impurity 
that did not allow us to fully characterised the compound. Extended reflux appears lead to 
slow decomposition of the compound. The conjugation with the phenyl ring stabilises the 
enamine form and inhibits the elimination of water that was proposed as the final step of 
the annulation (Scheme 2.2.3), making the synthesis of (2.2.51) more difficult.
Toluene
Reflux
H
2.1.7 2.2.51 
Scheme 2.2.5
2.2.6a OH
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2-Benzyl-2-imidazoline reacted with pent-2-enal under extensive reflux to give 
only the tetrahydroimidazo[ 1,2-a]pyridine (2.2.5J) in 15% yield. The intermediate alcohol 
was never isolated in this particular case. The extended reflux led to slow decomposition of 
the compound which could explain the low yield obtained.
The reaction of the 2-alkyl-2-imidazolines with a,p-unsaturated ketones was also 
investigated. But-3-en-2-one and pent-3-en-2-one reacted with 2-alkyl-2-imidazolines in 
the same fashion (Scheme 2.2.3 , RVH) to produce tetrahydroimidazo[l,2-<z]pyridines
(2.2.5) (Table 2.2.1).
Table 2.2.1
imidazoline R1 R2 R3 Imidazo[l,2-a]pyridine (yield)
2.1.15 CH2CH2CH3 Me H 2.2.5a 64%
2.1.4 CH2CH=CH2 Me H 2.2.1 36%
2.1.4 CH2CH=CH2 Ph H 2.2.5b 13%
2.1.4 CH2Ph Me H 2.2.5c 85%
2.1.22a CII2Ph CH2Me H 2.2.5d 91%
2.1.22a CH2Ph H Me 2.2.5e 38%
2.1.22b 2-PhC6H4CH2 Me H 2.2.5f 90%
2.1.22b 2-PhC6H4CH2 CH2Me H 2.2.5g 85%
2.1.22b 2-PhC6H4CH2 H Me 2.2.5b 66%
2.1.22b 2-PhC6H4CH2 Me Me 2.2.51 55%
2.1.7 Ph CH2Me H 2.2.5j 15%
2.1.7 Ph H Me 2.2.5k 88%
2.1.7 Ph Me H 2.2.51 33%
2.1.7 Ph Me Me 2.2.5m 86%
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In order to further investigate the sequence of bond formations in this annulation, 
some more experiments were carried out. 2-(But-3-enyl)-2-imidazoline was treated with 
but-2-enal in dichloromethane at 20°C in the presence of MgS04 and the intermediate 
alcohol (2.2.4a) was isolated in 27% yield which appears to exist in the imine form 
(Scheme 2.2.3). Similarly when 2-benzyl-2-imidazoline was reacted with but-3-en-2-one at 
20°C in dichloromethane the intermediate alcohol (2.2.4) precipitated out of solution as a 
white solid (42%). The white solid was filtered and the reaction mixture was purified by 
column chromatography to give only the dehydration product (2.2.5m) (21%). This alcohol 
is only soluble in warm methanol and NMR spectroscopy suggests that exists in 
equilibrium between its imine and enamine form (2.2.4a) and (2.2.4b). The equilibrium 
changes with time and the dehydrated product (2.2.5m) begins to form. Taken with the 
earlier findings using 2-benzyl-2-imidazolines, these results are supportive of the initially 
proposed mechanism but not conclusive.
This cyclocondensation reaction of 2-alkyl-2-imidazolines with ot,p-unsaturated 
aldehydes and ketones has not been reported before. It is in contrast with the reactions of 
enaminoester (2.2.7) with cx,P-unsaturated aldehydes and ketones. This enaminoester can 
be regarded as an imidazoline carrying an activating ethoxycarbonyl group at C(2a). With 
cx,P-unsaturated aldehydes and ketones the reactivity of (2.2.7) is dominated by conjugate 
addition of the enamine C(a) carbon atom to the carbonyl component (Scheme 2.2.6). ot,P- 
Enals afford the imidazo[ 1,2-a]pyridines (2.2.8);89 enones give the Michael adducts (2.2.9) 
but do not proceed to cyclisation.90 The regiochemistry of the initial reaction and eventual 
annulation with the enaminoester is thus opposite to that observed with simple 2-alkyl-2- 
imidazolines.
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2.2.2 2-Imidazolines in conjugate additions
As supportive evidence to the mechanism proposed above for the reaction with 0,0- 
unsaturatcd aldehydes and ketones, the reaction of 2-imidazolines with other unsaturated 
compounds conjugated with electron withdrawing groups was also investigated. 2-Benzyl-
2-imidazoline (2.1.7) and methyl propenoate react to give the conjugate addition product
(2.2.10) in 82% yield, when mixed in a concentrated solution of dichloromethane (Scheme 
2.2.7). In a similar fashion 2-benzyl and 2-(but-3-enyl)-2-imidazolines react with phenyl 
vinyl sulfonate and phenyl vinyl sulfone in dichloromethene to give the conjugate addition 
products (2.2.1 la-d) as colourless oils in 89%, 75%, 70% and 57% yield, respectively 
(Scheme 2.2.7).
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2.2.10 2.2.12
Scheme 2.2.7
The above observations reinforce the proposed annulation mechanism that the 2-
imidazoline adds first via a nitrogen atom to the double bond of the a,p-unsaturated 
carbonyls. Related results using alkynes conjugated to withdrawing groups have also been 
observed; these results are discussed separately, later in this thesis (Section 2.4).
It was anticipated that the ester (2.2.10) might undergo cyclisation (via enamine 
formation) upon heating in the presence of p-toluenesulfonic acid to give bicycle (2.2.12) 
(Scheme 2.2.7). Unfortunately the reverse of the conjugate addition reaction was observed 
after heating to reflux in toluene. 2-Benzyl-2-imidazoline was the only product isolated in a 
very low yield. The effect of base on the ester (2.2.10) was also studied. Sodium methoxide 
(2 equiv.) was added to a solution of (2.2.10) in dry methanol but again no cyclised product 
was observed. A stronger base such as sec-butyllithium (1 equiv.) was used which also 
failed to give the desired compound. Only when 2 equiv. of sec-butyllithium were added to
(2.2.12) was cyclisation achieved, but in only 34% yield. This compound appears to exist 
in its enamine form. A broad NH peak at 4.85 ppm and the disappearance of the ct-CH in 
the H NMR spectrum suggest the compound favours the enamine form. Evidence from the 
I.R. spectrum (KBr disc) that shows a broad NH peak at 3200 cm"1 and the broad
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vinylogous amide CO stretching band at 1563 cm'1, combined with that from the 13C NMR 
spectrum that exibits a carbonyl carbon resonance at 185.7 ppm, characteristic of a 
carbonyl group rather than an enol, indicates that the enaminoketone form is predominant. 
The result agrees with the tautomer observed in the 2-(oxoalkyl)-2-imidazolines (Section 
2.1.4).
The presence of the ester functionality on imidazoline (2.2.10) and the desire to 
form a variety of fused 2-imidazolines prompted us to reduce the ester to the alcohol
(2.2.13). Treatment of (2.2.10) with 2-equiv. of LiAlH4 afforded the alcohol (2.2.13) in 
55% yield (Scheme 2.2.8).
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The alcohol was then converted into the mesylate (2.2.14) using triethylamine and 
methanesulfonyl chloride (1.1 equiv.) compound at 20°C in 52% yield. This conversion 
proved to be problematic since it produced unidentified mixtures when excess of 
methanesulfonyl chloride was used, or when aqueous work up was carried out. Although 
the ^  NMR spectrum supported the structure, mass spectroscopy did not show the 
expected molecular ion; we did not pursue cyclisation of the putative mesylate (2.2.14).
2.2.3 Tetrahydroimidazo[l,2-a]pyridin-5-ones
The cyclisation reported in the previous section 2.2.1 prompted us to study the 
reaction of 2-alkyl~2-imidazolines with different 1,3-bis-electrophiles such as P-ketoesters 
in order to gain a better understanding of the behaviour of .^-imidazolines and their
synthetic utility, for the synthesis of heterocyclic systems such as those containing the
biological properties.
It was initially expected that the reaction between a 2-imidazoline and (3-ketoester 
would proceed via formation of the intermediate enaminoketone (2.2.15) which could 
tautomerise to the enediamine (2.2.16). The intramolecular acylation of (2.2.16) 
accompanied by loss of ethoxide and a proton shift (2.2.17) would have resulted in the 
formation of the tetrahydroimidazo[ 1,2-a]pyridin-7-ones (2.2.18) (Scheme 2.2.9).93
A number of 2-alkyl-2-imidazolines, prepared using the method described in 
Section 2.1.3, were reacted with ethyl acetoacetate, ethyl benzoylacetate and ethyl 
cyclohexanone-2-carboxylate in refluxing toluene using a Dean-Stark trap to give what 
were initially thought to be tetrahydroimidazo[ 1,2-a]pyridin-7-ones (2.2.18) as high 
melting solids. In fact it was found that the reaction proceeds via the alternative
reduced pyridine moiety. Dihydropyridines have shown coronary vasodilator activity91 and 
are the most potent calcium channel blockers92 and it was in our interest to incorporate the 
reduced pyridine moiety on the 2-imidazoline molecule in an effort to combine their
Toluene
Reflux
Scheme 2.2.9
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regiochemistry to afford 1,2,3,5-tetrahydroimidazo[ 1,2-a]pyridin-5-ones (2.2.19) and
(2.2.20) (Table 2.2.2 and Scheme 2.2.10).
r \
.1/
Toluene
Reflux
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HN.
2.2.19
Et02C
OX)
Toluene
Reflux
HN
2.2.20
Scheme 2.2.10
Table 2.2.2
Imidazoline R1 R1 Imidazo[l,2-a]pyridin-5-one 2.2.19 or 
2.2.20 (%yield)
2.1.4 CH2CH=CH2 Me 2.2.19a (44%)
2.1.4 CH2CH=CH2 Ph 2.2.19b (86%)
2.1.22a CH2Ph Ph 2.2.19c (75%)
2.1.7 Ph Me 2.2.19d (56%)
2.1.7 Ph Ph 2.2.19e (58%)
2.1.22a CH2Fh 2.2.20a (75%)
2.1.22b 2-PhC6H4CH2 2.2.20b (88%)
2.1.7 Ph 2.2.20c (66%)
It is not clear whether N-acylation occurs first followed by enamine-aldol 
condensation or vice versa. Enamine or imine formation is generally a reversible proccess 
and although in this case it may be the kinetic pathway (a), under the reaction conditions it
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may be reversed and the imidazoline NH react with the ester to form the more stable amide 
bond (pathway b) (Scheme 2.2.11). Intramolecular enamine-aldol condensation would then 
give then the l,2,3,5-tetrahydroimidazo[l,2-o]pyridin-5-ones (2.2.19). No intermediates 
have been isolated to support either of the two pathways.
a
OR
HN.
HN. HN.
2.2.19
Scheme 2.2.11
The regiochemical assignment of (2.2.19a-e) and (2.2.20a-c) was based on n.O.e 
experiments carried out on molecules (2.2.19a) and (2.2.19d). In both cases irradiation of 
the alkenyl-CHs gave enhancement of the pyridone alkenyl CH and a smaller enhancement 
of the adjacent vinyl or aromatic group.
Irradiated Enhanced
hny % ^ °  c h
I T  M e
CH2CH 
HNCH2 
2.2.19a NCH2
Me (3.4%)
CH (1.9%), CH2CH (1.4%) 
Me (3.2%), NH (1.9%) 
NCH2 (6.8%), NH (1.9%) 
HNCH2 (7.9%)
Figure 2.2.1
Irradiation of the pyridone alkenyl CH in compound (2.2.19a) gave enhancement of 
the methyl signal (3.4%) (Figure 2.2.1). Irradiation of the alkenyl CH3 in compound 
(2.2.19a) produced a 1.9% enhancement of the pyridone alkenyl CH signal and a 1.4% 
enhancement of the CH; of the adjacent allyl group. When the allyl CH2 was irradiated 
enhancement of 3.2% of the methyl group was observed. These results prove that the allyl 
and methyl groups are adjacent to each other. The irradiation of each of the 
“diaminoethane” backbone methylene signals resulted in enhancement of the other (7.9% 
and 6.8%).
In agreement with these results, the ^H n.0.e.experiments carried out on 
imidazo[ 1,2-a]pyridin-5-one (2.2.19c) revealed the same interactions and support the same 
regiochemistry (Figure 2.2.2).
Irradiation of the alkenyl CH3 in compound (2.2.19c) produced a 3.3% 
enhancement of the alkenyl CH signal and a 2.8% enhancement of the aromatic protons, 
confirming that the methyl and phenyl substituents are adjacent, which would not be the 
case in the 7-keto regioisomer. Irradiation of the alkenyl CH gave enhancement of the 
methyl signal (6.2%). The irradiation of each of the backbone methylene signals resulted in 
enhancement of the other (7.3% and 6.5%). Nonetheless no enhancement of the methyl
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signal was observed upon irradiation of the backbone methylene signals, something that 
would have been expected if the opposite regiochemistry was present.
I \
HN
Me
2.2.19c
Irradiated
CH
Me
HNCH2
n c h 2
Enhanced______
Me (6.2%) 
CH (3.3%), Ph(CHs) (2.8%) 
NCH2 (7.3%), NH (2.1%) 
HNCH2 (6.5%)
Figure 2.2.2
In addition compounds (2.2.19) and (2.2.20) exhibit more extended 
conjugation in the UV spectrum (Xmax—330-340 nm). The possible paths for delocalisation 
of the electrons (a and b) around the ring gives these molecules a pseudoaromatic character 
(Scheme 2.2.12) and higher Xmnx than would be expected for the 7-keto regioisomers.
HN
a
Scheme 2,2,12
A single crystal X-ray diffraction study was performed on the tricyclic compound 
(2.2.20c) which was recrystallised from water-ethanol (Figure 2.2.3). The crystal structure 
confirmed the regiochemistry that had been deduced from the spectroscopic data. The 
amide bond is present as predicted from the n.0.e. studies reported above. The bond 
lengths and angles for the x-ray are given in the appendix.
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Figure 2.23
The regiochemistry of these tetrahydroimidazo[l,2-a]pyridin-5-ones (2.2.19a-e) and
(2.2.20) is the same as that reported for the major product (2.2.21) from the reaction of the 
enaminoester (2.2.7) with P-ketoesters (Scheme 2.2.1S).94
O
 ^ \ |H  Di ^ x / C 0 2Et
PhCH
EtO,
2.2.21
PhH2C ''N
EtOaC^
2.2.7
Scheme 2.2.13
Reduction o f compounds (2.2.20a-c) would provide the hydroisoquinoline moiety that 
occurs in the yohimbine alkaloids (Scheme 2.2.14).95 Attempts to hydrogenate compound 
(2.2.20c) produced starting material. Treatment with excess LiAlBU failed to reduced the 
amide bond even in THF at reflux. The pseudoaromatic character exhibited by compounds 
(2.219a e) and (2.2.20) makes their reduction difficult. Alternative ways to reduce this 
system were not pursued due to lack of time.
HN
I \
HN N
Ph Ph
2.2.20c 2.2.22
Scheme 2.2.14
2.3 Imidazolines in Diels-Alder reactions studies 
2J.1 Studies towards the synthesis of N-butadienyl-2-imidazolines and 
their use in intramolecular Diels-Alder reactions
When the approach to dienamine (1.159) from 2-(but-3-enyl)-2-imidazoline (2.1.4) 
and butenal failed, an alternative route was attempted. The reaction of (2.1.4) and 4,4- 
diethoxy-1 -butene could produce the desired product (1.159). Unfortunately when the two 
materials were heated to reflux in toluene in the presence of /7-toluenesulfonic acid under 
Dean-Stark conditions no product was isolated but only starting material (Scheme 2.3.1).
A different method for the synthesis of N-butadienyl-2-imidazolines had to be
2.1.4 1.159
Scheme 23.1
devised. The addition of primary or secondary amines to ethynyl ketones (2.3.1) is a well 
reported reaction in the literature.^ This smooth reaction which occurs at room
temperature leads to p-aminoethylenic ketones (2.3.2) (Scheme 2.3.2.)
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RNH2 +  HC=C—COR ----------------   RNHCH=CHCOR
2.3.1 2.3.2
Scheme 23.2
Even in compounds in which the double and triple bonds are cross conjugated with 
the carbonyl group such as in (2.3.3) the addition reaction is restricted solely to the triple 
bond even with excess of amine (Scheme 2.3.3).96
RNH2 +  HC=C—C—CH=CHCH3 -------------- » RNHCH=CH—C—CH=CHCH3
O 2.3.3 O
Scheme 2 3 3
This reaction was an attractive alternative for the synthesis of the target dienamine. 
In a similar fashion 2-(but-3-enyl)-2-imidazoline (2.1.4) reacted with butynone in dry 
methanol at room temperature to produce solely the Æ-isomer of imidazoline (2.3.4) in 89% 
yield (Scheme 2.3.4).
/ \
NK NH _____________ ^
2.3.42.1.4
Scheme 2J.4
Imidazoline (2.3.4) could in principle undergo a hetero-Diels-Alder reaction under 
the right conditions. The compound was heated in toluene for 48 h, but no cyclisation was 
observed (Scheme 2.3.5). The effect of a Lewis acid such as BFs-etherate was briefly 
investigated but this appeared to have no particular effect. It possible that elevated 
temperatures or high pressure could facilitate cyclisation but the lack of suitable local 
facilities prohibited such investigations.
Scheme 2.3.5
The conversion of the vinylogous amide (2.3.4) into the corresponding silyl enol 
ether (2.3.6) was attempted as it was felt this would lead to a very electron-rich diene. 
Lithium diisopropylamide (1.2 equiv), freshly prepared from w-butyllithium and 
diisopropylamine, was added to imidazoline (2.3.4) in THF at -78°C under nitrogen. The 
resulting suspension was quenched with trimethylsilyl chloride. Aqueous work up followed 
by chromatography did not produce the expected silyl enol ether (2.3.6) (Scheme 2.3.6) and 
starting material was recovered.
The reaction was repeated using 2.2 equiv. of LDA and 2 equiv. of trimethylsilyl
order to ensure that hydrolysis of the enol ether (2.3.6) did not occur. The solvent was 
removed under reduced pressure and the crude reaction mixture was dissolved in toluene 
and heated to reflux for 36 h. Consumption of the starting material occurred and the crude 
reaction mixture was purified by chromatography only to afford the 2-(but-3 -enyl)-2-
order to test whether the silyl enol ether was actually formed, an attempt was made to trap 
it with an electron-deficient dienophile such as methyl propenoate, but no Diels-Alder 
adduct was observed.
n ' V n ^ ^ y x >™ s
2.3.4 2.3.6
Scheme 2.3.6
chloride in an attempt to ensure enol ether formation. The aqueous work up was avoided in
imidazoline (2.1.4) in 22% yield. No evidence of a Diels-Alder reaction was observed. In
2.3.2 The intermolecular approach
Disappointed by this result, it was decided to carry out some model studies on a 
more easily accessible molecule, in order to find out whether the synthesis of the target 
dienamine is possible and if so to investigate its reactivity. 2-Benzyl-2-imidazoline (2.1.7), 
a commercially available material, was reacted with butynone in dry methanol to give the 
^-vinylogous amide (2.3.7) as a white solid in 79% yield. This is an exothermic reaction 
and the temperature was kept below 40°C.
f ~ \M x N H
PI
2.3.7
Ph"
2.1.7
Scheme 2.3.7
We again attempted to form the silyl enol ether (2.3.8), under similar conditions, 
using 2.2 equiv. of LDA and quenching with 2.2 equiv. of TBDMS-C1 at -78°C. The crude 
!H NMR spectrum showed consumption of the starting material but attempts to isolate the 
compound by carrying out chromatography on the crude reaction mixture, produced 
starting material (30%). Methyl propenoate was added to a solution of the reaction mixture 
in toluene and was heated to reflux in an attempt to trap the expected diene but also proved 
unsuccessful, resulting in starting material. It was not clear whether diene formation was 
achieved.
Ph'
2.37
OTBDMS
Ph 2.3.8
Scheme 2.3.8
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An alternative approach to the diene was pursued. A possible Emmons-Wadsworth 
reaction between the vinylogous amide (2.3.7) and diethyl methylphosphonate would lead 
to the target dienamine. When 1 equiv. of diethyl methylphosphonate was used with sec- 
butyllithium as a base to generate the phosphonate anion (THF, -78 C), starting material 
was isolated. It was felt that the Emmons-Wadsworth reagent may be basic enough to 
abstract the proton at the C(2) position before reacting with the carbonyl group to give the 
desired dienamine (2.3.9). The reaction was repeated using 2 equiv. of diethyl 
methylphosphonate and 2.0 equiv. of w-butyllithium in order to ensure C(2) deprotonation 
as well as phosphonate anion formation. This resulted in disappearance of the starting 
material. Column chromatography of the crude reaction mixture produced a less polar spot. 
The NMR spectrum revealed a mixture of materials that contained no new olefinic 
signals. The starting material signals were no longer observed, with the CH3 and PhCH] 
signals disappearing and the alkenyl CHa’s moving upfield. It was impossible to deduce the 
outcome of that reaction but it was clear that the expected diene was not produced.
Ph'
2.3.7
PI
2.3.9
Scheme 23.9
Addition of an organolithium reagent to the carbonyl group of (2.3.7) would 
produce an intermediate alcohol that could undergo dehydration to give the target 
dienamine. This type of addition to vinylogous amides has been reported to give in some 
cases 1,2-addition97 and in other cases 1,4-additions.98 When imidazoline (2.3.7) was 
treated with 2 equiv. of MeLi in THF at -78°C, the tertiary alcohol (2.3.10) was isolated as 
an impure material in 26% yield (Scheme 2.3.10). No further attempts were carried out to 
increase the yield.
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Scheme 2.3.10
Reduction of the carbonyl would provide an alternative approach to the target
our case reduction of the imidazoline (2.3.7) with 2 equiv. of LiAlH4 in THF proceeded 
smoothly and afforded the allyl alcohol (2.3.11) in 75% yield (Scheme 2.3.11). In an 
attempt to force the alcohol (2.3.11) to undergo dehydration, it was heated to reflux in 
toluene in the presence of / 7-toluenesulfonic acid. Consumption of the starting material 
occurred and a less polar spot appeared on the TLC plate. The only product isolated after 
column chromatography was 2-benzyl-2-imidazoline (2.1.7). The presence of water in the 
reaction mixture, either from the /7-toluenesulfonic acid monohydrate or that produced 
from the dehydration of the alcohol (2.3.11), could be responsible for the enamine 
hydrolysis. It appears from that result that the allylic alcohol (2.3.11) is unstable under 
acidic conditions and easily hydrolyses to the starting material in the presence of water.
dienamine (2.3.12). Reductions of such vinylogous amides have been reported to give in 
some cases allylic alcohols and in other cases resulted in reduction of the double bond." In
n
r~\ I \
Ph Ph2.3.13 2.3.12
Scheme 2.3.11
Frustrated by this result and being one step away from the desired N-butadienyl-2- 
imidazoline (2.3.12), an alternative synthesis was investigated. Conversion of the alcohol 
(2.3.11) to the mesylate (2.3.13) and elimination of the mesyl group would produce the 
desired product (2.3.12). When compound (2.3.11) was treated with triethylamine and 
methanesulfonyl chloride in dichloromethane, the reaction unfortunately proved 
problematic and did not produce the expected product (Scheme 2.3.11). Instead a complex 
mixture was obtained that had no signal resembling either the starting material, the 
expected product or the N-butadienyl-2-imidazoline (2.3.12). This result was consistent 
with the previous effort to form an imidazoline mesylate in Section 2.2.2. No other 
approach to the dienamine was pursued due to lack of time.
2.3.3 2-Imidazolines in intramolecular Diels-Alder studies
The previous section has focussed on attempts to connect a diene at N(l) of an 
imidazoline, to partner a dienophile at C(2). Frustrations in those attempts led to an 
alternative approach to substrates for intramolecular Diels-Alder reactions. It has been 
shown in Section 2.1.3 that a diene can be easily introduced at C(2). A method for the 
introduction of a dienophile at N(l) was required. Amines have been found to undergo 
conjugate additions to activated acetylenic esters to give either transoid or cisoid 
products.100 This reaction, if applicable to 2-imidazolines, could prove synthetically useful 
for the introduction of the required dienophile at N(l) and therefore make the synthesis of 
the imidazoline templates (1.163) possible.
A model reaction was carried out, using 2-benzyl-2-imidazoline (2.1.7) as a starting 
material in order to test whether 2-imidazolines can undergo conjugate additions to 
acetylenic esters. Indeed when methyl propynoate was added to a solution of 2-benzyl-2- 
imidazoline in dry methanol, an exothermic reaction occurred and the temperature was kept
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below 40°C. The conjugate addition product (2.3.14) was isolated from the reaction 
mixture as a 2:1 ratio of separable Z:E geometric isomers in 65% yield.
NV NH _ H C ^ C -C 0 2Me . NV Nx^ C O , M e
MeOH
Ph 2.1.7 Ph 2.3.14
Scheme 2.3.12
This model experiment proved that 2-imidazolines could easily undergo conjugate 
additions to the triple bond of alkynyl esters and produce the target templates. The main 
disadvantage of such systems is the ability of the imidazoline nitrogen to donate electrons 
to the double bond, deactivating the dienophile (Figure 2.3.1).
n
NV ^ > ^ > t r 0MeJ  16
Figure 2.3.1
La a similar way imidazoline (2.1.22c), which contains a furan ring at C(2) that may 
be considered to be an electron-rich diene, reacted with methyl propynoate in dry methanol, 
to give compound (2.3.15) in a 2:1 ratio of separable Z\E isomers in 60% yield.
2.1.22c
/ \
HC=C—CQ2Me— ^  N ' V N ^ ^ C O , M e
MeOH
2.3.15 
Scheme 2.3.13
This com p o u n d  has the general structure of the initially proposed imidazoline 
templates that were suggested should undergo intramolecular Diels-Alder reaction. In an 
initial attempt to persuade these isomers (2.3.15) to undergo Diels-Alder reaction, they 
were heated to reflux in toluene for 18 h. No Diels-Alder adducts were observed but under
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these conditions conversion of the Z-isomer to the thermodynamically more stable E- 
isomer occurred. Starting materials were also isolated when the reaction was carried out in 
a sealed tube at 150°C. It has been reported in the literature that Diels-Alder reactions of 
the furan ring are best performed under pressure.101 Experiments were performed at the 
University of Reading on on both Z- and E-isomers of compound (2.3.15) at 19 kBar in 
dichloromethane which resulted in recovered starting materials unchanged except for the Z 
to E isomérisation.
The failure of that system to undergo intramolecular Diels-Alder reaction was 
attributed, at that particular time, to the ability of the furan cycloadducts to undergo retro- 
Diels-Alder reaction and revert to the starting material.
The introduction of an acyclic diene at the C(2) position would avoid this problem 
and enhance the possibility of a Diels-Alder reaction occurring. Imidazoline (2.1.22d) was 
reacted with methyl propynoate in dry methanol to give compound (2.3.16) as the separate 
Z\E isomers in a 2:1 ratio in 50% yield. Both Z- and E-isomers exist as a 3:1 mixture of 
heptadienyl-E^EyZ-isomers.
N>x ,NH HC=C—C 0 2Me
:02Me
2.3.16a-b
MeOH
2.1.22d
Scheme 2.3.13
The possibility of these two compounds (2.3.16a-b) undergoing Diels-Alder 
reaction under thermal conditions was investigated. When heated to reflux in toluene in a 
sealed tube at 150°C no reaction was observed. Lewis acids such as BF3 or AICI3 were also 
added but they led to diene polymerisation. No cycloadducts were isolated in either cases.
2.3.4 Molecular modelling studies
In an attempt to understand why these systems could not undergo intramolecular 
Diels-Alder reaction some simple molecular modelling was carried out. Typical minimum 
energy conformations for isomeric compounds (2.3.16a) and (2.3.16b) were calculated
are shown in (Figure 2.3.2). These two conformations were obtained by simply drawing the 
two starting materials and minimising their energy.
A different approach was also taken in order to access what other minimum energy 
conformation for compounds (2.1.16a) and (2.3.16b). The minimum energy conformation 
for the proposed cycloaddition products (2.3.17a) and (2.3.17b) were calculated. These two 
compounds were then disconnected at the bonds expected to be formed during the 
cycloaddition and the double bonds were introduced at the appropriate places. The 
minimum energy conformations were recalculated and are shown in Figure 2.3,3, It can be 
seen in this case that although the dienes fold in a slightly different way from the previous 
two conformations shown in Figure 2.3.2, they are pointing away from the dienophile 
which lies absolutely flat.
using Spartan 5.1 as the molecular modelling program and the semi-empirical routine and
2.3.16a 2.3.16b
Figure 2.3.2
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23.17b
2.3.16b 2.3.16b 
Figure 2 3 3
It was concluded from both efforts on the modelling that the dienophile moiety is 
flat and the diene appears to fold in such way that is actually pointing away from the 
dienophile. Although other minimum energy conformation may exist, it was not our target 
to establish that conformation, but to get a general idea how these molecules may like to 
fold in three dimensions.
An essential requirement for Diels-Alder reaction to take place is for the p-orbitals 
to approach each other head on, as shown in Figure 2.3.4. In the transition structure the p- 
orbitals have to be very close for the new a-bonds to be formed.
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Figure 2.3.4
In our case the chances of the diene and dienophile sitting above each other are
limited. The lack of flexibility from the dienophile makes the Diels-Alder reaction 
transition state difficult to access.
2.3.5 Alternative systems for intramolecular Diels-Alder reactions
It was suggested that the introduction of a CH2 group between the dienophile and 
the nitrogen would provide more flexibility and allow the diene and dienophile to approach 
in order to react. This system would not afford the original target molecules, but this 
approach was nevertheless of interest, since it would result in 5,7,6-tricyclic molecules.
N-Lithiation of 2-benzyl-2-imidazoline (2.1.7) with 1.1 equiv of sec-butyllithium 
and reaction with methyl 4-bromobut-2-enoate unfortunately did not produce the desired 
compound (2.3.18) and only starting material was isolated. This compound would have 
contained an electron-deficient dienophile on the nitrogen atom separated by a CH2 group 
from the ring rather than having the dienophile directly attached to the imidazoline 
nitrogen. In this case the electron donating effect of the nitrogen that was deactivating the 
dienophile would also be eliminated.
ii) BrCH2 CH=CHC0 2 Me
2.1.7 2.3.18
Scheme 23.15
It has been shown in Section 2.1.1 that N-allylated 2-imidazolines could be easily
synthesised. 2-Benzyl-2-imidazoline was treated with 2.2 equiv. of sec-butyllithium in 
THF at 0 °C and the dianion was quenched with 1.1 equiv. of 1,3-dibromopropane to give 
the l-(prop-2-enyl)-2-benzyl-2-imidazoline (2.3.19) in 48% yield as the product of N- 
alkylation and elimination. 1,3-Dibromopropane was used as the double electrophile in 
order to investigate whether doubly N- and C(2a) lithiated 2-imindazolines would be able 
to react twice and procuce a new six membered bicyclic 2-imidazoline. Compound (2.3.19) 
was lithiated again with 1 equiv. of w-butyllithium and addition of l-bromohexa-2-4-diene 
produced the desired template (2.3.20) in 50% yield. This system contained the dienophile 
one carbon atom away from the nitrogen atom although the absence of the congugating 
ester group would reduce the reactivity of the system. There have been reports of the same 
dienophile undergoing Diels-Alder reaction under thermal conditions.102 Nevertheless this 
molecule was heated in a sealed tube as a solution in toluene at 240°C for 48 h (Scheme 
2.3.16). No significant change was observed after that period and no indication that the 
cyclic product (2.3.21) was formed. The starting material remained unreacted.
NK. NH -----  '
Ü) BrGHgGHgCHgBr
/  \
i) n-BuLi
ii) BrCH2 CH=CHCH=CHCH3
/  \
2.3.20
Scheme 2.3.16
It was decided to see whether any change in reactivity would be observed if the
imidazoline was lithiated in the usual way, 1.1 equiv. of w-butyllithium, and alkylated with 
1 -bromohexa-2,4-diene to afford imidazoline (2.3.22) in 54% yield (Scheme 2.3.17). The 
resulting compound was alkylated at C(2a), by treatment with sec-butyllithium and 3- 
bromopropene to give the template (2.3.23) in 49% yield. The possibility of this system 
undergoing Diels-Alder reaction was investigated by heating a solution of (2.3.23) in 
toluene in a sealed tube at 240°C. Unfortunately the starting material remained unchanged 
and no cycloadduct (2.3.24) was observed.
The lack of activation on the dienophile and the presence of the methyl group on 
the diene (1,4-disubstitution) was thought to be possibly slowing the reaction down. Higher 
temperature and/or pressure may be required for the above systems to undergo 
cycloadditions. These conditions are less synthetically viable and were not explored here.
diene was placed on the nitrogen atom and the dienophile at the C-2 position. 2-Benzyl-2-
Ph
N  ^ NH i) 1.1 equiv. seo-BuLi______
ii) BrCH2 CH=CHCH=CHCH3
P 2.3.22
i) seoB uLi
ii) BrCHgCHzCHg
2.3.23
Scheme 23.17
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2.3.6 2-Imidazolines in intermolecular Diels-Alder studies
Our interest in forming rings associated with the imidazoline moiety and the lack of 
success with the intramolecular Diels-Alder approach directed our studies towards the 
intermolecular Diels-Alder reaction. It has been shown in Sections 2.1.3, 2.1.5 and 2.3.5 
that dienes can be easily introduced either at C(2) or at N(l) and was decided to investigate 
whether possible intermolecular Diels-Alder reaction would take place.
The first experiments were carried out on imidazoline (2.1.2If). Compounds 
containing furan rings have been reported to undergo Diels-Alder reactions, sometimes 
reversibly.103 An initial experiment was carried out by mixing imidazoline (2.1.2If) with 
methyl propenoate and stirring at 20°C for 24 h, which did not produce any cycloadducts 
but only starting material. Then the effect of higher temperatures was investigated. Methyl 
propenoate was added to a solution of compound (2.1.2If) in toluene and the resulting 
mixture was heated in a sealed tube at 120°C for 18 h. No reaction was observed under 
these conditions. Change of dienophile to dimethyl maleate did not prove successful. 
Dimethyl maleate is a good dienophile for undergoing Diels-Alder reactions with the furan 
ring.104 Addition of a catalytic amount of BFg-etherate and heating of the mixture in a 
sealed tube at 160°C resulted in cleavage of the terf-butyloxy group to give imidazoline 
(2.1.22c) and no cycloaddition products.
n n
N ^ N H  Y
Heat
+
2.1.211 2.3.25
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N -  NH
2.1.22c
Scheme 23.18
The furan ring was then introduced onto the nitrogen, in order to establish whether 
there would any effect in the reactivity of the furan ring. This was easily achieved by
equiv. of freshly prepared furfuryl chloride produced the desired compound (2.3.26) in 
60% yield along with the disubstituted imidazoline (2.3.27) in 9% yield (Scheme 2.3.19). 
Imidazoline (2.3.26) was heated in a sealed tube with ethyl propenoate and dimethyl 
maleate, in the absence or presence of either BFs-etherate or Et2AlCl but no cycloadducts 
(2.3.28) were obtained.
lithiation of 2-benzyl-2-imidazoline with 1.2 equiv of sec-butyllithium and addition of 1.2
PI
N>x ^ N H  j) 2 .2 equiv. seoB uLi
ii) Furfuryl chloride
2.3.26 2.3.27
\
X
X Heat
t
Scheme 2.3.19
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Directing our studies to the acyclic diene (2.1.21g) was thought to be more hopeful 
since the problem of cycloaddition reversibility would be eliminated. This type of diene has 
been repeatedly reported in the literature to undergo Diels-Alder reaction.105 A large 
number of experiments were carried out on imidazoline (2.1.21g) with a variety of 
dienophiles in attempts to generate adducts (2.3.29) (Scheme 2.3.20). These experiments 
are summarised in Table 2.3.1.
N Boc
2.1.21 g
Heat
NH X
2.3.29
Scheme 23.20
Table 23.1
Dienophile Solvent Lewis-
acid
Temperature/°C time/h Result
methyl propenoate toluene No 120°C 18 h No reaction
methyl propenoate toluene No 180/sealed tube 24 No reaction
methyl propenoate toluene BF3OEt2 180 /sealed tube 24 polymerisation
methyl propenoate toluene EtzAlCl 120 24 polymerisation
methyl propenoate trichlorobenzene No 200/sealed tube 48 No reaction
ethyl propenoate toluene No 120/sealed tube 48 No reaction
Maleic anhydride toluene no 160/sealed tube 24 polymerisation
tetracyanoethylene toluene BF3and
Et2AlCl
180/sealed tube 24 polymerisation
Dimethyl maleate toluene b f 3/s o 2 120/sealed tube 24 polymerisation
Tetracycanoethylene was also used as a dienophile, because it is a very electron deficient 
reagent due to the electron withdrawing ability of the four cyano groups on the double 
bond,106 but the diene polymerised and failed to undergo cycloaddition. A recent report that 
2,3-disubstituted-3-sulfolenes have been used as diene precursors in Diels-Alder reactions 
attracted our attention.107 In an attempt to form the 2,3-disubstituted-3-sulfolene we 
bubbled sulfur dioxide through a solution of diene (2.1.21g) in toluene at 0 C. A premixed 
solution of dimethyl maleate and BFg-etherate was added to the reaction mixture which 
was sealed and heated in a tube at 120 C. Removal of the solvent showed that the diene had 
polymerised.
Disappointed by the above results, we decided to introduce the diene onto the 
nitrogen atom , in the usual way, from 2-benzyl-2-imidazoline, sec-butyllithium and 1- 
bromohexa-2,4-diene, compound (2.3.22) was obtained as a yellow oil in 54% yield 
(Scheme 2.3.17). Attempted Diels-Alder reaction with methyl propenoate in the absence or 
presence of BFs-etherate did not give the cycloadduct (2.3.30). The Lewis acid catalyst 
again in this case caused diene polymerisation but no sensible cycloadduct was isolated.
N<y N—  ^ + |  ~ks”X-
J
Kn 2.3.22
Scheme 2.3.21
Unable to explain these negative results, it was suggested that the presence of the 
methyl group on the diene could be causing the problem by reducing the rate of the 
cycloaddition significantly and allowing polymerisation. The introduction of a diene that 
did not contain the methyl group could result in increase in reactivity and produce a 
cycloadduct.
It has been shown in Section 2.1.3 that imidazoline 2.1.21h, which contained a 
monosubstituted diene moiety at C(2), could be easily synthesised. Our studies were then
99
Ph 2.3.30
directed towards compound (2.1.21h). This particular type of diene has been used very 
often in both intermolecular or intramolecular Diels-Alder reactions.108 In an initial attempt 
to obtain a Diels-Alder cycloadduct a solution of imidazoline (2.1.21h) in toluene and ethyl 
propenoate (20 equiv.) was stirred at 20°C overnight but no reaction was observed. The 
solution was then heated in a sealed tube at 200°C but this resulted in polymerisation of the 
diene. When a premixed solution of BFg-etherate in 20 equiv. of ethyl propenoate was 
added to a solution of imidazoline (2.1.21h) in toluene and the mixture was heated to 
200°C, a possible Diels-Alder product (2.3.31) was isolated as a BF3 complex (Scheme 
2.3.29). Attempts to increase the yield of the reaction proved unsuccessful and small 
amounts of the cycloadduct were obtained as a mixture with diene rearrangement- 
polymerisation products. It was also found that the reaction was not reproducible. There 
appeared to be competition between diene polymerisation and cycloaddition.
When the reaction was carried out in the presence of BFg-etherate at 20°C, it has 
been possible to detect by TLC a very strong U.V. active less polar spot appeared. Column 
chromatography was carried out in order to isolate that newly formed material and a very 
small amount of the imidazoline BF3 complex was isolated. It appears that the particular 
complex breaks down in the column which explains the very small amount obtained. This 
observation suggested that Lewis-acids prefer to form stronger complexes with 2- 
imidazolines rather than coordinating with the dienophile which would result in 
acceleration of the Diels-Alder reaction.
2.1.21 h 2.3.31
Scheme 23.29
The diene was then attached on the nitrogen atom in the usual way, by lithiation of 
2-benzyl-2-imidazoline with «-butyllithium followed by addition of 5-bromohexa-1,3- 
diene, to afford imidazoline (2.3.32) in 57% yield (Scheme 2.3.27). The reactivity of 
compound (2.3.32) towards dienophiles was explored by carrying out some preliminary 
experiments. Ethyl propenoate and dimethyl maleate were used as dienophiles. Reactions 
carried out at 20°C in the absence of BF3 produced unreacted material. Heating the reaction 
mixture in toluene in a sealed tube at 200°C resulted in polymerisation of the diene even in 
the presence of catalytic amount of quinol as inhibitor. When B F 3 was present diene 
polymerisation or products were obtained but in all cases no sign of any of the desired 
cycloaddition products (2.3.33) were observed.
n
NK .NH
Ph
i) n-BuLi
ii) BrCH2 CH=CHCH=CH2
2.1.7
2.3.32
Ph
Ph 2.3.33
Scheme 2.3.23
2.3.7 2-Imidazoline templates for the synthesis of 5,5,6-systems
As was shown in Section 2.1.5, the introduction of a heteroatom such as 
phosphorus or selenium at the C(2cx)-position of the imidazoline allows the creation of
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double bonds directly attached to the imidazoline ring at C(2), and therefore makes the 
synthesis of alternative imidazoline Diels-Alder templates possible.
Initial attempts to introduce a dienophile onto imidazolines (2.1.34b) and (2.1.42c) 
at N(l) by metallation with /z-butyllithium at 0°C in THF, followed by addition of 1.1 
equiv. of 3-bromopropene did not proceed cleanly, producing traces of impure compounds 
(2.3.34a-b) that could not be utilised further (Scheme 2.3.24). It is possible that these 2- 
alkenyl-2-imidazolines are unstable under these metallation conditions.
i) n-BuLi
ii) BrCH2CH=CH2
i:!32=bS:SH- !li$5;SH*
Scheme 2.3.24
An alternative approach to these systems was devised by utilising the 2-(l- 
phenylselenenobut-3-enyl)-2-imidazoline (2.1.41c), whose synthesis has been described in 
Section 2.1.4. 2-(l-Phenylselenenobut-3-enyl)-2-imidazoline (2.1.41c) was treated with 1.0 
equiv. of sec-butylithium in THF at 20°C, and the lithioimidazoline salt was quenched with 
1.0 equiv. of 3-bromopropene to give the 2-(l-phenylselenenobut-3-enyl)-1 -(prop-2-enyl)- 
2-imidazoline (2.3.35) in 47% yield, based on recovered material. Oxidation of the 
selenium with 3-chloroperbenzoic acid in dichloromethane at 20°C, followed by 
spontaneous selenoxide elimination afforded the desired template (2.3.34b) in quantitative 
yield (Scheme 2.3.25),
ISK N H
ii) BrCH2CH=CH2
i) n-BuLi
Pnî>e
PhSe'
2.1.41c 2.3.35
iii) m-CPBA
2.3.34b
Scheme 23.25
It was felt that this synthesis could be made shorter by applying the dianion 
chemistry that had been effective in the dialkylation of 2-benzyl-2-imidazoline (Section 
2.1.1). 2-Phenylselenenomethyl-2-imidazoline (2.3.36), which was obtained by 
deprotection of the parent compound (2.1.38) with trifluoroacetic acid in 77% yield, was 
lithiated with 2,1 equiv of n-butyllithium followed by addition of 2.2 equiv of 3-bromo- 
propene to give compound (2.3.35) which was oxidised as before to obtain the compound 
(2.3.34b) (Scheme 2.3.26).
PhSe' 2.3.36
ii) 2.1 eq. n-BuLi
iii) 2. 2 eq. BrCH2CH=CH2
2.3.0HD
vi) m-CPBA
P n se  i 
2.3.35
Scheme 2.3.26
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In order to make the synthesis of compounds like (2.3.34b) even shorter, we 
attempted to introduce the selenium atom at C(2a) of 2-methyl-1 -(prop-2-enyl)-2- 
imidazoline (2.1.5) (Scheme 2.3.27) but treatment with sec-butyllithium and 
diphenyldiselenide failed to produce the expected compound (2.3.37), in accord with the 
result reported earlier in the N-benzyl series.109 The presence of the N-Boc group appears 
to be essential for the introduction of the selenium.
n
N <x i) seoB uLi y,
|  ii) P h S eS eP h  A
2.1.5 PhSe 2.3.37
Scheme 23.27
A solution of compound (2.3.34b) in dry toluene was then heated in a sealed tube at 
140°C. Removal of the solvent and crude ^  NMR spectroscopy showed that the 
compound had decomposed and that no cycloadducts (2.3.38) had been formed. We also 
investigated whether imidazoline (2.3.34b) could undergo intermolecular Diels-Alder 
reaction with an electron-rich dienophile, ethyl vinyl ether, at high temperatures. These 
experiments showed that the starting material had decomposed. It appears from the results 
obtained that compounds such as (2.3.34b) are unstable at high temperatures.
N
Heat „
A
2.3.34b 2.3.38
Scheme 2.3.28
2.3.8 Conclusions
Despite our efforts to utilise imidazoline templates that contained diene and dienophile 
functionalities in either intramolecular or intermolecular Diels-Alder reactions, for reasons 
we do not understand, no cycloadducts were obtained. Lack of sufficient conformational 
flexibility in the substrates may hinder intramolecular reaction, but this would not account 
for the failure to observe intermolecular cycloadditions. In only one case a cycloadduct was 
isolated but that was obtained as a complex and the result was not reproducible. It was 
found that the imidazoline molecule formed strong complexes with Lewis-acids therefore 
inhibiting any complexation with the dienophiles which could accelerate the reaction and 
reduce activation energies.
2.4 Reactions of 2-imidazolines with acetylenic esters
2.4.1 Reactions with non terminal propynoates
It has been shown in Section 2.3.3 that 2-imidazolines react readily with activated 
acetylenes to give the conjugate addition products. This ability of 2-imidazolines to add to 
the triple bond of activated acetylenic compounds was explored further. Using 2-benzyl-2- 
mudazoline (2.1.7) as a model substrate, two experiments were carried out in order to 
understand the behaviour of 2-imidazolines in the presence of non-terminal alkynyl esters. 
When ethyl pent-2-ynoate was added to a solution of 2-benzyl-2-imidazoline in methanol, 
the conjugate addition product (2.4.1a) was obtained after a week in 19% yield. Only one 
geometric isomer was obtained but we have been unable to deduce which one. Ester 
exchange also occurred and afforded the methyl ester. In a similar way, compound (2.4.1b) 
was isolated as a single isomer in 52%, when ethyl 3-phenylpropynoate was added to a 
solution of 2-benzyl-2-imidazoline in dry methanol (Scheme 2.4.1). Ester exchange 
occurred again and the methyl ester was isolated. In both cases only one isomer was 
isolated but it has been difficult to determine the stereochemistry of the double bond. It is 
most probable that it is the thermodynamically most stable E-isomer that has been isolated 
in both cases.
n  r~\
N<x / NH R =  COgEt N<x /N
MeOH
Ph Ph"
'CO,Me
R
2.1.7 2.4.1a, R = Et
2.4.1b, R = Ph
Scheme 2.4.1
The proposed mechanism for these additions involves an initial attack by the
imidazoline on the p-carbon of the acetylenic ester with initial formation of an
intramolecularly stabilised Z-intermediate (2.4.2a). This intermediate can then proceed to
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the Z-adduct (2.4.3a) by protonation (kinetic control) or isomerize to the ^-intermediate 
(2.4.2b). Protonation of the ^-intermediate leads to the is-adduct (2.4.3b) (Scheme 
2.4.2)."°
r™v
N ^ N H
R2
c o2r
2.4.2a
2.4.3a
2.4.2b
2.4.3b
Scheme 2.4.2
Other researchers have proposed that the solvent controls the stereochemistry of the 
products in the addition of amines onto activated acetylenic esters. It has been suggested 
that the methanol molecule (which was used as solvent in our case) functions as a proton 
donor in the six-membered transition state (2.4.4) to give predominantly .E-isomers.111 This 
does not agree with our results obtained with the terminal alkyne methyl propynoate where 
2:1 mixtures of Z:E isomers were isolated.
Me
2.4.4
COgR
2.4.3b
Scheme 2.43
Further experiments are required in order to confirm that these yields obtained are 
the optimum and to understand the effect of the R2 group on the 2-imidazoline conjugate 
additions.
Keteneaminals (2.4.5) containing the imidazolidine ring have been reported to react 
in completely the opposite way to the 2-imidazolines (Scheme 2.4.4).112 The a-carbon 
atom of these compounds possesses higher electron density and they act as C-nucleophiles 
which could attack electron-deficient compounds. Aminals (2.4.5) react smoothly with 
methyl propynoate in dioxane at ambient temperature to give the C-alkylated products 
(2.4.6) as their E-isomer. Where R1=H, Huang et a l have concluded that the reaction 
proceeds via an aza-ene mechanism.113 When the reaction is carried out in methanol at 
reflux, the C-adducts are converted into fused heterocycles (2.4.7) (Scheme 2.4.4).
n
H N _ , N COgMe
T
Dioxane
2.4.5
NH
COgEt
2.4.6
R = H, Me, PhCHg 
R2= Ar, EtO
2.4.7
Scheme 2.4.4
Cyclisation products similar to those isolated in the case of keteneaminals, have 
never been observed from the reaction of 2-alkyl-2-imidazolines and propynoates. The 
delocalisation of the pair of electrons from the ring nitrogen across the double bond in the
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initial adducts could be responsible for deactivating the ester functionality and inhibiting 
cyclisation (Scheme 2.4.5).
•OMeMe
Scheme 2.4.5
2.4.2 Reactions of 2-imidazolines with dialkyl acetylenedicarboxylate
Due to our interest in studying reactions of 2-imidazolines with electrophiles we 
investigated the behaviour of 2-alkyl-2-imidazolines with dialkyl acetylenedicarboxylates 
in order to utilise the outcome of those reactions in the synthesis of new heterocycles. 
Dialkyl acetylenedicarboxylates are more active electrophilic reagents than the activated 
acetylenic esters and were expected to react easily with 2-iimdazolines.
2-Benzyl-2-imidazoline (2.1.7) was reacted with diethyl acetylenedicarboxyalate in 
dry dichloromethane at 20°C. An exothermic reaction took place and the temperature was 
held below 30°C. The red solution that was produced was stirred overnight at 20°C and an 
orange precipitate was formed which was filtered immediately. This orange precipitate was 
found to be the cyclisation product (2.4.9). The mother liquor was concentrated and NMR 
spectroscopy showed that it contained the conjugate addition product (2.4.8) (Scheme 
2.4.6). The geometry of the conjugate addition product was assigned as £  by comparison of 
chemical shifts of the olefinic CH (5 = 5.05 ppm) of (2.4.8) with that of (2.4.13) (Ô = 4.91 
ppm) that was established by X-ray crystallography to be K (see later).
NnN /NH E t Q  c . HN
+COgEt
Ph2.4.8
2.4.9
f-BuOK
HN HN
Ph 2.4.10, R= Et, 
2.4.12, R = MePh2.4.11
Scheme 2.4.6
Compound (2.4.9) was recrystallised from methanol to give orange orthorhombic 
crystals which were submitted to X-ray crystallography. This confirmed the structure of 
the recrystallised bicyclic compound, which exists as the Z-isomer (Figure 2.4.1). (see 
appendix for bond lengths and angles).
Figure 2.4.1
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When a solution of adduct (2.4.8) in THF was added to a solution of potassium tert- 
butoxide in THF at 0°C, the cyclised products (2.4.9) and (2.4.10) were obtained as the 
separate Z  and E-isomers in a 5:2 ratio in 67% yield (Scheme 2.4.6).
The same reaction was repeated, this time using 2-benzyl-2-imidazoline and 
dimethyl acetylenedicarboxylate (Scheme 2.4.6). The reaction was stirred at 20°C for 72 h. 
In agreement to the previous result the Z-isomer of the cyclised product (2.4.11) 
precipitated out of the reaction mixture as an orange solid. The residue from the filtrate was 
recrystallised from methanol/hexane to give the E-isomer (2.4.12) as an orange solid. No 
conjugate addition products were isolated this time, just the cyclisation products in 57% 
combined yield. It appears that longer reaction times produce solely the cyclised 
compounds. The stereochemistry of the double bond was assigned by comparison of the 
chemical shifts of the olefinic CHs for (2.4.11) (8 = 5.49 ppm) and for (2.4.12) (8 = 4.98 
ppm) with those of (2.4.9) (8 = 5.48 ppm) and (2.4.10) (8 = 5.06 ppm), respectively.
The observed reaction proceeds via an initial conjugate addition of the imidazoline 
onto the triple bond followed by enamine attack on the carbonyl of the ot-ester to give the 
observed pÿrroloimidazoles (Scheme 2.4.7). The enamine has the choice of attacking the 
carbonyl of both esters but the delocalisation of the electrons across the double bond 
deactivates the P-ester (described in section 2.4.1) and cyclisation occurs only at the a- 
ester.
I l l
H N A zNx ^ v Vl(-I MO h
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Scheme 2.4.7
The presence of the phenyl group at C(2) position plays an important role in the 
formation of those cyclic pÿrroloimidazoles (2.4.9), (2.4.10), (2.4.11) and (2.4.12). The
a nucleophile and attack the ester carbonyl.
The reaction of other 2-alkyl-2-imidazolines with diethyl acetylenedicarboxylate 
was also investigated. 2-[(2-Phenyl)phenylethyl]-2-imidazoline (2.1.22b) was also reacted 
with diethyl acetylenedicarboxylate to give the conjugate addition product as the two 
isomers E  (2.4.13) and Z (2.4.14) in a 3:1 ratio in 65%. The is-isomer was the less polar 
compound and was obtained as a white crystalline solid which was recrystallised from 
hexane/ethyl acetate and geometry was assigned by obtaining an X-ray crystal structure 
(Figure 2.4.2). No cyclised products were isolated this time. The more polar material that 
was obtained as a yellow oil was assigned as the Z-isomer (2.4.14). The is-isomer of 
(2.4.13) was treated in THF at 0°C with potassium terf-butoxide to give the 
pyrroloimidazole (2.4.15) in 54% yield. The geometry of the double bond appears to be Z
conjugation with the benzene ring stabilises the formation of the en am in e  which can act as
by comparison of the chemical shift of the CH (8 -  5.77 ppm) of (2.4.15) with that of 
(2.4.9) (8 = 5.48 ppm) and of (2.4.17) (8 =5.83 ppm).
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Scheme 2.4.8
The stereochemistry of the double bond of (2.4.13) was determined by X-ray 
crystallography (Figure 2.4.2) and confirmed as the E-isomer.
COgEt
COgEt
Figure 2.4.2
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The above crystal structure shows that the system is well set for cyclisation, with 
the C(2) carbon and ot-ester being very close to each other, whereas the P-ester is coplanar 
with the N-C=C double bond, so conjugated and deactivated (see appendix for bond 
lengths and angles). The crystal structure also supports the result obtained from the 
molecular modelling (Section 2.34) that suggested that the dienophile was flat and lacked 
flexibility.
2-(But-3-enyl)-2-imidazoline was reacted in a similar way with diethyl 
acetylenedicarboxylate in dry dichloromethane at 20°C for 7 days to give after column 
chromatography the conjugate addition product (2.4.16) in 17% yield and the cyclisation 
compound (2.4.17) in 6% yield (Scheme 2.4.9). The low yields obtained were attributed to 
the poor quality of the starting material. The stereochemistry of these compounds was 
assigned based on comparison with the previous compounds. It appears that the conjugate 
addition product is the is-isomer based again on the chemical shift of the CH (8 = 5.02 
ppm) and the cyclised product is the Z-isomer (for CH, 8 = 5.83 ppm) (Scheme 2,4.9),
HNCOgEt
CHoCI-
2.1.4 2.4.16 2.4.17
Scheme 2.4.9
This reaction of 2-alkyl-2-imidazolines with diethyl acetylenedicarboxylate 
proceeds via a completely different route to the reported reaction of keteneaminals (2.4.5) 
with dimethyl acetylenedicarboxylate. Keteneaminals reacted with 1 molecule of dimethyl 
acetylenedicarboxylate to give imidazo[ 1,2-a]pyridin-5-ones (2.4.19). The reaction
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proceeds via C-alkylation to give the addition product (2.4.18) followed by the amide bond 
formation to afford the compound (2.4.19) (Scheme 2.4.10).114
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Scheme 2.4.10
Hydrogenation of the bicyclic Z-isomers, compounds (2.4.9) and (2.4.11), using 
10% Pd/C as catalyst in methanol under an atmosphere of hydrogen resulted in reduction of 
the vinylogous urethane bond and gave com pounds (2.4.20) an d  (2.4.21) in 69 and 92% 
yield, respectively (Scheme 2.4.11). The vinylogous amide bond remained untouched.
HN
Ph
Hg/ Pd/C
MeOH
HN
Ph
2.4.9, R = Me 
2.4.11, R = Et
2.4.20, R = Me
2.4.21, R = Et
Scheme 2.4.11
This difference in the reactivity of the two double bonds in the system is possibly 
caused by the aromatic character acquired in the pyrrole substructure upon reduction of the 
vinylogous urethane bond. Keto-enol tautomérisation gives the molecule a degree of 
aromatic character making the further hydrogenation of the system more difficult (Scheme
2.4.12). In addition the trisubstituted exocyclic double bond is expected to be reduced 
easier than the endocyclic tetrasubstituted double bond, could explain the observed result.
HN HN.
COgR
OHPti Ph
Scheme 2.4.12
2.4.3 2-Imidazolines in radical reactions
The possibility of forming rings fused to the 2-imidazoline nucleus by radical 
chemistry was investigated briefly. It has been shown in Section 2.3.5 that a selenium atom 
can be introduced at the C(2<x)-position. Alkyl selenides are well known for their ability to 
form free radicals and undergo radical reactions. Introduction of a carbon chain containing 
a double bond functionality on the N(l) of imidazoline (2.3.36) should allow the formation 
of a second ring under radical conditions.
Phenylselenenomethyl-2-imidazoline (2.3.36) was lithiated with 1.1 equiv. of n- 
butyllithium at 0°C followed by addition of 1.1 equiv. of 3-bromopropene to give an 
inseparable mixture of the N-alkylated (2.3.37) and C-alkylated (2.1.41c) products with the 
N-alkylated material being the major product. The insertion of the selenium atom at C(2a) 
makes that position more acidic and there now appears to be only a very small difference in 
acidity of the NH and C(2oc) positions. Nevertheless the mixture was reacted under the 
standard radical conditions with BugSnH (0.2 equiv.) and AIBN (catalytic amount) in 
toluene at reflux, using a syringe pump for the tin hydride addition. Unfortunately no 
cyclised products were obtained, only a 3:2 mixture of the reduced uncyclised materials 
(2.1.5) and (2.1.4) in 34% yield (Scheme 2.4.13).
PhSe"
2.3.36
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2.3.37
PhSe
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2.1.5 2.1.4
Scheme 2.4.13
Similar studies were carried out by Bowman et al. on the imidazole nucleus.115 
These researchers have found that imidazole (2.4.22a) yielded no 5-membered ring 
cyclisation to (2.4.23a) and gave only reduction to 1 -propylimidazole-5-carbaldehyde 
(2.4.24a), whereas (2.4.22b) gave the cyclised imidazole (2.4.23b) selectively with no 
uncyclised product (2.4.24b) (Scheme 2.4.14). This diference in reactivity is due to the fact 
that 6-exo cyclisation is more favourable than 5-exo cyclisation, which is disfavoured due 
to ring strain.
OHO
n SePh
OHO +  OHO
2.4.22a, n = 1 
2.4.22b, n = 2
2.4.23a, n = 1, 0% 2.4.24a, n = 1, 73%
2.4.23b, n = 2, 53% 2.4.24b, n = 2, 0%
Scheme 2.4.14
It was felt that this could also be the reason for not observing any cyclised products 
in our case. The introduction of a longer chain on the nitrogen should answer that particular 
question. Attempts to introduced a butenyl chain on the nitrogen by lithiation of (2.3.36)
with 1.0 equiv of w-butylithium or seobutyllithium at -78°C, 0°C or 20°C and addition of 
4-bromobut-l-ene did not prove successfiil and the desired product (2.4.25) was not 
obtained (Scheme 2.4.15). Starting material was isolated in all cases. The lithiated 2- 
imidazoline (2.3.36) is now too bulky and sterically hindered to act as a nucleophile and 
behaves like LDA, acting as a base rather than a nucleophile. It is also possible that the 
bromide is not reactive enough and acts as a proton donor. Perhaps conversion to the iodide 
could provide the desired compound. No other approaches were pursued due to lack of 
time but the possibility of radical cyclisation merits further investigation.
O h  ') seoB uLi__________x z
| ii) BrCH2CH2CH=CH2 J
PhSe PhSe
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Scheme 2.4.15
Chapter 3 
Experimental
General: Melting points were determined using an electrochemical digital melting point 
apparatus and are uncorrected. Infra-red spectra were recorded on a Perkin-Elmer 1710 
FTIR spectrometer. Ultraviolet spectra were recorded on a contron Uvikon 860 
spectrophotometer in ethanol. H NMR spectra were recorded in deuteriochloroform 
(unless otherwise stated) on JEOL LAMBDA300 or JEOL EX400 spectrometers at 300 or 
400 MHz and chemical shifts are quoted in parts per million (p.p.m) from tetramethylsilane 
as internal standard. Coupling constants (J), where appropriate, are quoted in Hz with 
multiplicities; s-singlet, d-doublet, t-triplet, q-quartet and m-multiplet. The prefix br-broad 
is used where applicable. 13C spectra were recorded at 75 MHz or 100 MHz, respectively, 
in deuteriochloroform (unless otherwise stated) and chemical shifts are quoted in parts per 
million (p.p.m) from tetramethylsilane as internal standard or from tetramethylsilane using 
CDCI3 as internal standard. Low resolution mass spectra were obtained using an AEI 
MS902 spectrometer in El-positive mode. High resolution EI/CI mass spectra were 
performed by the EPSRC National Mass Spestrometry Sevice. Microanalytical data were 
obtained from Medac LTD Analytical and Chemical Consultancy Services. Solvents were 
dried and distilled before use: chloroform and dichloromethane from CaH^; tetrahydrofuran 
(THF) and toluene from K; methanol and ethanol from Mg turnings and iodine imediately 
before use. n- and sec-Butyllithium were titrated with diphenylacetic acid before use. 
Column chromatography was performed under medium pressure using silica gel (Kieselgel 
60; 220-440 mesh) or neutral alumina (150 mesh) as indicated. Organic extracts were dried 
over anhydrous MgSO^.
2-(But-3-enyl)-2-imidazoline (2.1.4)
n  nN^s-NH ------------ ► N<s,NH
/z-Butyllithium (9.52 cm3 of a 2.5M solution in hexanes, 23.80 mmol) was injected to a 
stirred solution of 2-methyl-2-imidazoline (1.00 g, 11.90 mmol) in dry THF (119 cm3) at 
20°C under nitrogen. The yellow suspension that was formed was stirred at 20°C for 50 
min. The reaction mixture was cooled to 0°C and 3-bromopropene (1.02 cm3, 11.90 mmol) 
was injected to it. The reaction mixture was stirred at 0°C for 15 min. and at 20°C 
overnight. The reaction was quenched with water (100 cm3) and the organic layer was 
extracted with diethyl ether (3 x 100 cm3). The combined organic extracts were washed 
with brine (100 cm3) and water (100 cm3), dried and concentrated. The crude product was 
purified by column chromatography on silica gel (0:100—>5:97 v/v isopropylamine:ethyl 
acetate) to give the title compound as a yellow oil (0.15 g, 10%) (Found: NOT1" 124.1000. 
C7H12N2 requires: M 124.1000); (film)/cm  ^3200,2934,1610. 1540, 1369, 1150, 754, 
5h  (400 MHz) 2.37-2.45 (4H, br m, Œ 2Ctf2CH=CH2), 3.72 (4H, s, NCH2CH2N), 4.89 
(1H, br s, NH), 5.00-5.11 (2H, m, CT^CHzCH^C#), 5.78-5.87 (1H, m,
CH2CH2C/f=CH2), 5c (100 MHz) 28.6 (CH2CH2CH=CH2), 30.5 (CH2CH2CH=CH2), 49.7 
(NCH2CH2N), 115.4 (CH2CH2CH=CH2), 137.3 (CH2CH2CH=CH2), 167.2 (N=C-N); m/z 
124 (M% 2%) 123 (87), 113 (22), 109 (9), 84 (21), 67 (24), 55 (49), 43 (51).
l-(Prop-2-enyl)-2-methyl-2-imidazoline (2.1.5)
NU .NN-X/NH
zi-Butyllithium (14.28 cm3 of a 2.0M solution in hexanes, 28.57 mmol) was injected to a 
stirred solution of 2-methyl-2-imidazoline (2.00 g, 23.80 mmol) in dry THF (150 cm3) at
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20°C under nitrogen. The yellow suspension that was formed was stirred at 20°C for 50 
min. The reaction mixture was cooled to 0°C and 3-bromopropene (2.47 cm3, 28.57 mmol) 
was injected to it. The reaction mixture was stirred at 0°C for 15 min. and at 20°C 
overnight. The reaction was quenched with water (100 cm3) and the organic layer was 
extracted with diethyl ether (3 x 100 cm3). The combined organic extracts were washed 
with brine (100 cm3) and water (100 cm3), dried and concentrated. The crude product was 
purified by column chromatography on silica gel (0:100—>3:97 v/v isopropylamineiethyl 
acetate) to give the title compound as a yellow oil (1.30 g, 44%) (Found: M+ 124.0999. 
C7H12N2 requires: Af 124.1000); (film)/cm"' 2934,2866,1616,1490,1420,1258,934; 
Ôh (400 MHz) 1.93 (3H, s, CH3), 3.26-3.31 (2H, t, 7  9.8, NCH2CH2N), 3.63-3.68 (2H, t, /  
9.8, NCH2CH2N), 3.72 (2H, d, 75.8, NC/f2CH=CH2), 5.17-5.22 (2H, m, NC^CH^Ctfj), 
5.72-5.82 (1H, m, NCH2Œ ÉCH2); Sc (100 MHz) 13.9 (CH3), 49.4 (NCH2CH2N), 49.9 
(NCH2CH=CH2), 51.9 (NCH2CH2N), 117.1 (NCH2CH=CH2), 133.1 (NCHzCH^CHg), 
164.3 (N=C-N); m/z 124 (M+, 27%), 110 (1), 97 (5), 83 (24), 67 (19), 54 (100), 42 (30), 28 
(17).
2-(But-3-enyl)-l-(prop-2-enyl)-2-imidazoline (2.1.6)
N^x/NH
/ \ 
N<x/N .
«-Butyllithium (25.88 cm3 of a 1.8 M solution in pentane, 46.62 mmol) was injected to a 
stirred solution of 2-methyl-2-imidazoline (1.78 g, 21.19 mmol) in dry THF (150 cm3) at 
20°C under nitrogen. The milky suspension that was formed was stirred at 20°C for 1 h. 
The reaction mixture was cooled to 0°C and 3-bromopropene (4.00 cm3, 46.62 mmol) was 
injected to it. The suspension slowly disappeared and the reaction mixture was stirred at 0° 
C for 15 min and at 20°C for 48 h. The reaction was quenched with water (100 cm3) and
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the organic layer was extracted with diethyl ether (3 x 100 cm3). The combined organic 
extracts were washed with brine (100 cm3) and water (100 cm3), dried and concentrated. 
The crude product was purified by column chromatography on silica gel (0:100—>4:96 v/v 
isopropylamine:ethyl acetate) to give the title compound as a yellow oil (1.56 g, 45%) 
(Found: MH1" 165.1391. CioHi6N2 requires: MH 165.1391); v^ax (film)Zcm"1 2977, 2932, 
2862, 1642, 1615, i486, 1418, 1258, 1213, 995, 915; 5» (300 MHz) 2.24-2.29 (2H, m, 
CH2C^CH=CH2), 2.37-2.44 (2H, m, C ^C H 2CH=CH2), 3.27 (2H, t, /9 .7 , NO^CHzN), 
3.69 (2H, t, J9.7,  NCH2Cfl2N), 3.71 (2H, d, J4.0,  NCH2CH=CH2), 4.97-5.10 (2H, m, 
CH2CH2CH=CiJ2), 5.15-5.22 (2H, m, NCH2CH=C/f2), 5.71-5.92 (2H, m, NCH2Œ =CH2 
and CH2CH2C#=CH2); Ôc (75 MHz), 27.1 (CH2CH2CH=CH2), 30.4 (CH2CH2CH=CH2),
49.2 (NCH2CH2N), 50.1 (NCH2CH=CH2), 52.2 (NCH2CH2N), 115.1 (CH2CH2CH=CH2), 
117.0 (NCH2CH=CH2), 133.8 (NCH2CH=CH2), 137.5 (CH2CH2CH=CH2), 166.5 (N=C- 
N); m/z 164 (M+, 1%), 163 (4), 149 (4), 135 (2), 123 (10), 109 (3), 98 (2), 83 (32), 70 
(100), 55 (29), 41 (65).
2-[(l-Pheny)but-3-enyl))-l-(prop-2-enyl)-2-iimdazoline (2.1.8)
n
N<x .NH .N
Phy
M-Butyllithium (15.70 cm3 of a 2.5 M solution in hexanes, 39.37 mmol) was injected to a 
stirred solution of 2-benzyl-2-imidazoline (3.00 g, 18.75 mmol) in dry THF (188 cm3) at 20 
°C under nitrogen. The yellow suspension that was formed was stirred at 20°C for 50 min. 
The reaction mixture was cooled to 0°C and 3-bromopropene (3.40 cm3, 39.37 mmol) was 
injected to it. The reaction mixture went clear yellow when 3-bromopropene was added and 
was stirred at 0°C for 15 min. and at 20°C overnight. The reaction was quenched with 
water (100 cm3) and the organic layer was extracted with diethyl ether (3 x 100 cm3). The
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combined organic extracts were washed successively with brine (100 cm3) and water (100 
cm ), dried and concentrated. The crude product was purified by column chromatography 
on silica gel (0:100—>3:97 v/v isopropylamineiethyl acetate) to give the title compound as a 
yellow oil (4.10 g, 91%) (Found: C, 78.72; H, 8.36; N, 11.41%; (M-H)+ 239.1545. 
C,6H20N2 0.2H20 requires: C, 78.81; H, 8.37; N, 11.49%; M -//239.1548); v™, (film)/cm ' 
2932, 2862, 1641, 1611, 1416, 1210, 11074, 917, 702; 5h (400 MHz) 2.49-2.56 (1H, m, 
PhCHCHH), 2.84-2.91 (1H, m, PhCHCflH), 3.13-3.21 (1H, dd, J  8.8 and 17.1, 
NCHHCH=CH2), 3.26-3.33 (1H, dd, J  8.8 and 17.6, NCHHCH=CH2), 3.43-3.49 (2H, m, 
NCH2CH2N), 3.60-3.65 (1H, dd, J  5.9 and 15.2, PhCflCH2CH=CH2), 3.69-3.84 (2H, m, 
NCH2Cif2N), 4.92-4.97 (2H, m, PhCHCH2CH=C/f2), 5.01-5.07 (2H, m, NCH2CH=CH2), 
5.40-5.50 (1H, m, PhCHCH2C//=CH2), 5.69-5.75 (1H, m, NCH2C//=CH2), 7.20-7.32 (5H, 
m, Ar-H); 8c (100 MHz) 39.8 (PhCHCH2), 44.5 (PhCHCH2), 49.1 (NCH2CH2N), 50.2 
(NCH2CH=CH2), 52.6 (NCH2CH2N), 116.5 (PhCHCH2CH==CH2), 117.1 (NCH2CH=CH2), 
127.1, 128.2 and 128.8 (Ar-CH), 134.0 (PhCHCH2CH=CH2), 136.7 (NCH2CH=CH2), 
140.6 (Ar-C), 167.3 (N=C-N); m/z 240 (M+, 51%), 226 (5), 211 (11), 199 (43), 184 (5), 
170 (8), 156 (17), 149 (31), 135 (9), 129 (13), 121 (14), 103 (13), 91 (24), 82 (15), 77 (23).
Ethyl acetimidate hydrochloride (2.1.13)
  EtCX ^N H H C f
— C=N ---------------►
K ^ I
Freshly distilled acetyl chloride (41.57 cm3, 0.58 mol) was added dropwise to dry ethanol 
(25 cm3) at 0°C under nitrogen. A solution of acetonitrile (25.44 cm3, 0.48 mol) in dry 
ethanol (25 cm3) was added via cannula to the mixture at 0°C under nitrogen. The reaction 
mixture was stored at 0°C for 48 h. Dry diethyl ether (50 cm3) was added to it and the title 
compound precipitated out of solution as a white solid (19.18 g, 32%) 8h (400 MHz) 1.46
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(3H, t, J  7.2, Œ 3CH2), 2.48 (3H, s, CH3), 4.58 (2H, q, J 12,  (% ( % ) ,  11.42 (1H, br s, 
NH), 12.35 (1H, br s, NH).
l-Benzyl-2-methyl-2-imidazolme (2.1.9)
P h ^
/NH EtOyNHHCr ------------ » N y N x /P h
NH2 I
A solution of 1 -benzyl-1,2-diaminoethane (23.33 g, 0.15 mol) in dry ethanol (50 cm3) was 
added to a stirred suspension of ethyl acetimidate hydrochloride (19.18 g, 0.15 mol) in dry 
ethanol (150 cm3) at 20°C under nitrogen. The resulting mixture was heated at reflux for 3 
h. The ethanol was removed under reduced, pressure and the residue was partitioned 
between diethyl ether (100 cm3) and water (100 cm3). The aqueous layer was basified to 
pH 11 with 50% aq. NaOH and was extracted with chloroform (5 x 100 cm3). The 
combined organic extracts were dried and concentrated. The residue was distilled under 
reduced pressure and the title compound was obtained as a colourless liquid (19.02 g, 
70%), b.p. 92-94°C at 0.05 mmHg (lit.25'83 b.p. 102-106°C at 1 mmHg); Ôh (400 MHz)
2.02 (3H, s, CH3), 3,24 (2H, t, J  9.8, NCH2), 3.68 (2H, t, J  9.8, NCH2), 4.30 (2H, s, 
PhC#2), 7.22-7.37 (5H, m, Ar-H).
l-Benzyl-2-(but-3-enyl)-2-imidazolme (2.1.14)
/  \
M-Butyllithium (14.04 cm3 of a 1.8M solution in hexanes, 25.28 mmol) was injected to a 
stirred solution of 1 -benzyl-2-methyl-2-imidazoline (4.00 g, 23.00 mmol) in dry THF (80 
cm3) at -78°C under nitrogen. The solution was stirred at -78°C for 30 min and 3-
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bromopropene (2.18 cm3, 25.28 mmol) was injected to it. The reaction mixture was stirred 
at -78°C for 4 h. and at 20°C for 1.5 h. Wet diethyl ether (50 cm3) was added and followed 
by water (100 cm3). The organic layer was extracted with diethyl ether (3 x 100 cm3) and 
the combined organic extracts were washed with brine (100 cm3), dried and concentrated. 
The crude product was purified by column chromatography on silica gel (1:99 v/v 
isopropylaminetchloroform) to give the title compound as a yellow oil (3.85 g, 78%) 
(Found: (M-H)+ 213.1392. C|4H18N2 requires: (M-H) 213.1392); vmM (filmj/cm*1 3065, 
2934, 2863, 1612, 1496, 1453, 1274, 737; 5h (300 MHz) 2.39-2.49 (4H, br m, 
C//2CH2CH=CH2), 3.20 (2H, t, J  9.7, NCH2CH2N), 3.69 (2H, t, J  9.7, NCH2CH2N), 4.28 
(2H, s, PhC#2), 4.98-5.10 (2H, m, CH=C%), 5.82-5.93 (1H, m, C ffC H 2), 7.22-7.37 (5H, 
m, Ar-H); 8c (75 MHz; CDClj) 27.3 (CH2CH2CH=CH2), 30.5 (CH2CH2CH=CH2), 50.3 
(NCH2CH2N), 50.7 (PhCH2), 53.5 (NCH2CH2N), 115.4 (CH2CH2CH=CH2), 127.2, 127.4 
and 128.8 (Ar-CH), 137.4 (CH2CH2CH=CH2), 137.8 (Ar-C), 166.4 (N=C-N), m/z 214 (M+, 
1%), 213 (2), 203 (1), 190 (1), 174 (3), 160 (1), 149 (2), 133 (41), 120 (59), 106 (21), 91 
(100), 77 (3), 65 (15).
2-(But-3-enyl)-2-imidazolme (2.1.4) and 2-butyl-2-imidazoline (2.1.16)
NxX ,N N.x .NH N<s .NH
A solution of 1 -benzyl-2-(but-3-enyl)-2-imidazoline (1.00 g, 4.67 mmol) in dry diethyl 
ether (1.5 cm3) and ethanol (0.68 cm3, 11.68 mmol) was added to freshly distilled liquid 
ammonia (47 cm3) at -78°C. Freshly cut sodium (0.27 g, 11.68 mmol) was added in small 
portions over a period of 10 min. A blue colour was produced after each addition. When all 
the sodium was added the blue colour persisted for 15 min and the reaction was stirred at - 
78°C for a further 15 min. The ammonia was then allowed to evaporate at 20°C overnight
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and diethyl ether (50 cm3) was added to the white solid. The ether layer was washed with 
water (50 cm3), dried and concentrated. The yellow oil was purified by column 
chromatography on silica gel (1:99—>5:95 v/v isopropylaminexhroroform) to give an 
inseparable 2:1 mixture of 2-(but-3-enyl)-2-imidazoline and 2-butyl-2-imidazoline as a 
yellow oil (0.18 g, 32%). For 2-(but-3-enyl)-2-imidazoline: 5h (400 MHz) 2.37-2.45 (4H, 
br m, C #2(%CH=CH2), 3.72 (4H, s, NCH2CH2N), 4.89 (1H, br s, NH), 5.00-5.11 (2H, m, 
CH2CH2CH=C^2), 5.78-5.87 (1H, m, Œ =CH2), Sc (75 MHz; CDC13) 28.6 
(CH2CH2CH=CH2), 30.5 ( Œ 2CH2CH=CH2), 49.7 (NCH2CH2N), 115.4 (CH=CH2), 137.3 
(CH=CH2), 167.2 (N=C-N). For 2-(butyl)-2-imidazoline: Sh (400 MHz; CDC13) 0.92 (3H, 
t, J  7.2, CH2CH2CH2CH3), 1.31-1.41 (2H, m, CHîCHîC^CHs), 1.57-1.64 (2H, m, 
CH2CH2CH2CH3), 2.32 (2H, t, J7 .8 , C//2CH2CH2CH3), 3.70 (4H, s, NCH2CH2N); Sc (75 
MHz) 13.8 (CH2CH2CH2CH3), 22.5 (CH2CH2CH2CH3), 28.8 (CH2Œ 2CH2CH3), 29.2 
( Œ 2CH2CH2CH3), 49.9 (NCH2CH2N), 168.1 (N=C-N).
2-(But-3-enyl)-2-imidazoline (2.1.4)
N^s /N H
A solution of 1 -benzyl-2-(but-3-enyl)-2-imidazoline (1.00 g, 4.67 mmol) in dry diethyl 
ether (1.5 cm3) and ethanol (0.68 cm3, 9.34 mmol) was added to freshly distilled liquid 
ammonia (47 cm3) at -78°C. Freshly cut sodium (0.27 g, 9.34 mmol) was added in small 
portions over a period of 10 min. A blue colour was produced after each addition. When all 
the sodium was added the blue colour persisted for 15 min. and the reaction was stirred at - 
78°C for a further 15 m in . The am m o n ia  was then allowed to evaporate at 20°C overnight 
and diethyl ether (50 cm3) was added to the white solid. The ether layer was washed with 
water (50 cm3), dried and concentrated. The yellow oil was purified by column
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chromatography on silica gel (l:99->5:99 v/v isopropylaminexhlroroform) to give the title 
compound as a yellow oil (0.12 g, 21%); data identical to those reported before.
l-Benzyl-2-butyl-2-imidazoline (2.1.17)
r~\
N - X / N ^ / P h
/i-Butyllithium (1.91 cm3, of a 1.8M solution in hexanes, 3.44 mmol) was injected to a 
stirred solution of 1 -benzyl-2-methyl-2-imidazoline (0.50 g, 2.87 mmol) in dry THF (28 
cm3) at -78®C under nitrogen. The solution was stirred at -78°C for 30 min and 1- 
iodopropane (0.34 cm3, 3.44 mmol) was injected to it. The reaction mixture was stirred at - 
78°C for 4 h and at 20°C for 1.5 h. Wet diethyl ether (20 cm3) was added and followed by 
water (50 cm3). The organic layer was extracted with diethyl ether (3 x 50 cm3) and the 
combined organic extracts were washed with brine (50 cm3), dried and concentrated. The 
crude product was purified by column chromatography on silica gel (1:99 v/v 
isopropylaminexhloroform) to give the title compound as a yellow oil (0.60 g, 97%); Ôh 
(400 MHz) 0.87 (3H, t, J  7.3, C H ^ C H ^ ) ,  1.25-1.40 (2H, m, CH^CH^CT^CH^), 
1.53-1.63 (2H, m, CH2Œ /2CH2CH3), 2.15-2.25 (2H, t, 77.80, Œ 2CH2CH2CH3), 3.07-3.15 
(2H, t, 7  9.8, NC7/2CH2N), 3.59 (2H, t, 7  9.8, NCH2Œ 2N), 4.20 (2H, s, NŒfcPh), 7.10- 
7.30 (5H, m, Ar-H).
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2-Butyl-l-[(cyclohexa-l,4-dienyl)-l-methyl]-2-imidazoline (2.1.18)
A solution of 1 -benzyl-2-butyl-2-imidazoline (0.50 g, 2.31 mmol) in dry diethyl ether (1.5 
ml) and ethanol (0.31 cm3, 5.32 mmol) was added to freshly distilled liquid ammonia (23 
cm3) at -78°C. Freshly cut sodium (0.12 g, 5.32 mmol) was added in small portions over a 
period of 10 min. A blue colour was produced every time a small portion of sodium was 
added. When all the sodium was added the blue colour persisted for 15 min. and the 
reaction was stirred at -78°C for a further 15 min. The am m o n ia  was then allowed to 
evaporate at 20°C overnight and diethyl ether (20 cm3) was added to the white solid. The 
ether layer was washed with water (20 cm3), dried and concentrated. The yellow oil was 
purified by column chromatography on silica gel (1:99-3:97 v/v 
isopropylaminexhlroroform) to give the title compound as a white solid (0.25 g, 50%), 
m.p. 35-37°C 8h (400 MHz) 0.92 (3H, t, J  7.2, CH2CH2CH2C//3), 1.22-1.38 (2H, m, 
CH2CH2Œ 2CH3), 1.58-1.65 (2H, m, CH2C/J2CH2CH3), 2.18 (2H, t, J  7.8, 
C//2CH2CH2CH3), 2.60-2.75 (6H, m, NC/jfe and 2 x cyclohexadiene CH2), 3.12 (2H, s, 
NCtf2Cyclohexadiene), 3.34 (2H, m, NC//2CH2N), 5.62 (1H, s, C=CH), 5.69-79 (2H, m, 
CH2C#=C#CH2); 5c (100 MHz) 13.8 (CH3), 22.3 (CH2CH3), 26.5 (CH2CH2CH3), 27.5 
and 27.8 (CH2), 36.5 (Œ2CH2CH2CH3), 38.9 (NCH2Cyclohexadiene), 47.8 and 55.2 
(NCH2), 120.3,124.0 and 124.1 (CH), 133.2 (NCH2C), 173.3 (N-C=N).
l-tert-Butyloxycarbonyl-2-methyl-2-imidazoline (2.1.19)
/ \ n
n^ / N H  --------------------- N^ / N ^ Boc
Triethylamine (19.78 cm3, 0.14 mol) was added dropwise to a solution of 2-methyl-2- 
imidazoline (10.00 g, 0.12 mol) in dichloromethane (120 cm3) at 0°C. Y)i-tert- 
butyldicarbonate (31.11 g, 0.14 mol) was added to the solution in small portions and the 
reaction mixture was stirred at 0°C for 10 min. The ice bath was removed and the reaction 
was stirred at 20°C overnight. Water was added and the organic layer was extracted with 
dichloromethane (3 x 100 cm3). The combined organic extracts were washed with saturated 
aq. NaHCO] (100 cm3), dried and concentrated. The crude product was distilled under 
reduced pressure and the title compound was obtained as a white solid (16.75 g, 77%) b.p 
82-86°C at 0.15 mmHg, m.p 44-46° (Found: M+ 184.1212. C9H16N2O2 requires: M  
184.1212); Vmax (film)/cm'1 2995, 1714; 8h (400 MHz) 1.45 (9H, s, [C(CH3)3], 2.28 (CH3), 
3.68 (4H, s, NCH2CH2N); 5c (100 MHz) 17.9 (CH3), 28.1 [C(CH3)3], 46.4 and 51.7 
(NCH2), 81.4 [C(CH3)3], 150.9 (CO), 158.1 (N=C-N); m/z 184 (IVf, 7%), 128 (7), 84 (20), 
70 (24), 57 (100).
General method for the synthesis of 2-substituted l-te/t-butyloxycarbonyl-2- 
imidazolines (2.1.21)
n  n
NY N- B oc ----------------- - N' ^ / N' 'B oc
R
5ec-Butyllithium (1.3M solution in hexanes) was injected into a solution of 1 -tert- 
butyloxycarbonyl-2-methyl-2-imidazoline in dry THF/TMEDA (25-30:1 v/v; 0.1M in 
imidazoline) at -78°C under nitrogen. The bright yellow solution produced was stirred for
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20 min at -78°C. The organohalide was injected (when liquid) or added by cannula as a 
solution in THF (when solid) to the reaction mixture at -78°C under nitrogen. The reaction 
was allowed to warm to 20°C overnight. It was then quenched with water (100 cm3) and 
the organic layer was extracted with diethyl ether (3 x 100 cm3) and the combined extracts 
were washed with saturated aq. NaHC03 (100 cm3), water (100 cm3) and brine (100 cm3), 
dried and concentrated. The crude product was purified by column chromatography on 
silica (1:9—>2:3 v/v ethyl acetate:hexane) to give the product imidazoline.
2-(But-3-enyl)-l-teit-butyloxycarbonyl-2-imldazoline (2.1.21a)
n
n<x / N" B oc
This compound was prepared by the general method, using 1 -ferf-butyloxycarbonyl-2- 
methyl-2-imidazoline (4.00 g, 21.74 mmol), sec-butyllithium (26.08 cm3 of a 1M solution 
in hexanes, 26.08 mmol) and 3-bromopropene (2.25 cm3, 26.08 mmol). The title compound 
was obtained as a colourless oil (4.00 g, 82%) (Found: C, 63.20; H, 8.78; N, 12.72%; MH" 
225.1603. C12H20N2O2 O.2H2O requires: C, 63.24; H, 9.02; N, 12.29%; MH 225.1603); 
Vmax (film)/cm"' 2960, 2934, 1720, 1640. 1369, 1150, 754; Sh (400 MHz) 1.50 (9H, s, [C 
(CH3)3]), 2.40 (2H, q, J  8.0, CH2CH2CH C H 2), 2.78 (2H, t, J  8.0, C//2CH2CH=CH2), 3.77 
(4H, s, NCH2CH2N), 5.00-5.10 (2H, m, CH2CH2CH=C//2), 5.84 (1H, m, 
CH2CH2C7M H 2); Sc (100 MHz) 27.9 [€ (% ) :] ,  30.0 (CH2CH2CH=CH2), 30.4 
(CH2CH2CH=CH2), 46.6 (NCH2CH2N), 51.8 (NCH2CH2N), 81.4 [C(CH3)3], 114.8 
(CH2CH2CH=CH2), 137.3 (CH2CH2a i= C II2), 150.7 (CO), 160.57 (N=C-N); m/z 225 
(MH*, 0.9%), 208 (1), 169 (17), 124 (12), 97 (4), 84 (5), 58 (16
Boc
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2-Butyl-l-terf-butyloxycarbonyl-2-imidazolme (2.1.21b)
T
This compound was prepared by the general method, using l-terf-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec-butyllithium (9.19 cm3 of a 1.3M solution 
in hexanes, 11.95 mmol) and 1-iodopropane (1.16 cm3, 11.95 mmol). The title compound 
was obtained as a colourless oil (2.10 g, 86%), (Found: C, 63.29; H, 9.42; N, 12.29%; M*
(film)/cm"‘ 2960, 2875, 1722, 1642, 1369, 1322, 1151, 1004; Sh (400 MHz) 0.92 (3H, t, J  
7.3, CH2CH2CH2CH3), 1.40 (2H, m, CH2CH2CH2CH3), 1.50 [9H, s, C(CH3)3], 1.63 (2H, 
m, CH2CH2CH2CH3), 2.72 (2H, t, 7  7.8, CH2CH2CH2CH3), 3.75 (4H, s, NCH2CH2N); Sc 
(75 MHz) 13.9 (CH2CH2CH2CH3), 22.5 (CH2CH2CH2CH3), 28.2 [C(CH3)3], 28.7 
(CH2CH2CH2CH3), 30.6 (CH2CH2CH2CH3), 46.7 (NCH2CH2N), 51.80 (NCH2CH2N), 81.5 
[C(CH3)3], 150.8 (CO), 161.6 (N=C-N); m/z 226 (M \ 0.8%), 184 (1), 171 (2), 128 (2), 85 
(3), 58(8).
l-tert-butyloxycarbonyl-2-(pent-4-enyl)-2-iiiiidazolme (2.1.21c)
This compound was prepared by the general method, using 1 -ferf-butyloxycarbonyl-2- 
methyl-2-imidazoline (1.50 g, 8.15 mmol), sec-butyllithium (6.89 cm3 of a 1.3M solution 
in hexanes, 8.96mmol) and 4-bromobut-l-ene (0.91 cm3, 8.96 mmol). The title compound 
was obtained as a colourless oil (1.25 g, 64%) (Found: MH1" 239.1759. C13H22N2O2 
requires: M / 239.1759); Vmax (fihnycm"1 2977, 2934, 1719, 1641, 1369, 1148; Ôh (400
226.1681. C12H22N2O2 requires: C, 63.69; H, 9.80; N, 12.38%; M  225.1681); v,max
T
MHz; CDCb) 1.50 [9H, s, C(CH3)3], 1.73-1.80 (2H, m, OH3C ^C H 3CH=OH^. 2.13-2.18 
(2H, m, CHîCHîCT/îCHCHz), 2.71 (2H, t, J  7.5, O ^O H 3OH3CH=OH^, 3.73 (4H, s, 
NCH2CH2N), 4.97-5.07 (2H, m CH2CH2CH2C H C 7Î2), 5.78-5.88 (1H, m,
CH2CH2CH2C77=CH2); 5c  (100 MHz) 25.7 (CH2CH2CH2CH=CH2), 28.0 [C (Œ 3)3], 30.3 
(CH2CH2CH2CH=CH2), 33.4 (CH2CH2CH2CH=CH2), 46.6 (NCH2CH2N), 51.8 
(NCH2CH2N), 81.6 [C(CH3)3], 114.9 (CH2CH2CH=CH2), 138.3 (CH2CH2CH=CH2), 150.9 
(CO), 161.5 (N=C-N); m/z 239 (MH*, 3%), 201 (9), 183 (26), 157 (16), 140 (26), 129 (10), 
88 (18), 57 (100).
l-tert-Butyloxycarbonyl-2-(2-phenylethyl)-2-iimdazoline (2.1.21d)
n  r x ,
N<s /N -^ boc ---------------------   ^ l/  Boc
ï V
This compound was prepared by the general method, using 1 -fert-butyloxycarbonyl-2- 
methyl-2-imidazoline (1.00 g, 5.43 mmol), sec-butyllithium (0.71 cm3 of a 1.3M solution 
in hexanes, 5.97 mmol) and benzyl bromide (0.71 cm3, 5.97 mmol). The title compound 
was obtained as a colourless oil (1.36 g, 92%) (Found: C, 70.04; H, 8.07; N, 10.16%; M+
274.1681. C16H22N2O2 requires: G, 70.04; H, 8.08; N, 10.21; M274.1681); (filmycm"1 
2977, 2934, 1718, 1644, 1370, 1143; Sh (400 MHz) 1.50 [9H, s, C(CH3)3], 3.00 (4H, br s, 
CftCffcPh), 3.75 (4H, s, NCH2CH2N), 7.20-7.50 (5H, m, Ar-H); 5c (100 MHz), 28.2 
[C(CH3)3], 32.5 (CHzOfePh), 32.6 (CH2CH2Ph), 46.8 (NCH2CH2N), 52.0 (NCH2CH2N),
81.5 [C(CH3)3], 125.9,128.3,128.4 (Ar-CH), 141.3 (Ar-C), 151.0 (CO), 160.90 (N=C-N); 
m/z 274 ( M \  0.6%), 218 (49), 174(8), 145 (6), 97 (11).
l-tert-Butyloxycarbonyl-2-[2-(2-phenyl)phenylethyl]-2-imidazoline (2.1.21e)
This compound was prepared by the general method, using 1 -ter/-butyloxycarbonyl-2- 
methyl-2-imidazoline (1.00 g, 5.43 mmol), sec-butyllithium (5.43 cm3of a 1.1M solution in 
hexanes, 5.97 mmol) and 2-phenylbenzyl bromide (1.09 cm3, 5.97 mmol). The title 
compound was obtained as a colourless oil (1.55 g, 81%) (Found: C, 74.79; H, 7.52; N,
350.1994); Vmax (filmycm"1 2977, 2934, 1718, 1642 1480, 1370, 1145; Ôh (400 MHz) 1.47
s, NCH2CH2N), 7.15-7.40 (9H, m, Ar-H); ôc (100 MHz) 28.0 [€ (% )]] , 29.5 
(CH2CH2Ar), 32.3 (OfcOfcAr), 46.6 (NCH2CH2N), 51.9 (NCH2CH2N), 81.4 [C(CH3)3], 
125.9, 126.7, 127.5, 128.1, 129.2, and 130.1 (Ar-CH), 138.7, 141.7 and 141.9 (Ar-C),
150.8 (CO), 160.7 (N=C-N); m/z 350 (M+, 9%), 294 (48), 249 (60), 217 (12), 165 (39), 115 
(97), 97 (11), 71 (14), 57 (100).
1 -te7*-Butyloxycarbonyl-2-[2-(2-furyl)ethyl] -2-imidazolme (2.1.211)
This compound was prepared by the general method, using 1 -fgrf-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec-butyllithium (14.94 cm3 of a 0.8M in 
hexanes, 11.95 mmol) and furfuryl chloride (1.20 g, 11.97 mmol). The title compound was
/ \
7.53%; M* 350.1995. C22H26N2O2.O.IH2O requires: C, 75.00; H, 7.44; N, 7.95%; M
[9H, s. C(CH3)3], 2.85 (2H, 1,78.0, CHzC^Ar), 2.98 (2H, t, 78.0, CW H zA r), 3.65 (4H,
r~ \
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obtained as a colourless oil (2.03 g, 71%) (Found: C, 60.88; H, 7.48; N, 10.08%; M+
2H); 8c (100 MHz) 25.0 (OfeCHiFuryl), 28.2 [CfCH,),], 29.5 (CHiCHzFuryl), 46.8 
(NCH2CH2N), 51.9 (NCH2CH2N), 81.8 [C(CH3)3], 105.0, 110.1 and 140.9 (Fuiyl-C),
150.8 (CO), 154.9 (Furyl-C), 160.4 (N=C-N); m/z 264 (M+, 2%), 208 (68), 191 (16), 163 
(41), 135 (55), 121 (24), 94 (17), 84 (15), 81 (33), 70 (14), 58 (100).
l-fefl-Butyloxycarbonyl-2-(hepta-3,5-dienyl)-2-iiiiidazolme(2.t.21g)
This compound was prepared by the general method, using l-<erf-butyloxycarbonyl-2- 
methyl-2-imidazoline (1.50 g, 8.15 mmol), sec-butyllithium (6.89 cm3 of a 1.3 M solution 
in hexanes, 8.96 mmol) and 6-bromohexa-2,4-diene (1.44 g, 8.96 mmol). The compound 
was obtained as a colourless oil, 4:1 mixture of E,E:E,Z isomers (1.55 g, 81%), (Found: M+
264.1474. C15H24N2O2 requires: M 264.1473); vm« (filmycm-1 2977, 2934, 1718, 1644, 
1479, 1369,1331, 1222, 1147,1000; for E,E isomer: 8h (400 MHz) 1.50 [9H, s, C(CH3)3], 
1.71 (3H, d, J  6.8, C //3CH=CH), 2.33 (2H, q, J  7.6, CHCH=CHCFf2CH2), 2.73 (2H, t, J  
7.6, CHCHCH2CH2), 3.72 (4H, s, NOfeCHjN), 5.58-5.63 (2H, m,
CH3C//=CHCH=CtfCH2CH2), 5.98-6.10 (2H, m, CH3CH=C//Cff=CHCH2CH2); Sc (100 
MHz) 17.9 (CH3CH=), 28.2 [C(CH3)3], 29.3 CH=CHCH2CH2), 30.6 (CHCHCH2CH2),
46.7 (NCH2CH2N), 51.9 (NCH2CH2N), 81.5 [C(CH3)3], 127.2 (CH3CH=CHCH=CH),
130.2 (CH3CH=CHCH=CH), 130.8 (CH3CH=CHCH=CH), 131.4
264.1474. C14H20N2O2.O.8H2O requires: C, 60.34; H, 7.18, N,10.05%; M  264.1473); 
(film)/cm-1 2977, 2934, 1718, 1644, 1479, 1369, 1331, 1222, 1147, 1000; Sh (400 MHz)
1.45 [9H, s, C(CH3)3], 2.92-3.02 (4H, br m, CHzCHjFuryl), 3.68 (4H, s, NCH2CH2N), 5.95 
(1H, d, J  2.9, Furyl-4H), 6.18 (1H, dd, 72.0 and 2.9, Fuiyl-3H), 7.28 (1H, d, 71.5, Furyl-
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(CH3CH-CHCH-CHCH2CH2), 150.8 (CO), 160.7 (N-C-N); for E:Z isomer 8h (400 MHz) 
1.11 (3H, d, J  6.8, CH3CH CH ), 1.50 [9H, s, C(CH3)3], 2.42 (2H, q, J  7.6, 
CHCH=CHC//2CH2), 2.76 (2H, 1,77.6, CH=CHCH2CH2), 3.72 (4H, s, NCH2CH2N), 4.97 
(1H, dd, J  1.7 and 10.2, CH3CH=C7/CH=CHCH2), 5.12 (1H, dd, J  1.7 and 17.1, 
CH3CH=CHCf£=CHCH2), 5.98-6.10 (1H, m, CH3CH=CHCH=CHCH22) 6.28-6.35 (1H, m, 
CH3CH=CHCH=C//CH2); 8c (100 MHz) 17.9 (CH3CH=CH), 28.2 [C(CH3)3], 34.3 
CH=CHCH2CH2), (CH=CHCH2CH2), 46.7 (NCH2CH2N), 51.9 (NCH2CH2N), 81.5 
[C(CH3)3], 127.1 (CH3CH=CHCH=CH), 128.5 (CH3CH=CHCH=CH), 137.6
(CH3CH=CHCH=CHCH2CH2), 139.1 (CH3CH=CHCH=CHCH2CH2), 150.8 (CO), 160.7 
(N=C-N); m/z 264 (M+, 0.7%), 208 (65), 193 (35), 179 (23), 149 (33), 135 (19), 123 (20), 
109 (48), 83 (39), 57 (100).
l-tert-Butyloxycarbonyl-2-(hexa-3,5-dienyl)-2-iimdazoline (2.1.21b)
Boc
This compound was prepared by the general method, from l-tert-butyloxycarbonyl-2- 
methyl-2-imidazoline (1.20 g, 6.52 mmol), sec-butyllithium (6.01 cm3 of a 1.3M solution 
in hexanes, 7.82 mmol) and 5-bromopenta-1,3-diene (1.15 cm3, 7.82 mmol). The title 
compound was obtained as a colourless oil (1.09 g, 67%) (Found: C, 65.70; H, 8.84; N, 
10.94%; MH+ 251.1755. C14H22N2O2 0.4H2O requires: C, 65.42; H, 8.86; N, 10.88%; MH 
251.1579); V™* (filmycm"1 2977, 1718, 1643, 1369, 1317, 1256, 1143, 1005, 768; ÔH 
(300 MHz) 1.50 [9H, s, C(CH3)31,2.48 (2H, q, 77.6, CH=CHC%CH?), 2.79 (2H, t, 77.6, 
CH=CHCH2C//2), 3.74 (4H, s, NCH2CH2N), 4.97 (1H, m, CH=CHfl), 5.10 (1H, dd, 71.1 
and 16.8 CH=CflH), 5.72-5.81 (1H, m, CH=CHCH=CH2), 6.05-6.14 (1H, m, CH=Cfl- 
CH=CH2), 6.10-6.34 (1H, m, CH=CH-CH=CH2); 8c (75 MHz) 28.2 [C(CH3)3], 29.4
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(C H Œ 2CH2), 30.5 (CHCH2CH2), 46.8 and 52.0 (NCH2), 81.6 [C(CH3)3], 115.2 
(CH2=CH), 130.9, 133.7 and 137.1 (CH), 150.9 (CO), 160.7 (N=€-N); m/z 251 [(MH4), 
100%], 195 (21), 185 (10), 151(11), 135 (2), 129 (4), 99 (2), 85 (9).
General method for the synthesis of 2-substituted 2-imidazolines (2.1.22)
I .
N<v ,NH
X,R R
Trifluoroacetic acid (5 cm3) was added to the 2-substituted 1 -tez*/-butyloxycarbonyl-2-
imidazolines and the resulting solution was stirred at 20°C for 20-60 min. The 
trifluoroacetic acid was removed under reduced pressure and the imidazoline 
trifluoroacetate salt was dissolved in dichloromethane (100 cm3). The solution was then 
washed with aq. NaOH (10% w/v; 100 cm3) and the organic layer was dried and 
concentrated. The crude product was then purified by column chromatography on silica gel 
(0:100—>4:96 v/v isopropylamine:ethyl acetate) to give the desired imidazoline.
2-(But-3-enyl)-2-imidazoline (2.1.4)
This compound was prepared by the general method, using 2-(but-3-enyl)-1 -tert- 
butyloxycarbonyl-2-imidazoline (1.45 g, 6.47 mmol) and TFA (3 cm3). The title compound 
was obtained as a white solid (0.66 g, 82%), m.p. 29-31 °C (Found: 124.1000.
C7H12N2 requires: Af 124.1000); vmax (filmycm1 3200,2934,1610.1540,1369,1150, 754; 
Ôh (400 MHz) 2.37-2.45 (4H, br m, Cf&CazCH^CHz), 3.72 (4H, s, NCH2CH2N), 4.89 
(1H, br s, NH), 5.00-5.11 (2H, m, CH zCH zCH ^#), 5.78-5.87 (1H, m,
N -  NH
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CH2CH2C/é=CH2); 8c (75 MHz) 28.6 (CH2CH2CH=CH2), 30.5 (CH2CH2CH=CH2), 49.7 
(NCH2), 115.4 (CH=CH2), 137.3 (CH=CH2), 167.2 (N=C-N); m/z 124 (M*, 2%) 123 (87), 
113 (22), 109 (9), 84 (21), 67 (24), 55 (49), 43 (51).
2-Butyl-2-îmidazoline (2.1.15)
Ncs ,NH
This compound was prepared by the general method, using 2-butyl-1-tert- 
butyloxycarbonyl-2-müdazoline (1.25 g, 5.53 mmol) and TFA (3 cm3). The title compound 
was obtained as a white crystals (0.61 g, 87%), m.p 39-41 °C (Found: C, 66.32; H, 10.94; 
N, 21.96%; MH* 127.1235. C7Hi4N2 requires: C, 66.62; H, 11.18; N, 22.20%; M  
127.1235); V™, (KBr)/cm ' 3230, 2958, 2871, 1615, 1495, 1467, 1289, 1268; 8h (400 
MHz) 0.92 (3H, t, J  7.2, CH2CH2CH2CH3), 1.31-1.41 (2H, m, CH2CH2CiT2CH3), 1.57-
1.64 (2H, m, CH2CH2CH2CH3), 2.32 (2H, t, J  7.8, CH2CH2CH2CH3), 3.70 (4H, s, 
NCH2CH2N); 8c (75 MHz) 13.8 (CH2CH2CH2CH3), 22.5 (CH2CH2CH2CH3), 28.8 
(CH2CH2CH2CH3), 29.2 (CH2CH2CH2CH3), 49.9 (NCH2), 168.1 (N=C-N); m/z 127 (M \ 
80%), 115 (5), 98 (8), 84 (100), 73 (15), 69 (11), 57 (15), 44 (23).
2-(2-Phenylethyl))-2-lmidazoline (2.1.22a)
N% / N^ b o c -------------------► N < s/M H
Ph •Ph
This compound was prepared by the general method, from l-ter/-butyloxycarbonyl-2-(2- 
phenylethyl)-2-imidazoline (2.00 g, 7.29 mmol) and TFA (4 cm3). The title compound was 
obtained as a white solid (0.93 g, 73%), m.p. 102-104 °C (Found: C, 75.83; H, 8.12; N,
137
15.86%; M* 174.1146. C11H14N2 requires: C, 75.82; H, 8.10; N, 16.07%; M  174.1157); 
Vmax (KBr)/cm"‘ 3158,3059,3001,2926,2859,1606,1498, 1286; 8h (400 MHz) 2.52-2.56 
(2H, t, J  8.0, CHzCfliPh), 2.94-2.98 (2H, t, J  7.8, CH2CH2Ph), 3.56 (4H, br s, 
NCH2CH2N), 7.20-7,50 (5H, m, Ar-H), 5c (100 MHz) 31.1 (CH2CH2Ph), 32.8 
(CH2CH2Ph), 49.4 (NCH2), 126.2, 128.2 and 128.4 (Ar-CH), 141.1 (Ar-C), 167.2 (N=C- 
N); m/z 174 (M*, 33%), 173 (100), 144 (8), 117 (16), 97 (38), 91 (25), 84 (10), 65 (33).
2-K2-Phenyl)phenylethyl]-2-imidazolmc (2.1.22b)
N Boc
Ph Ph
This compound was prepared by the general method, from 2-[2-(2-phenyl)phenylethyl]-l- 
tert-butyloxycarbonyl-2-imidazoline (1.38 g, 3.94 mmol) and TFA (3 cm3). The title 
compound was obtained as a white solid (0.79 g, 80%), m.p. 118-120 °C (Found: C, 81.68; 
H, 7.25; N, 11.17%; (M-H)+ 249.1382. C22H26N2O2 requires: C, 81.56; H, 7.25; N,
11.18%; M-H 249.1392); Vmax (KBr)/cm^ 3152, 3104, 2932, 1608, 1558, 1538, 1505, 
1479, 1310, 1279; Ôh (400 MHz) 2.30-2.33 (2H, t, J8 .0 , CHzCf&Ar), 2.92-2.95 (2H, t, J  
8.0, Ctf2CH2Ar), 3.47 (4H, s, NCH2CH2N), 4.11 (1H, br s, NH), 7.15-7.40 (9H, m, Ar-H); 
ôc (100 MHz) 30.2 (CH2CH2Ar), 30.7 (O^CHzAr), 50.2 (NCH2), 126.3, 127.0, 127.6, 
128.2, 129.1, 129.2 and 130.2 (Ar-CH), 138.3, 141.5 and 141.8 (Ar-C), 167.1 (N=C-N); 
mlz 250 (M+, 33%), 249 (100), 173 (30), 165 (40), 152 (13), 115 (10), 97 (25), 71 (22).
138
2-[2-(2-Furyl)ethyl]-2-imidazolme (2.1.22c)
r~\
N.x ,NH
This compound was prepared by the general method, from l-tert-butyloxycarbonyl-2-[2-(2- 
furyl)ethyl]-2-imidazoline (0.30 g, 1.13 mmol) and TFA (2 cm3). The title compound was 
obtained as a white solid (0.12 g, 65%), m.p. 98-100 °C (Found: M+ 164.0950. C9H12N2 
requires: M l64.0949); (KBr)/cm"‘ 3165, 3118, 2927, 2862, 1606, 1511, 1377, 1289,
1001; Sh (400 MHz) 2.48-2.52 (2H, t, J  7.8, OfeCftFuryl), 2.88-2.93 (2H, t, J  7.8, 
Ctf2CH2Furyl), 3.48 (4H, s, NCH2CH2N), 4.31 (1H, br s, NH), 5.95 (1H, d, J  3.0, Fuiyl- 
3H), 6.21 (1H, dd, 72.0  and 3.0, FuryWH), 7.29 (1H, d, 72.0 , Furyl-5H); Sc (100 MHz)
25.1 (CH2CH2Furyl), 27.8 (OfeCHzFuryl), 49.8 (NCH2), 105.3, 110.2, 141.1 and 154.6 
(Furyl-C), 166.7 (N=C-N); m/z 164 (M*, 100%), 135 (92), 121 (40), 110 (11), 94 (17), 84 
(65), 54 (37).
2-(Hepta-3,5-dienyl)-2-imidazoline (2.1.22d)
n
N< S / NH /
This compound was prepared by the general m ethod , fro m  l-terf-butyloxycarbonyl-2- 
(hepta-3,5-dienyl)-2-imidazoline (1.20 g, 4.54 mmol) and TFA (3 cm3). The title 
compound was obtained as a 4:1 mixture of geometric isomers E,E:E,Z as a white solid 
(0.50 g, 67%), m.p. 68-70 °C (Found: 164.1317. CioHigN: requires: Af 164.1313); Vmax
(KBr)/cin1 3154, 3017, 2932, 2862, 1606, 1505, 1475, 1451, 1376, 1284, 1146, 987; data 
for E:E isomer 5» (400 MHz) 1.73 (3H, d, J  6.8, C/f3CH=CH), 2.28-2.42 (4H, m, 
CH=CHC/f2C/f2), 3.58 (4H, s, NCH2CH2N), 3.80 (1H, br s, NH), 5.52-5.68 (2H, m,
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CH3Cti=CHCH=CHCH2), 5.98-6.10 (2H, m, CHjCH^CHCffCHCHzCHj); Sc (100 
MHz), 18.0 (CH,), 29.2 (CH=CHCH2CH2), 29.4 (CH=CHCH2CH2), 49.9 (NCH2), 127.9 
130.3,131.3 and 136.9 (CH), 167.4 (N=C-N); data for E:Z isomer Sh (400 MHz) 1.08 (3H, 
d, 76.8, CH;), 2.28-2.42 (4H, m, CH=CHCH2CH2), 3.58 (4H, s, NCH2CH2N), 3.80 (1H, br 
s, NH), 5.04-5.52-5.68 (1H, dd, 71.7 and 10.2, CH;CH=CflCH=CH), 5.12 (1H, dd, 71.7 
and 17.2, CH;CH=CHCH=CH), 5.98-6.10 (1H, m, CH;CH=CHCH=C7fCH2CH2), 6.24- 
6.34 (1H, m, CH;C7f=CHCH=CHCH2CH2); Sc (100 MHz) 20.1 (CH;), 29.2 
(CH=CHCH2CH2), 29.4 (CH=CHCH2CH2), 49.9 (NCH2), 115.9, 130.3, 131.3 and 139.1 
(CH), 166.5 (N=C-N); mlz 164 (M*, 57%), 149 (93), 135 (57), 123 (25), 97 (22), 84 (100), 
79 (44), 54 (35).
General method for the synthesis of 2-disubstituted l-terf-butyloxycarbonyl-2- 
imidazoline (2.1.23)
N- ^ / N" B oc Boc
Sèc-Butyllithium (1.3M solution in hexanes) was injected to a solution of 1-terf- 
butyloxycarbonyl-2-substituted-2-imidazoline in dry THF/TMEDA (25-30:1 v/v; 0.1M in 
imidazoline) at -78°C under nitrogen. The bright yellow solution produced was stirred for 
20 min at -78°C. The organohalide electrophile was injected (when liquid) or added by 
cannula as a solution in THF (when solid) to the reaction mixture at -78°C under nitrogen. 
The reaction was allowed to warm to 20°C overnight. The reaction was quenched with 
water (100 cm3) and the organic layer was extracted with diethyl ether (3 x 100 cm3) and 
the combined extracts were washed with saturated aq. NaHCOg (100 cm3), water (100 cm3) 
and brine (100 cm3), dried and concentrated. The crude product was purified by column
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chromatography on silica gel (1:9—>4:6 v/v ethyl acetate:hexane) to give the product 
imidazoline.
l-tert-Butyloxycarbonyl-2-[l-(prop-2-enyl)but-3-enyl]-2-imidazoIine (2.1.23a)
Boc
This compound was prepared by the general method, from 2-(but-3-enyl)-l-/er/- 
butyloxycarbonyl-2-imidazoline (0.60 g, 2.67 mmol), sec-butyllithium (2.67 cm3 of a 1.1M 
solution in hexanes, 2.94 mmol) and 3-bromopropene (0.25 cm3, 2.94 mmol). The title 
compound was obtained as a colourless oil (0.59 g, 84%) (Found: MH* 265.1916. 
C,5H24N202 requires: M f 265.1916); v™* (frlm)/cm ' 2996,2972,1720, 1644,1483,1369, 
1329, 1149, 1010, 915; 8h (400 MHz) 1.52 [9H, s, C(CH3)3], 2.29-2.35 (2H, m, 2 x 
CHCffflCH=CH2), 2.40-2.50 (2H, m, 2 x CHCHflCH=CH2), 3.58 (1H, t, J  6.6, 
CHCH2CH=CH2), 3.77 (4H, s, NCH2CH2N), 4.98-5.08 (4H, m, 2 x CH2CH2CH=Cff2), 
5.75-5.86 (2H, m, 2 x CH2CH2CFM H 2); 5c (75 MHz) 28.3 [C(CH3)3], 36.6 
[CH(CH2CH=CH2)2], 37.8 [CH(CH2CH=CH2)2], 47.1 (NCH2CH2N), 51.9 (NCH2CH2N),
81.7 [C(CH3)3], 116.6 [CH(CH2CH=CH2)2], 136.1 6 [CH(CH2CH=CH2)2], 150.8 (CO),
163.6 (N=C-N); m/z 265 (MH*, 2%), 209 (19), 191 (5), 165(27), 154 (14), 149 (14), 123 
(25), 108 (8), 83 (3), 57 (100). .
l-(ezt-Butyloxycarbonyl-2-[l-(prop-2-cnyl)pent-4-cnyl)-2-imidazoline (2.1.23b)
This compound was prepared by the general method, from l-ferf-butyloxycarbonyl-2- 
(pent-4-enyl)-2-imidazoline (0.77 g, 3.23 mmol), sec-butyllithium (2.73 cm3 of a 1.3M 
solution in hexanes, 3.55 mmol) and 3-bromopropene (0.31 cm3, 3.55 mmol). The title 
compound was obtained as a yellow oil (0.78 g, 87%), (Found: C, 67.14; H, 9.18, N,
CHCHHCH2CH=CH2), 1.77-1.84 (1H, m, CHCflHCHzCHCHz), 2.03-2.15 (2H, m, 
CHCHzO&CHCHz), 2.26-2.34 (1H, m, CHCHflCH=CH2), 2.39-2.49 (1H, m.
5.07 (4H, m, CH2CH2CH=Ctf2 and CHCH2CH=Cff2), 5.75-5.86 (2H, m, 
CHCH2CH2C7/=CH2 and CHCH2C//=CH2); 8c (100 MHz) 28.5 [C(CH3)3], 31.4 
(CHCH2CH2CH=CH2), 31.5 (CHCH2CH2CH=CH2), 37.4 (CHCH2CH=CH2), 37.7 
(CHCH2CH=CH2), 47.2 (NCH2CH2N), 51.9 (NCH2CH2N), 114.7 (CHCH2CH2CH=CH2),
116.7 (CHCH2CH=CH2), 136.1 (CHCH2CH=CH2), 138.9 (CHCH2CH2CH=CH2), 151.0 
(CO), 164.1 (N=C-N), mlz 279 (MH+, 12%), 223 (82), 179 (14), 168 (12), 137 (8), 123 (9), 
97 (13), 67 (11), 57 (100).
r \
9.81%; MH* 279.2084. C|sH2sH2O2.O.5H2O requires: C, 66.89, H, 9.05, N, 9.75%; MH 
279.2072); w  (film)/cm"' 3076, 2977, 2933, 2878, 1718, 1640, 1479, 1455, 1363, 1321,
1215, 1175, 1157, 1005; Sh (400 MHz) 1.50 [9H, s, C(CH3)3], 1.60-1.70 (1H, m.
CHC#HCH=CH2), 3.50-3.58 (1H, m, CHCH2CH=CH2), 3.77 (4H, s, NCH2CH2N), 4.90-
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l-Zert-Butyloiycarbonyl-2-[(l-phenylmethyl)but-3-enyl]-2-imidazoline (2.1.23c)
N ^ N ^ boc
This compound was prepared by the general method, from 2-(but-3-enyl)-1 -tert- 
butyloxycaibonyl-2-imidazoline (0.30 g, 1.34 mmol), sec-butyllithium (1.47 cm3 of a 1.0M 
in hexanes, 1.47 mmol) and benzyl bromide (0.18 cm3, 1.47 mmol). The title compound 
was obtained as a yellow oil (0.32 g, 76%) (Found: C, 71.82; H, 8.38; N, 9.45 %; M* 
314.1995. CwHwNz requires: C, 71.49; H, 8.67; N, 9.26%; M 314.1994); V™» (film)/cm ' 
2976,1669,1610, 1296,1200,1178,1130; 8» (400 MHz) 1.50 [9H, s, C(CH3)3], 2.27-2.34 
(1H, m, CHCHHCH=CH2), 2.40-2.47 (1H, m, CHCflHCH=CH2), 2.78-2.84 (1H, dd, /7 .8  
and 13.6, CHCHHPh), 3.02-3.07 (1H, dd, .77.6 and 13.6, CHCflHPh), 3.60-3.77 (4H, m, 
NCH2CH2N), 3.87-3.92 (1H, m, CflCH2Ph), 5.00-5.05 (2H, m, CHCH2CH=Ctf2), 5.65- 
5.75 (1H, m, CHCH2C77=CH2), 7.15-7.28 (5H, m, Ar-H); 8c (100 MHz) 28.2 {C(CH3)3],
36.6 (CHCH2CH=CH2), 38.8 (C Iia i2Ph), 39.6 (CHCH2Ph), 46.9 (NCH2CH2N), 51.8 
(NCH2CH2N), 81.5 [OC(CH3)3], 116.6 (CHCH2CH=CH2), 126.0, 128.1 and 129.3 (Ar- 
CH), 135.9 (CHCH2CH=CH2), 139.9 (Ar-C), 150.6 (CO), 163.5 (N=C-N); m/z 315 (MH% 
2%), 259 (24), 217 (26), 213 (15), 173 (24), 167 (28), 123 (26), 91 (21), 57 (100).
General method for the synthesis of 2a-disubstituted 2-imidazolines (2.1.24)
Boc
Trifluoroacetic acid (5 cm3) was added to the 2a-disubstituted l-ferf-butyloxycarbonyl-2- 
imidazolines and the resulting solution was stirred at room temperature for 20-60 min. The 
trifluoroacetic acid was removed under reduced pressure and the imidazoline salt was
143
dissolved in dichloromethane (50 cm3). The solution was then washed with a 10% w/v 
solution of aq.NaOH (50 cm3) and the organic layer was dried and concentrated. The crude 
product was then purified by column chromatography on silica gel (0:100—>4:96 v/v 
isopropylamine:ethyl acetate) to give the 2-disubstituted 2a-imidazolines.
2 [-l-(Prop-2-enyl)but-3-enyl]-2-imidazoline (2.1.24a)
NHBoc
This compound was prepared by the general method, from 1 -ferf-butyloxycarbonyl-2-[ 1 - 
(prop-2-enyl)but-3-enyl]-2-imidazoline (1.20 g, 4.54 mmol) and TFA (3 cm3). The title 
compound was obtained as a yellow oil (0.50 g, 67%) (Found: M+ 165.138. CioHigN] 
requires: MH 165.139); (film)/cm  ^ 3196, 3077, 2977, 2864, 1642, 1612, 1495, 1472, 
1452, 1288, 994, 914; 8h (400 MHz) 2.25-2.35 (4H, m, 2 x CHCfl2CH=CH2), 2.46 (1H, m, 
CifCH2CH=CH2), 3.52 (4H, s, NCH2CH2N), 3.95 (1H, hr s, NH), 4.95-5.10 (4H, m, 2 x 
CH=C^2), 5.70-5.86 (2H, m, 2 x C /^C H 2); 5c (100 MHz), 36.9 (CHCH2CH=CH2), 39.7 
(CHCH2CH=CH2), 49.5 (NCH2), 116.8 (CH=CH2), 135.9 (CH=CH2), 169.9 (N=C-N); m/z 
165 (MH^, 100%), 149 (14), 135 (14), 121 (34), 110 (10), 94 (4), 82 (9), 67 (6).
2-[l-(Prop-2-enyl)pent-4-enyl]-2-imidazoline (2.1.24b)
Boc
This compound was prepared by the general method, from 1 -ter/-butyloxycarbonyl-2-[ 1 - 
(prop-2-enyl)pent-4-enyl]-2-imidazoline (0.50 g, 1.80 mmol) and TFA (2 cm3). The title 
compound was obtained as a pale yellow oil (0.26 g, 81%) (Found: MH+ 179.1548.
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CiiHigNz requires: MH 179.1548); vmax (film)/cm1 3176, 3077, 2976, 2933, 2863, 1641, 
1611, 1495, 1472, 1455, 1289, 994, 912; 5h (400 MHz) 1.58-176 (2H, m, 
CHC1Ï2CH2CH=CH2), 2.05-2.15 (2H, m, CHCH2C//2CH=CH2), 2.26-2.34 (2H, m, 
CHCH2CH=CH2), 2.38-2.44 (1H, m, CflCH2CH=CH2), 3.56 (4H, s, NCH2CH2N), 4.08 
(1H, br s, NH), 4.95-5.10 (4H, m, 2 x CH=C%), 5.72-5.86 (2H, m, 2 x C/f=CH2); 8c (100 
MHz) 31.3 (CHCH2CH2CH=CH2), 31.8 (CHCH2CH2CH=CH2), 37.6 (CHCH2CH=CH2),
39.4 (CHCH2CH=CH2), 49.6 (NCH2), 114.4 and 116.5 (CH=CH2), 135.9 and 138.1 
(CH=CH2), 169.9 (N=C-N); m/z 1164 (M*, 9%), 163 (18), 135 (32), 124 (86), 123 (100), 
109(28), 97 (49), 67 (21).
2-[(l-Phenylmethyl)but-3-enyl]-2-imidazolme (2.1.24c)
NHBoc
This compound was prepared by the general method, from l-fer/-butyloxycarbonyl-2-[(l- 
phenyl)methylbut-3-enyl]-2-imidazoline (0.20 g, 0.64 inmol) and TFA (1 cm3). The title 
compound was obtained as a white solid (0.09 g, 67%), m.p. 76-78 °C (Found: M* 
214.1470. Ci4H18N2 requires: A/214.1470); vmax (KBr)/cm ' 3120,2976,1669,1610, 1296, 
1200, 1178, 1130; 8h (400 MHz) 2.35-2.41 (1H, m, CHCflHCH=CH2), 2.48-2.56 (1H, m, 
CHCHHCH=CH2), 2.91-2.98 (1H, dd, 7  7.6 and 13.6, CHCHH2Ph), 3.02-3.09 (1H, dd, J
7.6 and 13.6, CHCHHPh), 3.20-3.30 (1H, m, CHCHjPh), 3.99-3.87 (4H, m, NCH2CH2N), 
5.05 (1H, d, J  10.2, CHCH2CH=CHH), 5.12 (1H, d, J  17.1, CHCH2CH=CHH), 5.65-5.75 
(1H, m, CHCH2CH-CH2), 7.15-7.30 (5H, m, Ar-H), 8c (100 MHz) 36.1 
(CHCH2CH=CH2), 37.8 (CHCH2Ph), 40.2 (CHCH2Ph), 44.7 (NCH2), 118.2 
(CHCH2CH=CH2), 126.9, 128.6 and 128.9 (Ar-CH), 133.8 (CHCH2CH=CH2), 137.4 (Ar-
C), 173.3 (N=C-N); m/z 214 (M% 18%), 213 (36), 173 (61), 171 (24), 167 (10), 137 (16) 
123 (100), 108 (12), 91 (38), 77 (10), 65 (20), 57 (57).
General method for the synthesis of l-te/t-butyloxycarbonyl-2-(2- 
oxoalkylidene)imidazolidines (2.1.30)
HNBoc Boc
S'ec-Butyllithium (1.3M solution in hexanes) was injected to a solution of 1 -tert- 
butyloxycarbonyl-2-methyI-2-imidazoline in dry THF/TMEDA (25:1 v/v; 0.1M in 
imidazoline) under nitrogen at -78°C. The bright yellow solution produced was stirred for 
20 min at -78°C. The freshly distilled ester electrophile was injected to the reaction mixture 
at -78°C under nitrogen and the mixture was allowed to warm to 20°C overnight. The 
reaction was quenched with water (100 cm3) and the organic layer was extracted with 
diethyl ether (3 x 50 cm3) and the combined extracts were washed successively with 
saturated aq. NaHCOs (100 cm3), water (100 cm3) and brine (100 cm3), dried and 
concentrated. The crude product was purified by column chromatography on silica gel 
(1:9—>1:1 v/v ethyl acetate:hexane) to give the acylatedproduct.
l-te/t-Butyloxy-2-(2-oxopropylidene)imidazolidine (2.1.30a)
/ \ 
,N-
r~\
Boc HNX / N" B oc
T
This compound was prepared by the general method, from 1 -terf-butyloxycarbonyl-2- 
methyl-2-imidazoline (0.55 g, 2.99 mmol), sec-butyllithium (3.58 cm3 of a 1.0 M solution
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in hexane, 3.58 mmol) and ethyl acetate (0.70 cm3, 6.00 mmol). The title compound was 
obtained as white crystals (0.49 g, 72%), m.p. 125-127°C (Found: C, 58.12; H, 8.11; N, 
12.11%; M 226.1317. C ,1H18N203 requires: C, 58.39; H, 8.02; N, 12.37%; M  226.1317); 
Vm« (KBr)/cm'* 3253,2976,2936,1725,1622,1557,1318,1253,1149; 8h (400 MHz) 1.45 
[9H, s, C(CH3)3], 2.03 (3H, s, CH3), 3.57 and 3.80 (each 2H, t, J  9.0, NCH2CH2N), 5.92 
(1H, s, CH), 9.96 (1H, br s, NH); 8c (100 MHz) 28.0 [C(CH3)3], 29.3 (CH3), 41.1 and 44.9 
(NCH2), 81.6 (CH), 82.7 [C(CH3)3], 150.4 (CO), 157.6 (N=C-N), 195.2 (CH3CO); m/z 226 
(M*, 10%), 170 (32), 153 (10), 126 (31), 111 (68), 84 (41), 70 (12) 57 (100) 43 (29).
l-Zc/t-Butyloxy-2-(2-oxo-2-phenylethylidene)imidazolidine (2.1.30b)
n
N .x .N .Boc --------------------------------- » HN
Boc
P h
This compound was prepared by the general method, from 1 -ter/-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec-butyllithium (10.86 cm3 of a 1.1M 
solution in hexane, 11.95 mmol) and methyl benzoate (1.48 cm3, 11.95 mmol) in THF (108 
cm3) and TMEDA (4 cm3). The title compound was obtained as white crystals (2.00 g, 
64%), m.p 170-172 °C (Found: C, 66.50; H, 7.00; N, 9.63%; MH+ 289.1545; C,6H2oN20 3 
requires: C, 66.65; H, 6.99; N, 9.71%; MH 289.1552); Vmax (KBrl/cm"1 3253, 2979, 
1733, 1608, 1557, 1581, 1532, 1358, 1317, 1146; 8h (300 MHz) 1.57 [9H, s, C(CH3)3], 
3.67 and 3.88 (each.2H, t, J  8.5, NCH2CH2N), 6.69 (1H, s, CH), 7.86-7.95 (5H, m, Ar-H)
10.47 (1H, br s, NH); 8c (75 MHz) 28.1 [C(CH3)3], 41.2 and 45.1 (NCH2), 78.8 (C=CH),
82.9 [C(CH3)3], 126.9, 128.1, 130.4 (Ar-CH), 140.5 (Ar-C), 150.5 (CO), 159.1 (NCN),
188.2 (PhCO); m/z 288 (M+, 11%), 232 (22), 215 (8), 204, (7), 187 (100), 159 (24), 146 
(3), 131 (8), 111 (41), 105 (33), 77(34).
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l-teit-Butyloxy-2-(2-oxobut-3-enylidene)imidazolidine (2.1.30c)
HN.Boc Boc
This compound was prepared by the general method, from l-ter/-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec-butyllithium (11.95 cm3 of a 1.0M 
solution in hexane, 11.95 mmol) and methyl propenoate (1.86 cm3, 11.95 mmol). The title 
compound was obtained as white crystals (1.05 g, 42%), m.p 145-147 °C (Found: C, 60.63; 
H, 7.69; N, 11.77%; MH+ 239.1383. C12H17N2O3 requires: C, 60.74; H, 7.22; N, 11.80%;
239.1396); v,** (KBrVcm1 3245, 2971, 2930, 1732, 1601, 1541, 1514, 1476, 1313, 
1250,1151; 1040; Ôh (400 MHz) 1.55 [9H, s, C(CH3)3], 3.67 and 3.88 (each 2H, t, J7 .8  
NCH2CH2N), 5.44-5.47 (1H, dd, 72.0 and 10.4, CH=CHfl), 6.06 (1H, s, C=CHCO), 6.11- 
6.16 (1H, dd, 72.0 and 17.2, CH=CHfl), 6.34-6.41 (1H, dd, 7  10.4, and 17.2, Ci£=CH2),
10.48 (1H, br s, NH); 8c (100 MHz) 28.0 [C (Œ 3)3], 41.3 and 44.0 (NCH2), 81.9 (CHCO),
83.0 [C(CH3)3], 122.1 (CH=CH2), 138.3 (CH=CH2), 150.4 (CO), 159.1 (N-C-N), 186.3 
(C=CHCO); m/z 239 (M+, 5%), 183 (12), 165 (3), 149 (5), 139 (12), 123 (2), 108 (6), 87 
(5) 57 (100).
2-(2-Oxopropylidene)imidazolidme (2.1.31a)
HN Boc
Trifluoroacetic acid (1 cm3) was added to 1 -ter/-butyloxy-2-(2-
oxopropylidene)imidazolidine (0.20 g, 088 mmol) and the resulting solution was stirred at
20°C for Ih. The trifluoroacetic acid was removed under reduced pressure and the
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imidazolidine trifluoroacetate salt was dissolved in dichloromethane (20 cm3). The solution 
was then washed with aq. NaOH (20 cm3, 10 % w/v) and the organic layer was dried and 
concentrated. The crude product was then purified by column chromatography on silica gel 
(0:100—>3:97 v/v isopropylamine:chloroform) to give the title compound as a yellow solid 
(0.09 g, 81 %), m.p.157-159 °C (Found: M+ 126.0793. C6HioN20  requires: M  126.0793); 
Vmax (KBrVcm"1 3279, 3116, 1605, 1557, 1490, 1323; Sh (400 MHz) 1.98 (3H, s, CH3), 
3.55 and 3.70 (each 2H, t, /7 .8 , NCH2CH2N), 4.77 (IH, s, CH), 5.40 (IH, br s, NH), 9.20 
(IH, br s, NH); 5c [100 MHz; (CDs^SO] 28.5 (CH3), 41.8 and 43.5 (NCH2), 76.0 (CH),
164.4 (N-C-N), 188.1 (CO); mlz 126 (M \ 44%), 111 (100) 97 (12), 84 (39), 70 (23), 54 
(40) 43 (73).
2-(2-Oxo-(3-phenyl)ethylidene)imidazolidine (2.1.3 lb)
HN
Boc
Ph
HN NH
Ph
Trifluoroacetic acid (4 cm3) was added to 1 -ter/-butyloxy-2-(2-oxo-3- 
phenylethylidene)irmdazolidine (1.20 g, 4.16 mmol) and the resulting solution was stirred 
at 20°C for 40 min. The trifluoroacetic acid was removed under reduced pressure and the 
imidazolidine salt was dissolved in dichloromethane (20 cm3). The solution was then 
washed with a solution of aq. NaOH (20 cm3, 10% w/v) and the organic layer was dried 
and concentrated. The crude product was purified by column chromatography on silica gel 
(0:100—>3:97 v/v isopropylamine:ethyl acetate) to give the title compound as white crystals 
(0.70 g, 90 %), m.p. 203-205°C (lit.,116 208°C) (Found: C, 69.88; H, 6.48; N, 14.73%; (M- 
H)+ 187.0864. C11H12N2O requires: C, 70.19; H, 6.43; N, 14.88%; M-H 187.0871); vmax 
(KBrycm1 3310, 2987, 2860, 1603, 1582, 1554, 1503, 1477, 1451, 1332, 1290, 1213,
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1054, 720; Sh [300 MHz; (CT^SO ] 3.45 and 3.59 (each 2H, t, J  8.0, NCH2), 5.54 (IH, s, 
CH), 7.30-7.39 (3H, m, Ar-H), 7.69-7.75 (2H, m, Ar), 9.28 (IH, br s, NH); 8c [75 MHz; 
(CDsbSO] 41.8 and 43.5 (NCH2), 73.1 (CH), 126.1, 127.9 and 129.4 (Ar-CH), 141.5 (Ar- 
C), 165.4 (N-C-N), 181.9 (CO); m/z 188 (M+, 67%), 159 (30), 131 (18), 111 (100), 105 
(37), 81 (8), 77 (85).
l-te/?-Butyloxycarbonyl-2-(diethylphosphonomethyl)-2-imidazoline (2.1.32)
n .  . n .
' s i /  Boc NY N- B ocv
Etc/ \)E t
S'ec-Butyllithium (18.39 cm3 of a 1.3M solution in cyclohexane, 23.91 mmol) was injected 
to a solution of l-tor/-butyloxycarbonyl-2-methyl-2-imidazoline (4.00 g, 21.74 mmol) in 
dry THF (200 cm3) and TMEDA (5 cm3) at -78°C under nitrogen. The bright yellow 
solution produced was stirred for 20 min at -78°C under nitrogen before diethyl 
chlorophosphate (3.45 cm3, 23.91 mmol) was injected into the reaction mixture. The 
mixture was allowed to warm to 20°C overnight and the reaction was quenched with water 
(100 cm3). The organic layer was extracted with diethyl ether (3 x 100 cm3) and the 
combined organic extracts were washed successively with saturated aq. NaHCOg (100 
cm3), water (50 cm3) and brine (50 cm3), dried and concentrated. The crude product was 
purified by column chromatography on silica gel (0:100—>1:99 v/v 
isopropylamine:chloroform) to give the title compound as a yellow oil (3.56 g, 51%) 
(Found: C, 45.14; H, 7.86; N, 7.90%, M+ 320.1501. C13H25N2O5P I.5H2O requires: C, 
44.95; H, 8.07; N, 8.07%; Af 320.1501); v™» (filmycm1 2981, 2935, 1713, 1639, 1371, 
1254, 1165, 1028, 971; 5h (400 MHz) 1.31-1.34 (6H, t, J  7.2, (% (% ), 1.50 [9H, s, 
C(CH3)3], 3.56-3.62 (2H, d, .722.0, CH2?(0 )(OEt)2), 3.80 (4H, s, NCH2CH2N), 4.14-4.21
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(4H, q, J  7.2, CH3CH2), 8c (100 MHz) 16.1 (CH3CH2), 27.9 [C(CH3)3], 40.2 (CH3CH2),
46.6 and 52.2 (NCH2), 62.6 (CH2P), 82.1 [C(CH3)3], 150.8 (CO), 153.6 (N=C-N); mlz 321 
(MH*, 2%), 220 (18), 192 (8), 179 (8), 166 (11), 138 (8), 123 (2), 110 (9), 84 (95), 57 
(100).
General method for the synthesis of l-terf-butyloxycarbonyl-2-(l-alkenyl)-2- 
imidazolines (2.1.33)
n
N^ % 0CBoc
OEt R
5ec-Butyllithium (solution in cyclohexane, 1.1 equiv.) was added dropwise to a stirred 
solution l-ter/-butyloxycarbonyl-2-(diethylphosphonomethyl)-2-imidazoline in dry 
THF/TMEDA (25:1 v/v; 0.1M in imidazoline) at -78°C under nitrogen. The red solution 
produced was stirred for 20 min at -78°C. Freshly distilled aldehyde electrophile (1.1 
equiv.) was injected rapidly to the reaction mixture at -78°C under nitrogen and the stirred 
reaction mixture was allowed to warm to 20°C overnight. It was then quenched with water 
(100 cm3). The organic layer was extracted with diethyl ether (3 x 100 cm3) and the 
combined organic extracts were washed successively with saturated aq. NaHCOs (100 cm3) 
and brine (100 cm3), dried and concentrated. The crude product was purified by column 
chromatography on silica gel (1:9—>2:3 ethyl acetate/hexane) to give the l-Boc-2-(l- 
alkenyl)-2-imidazoline.
l-tert-Butyloxycarbonyl-2-(pent-l-enyl)-2-iimdazoline (2.133a)
Boc■*-Boc
EtO
The compound was synthesised by the general method, from 1 -ferf-butyloxycarbonyl-2- 
(diethylphosphonomethyl)-2-imidazoline (0.50 g, 1.56 mmol), sec-butyllithium (1.72 cm3 
of a 1M solution in cyclohexane, 1.72 mmol) and butanal (0.15 cm3, 1.72 mmol). The title 
compound was obtained after column chromatography on silica gel (1:9—>1:1 v/v ethyl 
acetate:hexane) as a colourless oil (0.25 g, 67%; 0.19 g of E-isomer and 0.06 g of Z- 
isomer). The Z-isomer converts to the E-isomer upon standing; (Found: C, 63.51; H, 9.22; 
N, 11.74%; MH* 239.1760. C13H22N2O2 O.4.H2O requires: C, 63.31; H, 9.25; N, 11.36%; 
M f 239.1759); v™» (filmycm"1 2961,2932, 1718, 1654, 1614, 1370, 1149,1014; data for 
£-isomer: Sh (400 MHz) 0.93 (3H, 1,77.2 CH3CH2CH2), 1.48-1.53 (2H, m, CH3CH2CH2), 
1.52 [9H, s, C(CH3)3], 2.15-2.20 (2H, dt, 77.2 and 7.6, CHjCHzCTfcCH^CH), 3.78 (4H, s, 
NCH2CH2N), 6.72 (2H, s, CH=CH); Sc (100 MHz) 13.9 (CH3CH2), 21.7 (CH3CH2CH2), 
28.2 [C(CH3)3], 35.3 (CH3CH2CH2), 46.8 and 52.0 (NCH2), 81.6 [C(CH3)3], 119.6 
(CH2CH=CH), 141.8 (CH2CH=CH), 151.1 (CO), 157.3 (N=C-N); m/z 239 (MH*. 100%), 
183 (84), 167 (16), 139 (39), 123 (14), 109 (25), 84 (5), 81 (11), 57 (99). Data for Z- 
isomer: Sh (400 MHz) 0.92 (3H, t ,77.2, CH3CH2), 1.48-1.53 (2H, m, CH3CH2), 1.52 [9H, 
s, C(CH3)3], 2.42-2.47 (2H, dt, 7  7.2 and 7.6, CH3CH2C//2CH), 3.71-3.76 and 3.86-3.90 
(each 2H, t, 7  9.2, NCH2CH2N), 5.92 (IH, m, CH2C//=CH ), 6.42 (IH, d, 7  11.6, 
CH2CH=CH); 5c (100 MHz) 13.9 (CH3CH2), 22.5 (CH3CH2CH2), 28.2 [C(CH3)3], 31.4 
(CH3CH2CH2CH-CH), 45.9 and 52.8 (NCH2), 81.6 [C(CH3)3], 118.8 and 141.3 (CH=CH),
151.1 (CO), 155.8 (N=C-N).
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l-tert-Butyloxycarbonyl-2-(penta-l^-dienyl)-2-imdazoline (2.1.33b)
E tO " ^
N ^ ,N x
OEt
J Boc Boc
The compound was synthesised by the general method, from l-terf-butyloxycarbonyl-2- 
(diethylphosphonomethyl)-2-imidazoline (1.42 g, 4.44 mmol), sec-butyllithium (6.10 cm3 
of a 0.8M solution in cyclohexane, 4.48 mmol) and but-2-enal (0.40 cm3, 4.48 mmol). The 
title compound was obtained after column chromatography on silica gel (1:9—>2:8 v/v ethyl 
acetate:hexane) as an orange solid (0.68 g, 65%), m.p 58-60°C (Found: C, 65.82; H, 8.56; 
N: 11.43%; MH* 237.1603. C13H20N2O2 requires: C, 66.07; H, 8.53; N, 11.85%; MH 
237.1603); v ^  (KBrVcm1 2977, 2934, 1714, 1646, 1617, 1596, 1375, 1166, 1140, 1011; 
8h (400 MHz) 1.52 [9H, s, C(CH3)3], 1.83 (3H, d, J  6.8, Ctf3CH), 3.80 (4H, s, 
NCH2CH2N), 5.96-6.01 (IH, m, CH3C#), 6.20 (IH, dd, J  13.0, 13.2,
CH3CH=CffCH=CH), 6.78-6.82 (IH, d, J  15.6, CH3CH=CHCH=CH), 7.15-7.21 (IH, dd, 
J  13.2 and 15.6, CHsCH^CHCJ^CH); 5c (100 MHz) 18.5 (CH3), 28.3 [C(CH3)3], 46.9 
and 52.1 (NCH2), 81.7 [C(CH3)3], 117.9, 131.1, 135.7 and 139.3 (CH), 151.2 (CO), 157.5 
(N=C-N); m/z 237 (MH*, 18%), 221 (49), 181 (38), 165 (100), 135 (17), 121 (52), 107
(12), 83 (92), 57 (100).
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l-te#t-Butyloxycarbonyl-2-(2-phenylethenyl)-2-imidazoline (2.1.33c)
N - m
Boc
E tO ^^  
OEt
The compound was synthesised by the general method, from l-terf-butyloxycarbonyl-2- 
(diethylphosphonomethyl)-2-imidazoline (0.50 g, 1.56 mmol), sec-butyllithium (1.72 cm3 
1M of a solution in cyclohexane, 1.72 mmol) and benzaldehyde (0.17 cm3, 1.72 mmol). 
Column chromatography on silica gel (1:9—>2:3 v/v ethyl acetaterhexane) afforded the title
MHz) 1.50 [9H, s, C(CH3)3], 3.80 (4H, s, NCH2CH2N), 7.22-7.32 (4H, m, PhCJ^CH, and 
3 x Ar-H), 7.47 (3H, m PhCH=Ctf and 2 x Ar-H); 5c (100 MHz) 28.2 [C(CH3)3], 46.9 and
52.1 (NCH2), 81.7 [C(CH3)3], 117.2 (PhCH=CH), 127.5, 128.6 and 128.9 (Ar-CH), 135.9 
(Ar-C), 138.2 (PhCH=CH), 151.1 (CO), 157.4 (N=C-N); m/z 272 (M+, 13%), 244 (13), 215 
(100), 199 (25), 171 (100), 143 (29), 115 (55), 107 (62), 91 (73) 79 (71) 57 (100).
General method for the one pot synthesis of l-tert-butyloxycarbonyl-2-(l-alkenyl)-2- 
imidazolines (2.133)
compound as a white solid (0.28 g, 66%), m.p. 63-65°C (Found: C, 69.90; H, 7.45; N, 
9.89%; M+ 272.1525. C16H20N2O2 O.IH2O requires: C, 70.08; H, 7.37; N, 10.22%; M  
272.1525); v ^  (KBrVcm"1 2979, 1713, 1641, 1608, 1371, 1316, 1148, 1015, 756; 5h (400
N v N
r \
N» KL
Boc
R
«S'ec-Butyllithium (1.3M solution in cyclohexane) was injected to a stirred solution of 1- 
/er/-butyloxycarbonyl-2-methyl-2-imidazoline in dry THF/TMEDA (25:1 v/v; 0.1M in
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imidazoline) stirred at -78°C under nitrogen. The bright yellow solution produced was
stirred for 20 min at -78°C, when diethyl chlorophosphate (1.1 equiv.) was injected a pale
nitrogen. The reaction mixture was cooled to -78°C and a second equiv. of sec-butyllithium 
(1.3M solution in cyclohexane) was added. The bright red solution produced was stirred at 
-78°C for 20 min and freshly distilled aldehyde (1.1 equiv.) was injected to it. The stirred 
reaction mixture was allowed to warm to 20°C overnight. It was then quenched with water
combined organic extracts were washed successively with saturated aq. NaHCOs (100
purified by column chromatography on silica gel (1:4—>2:3 v/v ethyl acetate:hexane) to 
give the 1 -ter/-butyloxycarbonyl-2-( 1 -alkenyl)-2-imidazoline.
One pot synthesis of l-te#t-butyloxycarbonyl-2-(pent-l-enyl)-2-imidazoline (2.133a)
The compound was synthesised by the general method, from 1 -ferf-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec-butyllithium (2 x 9.19 cm3 of a 1.3M 
solution in cyclohexane, 11.95 mmol), diethyl chlorophosphate (1.32 cm3, 10.86 mmol) 
and butanal (1.05 cm3, 11.95 mmol) in THF (108 cm3) and TMEDA (3 cm3). The title 
compond was obtained as a yellow oil (0.85 g, 33%), (0.68 g of E-isomer and 0.17 g of Z- 
isomer). They have data identical to those reported for the two-stage synthesis.
yellow solution was produced that was stirred at -78°C for Ih and at 20°C for 4 h under
(100 cm3), the organic layer was extracted with diethyl ether (3 x 100 cm3) and the
cm3), water (50 cm3) and brine (50 cm3), dried and concentrated. The crude product was
r~\
One pot synthesis of l-te/f-butyloxycarbonyl-2-(penta-l,3-dienyl)-2-iinidazoline
(2.1.33b)
The compound was synthesised by the general method, from 1 -/er/-butyloxycarbonyl-2- 
methyl-2-imidazoline (4.00 g, 21.70 mmol), sec-butyllithium (2 x 18.4 cm3 of a 1.3 M 
solution in cyclohexane, 2 x 23.90 mmol), diethyl chlorophosphate (3.45 cm3, 23.90 mmol) 
and 2-butenal (1.98 cm3, 23.90 mmol) in THF (217 cm3) and TMEDA (3 cm3). The title 
compound was obtained as a white solid (1.75 g, 33%), m.p 58-60 °C, having data identical 
to those reported for the two-stage synthesis.
One pot synthesis of l-tert-butyloxycarbonyl-2-(2-phenylethenyl)-2-iinidazoline 
(2.1.33c)
The compound was synthesised by the general method, from 1 -fgrf-butyloxycarbonyl-2- 
methyl-2-imidazoline (2.00 g, 10.86 mmol), sec butyllithium (2 x 9.19 cm3 of a 1.3 M 
solution in cyclohexane, 2 x 11.95 mmol), diethyl chlorophosphate (1.32 cm3, 10.86 mmol) 
and benzaldehyde (1.21 cm3, 11.95 mmol) in THF (108 cm3) and TMEDA (3 cm3). The 
title compound was obtained as a white solid (1.20 g, 40%), m.p. 63-65 °C, having data 
identical to those reported for the two-stage synthesis.
r~\
Ph
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General method for the synthesis of 2-(l-alkenyl)-2-imidazolines from 1-tert- 
butyloxycarbonyl-2-(l-alkenyl)-2-imidazolines (2.134)
r \
N ^ N
Boc
i
N>x ,NH
R R
Trifluoroacetic acid (1 cm3) was added to the l-terf-butyloxycarbonyl-2-(l-alkenyl)-2- 
imidazoline and the resulting solution was stirred at 20 C for 20-60 m in. The 
trifluoroacetic acid was removed under reduced pressure and the crude product was then 
purified by column chromatography on neutral alumina (activation grade IH) (0:100—>2:98 
v/v isopropylamine:ethyl acetate) to give the 2-(l-alkenyl)-2-imidazoline.
2-(Penta-l-enyl)-2-imidazoline (2.1.34a)
n
N -X /N .
Boc N x  /N H
The compound was synthesised by the general method, from 1 -tert-butyloxycarbonyl-2- 
(pcnt-1 -enyl)-2-imidazoline (0.20 g, 0.84 mmol) and trifluoroacetic acid (1 cm^). The title 
compound was obtained as a white gum (0.095 g, 82%) (Found: M" 138.1157. CgHi^N: 
requires: M*, 138.1157); (filmycm"1 3197,2956,2932,2871, 1699, 1603,1580, 1500, 
1470,1278, 973; 8h (400 MHz) 0.85 (3H, t, 77.2, CH,), 1.37-1.43 (2H, m, CH,C%CHz), 
2.07-2.13 (2H, dt, J  7.2 and 7.6, CH,CH,C%CH=CH), 3.60 (4H, s, NCH2CH2N), 5.95-
6.00 (IH, d, J  16.1, CH2CH=Cfl), 6.17-6.24 (IH, m, CH2C/7CH ); Sc (100 MHz) 13.6 
(CH,), 21.7 (CH3CH2), 34.6 (CH2CH=CH), 50.0 (NCH2), 120.9 and 139.9 (CH=CH),
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164.2 (N-C=N); mlz 138 (M*, 61%), 123 (31), 109 (100), 94 (37), 81 (96), 67 (26), 56 (34), 
41(48).
2-(Penta-l,3-dienyl)-2-imidazolme (2.1.34b)
n
N<s /N -
Boc
%
r \
N<x ,NH
The compound was synthesised from l-/erf-butyloxycarbonyl-2-(penta-l,3-dienyl)-2- 
imidazoline (0.54 g, 2.28 mmol) and trifluoroacetic acid (1 cm3) using the general method 
described before. The title compound was obtained as a white solid (0.20 g, 64%), m.p 
112-114 °C (Found: M+ 136.1000. CgH^N; requires: Af 136.1000); vm„  (KBrycm"1 3178, 
2936, 2870, 1651, 1630, 1505, 1475, 1276, 988; 8h  (400 MHz) 1.83 (3H, d, J  6.8 Hz, 
C //3CH=CHCH=CH), 3.68 (4H, s, NC/f2C/f2N), 4.40 (IH, br s, NH), 5.95-6.00 (IH, m, 
CH3C/f=CHCH=CH), 6.02-6.06 (IH, d, J  15.6, CH3CH=CHCH=CH), 6.14-6.20 (IH, dd, 
J  13.2 and 13.0, CH3CH=OfCH=CH), 6.72-6.68 (IH, dd, J  13.2 and 15.6, 
CH3CH=CHGH=CH); 5c  (100 MHz) 18.5 (CH3CH=CHCH=CH), 49.6 (NCH2CH2N), 
118.4, 130.5, 135.8 and 138.0 (CH), 164.3 (N=C-N); m/z 136 (M+, 100%), 135 (64),121 
(49), 106 (66), 92 (26), 79 (38), 66 (22), 41 (18), 18 (16).
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2-(2-Phenylethenyl)-2-imidazoline (2.1.34c)
.NH
»h
The compound was synthesised from 1 -ter/-butyloxycarbonyl-2-(2-phenylethenyl)-2- 
imidazoline (0.17 g, 0.62 mmol), and trifluoroacetic acid (2 cm3) using the general method. 
The title compound was obtained as a white solid (0.098 g, 91%), m.p 154-156 °C (Found: 
M4 172.1000. C11H12N2 requires: M  172.1000); vmto (KBrVcm'1 3171, 2926, 2867, 1651, 
1597, 1581, 1501, 1292,982,760; Sh (400 MHz) 3.70 (4H, s, NCHjCHjN), 4.32 (IH, br s, 
NH), 6.68 and 7.05 (each IH, d, J  16.6, CH=CH), 7.30 (3H, m, Ar-H), 7.46 (2H, m, Ar-H), 
8c (100 MHz) 50.0 (NCH2), 118.3 (CH), 127.2, 128.8, 128.9 and 135.4 (Ar-C), 136.7 
(CH), 164.1 (N=C-N); m/z 172 (M% 65%), 171 (79), 143 (23), 128 (13), 115 (100), 103 
(8), 77 (17), 57 (36).
l-tert-Butyloxycarbonyl-2-phenylthiomethyI-2-imidazoline (2.1.35) and 1-tert- 
butyloxycarbonyl-2^-bis(phenylthiomethyl)-2-imidazoline (2.1.36)
n  n
NV N" B oc --------------------   N ^ N ^ bqc + N^ N- B oc
PhS PhS SPh
«S'ec-Butyllithium (4.97 cm3 of a 1.2M solution in cyclohexane, 5.97 mmol) was injected to 
a stirred solution of l-/er/-butyloxycarbonyl-2-methyl-2-imidazoline (1.00 g, 5.43 mmol) 
in dry THF (54 cm3) and TMEDA (2 cm3) at -78°C under nitrogen. The bright yellow 
solution produced was stirred for 20 min at -78°C when diphenyl disulphide (1.30 g, 5.97 
mmol) in THF (20 cm3) was added via cannula to the reaction mixture at -78°C under 
nitrogen and the mixture was allowed to warm to 20°C overnight. The reaction was
159
quenched with water (100 cm3), the organic layer was extracted with diethyl ether (3 x 100 
cm ) and the combined organic extracts were washed successively with aq. NaHCOs (100 
cm ), water (50 cm3) and brine (50 cm3), dried and concentrated. The crude product was 
purified by column chromatography on silica gel (l:9-»2:3 v/v ethyl acetate:hexane) to 
give the monosulphenated 2-imidazoline as a white solid (0.60 g, 38%), m.p 77-79 °C 
(Found: C, 61.55; H, 6.98; N, 9.50%; M+ 292.1245. C isH joh^S  requires: C, 61.62; H, 
6.89; N, 9.58%; M 292.1245); Vmm (KBrVcm"1 2974, 1703, 1635, 1483, 1379, 1142, 737; 
Sh (400 MHz) 1.46 [9H, s, C(CH3)3], 3.70 (4H, s, NCH2CH2N), 4.07 (2H, s, PhSC#2), 
7.22-7.35 (3H, m, Ar-H), 7.38-7.42 (2H, m, Ar-H); Sc (100 MHz) 28.1 [C(CH3)3], 34.0 
(PhSCH2), 46.8 and 52.2 (NCH2), 82.2 [C(CH3)3], 126.4, 128.9 and 129.8 (Ar-CH), 136.0 
(Ar-C), 150.6 (CO), 157.7 (N=C-N); m/z 292 (M1, 8%), 236 (41), 219 (5), 203 (14), 191
(13), 159 (22), 123 (12), 109 (10), 57 (100), and the disulphenated 2-imidazoline as a white 
solid (0.65 g, 28%), m.p. 91-93 °C (Found: C, 62.93; H, 6.13; N, 7.03%; M 1" 400.1279. 
Ci5H2ON202S requires: C, 62.97; H, 6.04; N, 6.99%; Af 400.1279); v™, (KBrVcm"1 2977, 
1698, 1634, 1482, 1364, 1133, 1006, 739; 8» (400 MHz; CDC13) 1.52 [9H, s, C(CH3)3], 
3.66-3.68 and 3.74-3.77 (each 2H, t, J  8.0, NCH2CH2N), 6.20 (IH, br s, CH), 7.31-7.35 
(6H, m, Ar-H), 7.48-7.51 (4H, m, Ar-H); Sc (100 MHz) 28.7 [C(CH3)3], 47.5 and 52.4 
(NCH2), 54.5 ((PhS)2CH), 82.7 [C(CH3)3], 128.6,129.2 and 132.7 (Ar-CH), 134.4 (Ar-C),
150.7 (CO), 157.8 (N=C-N); m/z 400 (M+, 2%), 291 (19), 235 (100), 191 (38), 139 (43), 
121 (27), 110 (21), 97 (80), 77 (18), 70 (23), 57 (85).
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2-Phenylthiomethyl-2-imidazoline (2.1.37)
n  / \
NY N- B oc ____________ .  N y N H
PhS PhS
Trifluoroacetic acid (2 cm3) was added to l-ter/-butyloxycarbonyl-2-phenylthiomethyl-2- 
imidazoline (0.30 g, 1.02 mmol) and the resulting solution was stirred at 20°C for 1 h. The 
trifluoroacetic acid was removed under reduced pressure and the imidazoline salt was 
dissolved in chloroform. (10 cm3). The solution was then washed with aq. NaOH (10% 
w/v; 10 cm3) and the organic layer was dried and concentrated. The crude product was 
purified by column chromatography on neutral alumina (activation grade III) (0:100-» 1:99 
v/v isopropylamine : chloroform) to give the title compound as a white solid (0.16 g, 81 %), 
m.p. 83-85 °C (Found: C, 62.38; H, 6.37; N, 14.51%; M* 192.0721. C10H12N2S requires: 
C, 62.47; H, 6.29; N, 14.56%; M  192.0721); v™* (KBrVcm1 3207, 3057, 2928, 1613, 
1482, 1464, 1448, 1439, 1292, 1278, 1094, 980, 734; Ôh (400 MHz) 3.57 (4H, s, 
NCH2CH2N), 3.75 (2H, s, PhSCTfz), 4.58 (IH, br s, NH), 7.22-7.35 (3H, m, Ar-H), 7.42-
7.45 (2H, m, Ar-H); Ôc (100 MHz) 31.9 (PhSCH2), 50.2 (NCH2), 126.5, 128.8, 129.3 (Ar-
CH), 135.0 (Ar-C), 164.3 (N=C-N); mlz 192 (M% 100%), 177 (5), 159 (55), 123 (9), 109
(39), 81 (50), 65(25), 54(74).
l-teit-Butyloxyçarboiiyl-2-phenylselenenomethyl-2-imidazoline (2.1.38) and \-tert- 
butyloxycarbonyl-2,2-bis(phenylseleneno)methyl-2-imidazoline (2.1.39)
. 0 . .  . n .  . r \
^ j /  Boc N< y ,N^ B o c  +  n - X / n " Boc
PhSe PhSe/ ^ S e P h
S'ec-Butyllithium (12.32 cm3,of a 1.3M solution in cyclohexane, 16.02 mmol) was 
injected to a stirred solution of l-ter/-butyloxycarbonyl-2-methyl-2-imidazoline (2.95 g,
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16.02 mmol) in dry THF (100 cm3) and TMEDA ( 0.5 cm3) at -78°C under nitrogen. The 
bright yellow solution produced was stirred for 20 min at -78°C, when diphenyl diselenide 
(5.00 g, 16.02 mmol) in THF (60 cm3) was added via cannula and the mixture was allowed 
to warm to 20°C overnight. The reaction was quenched with water (100 cm3), the organic 
layer was extracted with diethyl ether (3 x 100 cm3) and the combined organic extracts 
were washed successively with saturated aq. NaHCOs (100 cm3), water (50 cm3) and brine 
(50 cm3), dried and concentrated. The crude product was purified by column 
chromatography on silica gel (1:9—>2:3 v/v ethyl acetate:hexane) to give the monoselenated
2-imidazoline as a white solid (2.86 g, 52%), m.p. 76-78 °C (Found: C, 53.13; H, 6.03; N, 
8.29%, M+ 340.0689. C ^ H ^ O ^ S e  requires: C, 53.10; H, 5.94; N, 8.25%; M  340.0689); 
Vmax (KBrycm1 2974, 1702, 1636, 1480, 1380, 1141, 732; Ôh (400 MHz) 1.55 [9H, s, 
C(CH3)3], 3.76 (4H, s, NCH2CH2N), 4.05 (2H, s, PhSeC #), 7.25 (3H, m, Ar-H), 7.60 (2H, 
m, Ar-H); ôc (100 MHz) 26.2 (PhSeCH2), 28.5 [C(CH3)3], 46.6 and 52.2 (NCH2CH2N),
82.2 [C(CH3)3], 127.5, 128.7 and 130.6 (Ar-CH), 133.3 (Ar-C), 150.7 (CO), 159.1 (N=C- 
N); m/z 340 (M% 1.5%), 282 (12), 215 (17), 203 (11), 159 (45), 127 (7), 91 (8), 57 (100); 
and the diselenenated 2-imidazoline as a yellow oil (0.63 g, 8%) (Found: C, 51.58; H, 4.85; 
N, 5.59%; M+ 496.0163. C16H20N2O2 requires: C, 51.01; H, 4.85; N, 5.66%; M496.0168); 
Vmax (filmycm"1 2977,2930,1708,1628,1477,1371,1141,1002; 8h (300 MHz) 1.47 [9H, 
s, C(CH3)3], 3.63 and 3.68 (each 2H, t, 7  7.0, NCH2CH2N), 6.14 (IH, br s, CH), 7.25-7.29 
(6H, m, Ar-H), 7.59-7.71 (4H, m, Ar-H); 8c (75 MHz) 28.2 [C(CH3)3], 37.5 (CH), 47.3 and
51.9 (NCHz), 82.1 [C(CH3)3], 128.7, 129.1, 135.1 (Ar-CH), 131.5 (Ar-C), 150.4 (CO),
159.1 (N-C=N); mlz 494 (M+, 2%), 439 (1), 397 (1), 395 (1), 339 (2), 314 (12) 283 (11), 
234 (7), 157 (100), 130 (8), 117 (21), 97 (18), 77 (100).
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l-tert-Butyloxycarbonyl-2-(l-phenylseleneno-2-phenylethyl)-2-iimdazoline (2.1.40a)
Boc Boc
PhPhSe PhSe
S'ec-Butyllithium (0.62 cm3 of a 1.2M solution in cyclohexane, 0.74 mmol) was injected to 
a solution of l-/cr/-butyloxycarbonyl-2-phenylselenenomethyl-2-imidazoline (0.21 g, 0.62 
mmol) in dry THF (7 cm3) and TMEDA (0.5 cm3) at -78°C under nitrogen. The dark 
orange solution produced was stirred for 20 min at -78°C, when benzyl bromide (0.09 cm3, 
0.74 mmol) was injected into the reaction mixture under nitrogen and the mixture was 
allowed to warm to 20°C overnight. The reaction was quenched with water (100 cm3), the 
organic layer was extracted with diethyl ether (3 x 100 cm3) and the combined organic 
extracts were washed successively with saturated aq. NaHCO] (100 cm3), water (100 cm3) 
and brine (100 cm3), dried and concentrated. The crude product was purified by column 
chromatography on silica gel (1:9—>2:3 v/v ethyl acetate:hexane) to give the title compound 
as a yellow oil (0.21 g, 79%) (Found: C, 60.66; II, 6.27; N, 6.33%; M+ 430.1159. 
C22H26N2O2Se 0.2H2O requires: C, 60.86; H, 6.08; N, 6.45%; Af430.1159); v™* (film)/cm' 
12977, 1713, 1630, 1370, 1144,999, 766, 696; Ôh (400 MHz) 1.48 [9H, s, CfCHs);], 3.10- 
3.18 (IH, dd, J  6.8 and 13.8, CHflPh), 3.38-3.48 (IH, dd, J  6.8 and 13.8, CflHPh), 3.60- 
3.77 (4H, m, NCH2CH2N), 5.15 (IH, br s, CH), 7.15-7.40 (8H, m, Ar-H), 7.53 (2H, m. Ar­
il); ôc (100 MHz) 28.2 [€ ((% ),], 39.0 (CH2Ph), 39.2 (CH), 46.8 and 51.8 (NCH2), 81.8 
[C(CH3)3], 126.3, 128.1 128.4, 128.6, 128.8 and 136.5 (Ar-CH), 137.1 and 139.4 (Ar-C),
150.5 (CO), 160.8 (N=C-N); m/z 430 (M+, 1%), 374 (5), 324 (5), 293 (3), 217 (32), 173 
(24), 141 (19), 123 (31), 77 (18), 57 (100).
163
l-tert-Butyloxycarbonyl-2-(l-phenylselenenobutyl)-2-imidazolme (2.1.40b)
PhSe'
«S'ec-Butyllithium (5.38 cm3 of a 1.3M solution in cyclohexane, 7.00 mmol) was injected to 
a solution of l-/er/-butyloxycarbonyl-2-phenylselenenomethyl-2-imidazoline (2.00 g, 5.89 
mmol) in dry THF (59 cm3) and TMEDA (2 cm3) at -78°C under nitrogen. The brown 
solution produced was stirred for 20 min at -78°C when 1-iodopropane (0.70 cm3, 7.00 
mmol) was injected to the reaction mixture. The reaction was allowed to warm to 20°C 
overnight and was quenched with water (100 cm3). The organic layer was extracted with 
diethyl ether (3 x 100 cm3) and the combined organic extracts were washed successively 
with saturated aq. NaHCOs (100 cm3), water (100 cm3) and brine (100 cm3), dried and 
concentrated. The crude product was purified by column chromatography on silica gel (1:9- 
2:3 v/v ethyl acetate:hexane) to give the title compound as a yellow oil (1.80 g, 80%)
m, CH3CH2CH//CH), 1.83-1.91 (IH, m, CH3CH2C//HCH), 3.57-3.80 (4H, m.
13.6 (CH3CH2), 21.0 (CH3Œ 2), 28.2 [C(CH3)3], 33.6 (PhSeCHCH2), 38.8 (PhSeCH), 46.8 
and 51.8 (NCH2), 81.8 [C(CH3)3], 128.4, 128.5 and 128.8 (Ar-CH), 136.8 (Ar-C), 150.68 
(CO), 161.3 (N=C-N); m/z 382 (M+, 7%), 326 (33), 284 (15), 245 (32), 201 (27), 169 (30), 
141 (14), 125 (58), 123 (13), 78 (9), 57 (100).
(Found: C, 56.98; H, 7.23; N, 7.48%; M+ 382.1158. C is^ ^ O a S e  requires: C, 56.69; H, 
6.87; N, 7.34; A/382.1158); Vm» (film)/cm  ^2960, 1713, 1613, 1368, 1146; Ôh (400 MHz) 
0.82 (3H, 1,77.2, CHZCR2\  1.45 (2H, m, CH3CÆ2), 1.52 (9H, s, [C(CH3)3], 1.68-1.75 (IH,
NCH2CH2N), 4.71 (IH, br s, CH), 7.25 (3H, m, Ar-H), 7.53 (2H, m, Ar-H); ôc (100 MHz)
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l-tert-Butyloxycarbonyl-2-(l-phenylselenenobut-3-cnyl)-2-imidazoline (2.1.40c)
n  n
N< V  Boc ------------------ - N^ / N- B oc
PhSe PhSe'
5ec-Butyllithium (3.09 cm3 of a 1.1M solution in cyclohexane, 3.4 mmol) was injected to a 
stirred solution of l-/erf-butyloxycarbonyl-2-phenylselenenomethyl-2-imidazoline (1.05 g,
3.09 mmol) in dry THF (31 cm3) and TMEDA (1 cm3) at -78°C under nitrogen. The dark 
orange solution produced was stirred for 20 min at -78°C. 3-Bromopropene (0.29 cm3, 3.40 
mmol) was injected to the reaction mixture at -78°C under nitrogen and the mixture was 
allowed to warm to 20°C overnight. The reaction was quenched with water (100 cm3), the 
organic layer was extracted with diethyl ether (3 x 100 cm3) and the combined organic 
extracts were washed successively with saturated aq. NaHCOs (50 cm3) and brine (50 cm3), 
dried and concentrated. The crude product was purified by column chromatography on 
silica gel (1:9—>2:3 v/v ethyl acetateihexane) to give the title compound as a yellow oil 
(1.06 g, 90%) (Found: M 1 380.1002. requires: Af 380.1002); Vm» (filmycm"1 2977, 1714, 
1631,1478,1147; Ôh (400 MHz) 1.52 [9H, s, C(CH3)3], 2.45-2.52 (IH, m, CHtfCH=CH2), 
2.67-2.74 (IH, m, C/fHCH=CH2), 3.60-3.80 (4H, m, NCH2CH2N), 4.75 (IH, br s, 
PhSeCti), 5.00-5.09 (2H, m, CH=C/f2), 5.80-5.90 (IH, m, Ctf=CH2), 7.25 (3H, m, Ar-H), 
7.55 (2H, m, Ar-H); ôc (100 MHz) 28.2 [C(CH3)3], 37.7 (CH2CH=CH2), 38.3 (ArSeCH),
46.9 and 51.8 (NCH2), 81.8 [C((CH3)3], 116.6 (CH~CH2), 128.2, 128.4, and 128.5 (Ar- 
CH), 135.8 (CH=CH2), 136.8 (Ar-C), 150.6 (CO), 160.6 (N=C-N); mlz 380 (M+, 1%), 243
(10), 224 (6), 169 (49), 141 (16), 123 (56), 78 (8), 70 (10) 57 (100).
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2-(l-Phenylseleneno-2-phenylethyl)-2-imidazoline (2.1.41a)
r~\
N<x .NH
Ph Ph
PhSe^ PhSe"
Trifluoroacetic acid (4 cm3) was added to 1 -ter/-butyloxycarbonyl-2-( 1 -phenylseleneno-2- 
phenylethyl)-2-imidazoline (1.25 g, 2.91 mmol) and the resulting solution was stirred at 
20°C for 1 h. The trifluoroacetic acid was removed under reduced pressure and the 
imidazoline salt was dissolved in dichloromethane (20 cm3). The solution was then washed 
with aq.NaOH (10% w/v; 20 cm3) and the organic layer was dried and concentrated. The 
crude product was then purified by column chromatography on silica gel (ethyl acetate) to 
give the title compound as a white solid (0.68 g, 71 %), m.p 103-105 °C (Found: C, 61.27; 
H, 5.53; N, 8.91%; M+ 330.0634. C ^ H ^ 2Se O.2H2O requires: C, 61.14; H, 5.51; N, 
8.39%; Af 330.0634); v™* (filmycm1 3061, 2926, 1601, 1498, 1270, 740, 693; Ôh (400 
MHz) 3.00-3.10 (IH, dd, J  6.8 and 13.7, CHflPh), 3.26-3.35 (IH, dd, J  6.8 and 13.7, 
CHHPh), 3.42 (4H, m, NCH2CH2N), 4.03 (IH, t, J 6.8, PhSeCH), 7.10-7.28 (8H, m, Ar- 
CH), 7.48 (2H, m, Ar-CH); ôc (100 MHz) 39.3 (CH2Ph), 42.1 (PhSeCH), 50.1 (NCH2),
126.7, 128.2, 128.4, 128.9,129.0 and 134.4 (Ar-CH), 134.9,138.7 (Ar-C), 167.4 (N=C-N); 
m/z 330 (M+, 6%), 249 (62), 239 (26), 173 (100), 158 (12), 132 (14), 115 (15), 105 (26), 91
(22), 77 (22).
2-(2-Phenylselenenobutyl)-2-imidazoline (2.1.41b)
n
N<^ / N" B oc
n
N<s /N H
PhSe^ ^  PhSe"
Trifluoroacetic acid (3 cm3) was added to 1 -ter/-butyloxycarbonyl-2-( 1 -phenylselenobutyl)- 
2-imidazoline (1.50 g, 3.93 mmol) and the resulting solution was stirred at room
temperature for 1 h. The trifluoroacetic acid was removed under reduced pressure and the 
imidazoline salt was dissolved in dichloromethane (20 cm3). The solution was then washed 
with of aq.NaOH (10% w/v; 30 cm3) and the organic layer was dried and concentrated. The 
crude product was then purified by column chromatography on silica gel (ethyl acetate) to 
give the title compound as a yellow solid (1.00 g, 91 %), m.p 67-69 °C (Found: C, 55.55; 
H, 6.56; N, 9.96%; M+ 282.0635. CuH^NzSe requires: C, 55.52; H, 6.45; N, 9.96%; M  
282.0635); v ^  (KBrycm"1 3176, 2955, 1605, 1495, 1466, 1276, 978, 746, 694; Sh (400 
MHz) 0.87 (3H, t, J7 .4 , CftCHjCHz), 1.34-1.52 (2H, m, CH3CH2CH2), 1.70-1.80 (IH, m, 
CH3CH2CHHCH), 1.86-1.96 (IH, m, CH3CH2CHHCH), 3.45 (4H, s, NCH2CH2N), 3.85 
(IH, t, 76.8, CH2Cfl), 4.40 (IH, br s, NH), 7.28 (3H, m, Ar-CH), 7.52 (2H, m, Ar-CH); Sc 
(100 MHz) 13.5 (CH3CH2CH2), 21.4 (CH3CH2CH2), 35.1 (CH3CH2CH2CH), 41.0 
(CHSePh), 50.1 (NCH2), 127.9, 128.5 and 128.9 (Ar-CH), 134.5 (Ar-C), 167.8 (N=C-N); 
m/z 282 (M% 3.5%), 253 (2), 240 (2), 201 (11), 160 (7), 125 (5), 97 (7), 84 (9).
2-(l-Phenylsclcncnobut-3-cnyl)-2-imidazoline (2.1.41c)
Boc
PhSe'PhSe'
Trifluoroacetic acid (1 cm3) was added to 1 -ter/-butyloxycarbonyl-2-( 1 -phenylselenenobut-
3-nyl)-2-imidazoline (0.29 g, 0.76 mmol) and the resulting solution was stirred at room 
temperature for 20-60 min. The trifluoroacetic acid was removed under reduced pressure 
and the imidazoline salt was dissolved in dichloromethane. (20 cm3). The solution was then 
washed with aq.NaOH (30 cm3; 10% w/v) and the organic layer was dried and 
concentrated. The crude product was then purified by column chromatography on silica gel 
(0:100—>4:96 v/v isopropylamine:ethyl acetate) to give the title compound as a yellow oil 
(0.17 g, 80 %) which solidified upon standing, m.p. 41-43 C (Found: C, 55.00; H, 5.72; N,
167
9.40%; Ivf 280.0478. CisHieN^Se O.ZHzO requires: C, 54.99; H, 5.78; N; 9.87%; M  
280.0478); Vm« (fihnycm"1 3175, 3073, 2932, 1607, 1477, 1438, 1286, 919, 740; 8» (400 
MHz) 2.55-2.6 (1H, m, CflHCH=CH2), 2.70-2.80 (1H, m, CHffCH=CH2), 3.50 (4H, s, 
NCH2CH2N), 3.90 (1H, t, J  6.8, PhSeCfl), 4.75 (1H, br s, NH), 5.10-5.20 (2H, m, 
CH=C%), 5.80-5.90 (1H, m, Cff=CH2), 7.26-7.32 (3H, m, Ar-H), 7.57 (2H, m, Ar-H), 8c 
(100 MHz) 37.2 (CH2CH=CH2), 40.2 (PhSeCH), 50.1 (NCH2), 117.4 (CH=CH2), 128.2,
29.1 and 134.9 (Ar-CH), 135.2 (CH=CH2), 137.5 (Ar-C), 167.4 (N=C-N); m/z 280 (M+, 
9%), 279, (17), 239 (13), 199 (61), 157 (12), 123 (100), 97 (14), 77 (19), 67 (16).
General method for the synthesis of 2-(l-alkenyl)-2-imidazolines from 2-(l- 
phenylselenenoalkyl)-2-imidazolines (2.1.42)
n
N ^ N H  __________________ NxX .NH
P h S e ^ '^
A solution of m-chloroperbenzoic acid (1.1 equiv.) in dry dichloromethane was added via a 
cannula to a solution of the 2-(l-phenylselenenoalkyl)-2-imidazoline in dry 
dichloromethane (0.1M in imidazoline) at 0 °C under nitrogen. The resulting yellow 
solution was stirred at 0 °C for 1 h and further 2 h at room temperature. The 
dichloromethane was removed under reduced pressure and the crude product was purified 
by column chromatography on neutral alumina (activation grade HI) (0:100—>4:96 v/v 
isopropylamine : ethyl acetate) to give the 2-(l-alkenyl)-2-imidazolines.
2-(2-PhenyIethenyl)-2-imidazoline (2.1.42a)
N.x .NH .NH
PhSe" ' 'Ph i
»h
The compound was prepared by the general method, from 2-(l -phenylseleneno-2- 
phenyethyl)-2-imidazoline (0.30 g, 0.91 mmol) and m-chloroperbenzoic acid (0.17 g, 1.00 
mmol). Chromatography on alumina (0:100—>3:97 v/v isopropylamine:ethyl acetate) 
afforded the title compound as a white solid (0.16 g, 90%), m.p 154-156 °C, having data 
identical to those reported before.
2-(But-l-enyl)-2-imidazoline (2.1.42b)
PhSe
/ \ 
N<yNH
The compound was prepared by the general method, from 2-(l-phenylselenenobutyl)-2- 
imidazoline (0.30 g, 1.06 mmol) and m-chloroperbenzoic acid (0.20 g, 1.17 mmol). The 
product was obtained after chromatography on neutral alumina (0:100—>5:95 v/v 
isopropylamine:ethyl acetate) as a thick colourless oil (0.12 g, 92%) (Found: M+ 124.1000. 
C7H12N2 requires: M  124.1000); vmK (film)/cm"‘ 3197, 2965, 2864, 2873, 1663, 1602, 
1500,1461,1274,986; Sh (400 MHz) 1.00 (3H, t, 77.2, CH3CH2CH=CH), 2.10-2.20 (2H, 
m, CH3CJf2CH=CH), 3.60 (4H, s, NCH2CH2N), 3.95 (1H, br s, NH), 5.98 (1H, d, J  16.6, 
CH3CH2CH=CH), 6.23-6.32 (1H, m, CHjCHjC/^CH); 8c (100 MHz) 12.6 
(CH3CH2CH=CH), 25.6 (CH3CH2CH=CH), 51.6 (NCH2CH2N), 119.9 and 141.3
(CH=CH), 164.0 (N=C-N); m/z 124 (M+, 84%), 123 (55), 109 (56), 94 (88), 80 (29), 67 
(100).
2-(Buta-l^-dienyl)-2-iimdazolme (2.1.42c)
/ ~ \  nN<x/NH _____________ N<v,NH
S '
k -
The compound was prepared from 2-( 1 -phenylselenenobut-3-enyl)-2-imidazoline (0.30 g,
1.07 mmol) and m-chloroperbenzoic acid (0.22 g, 1.29 mmol) using the general method. 
Chromatography on neutral alumina (0:100->2:98 v/v isopropylamine:ethyl acetate) 
afforded the title compound as a white solid (0.12 g, 92%), m.p. 220 °C (decomp.) (Found: 
N f 122.0844. C7H10N2 requires: M  122.0844); Vmm (KBr)/cm ' 3176, 2936, 2864, 1643, 
1614, 1566, 1497, 1276, 1000, 982; Sh (400 MHz) 3.70 (4H, s, N O feO feN ), 4.40 (1H, br 
S, NH), 5.35-5.40 (1H, d, ./ 10.0, CH=CHCH=C//H), 5.50 (1H, d, J  16.2, 
CH=CHCH=CHH), 6.20-6.26 (1H, d, J  16.2, C//=CHCH=CH2), 6.43-6.55 (1H, m, 
CH=CHCtf=CH2), 6.71-6.80 (1H, dd, J  10.0 and 16.2, CH=CHCH=CH2); Sc (100 MHz)
50.4 (NCH2CH2N), 121.9 (CH=CHCH=CH2), 122.4, 135.7 and 137.0 (CH), 163.8 (N=C- 
N); m/z 122 (M+, 100%), 121 (52), 106 (16), 93 (75), 66 (57), 53 (23).
l-te/t-butyloxycarbonyl-2-[l-(prop-2-enyl)but-3-enyl]-2-imidazoline (2.1.24a)
n
N^ / N- B oc ----------------- -
sec-Butyllithium (1.04 cm3 of a 1.3M solution in hexanes, 1.36 mmol) was injected to a 
solution of 1 B/erfBbutyloxycaibonyl-2-(phenylseleuenomethylbut-3-enyl)-2-iiiiidazoline
(0.47 g, 1.24 mmol) in THF (12 cm3) at -78 C under nitrogen. The yellow solution that was 
produced was stirred at -78 C for 20 min. 1-Bromopropene (0.12 cm3, 1.36 mmol) was 
injected to the reaction mixture which was stirred overnight (-78 C->20 C). The reaction 
was quenched with water (20 cm3) and the organic layer was extracted with diethyl ether (3 
x 20 cm3). The combined organic extracts were washed with saturated aq. NaHCOg (30 
cm3), brine (30 cm3), dried and concentrated. The crude product was purified by column 
chromatography on silica gel (1:9—>2:3 v/v ethyl acetate:hexane) to give the title compound 
as a colourless oil (0.20 g, 61%); data as before.
General method for the synthesis of 2,3>5,6-tetrahydroimidazo[l,2-a]pyridines
The a,P-unsaturated aldehyde or ketone (1.5-2 equiv.) was added to a solution of 2- 
substituted 2-imidazoline in toluene (20 cm3) at 20°C. The mixture was heated to reflux 
using a Dean-Stark trap for 12 h. The toluene was removed under reduced pressure and the 
residue was purified by column chromatography on silica gel (100:0-98:2 v/v ethyl 
acetate:isopropylamine) to give the 2,3,5,6,-tetrahydroimidazo[l,2-û]pyridine.
5-Methyl-8-(prop-2-enyl)-23,5,6-tetrahydroimidazo [l,2-a]pyridine (2.2.1)
The compound was synthesised by the general method, from 2-(but-3-enyl)-2-imidazoline 
(0.10 g, 0.80 mmol) and but-2-enal (0.085 g, 1.2 mmol) in toluene (20 cm3). The title 
compound was obtained as yellow oil (0.05 g, 36%) (Found: M+ 176.1300. CiiHi6N2
CH3CHCHHCH=CH), 2.30-2.37 (1H, m, CH3CHCHH:H=C), 2.76-2.83 (1H, m, 
CH2=CHCHfl), 2.96-3.08 (1H, m, CH2=CHCiffl), 3.09-3.11 (2H, m, NCi/2CH2N), 3.51- 
3.64 (2H, m, NCH2C #2N), 3.83-3.89 (1H, m, CH30¥CH2), 5.03-5.10 (2H, m, CH=C%),
5.85-5.95 (1H, m, C^=CH2), 6.05 (1H, dd J  3.4 and 1.9, C#=C); 8C (100 MHz) 20.7 
(CH3CH), 33.7 (CH2=CHCH2), 34.8 (CH3CHCH2CH), 50.1 (NCH2CH2N), 51.8 
(NCHCH2), 52.8 (NCH2CH2N), 116.2 (CH=CH2), 129.4 (CH3CHCH2CH=C), 131.9
/  \
requires: M  176.1313); Vm« (Glm)/cm ' 2967, 2929, 2853, 2824, 1654, 1592, 1496, 1454, 
1423, 1258, 1199, 1157; Ôh (400 MHz) 1.18 (3H, d, J  6.4, CH3), 2.16-2.23 (1H, m.
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(CH2CH=C), 135.8 (CH=CH2), 163.8 (N-C=N); m/z 176 (M+, 31%), 175 (100), 161 (34), 
147 (18), 133 (17), 119 (19), 106 (9), 92 (7), 79 (11), 77 (9), 65 (11), 53 (15).
5-Methyl-8-propyl-23»5,6-tetrahydroimidazo[l,2-<z]pyridme (2.1.5a)
The compound was synthesised from 2-butyl-2-imidazoline (0.10 g, 0.79 mmol) and but-2- 
enal (0.10 g, 1.19 mmol) in toluene (20 cm3) by the general method and was obtained after 
purification as yellow oil (0.09 g, 64%) (Found: M+ 178.1470. CnH,8N2 requires: M  
178.1470); V™, (film)/cm"' 2965,2932,1655,1589,1467,1451,1425,1258,1198, 1154; 
5,, (400 MHz) 0.90 (2H, t,77 .2 , CH3CH2CH2), 1.15 (3H, d, J 6.4, Cff3CHCH2), 1.45-1.60 
(2H, m, CH3C/f2CH2), 2.11-2.40 (4H, m, CH3CH2CFf2, CH3CHC//2CH=C), 2.76-2.82 
(1H, m, NCHHCH2N), 2.96-3.05 (1H, m, NCflHCH2N), 3.51-3.66 (2H, m, NCH2CFf2N),
3.85-3.90 (1H, m, NCflCH2), 6.05 (1H, dd, J  3.4 and 1.9, CH3CHCH2Cf/=C); Sc (100 
MHz) 14.0 (CH3CH2), 20.6 (CH3CHCH2), 21.5 (CH3CH2CH2), 33.0 (CH3CH2CH2), 33.6 
(CH3CHCH2CH=CH), 49.9 (NCH2CH2N), 51.8 (CH3CHCH2CH=C), 52.6 (NCH2CH2N),
130.1 (CH3CHCH2CH=Q, 131.0 (CH3CHCH2CH=C), 164.0 (N-C=N); m/z 178 (IvT, 
57%), 163 (100), 149 (100), 135 (74), 121 (32), 108 (6), 106 (5), 94 (12), 79 (8), 70 (19), 
65 (11), 53 (11), 42 (24).
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5-Phenyl-2-(prop-2-enyl)-2,3,5,6-tetrahydroimidazo[l,2-ti]pyridine (2.2.5b)
The compound was synthesised by the general method, from 2-but-3-enyl-2-imidazoline 
(0.20 g, 1.60 mmol) and 3-phenylprop-2-enal (0.30 cm3, 2.41 mmol) in toluene (20 cm3). 
The title compound was obtained after purification as a thick yellow oil (0.05 g, 13%) 
(Found: M+ 238.1470. CisHiaN; requires: M  238.1470); (KBr)/cm"‘ 2968, 2932,
N Œ 2CH2N), 3.21-3.25 (1H, m, PhCHCflHCH=C), 3.58-3.67 (1H, m, NCH2CHHN), 
3.80-3.90 (1H, m, NCH2CflHN), 3.99 (1H, t, J  7.8, PhCflCH2), 5.10-5.20 (2H, m, 
CFf2=CHCH2), 5.90-6.00 (1H, m, CH2=CflCH2), 6.12 (1H, dd J3 .4  and 1.9, CH2C//=C),
7.30-7.42 (5H, m, Ar-H); Sn (100 MHz) 34.9 (PhCHCH2CH=CH), 35.4 
(CH2=CHCH2C=CH), 51.3 and 52.7 (NCH2), 61.9 (PhCHCH2CH=C), 116.5 
(CH2=CHCH2), 127.2, 128.3 and 128.9 (Ar-CH), 129.0 (PhCHCH2CH=Q, 131.5 
(PhCHCH2CH=C), 135.8 (CH2=CHCH2), 142.1 (Ar-C), 163.7 (N-C=N); m/z 238 (M+, 
46%), 237 (100), 2.09 (10), 173 (8), 161 (17), 147 (6), 145 (8), 133 (8), 119 (11), 115 (12), 
105 (22), 91 (28), 84 (15), 78 (14), 63 (7), 51 (19).
2855, 2824, 1657, 1592, 1454, 1423, 1257, 1223, 1199, 1157; Ôh (400 MHz) 2.54-2.60 
(2H, m, CH2=CHCj¥2C=CH), 2.68-2.76 (1H, m, PhCHCHtfCH=C), 3.15-3.20 (2H, m.
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8-Benzyl-5-methyl-2^£,6-tetrahydroimidazo[l»2-fl]pyridine (2.2.5c)
Nov ,N H Nov ,N
P h  P h
The compound was synthesised from 2-(2-(phenylethyl)-2-miidazolme (0.23 g, 1.32 mmol) 
and but-2-enal (0.15 cm3, 1.84 mmol) in toluene (20 cm3) by the general method and was 
obtained after purification as yellow oil (0.24 g, 80%) (Found: C, 78.57; H, 8.02; N, 
12.11%; (M-H)+ 225.1390. C15H18N2 0.2H2O requires: C, 78.39; H, 7.83; N, 12.19%; M-H 
225.1392); (fihn)/cm ' 2967, 2929, 2853, 2824, 1654, 1592, 1496, 1454, 1423, 1258, 
1199, 1157; 8H (400 MHz) 1.11 (3H, d, J  6.4, C //3CHCH2), 2.08-2.16 (1H, m, 
CH3CHCHHCH=CH), 2.19-2.26 (1H, m, CH3CHCflHCH=C), 2.70-2.81 (1H, m, 
NCHHCH2N), 2.90-3.00 (1H, m, NCHHCH2N), 3.48-3.58 (2H, m, NCH2C7f2N), 3.60 (2H, 
s, P h C /y , 3.80-3.87 (1H, m, NCflCH2CH=C), 5.67 (1H, dd, J  1.9 and 3.4, 
CH3CHCH2C/f=C), 7.10-7.18 (3H, m, Ar-H), 7.20-7.25 (2H, m, Ar-H); Sc (100 MHz)
20.6 (CH3CHCH2), 33.7 (CH3CHCH2CH=CH), 36.5 (PhCH^, 50.1 (NCH2CH2N), 51.8 
(NCHCHj), 52.9 (NCH2CH2N), 126.0 (CH=C), 128.2,129.4 (Ar-C), 130.7 (CH=Q, 132.7 
and 139.2 (Ar-C), 164.0 (N-C=N); m/z 225 (M+, 100%), 211 (15), 184 (3), 149 (4), 133 
(3), 128 (5), 119 (7), 105 (13), 91 (16), 70 (6), 65 (6), 56 (3).
8-Benzyl-5-ethyl-2,3,5,6-tetraliydroimidazo[l,2-a]pyridine (2.2.5d)
n
N ^  .N H
P h
The compound was synthesised by the general method, from 2-(2-phenylethyl)-2- 
mndazoline (0.15 g, 0.86 mmol) and pent-2-enal (0.17 cm3, 1.72 mmol) in toluene (20
175
cm3). The title compound was obtained as a pale yellow oil (0.19 g, 91%) (Found: C, 
78.54; H, 8.34; N, 11.43%; (M-H)+ 239.1542. Ci6H2oN2 0.2H20  requires: C, 78.81; N, 
8.37; N, 11.49%; M-H 239.1548); v™» (glm)/cm 3 2966, 2933, 2858, 1656, 1593, 1495, 
1454, 1426,1249, 1192,1158; %  (400 MHz) 0.83 (3H, t,7 7 .3 , CHjCHj), 1.35-1.44 (1H, 
m CHaCHH), 1.57-1.64 (1H, m CH3CflH), 2.07-2.14 (1H, m, CHCflHCH=C), 2.19-2.26 
(1H, m, CHCHHCH=C), 2.73-2.83 (2H, m, NC%CH2N), 3.46-3.57 (2H, m, NCH2C%N), 
3.60 (2H, s, ArC%), 3.82-3.86 (1H, m, CH3CH2CHCH2), 5.68 (1H, dd, J  1.9 and 5.4, 
CH=C), 7.11-7.23 (5H, m, Ar-H), 8c (100 MHz) 8.7 (CH3), 26.9 (CH3CH2), 29.9 
(CHCH2CH=CH), 36.5 (PhCH2), 50.1 and 52.9 (NCH2), 57.0 (NCHCH2), 126.0 (CH=C),
128.5, 129.5 and 130.7 (Ar-CH), 132.6 (CH=Q, 139.2 (Ar-C), 164.2 (N-C=N); m/z 240 
(M+, 35%), 239 (100), 225 (10), 211 (52), 197 (3), 155 (3), 140 (3), 119 (21), 105 (15), 91
(28).
7-Mcthyl-8-phenylmethyl-2,3,5,6-tetrahydroimidazo[l,2-ti]pyridine (2.2.5e)
The compound was synthesised by the general method, from 2-(2-phenylethyl)-2- 
imidazoline (0.11 g, 0.63 mmol) and but-2-en-3-one (0.10 cm3, 1.26 mmol) in toluene (20 
cm3). The title compound was obtained as a yellow oil (55 mg, 38 %) (Found: (M-H)+ 
225.1389. Ci;Hi;N2 requires: M-H 225.1392); vm  (frlm)/cm ' 2921, 2852, 2823, 1650, 
1586, 1494, 1454, 1419, 1279, 1238, 1210, 1057, 1031, 1015, 754, 737, 700; 8h (400 
MHz) 1.77 (3H, s, CH3), 2.39-2.43 (2H, t, J  6.6, CH3CCH2CH2N), 2.99-3.02 (2H, t, J  6.6, 
CH3CCH2C/f2N), 3.12-3.17 (2H, t, J  8.8, NCH2CH2N), 3.65-3.70 (2H, t, J  8.8, 
NCH2CH2N), 3.76 (2H, s, CH3C=CCH2Ph), 7.13-7.19 (5H, m, Ar-H); 8c  (100 MHz) 20.1
(CH3), 31.8 (CH3CCH2CH2N), 32.2 (CH3C=CCH2Ph), 45.5 and 53.0 (NCH2CH2N), 53.2 
(CH3CCH2CH2N), 123.9 (CH3C=CCH2Ph), 125.5, 128.1 and 128.2 (Ar-CH), 140.4 
(CH3C=CCH2Ar), 142.6 (Ar-C), 164.6 (N-C=N); m/z 226 (M+, 28%), 225 (100), 199 (5), 
171 (3), 149 (9), 128 (4), 115 (4), 105 (3), 91 (9), 56 (4).
5-Methyl-8-[(2-phenyl)phenylmethyl]-2^^,6-tetrahydroimidazo[l^-<i]pyridme
(2.2.51)
NH
Ph Ph
The compound was synthesised from 2-[2-(2-phenyl)phenylethyl]-2-miidazoline (0,16 g, 
0.62 mmol) and but-2-enal (0.10 cm3, 1.25 mmol) in toluene (20 cm3) using the general 
method. The title compound was obtained after purification as a colourless oil (0.17 g, 
90%) (Found: C, 81.47; H, 7.24; N, 9.05%; (M-H)+ 301.1701. C21H22N2 O.4H2O requires: 
C, 81.50; H, 7.37; N, 9.05%; M-H 301.1701); Vm™ (film)/cm ' 2968, 2930, 2855, 2825, 
1655,1592,1479,1425,1258,1200,1157; 8h (400 MHz) 1.06 (3H, d, J6 .4 , CH3CHCH2), 
1.99-2.07 (1H, m, CH3CHCflHCH=CH), 2.12-2,20 (1H, m, CH3CHCHHCH=C), 2.67- 
2.74 (1H, m, NCHHCHzN), 2.83-2.83 (1H, m, NCHHCH2N), 3.41-3.55 (2H, m, 
NCH2C//2N), 3.60 (2H, s, AiCHi), 3.72-3.78 (1H, m, NCflCH2), 5.47 (1H, dd, J  1.9, 3.4, 
CH2C7f=C), 7.16-7.28 (9H, m, Ar-H); 6c (100 MHz) 20.5 (CH3CH), 33.7 
(CHCH2CH=CH), 33.8 (ArCH2), 50.1 (NŒ 2CH2N), 51.7 (NCH), 52.8 (NCH2CH2N),
126.2 (CH2CH=C), 126.7, 127.2, 128.0, 128.8, 130.1, 130.9, 131.0 (Ar-CH), 132.6 
(CH2CH=C), 136.3, 141.5 and 142.6 (Ar-C), 163.9 (N-C=N); m/z 302 (M+, 43%), 301
(75), 287 (16), 273 (3), 260 (3), 231 (2), 225 (100), 209 (4), 165 (15), 143 (10), 127 (3), 83 
(3).
5-Ethyl-8-[(2-phenyl)phenylmethyl]-2^,5,6-tetrahydroimidazo[l,2-<i]pyridme (2.2.5g)
NH
Ph Ph
The compound was synthesised by the general method, from 2-[2-(2-phenyl)phenylethyl]- 
2-imidazoline (0.13 g, 0.52 mmol) and pent-2-enal (0.10 cm3, 1.04 mmol) in toluene (20 
cm3). The title compound was obtained as a pale yellow oil (0.14 g, 85%) (Found: (M-H)+ 
315.1861. C22H24N2 requires: M-H 315.1865); Vm* (glm)/cm ' 2965, 2933, 2862, 1656, 
1594, 1479, 1451, 1435, 1247, 1194, 1158 703; 8» (400 MHz) 0.80 (3H, t, J  7.3, 
C&CH2CH), 1.31-1.37 (1H, m CHjCHHCH), 1.52-1.60 (1H, m CH,CHHCH), 2.02-2.07 
(1H, m, CH3CH2CHCHflCH=C), 2.13-2.20 (1H, m, CH3CH2CHCHHCH=C), 2.67-2.74 
(2H, m, NC//2CH2N), 3.40-3.53 (2H, m, NCH2C//2N), 3.60 (2H, s, AiCHi), 3.72-3.75 
(1H, m, CH3CH2CHCH2), 5.49 (1H, dd, J  1.9 and 5.4, CH=C), 7.19-7.26 (9H, m, Ar-H); 5 
c (100 MHz) 8.7 (CH3), 26.7 (CH3CH2CH), 29.9 (CHCH2CH=CH), 36.7 (ArCH2), 50.1 
and 52.8 (NCH;), 56.9 (NCHCH2), 126.2 (CH=C), 126.3, 126.7, 127.2, 127.9, 128.1, 
128.8, 130.0 and 130.9 (Ar-CH), 132.5 (CH=Q, 136.4,141.5 and 142.6 (Ar-C), 164.0 (N- 
C=N); m/z 316 (M+, 56%), 315 (75), 287 (60), 239 (100), 225 (11), 165 (31), 142 (22), 127
(7), 84 (5), 44 (10).
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7-Methyl-8-[(2-phenyl)phenylmethyl]-2,3,5,6-tetrahydroiimdazo[l,2-a)pyridine
(2.2.5h)
PhPh
The compound was synthesised by the general method, from 2-[2-(2-phenyl)phenylethyl]-
2-imidazoline ( 0.11 g, 0.44 mmol) and but-2-en-3-one (77 pcm3, 0.88 mmol) in toluene 
(20 cm3). The title compound was obtained as a white solid (0.09 g, 66%), m.p. 111-113°C 
(Found: (M-H)+ 301.1705. C21H22N2 requires: M-H 301.1705); (frlm)/cm ' 2956, 
2917, 2859, 2820, 1651, 1588, 1476,1431, 1279, 754; 5h (400 MHz) 1.42 (3H, s, CH3),
2.31-2.35 (2H, t, J  6.3, CH3CCH2CH2N), 2.95-2.98 (2H, t, J  6.3, CH3CCH2CH2N), 3.12- 
3.17 (2H, t, 78.8, NCH2CH2N), 3.66-3.69 (2H, t, 78.8, NCH2CH2N), 3.70 (2H, s, CFfeAr), 
7.06-7.32 (911, m, Ar-H); Sc (100 MHz) 20.0 (CH3), 30.2 (ArOfe), 31.7 (CH3CCH2CH2N),
45.5 and 53.0 (NCH2CH2N), 53.3 (CH3CCH2CH2N), 124.3 (CH3C=CCH2Ar), 125.4,
126.7, 127.6, 128.0, 129.3, 129.3, 137.8 (Ar-CH), 141.5 (CHjC^CHjAr), 141.8 and
142.0 (Ar-C), 165.1 (N-C=N); m/z 302 (M+, 25%), 301 (53), 287 (19), 225 (100), 165 (9), 
149 (11), 115 (3), 105 (2), 91 (5), 56 (5).
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5,7-Dimethyl-8-[(2-phenyl)phenylmethyl]-2^^,6-tetrahydroimidazo[l,2-fl]pyridine
(2.5.5i)
PhPh
The title compound was synthesised by the general method, from 2-[2-(2- 
phenyl)phenylethyl]-2-imidazoline (0.11 g, 0.43 mmol) and pent-2-en-3-one (84 pcm3, 
0.86 mmol) in toluene (20 em3) described before and was obtained after purification as a 
colourless oil (75 mg, 55 %), (Found: (MH)+ 317.2005. C22H24N2 requires: Afff 317.2017); 
Vmax (filmycm'1 2968, 2852,1651, 1588, 1478,1416, 1329, 1281, 1209, 750, 704; Ôh (300 
MHz) 1.17 (3H, d, J  6.2, CtfjCH), 1.47 (3H, s, Ctf3C=CCH2Ar), 2.13-2.32 (2H, m, 
CH3CHCÆ2C), 2.79-2.86 (1H, m, NCHM:H2N), 2.95-3.02 (1H, m, NCflHCH2N), 3.53- 
3.59 (2H, m, NCH2C/i2N), 3.75 (2H, s, AiCHi), 3.80-3.91 (1H, m, CH3CBCH2C), 7.12-
7.41 (9H, m, Ar-H); ôc (75 MHz) 19.7 (CH3CH), 20.6 (Œ 3C=CCH2Ar), 30.4 
(CH3C H Œ 2C), 40.3 (CH2Ar), 50.8 (NCH2CH2N), 51.4 (NCH2CH2N), 53.2 (CH3CH), 
124.1, 125.3, 126.7, 127.6 and 129.3 (Ar-CH), 128.0 (CHgOCCHzAr), 137.9 
(CH3C=CCH2Ar), 141.4,141.8 and 142.5 (Ar-C), 165.5 (N-C=N); m/z 316 (M \ 34%), 315 
(55), 301 (28), 239 (100), 165 (33), 152 (17), 135 (12) 115 (8), 77 (20).
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5-Ethyl-8-phenyl-23,5,6-tetrahydroimidazo[l,2-fl]pyridme (2.2.5j)
r~\
.NH Nos M
Phy
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (0.55 
g, 3.44 mmol) and pent-2-enal (0.67 cm3, 6.88 mmol). The title compound was obtained 
after purification as a dark yellow oil (012 g, 15 %) (Found: (M-H)+ 227.1540. CisHisN? 
requires: M-H 227.1548); Vmm (filmycm1 2966, 2936, 1619, 1586, 1495, 1448, 1423, 
1282, 1246, 1180, 996, 753; Sh (400 MHz) 0.97 (3H, t, J7 .8 , CH3CH2CHCH2), 1.46-1.59 
(1H, m, CH3C//HCH), 1.71-1.80 (1H, m, CH3CHHCH), 2.37-2.44 (1H, m, 
CHCHHCH=C), 2.50-2.57 (1H, m, CHCflHCH=C), 2.85-2.95 (1H, m, NCHHCH2N), 
2.98-3.05 (1H, m, NCHHOfeN), 3.57-3.68 (2H, m, NCH2Œ 2N), 3.91-3.95 (1H, m, 
NCHCH2), 6.38 (1H, dd, J  2.1 and 6.1, CH=C), 7.26-7.50 (5H, m, Ar-H); Sc (100 MHz)
8.8 (CH,), 27.1 (CH3CH2CH), 30.5 (CHCH2CH=CH), 49.9 and 53.3 (NCH2), 56.8 (NCH),
127.4 (CH=C), 127.9, 128.2, 128.7 (Ar-CH), 134.7 (CH=Q, 137.8 (Ar-C), 163.1 (N- 
C=N); m/z 227 (MH+, 100%), 197 (6), 171 (3), 159 (6), 91 (2), 71 (2).
7-Methyl-8-phenyl-2,3,5,6-tetrahydroimidazo[l,2-a]pyridine (2.2.5k)
n
N<x ,NH
Ph
r~\
N < s/N .
Ph^Y
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (0.50 
g, 3.12 mmol) and but-2-en-3-one (0.50 cm3, 6.24 mmol) in toluene (30 cm3). The title 
compound was obtained after purification as a yellow oil (0.65 g, 98 %) (Found: C, 77.14; 
H, 7.69; N, 13.16%; (M-H)+ 211.1234. O ^ ^  O.3^O requires: C, 77.27; H, 7.63; N,
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12.88%; M-H 211.1235); vmu (filmycm"1 2918, 2851, 2821, 1636, 1587, 1494, 1466, 
1442. 1418, 1285, 1229, 1190, 1168,978; 8h (400 MHz) 1.65 (3H, s, CH3), 2.48-2.51 (2H, 
t, J  6.6, CH3CCH2CH2N), 3.06-3.10 (2H, t,J6 .6 , CH3CCH2CH2N), 3.11-3.16 (2H, t, J8 .8 , 
NCH2CH2N), 3.62-3.67 (2H, t, J  8.8, NCH2CH2N), 7.10-7.28 (5H, m, Ar-H); Sc (100 
MHz) 20.9 (CH3), 31.5 (CH3CCH2CH2N), 45.4 (NCH2CH2N), 52.8 (NCH2CH2N), 53.6 
(NCH2CH2C), 126.8 (CH3C=CPh), 127.7, 127.8 and 129.8 (Ar-CH), 136.6 (CH3C=CPh),
142.5 (Ar-C), 164.3 (N-C=N); m/z 212 (M+, 56%), 211 (100), 195 (5), 183 (2), 154 (2), 
128 (6), 115 (7), 105 (5), 69 (3), 56 (4).
5-Methyl-8-phenyl-2^,5,6-tetrahydroimidazo[l,2-fl]pyridine (2.2.51)
Ph"
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (0.50 
g, 3.12 mmol) and but-2-enal (0.28 g, 3.43 mmol) in toluene (31 cm3). The title compound 
was obtained as yellow oil (0.22 g, 33%), vmax (film/cm1) 2967, 2936, 1619, 1586, 1495, 
1495,1448,1282,1246,1180,996; Sh (400 MHz) 1.23 (3H, d ,/6 .4 , CH,), 2.30-2.41 (1H, 
m, CH,CHCHHCH=CH), 2.47-2.55 (1H, m, CH,CHCHHCH=C), 2.82-2.91 (1H, m, 
NCHHCH2N), 3.09-3.19 (1H, m, NCHHCH2N), 3.55-3.70 (2H, m, NCH2CH2N), 3.51-3.64 
3.87-3.96 ( 1H, m, NCHCH2), 6.32 (1H, dd J3 .4  and 1.9, CH=C), (7.25-7.38 (3H, m. Ar­
il), 7.45-7.49 (2H, m, Ar-H); 8C (100 MHz) 20.7 (CH,), 34.1 (NCHOfeCH), 49.8 
(NCH2CH2N), 51.5 (NCHCH2), 53.2 (NCH2CH2N), 127.8, 128.1 and 128.7 (Ar-CH), 
132.4 (CH=Q, 134.5 (CH=C), 137.6 (Ar-C), 162.8 (N-C-N).
5,7-Dimethyl-8-phenylmethyl-23A6,-tetrahydroiimdazo[l£-a]pyridiiie (2.2.5m)
n
N.x ,NH
The compound was synthesised by the general method, from 2-benzyl-2-imidazolme (1.00 
g, 6.25 mmol) and pent-2-en-3-one (1.20 cm3, 12.5 mmol) in toluene (62 cm3). The title 
compound was obtained as a yellow oil (1.22 g, 86 %) (Found: (M-H)* 225.1393; 
C15H18N2 requires: M-tf 225.1392); \ rtaa (filmycm"1 2967,2930, 2851, 1642, 1590, 1495, 
1443, 1411, 1378, 1282,1252, 1229, 1177, 990, 700; W n m  219 (Em.x/mol.dm-313092);
8h (400 MHz) 1.23 (3H, d, J  6.2, CfljCHCH2), 1.72 (3H, s, C%C=CPh), 2.39-2.43 (2H, 
m, NCHC//2), 2.78-2.87 (1H, m, NCHflCH2N), 3.11-3.20 (1H, m, NCHHCH2N), 3.53- 
3.66 (2H, m, NCH2CH2N), 3.80-3.90 (1H, m, NCH), 7.16-7.37 (5H, m, Ar-H); 5c (100 
MHz) 20.8 (CH3C=CPh), 21.0 (CH3CH), 40.2 (CH3CHCH2C), 50.4 (NCH2CH2N), 51.4 
(NCH2CH2N), 53.8 (CH3CHCH2), 127.7, 128.4 and 129.9 (Ar-CH), 128.1 and 136.9 
(C=C), 142.4 (Ar-C), 164.8 (N-C=N); m!z 226 (M*. 75%), 225 (100), 211 (21), 195 (10), 
183 (4), 166 (5), 154 (4), 128 (9), 115 (10), 91 (4), 70 (9), 42 (10).
7-Hydroiy-5-methyl-8-phenyl-l,2,3,5>6,7-hexahydroxyimidazo[l,2-<!]pyridine (2.2.6a)
n  r \
N.X /N H  
Ph
But-2-enal (0.19 cm3, 2.34 mmol) was added in a solution of 2-benzyl-2-imidazoline (0.25
g, 1.56 mmol), in touluene (30 cm3) and the resulting soultion was heated to reflux for 12
h. The toluene was removed and the crude reaction mixture was purified with column 
chromatography on silica gel (0:100—>1:99 isopropylaminexhloroform) to give the title
183
HN
Ph
OH
compound as a yellow oil (0.13 g, 37%) (Found M+ 230.1419. CuHigNzO requires: M  
230.1419); Vmax (film) 3401, 2968,2931, 2851,1636,1585,1494,1249,1196, 990, 774; Ôh 
(400 MHz) 1.12 (3H, d, 7  6.4, Ctf3CH), 1.88-1.93 (1H, dd, J  10.9 and 15.6, NCHCHfl), 
2.28-2.34 (2H, dt, J  3.6 and 10.9, NCHŒH), 2.80-2.92 (1H, m, N Œ 2CH2N), 2.98-3.08 
(1H, m, NC^2CH2N), 3.28 (1H, m, NCi/2), 3.50-3.60 (2H, m, NCM i and NC//CH3), 3.74 
(1H, t, J  10.9, CfiTOH), 7.20-7.35 (3H, m, Ar), 7.40 (2H, m Ar); 5C (100 MHz) 20.7 (CH3),
32.9 (NCHCH2), 46.6 (NCH), 49.8 and 52.6 (NCH*), 56.2 (NC=CPh), 61.3 (CHOH),
126.6, 127.9 and 128.1 (Ar-CH), 135.8 (Ar-C), 163.9 (NC=CPh); mlz 230 (M+, 16%), 213
(29), 199 (26), 185 (46), 170 (5), 157 (25), 143 (7), 129 (14), 115 (12), 105 (38), 91 (12), 
77 (31).
7-Hydroxy-5-methyl-8-(prop-2-enyl)-2^34,6,7,8-hexahydroxyimidazo[l)2-a]pyridine
(2.2.4a)
But-2-enal (47 mg, 0.67 mmol) was added in a solution of 2-(but-3-enyl)-2-imidazoline (70 
mg, 0.56 mmol), in anhydrous dicloromethane (6 cm3). A small amount of MgSCU was 
added to the reaction mixture and the reaction was stirred at 20°C for 12 h. The MgSC>4 
was filtered and the dichloromethane was removed under reduced pressure. The crude 
reaction mixture was purified by column chromatography on silica gel eluting (0:100-» 
3:97 isopropylaminexhloroform) to give the title compound as a white solid (30 mg, 27%) 
(Found: M+ 194.1419. Cn H18N20  requires: M  194.1491); (film) 3100, 2972, 2936, 
1612, 1424, 1346, 1277, 1139; 8h (400 MHz) 1.18 (3H, d, J6 .4 , C //3CH), 1.60-1.69 (1H, 
dd, J  11.2 and 24.4, NCHCHfl), 2.06-2.11 (2H, dt, J  3.6 and 11.2, CHCflH), 2.34-2.37
184
(1H, m, CHHCH=CH2), 2.56-2.62 (1H, m C#HCH=CH2), 2.79-2.86 (3H, m, NC/f2CH2N 
and CHCH2CH=CH2), 3.55-3.60 (2H, m, NCH2C/f2N), 3.69-3.75 (1H, m, NCH), 3.85 (1H, 
t, J  11.2, CHOH), 5.05 (1H, m, CH^CHH), 5.17-5.21 (1H, m, CH=CHH), 6.00-6.07 (1H, 
m, CH=CH2); 5c  (100 MHz) 22.7 (CH,), 33.0 (NCHCH2), 40.8 (CH2CH=CH2), 44.5 
(CHCH2CH=CH2) 50.3 and 51.6 (NCH2), 53.0 (NCHCH3), 69.9 (CHOH), 116.7 
(CH=CH2), 137.5 (CH=CH2), 166.9 (NC=CCHOH); mlz 194 (M+, 24%), 176 (80), 161 
(32), 150 (28), 137 (21), 132 (17), 121 (34), 109 (15), 106 (11), 94 (100), 81 (16), 67 (17).
7-Hydroxy-7-methyl-8-phenyl-l,2^,5,6,7-hexahydroxyimidazo[l,2-a]pyridine (2.2.4b) 
and 7-hydroxy-5-methyl-8-phenyl-2r3^)6,7,8-hexahydroxyimidazo[l,2-«]pyridine 
(2.2.4b)
r \
N .x .NH HN
Phr
OH
PI
OH
But-3-en-2-one (1.97 cm3, 23.77 mmol) was added to a solution of 2-benzyl-2-imidazoline 
(3.17 g, 19.81 mmol), in dichloromethane (100 cm3) and the resulting soultion was stirred 
at 20 C for 12 h. The title compound precipitate out of solution as a white solid (1:1 
mixture of regioisomers) which was filtered (1.93 g, 42%), m.p. 141-143 C (Found: C, 
72.57; H, 7.84; N, 12.03%; M+ 230.1419. CwH,aN20  requires: C, 73.01; H, 7.88; N, 
12.16%; M  230.1417); v™,, (film) 3435, 3083, 3063,2970, 1616, 1495, 1424, 1344, 1276, 
1139, 704; 8h (400 MHz, CDjOD) 1.01 and 1.14 (3H, s, CH3), 1.63-1.72 [1H, m, 
NCH2CHHC(OH)], 1.88-1.93 [1H, m, NCH2CHHC(OH)], 1.98-2.03 [1H, m,
NCH2CHHC(OH)], 2.05-2.09 [1H, m, NCH2CHHC(OH)], 3.09-3.21 (4H, m, NCH2), 3.28-
3.42 (4H, m, 2x NCH2CH2N and 2x NCH2CH2CCH3), 3.53-3.63 (4H, m, 2x NCH2CH2N 
and 2x NCH2CH2CCH3), 3.69-3.72 (1H, m, PhCfl), 7.22-7.36 (10H, m, Ar-H); 5h  (100 
MHz, CD3OD) 27.7 and 28.0 (CH3), 32.2 and 32.4 [NCH2CH2C(OH)], 44.8 and 48.1
185
[NCH2CH2C(OH)], 49.5 and 49.8 (NCHjCHjN), 48.4 (PhCH), 52.5 and 52.8 
(NCH2CH2N), 55.9 (NC=CPh), 71.2 and 71.8 (COM), 128.2, 128.6, 129.2, 130.1, 132.0 
(Ar-CH), 138.4 and 140.5 (Ar-C), 169.0 (NC=CPh); mlz 230 (M+, 6%), 211 (100), 196 (4), 
183 (3), 171 (9), 159 (7), 128 (9), 115 (11), 102 (3), 91 (12), 77 (7), 56 (5); and the 
tetrahydroimidazo[l,2-<z]pyridine as a yellow oil (0.91 g, 21%).Data given before.
Methyl 3-(2-beiizylimidazoIin-l-yl)propenoate (2.2.10)
n  r \
N ^ . N H  _______^ N ^ N .
PhT PhT C 02Me
Methyl propenoate (3.37 cm3, 37.5 mmol) was injected to a solution of 2-benzyl-2- 
imidazoline (3.00 g, 18.75 mmol) in dry dichloromethane (18 cm3). The resulting solution 
was refluxed overnight under nitrogen. The dichloromethane was removed under reduced 
pressure and the crude product was purified by column chromatography on silica gel 
(100:0-99:1 ethyl acetate:isopropylamine) to give the title compound as a yellow oil (3.75 
g, 81%) (Found: C, 64.12; H, 7.39; N, 11.11%; (M-H)+ 245.1288. C ^ H ^ O r  O ^ O  
requires: C, 64.51; H, 6.91; N, 10.75%; M -tf 245.1290); v™, (filmycm"1 2951,2862,1737 
(CO), 1615 (C=N), 1496, 1456, 1437, 1271, 1175, 1007; 8h (400 MHz) 2.33 (2H, t , / 6.8, 
NCH2CH2CO2CH3), 3.28 (2H, t, J  9.0, NCH2CH2N), 3.32 (2H, t, J  6.8, 
NCH2CH2CO2CH3), 3.64 (3H, s, CO2CH3), 3.65 (2H, s, PhC%), 3.70 (2H, t, J  9.0, 
NCH2CH2N), 7.21-7.33 (5H, m, Ar-H); 5c (75 MHz; CDC1,), 33.5 (NCH2CH2CO2CH3),
34.5 (PhCHz), 42.9 (CO2CH3), 50.1, 51.7 and 52.4 (NCH2), 126.7, 128.6 and 128.7 (Ar- 
CH), 135.9 (Ar-C), 165.2 (N=C-N), 171.9 (C02Me); m/z 246 (M+, 38%), 187 (95), 173 
(28), 158 (20), 130 (12), 117 (10), 115 (10), 103 (7), 92 (7), 83 (35), 56 (100), 42 (23).
186
General method for the synthesis of phenyl 2-(2-alkylimidazolin-l-yl)ethyl sulfonate
The phenyl vinylsulfonate (1.2 equiv.) was added to a solution of the 2-alkyl-2-imidazoline
The dichloromethane was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (0:100—>3:97 v/v isopropylamine:ethyl 
acetate) to give the desired compounds.
Phenyl 2-(2-benzylimidazolin-l-yl)ethyl sulfonate (2.2.11b)
Prepared by the general method, using 2-benzyl-2-imidazoline (0.25 g, 1.56 mmol) and 
phenyl vinylsulfonate (0.31 g, 1.71 mmol) to give the title compound as a yellow oil (0.40 
g, 75%) (Found: (M-H)+ 343.1122. Ci8H2oN20 3S requires: {M-H) 343.1116); vmto 
(filmycm"1 2936, 1618, 1488, 1366, 1263, 1170, 1145, 866; 6» (300 MHz) 3.05 (2H, t, J
7.2, NCHjCfljSOsPh), 3.34 (2H, t, J  9.6 NCH2CH2N), 3.63 (2H, J  7.2, NC//2CH2S03Ph), 
3.69 (2H, s, PhCff2), 3.79 (2H, t, J9 .6  NCH2Ctf2N), 7.13-7.43 (10H, m, Ar-H); 5c (75 
MHz) 34.7 (PhCH2), 41.7 (NCH2CH2S03Ph), 48.5 (NCH2CH2N), 50.2 (NCH2CH2S03Ph),
52.6 (NCH2CH2N), 121.9, 127.1 127.4, 128.6, 128.9 and 130.0 (Ar-CH), 135.4 and 148.5 
(Ar-C), 164.4 (N-C=N); m k  343 [(M-H)+, 4%], 279 (2), 203 (3), 187 (100), 159 (21), 131 
(9), 117 (7), 103 (7), 91 (100), 77 (18), 65 (54).
R/ F T
(1 equiv) in dichloromethane (10 cm3). The reaction mixture was stirred at 20°C overnight.
/ \
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Phenyl 2-[2-(but-3-enyl)imldazolin-l-yl]ethyl sulfonate (2.2.11d)
Prepared by the general method, using 2-(but-3-enyl)-2-mndazoline (0.37 g, 2.98 mmol) 
and phenyl vinylsulfonate (0.66 g, 3.58 mmol) to give the title compound as a colourless oil
C/f2CH2CH), 2.41 (2H, m, CH2Ctf2CH=CH2), 3.30 (2H, t,7 9 .6  NC/f2CH2N), 3.44 (2H, t, 
J  7.3, NCHîC^SOaPh), 3.68-3.75 (4H, m NCH2C7f2N and NC//2CH2S 03Ph), 4.98-5.11 
(2H, m, CR=CH2), 5.82-5.91 (1H, m, C/7=CH2), 7.25-7.46 (5H, m, Ar-H); 5c (75 MHz)
27.0 (CH2CH2CH=CH2), 30.3 (CH2CH2CH=CH2), 41.7 (NCH2CH2S03Ph), 49.0 
(NCH2CH2N), 50.2 (NCH2CH2N), 52.5 (NCH2CH2SO,Ph), 115.5 (CH=CH2), 121.8,127.5 
and 130.1 (Ar-CH), 137.1 (CH=CH2), 148.9 (Ar-C), 165.4 (N-C=N); m/z 308 (M+, 8%), 
297 (1), 284 (2), 268 (4), 243 (2), 233 (2), 215 (11), 204 (3), 184 (2), 175 (4), 167 (5), 151
(23), 123 (100), 109 (14), 97 (5), 94 (10), 84 (14), 67 (30).
General method for the synthesis of phenyl 2-(2-alkylimidazolin-l-yl) sulfones
The phenyl vinylsulfone (1.2 equiv.) was added to a solution of the 2-alkyl-2-imidazoline
The dichloromethane was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel eluting with 0:100—>3:97 v/v 
isopropylamine:ethyl acetate to give the title compounds.
(0.52 g, 57%), (Found: M+ 308.1189. C ^H ^N A S  requires: Af308.1195); (film)/cm ' 
2936, 1618, 1489, 1366, 1191, 1170, 1145, 867; 5» (300 MHz) 2.30 (2H, t, J  7.8,
(1 equiv) in dichloromethane (10 cm3). The reaction mixture was stirred at 20°C overnight.
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Phenyl 2-(benzylimidazolin-l-yl)ethyl sulfone (2.2.11a)
N ^/N H
Phr
Prepared by the general method, using 2-benzyl-2-imidazoline (0.58 g, 3.62 mmol) and 
phenyl vinylsulfone (0.73 g, 4.35 mmol) to give the title compound as a colourless oil (1.05 
g, 89%), (Found: (M-H)* 327.1173. requires: (M-H) 327.1167);
(filmycm"1 2934, 2866, 1615,. 1585, 1495, 1447, 1304, 1148, 1087, 1005, 726, 691; Sh 
(300 MHz) 2.97 (2H, 1,77.2, NCH2C/f2S02Ph), 3.10 (2H, t, 79.8 NCff2CH2N), 3.44 (2H,
77.2, NCH2CH2S0 2Ph), 3.58 (2H, s, PhCtf2), 3.61 (2H, t, 79.8 NCH2CH2N), 7.17 (2H, m, 
Ar-H), 7.23-7.31 (3H, m, Ar-H), 7.56 (2H, m, Ar-H), 7.68 (2H, m, Ar), 7.79 (1H, m, Ar); 5 
c (75 MHz) 34.6 (PhCH2), 41.1 (NCH2CH2S02Ph), 49.9 (NCH2CH2N), 52.4 
(NCH2CH2N), 54.0 (NCH2CH2S02Ph), 127.0 127.9, 128.6, 128.9 and 133.9 (Ar-CH),
135.5 and 139.3 (Ar-C), 164.4 (N-C=N); m/z 327 [(M-H)*, 7%], 187 (100), 171 (13), 159
(11), 141 (2), 131 (8), 125 (9), 103 (8), 91 (100), 77 (67).
2-(But-3-enyl)-l-(2-phenyl)ethylsulfonyl)-2-iniidazolme (2.2.11c)
S 02Ph
Prepared by the general method, using 2-(but-3-enyl)-2-imidazoline (0.25 g, 2.01 mmol) 
and phenyl vinylsulfone (0.40 g, 2.41 mmol) to give the title compound as a colourless oil 
(0.41 g, 70%) (Found: (M-H)+ 291.1173. Q s IW tA S  requires: M-H 291.1167); vmax 
(filmycm"1 2932, 2863, 1641, 1616, 1447, 1305, 1146, 1087, 1005, 730; 5» (300 MHz) 
2.20 (2H, t, 7  7.6, CH2CH2CH), 2.34 (2H, m, CH2CH2CH=CH2), 3.04 (2H, t, 7  9.5 
NCH2CH2N), 3.30 (2H, 7  7.3, NCH2CH2S02Ph), 3.50-3.57 (4H, m NCH2C7f2N and
SOgPh
Ph-
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NC/f2CH2S02Ph), 4.96-5.08 (2H, m, CH=CH2), 5.76-5.90 (1H, m, CH=CH2), 7.55-7.71 
(3H, m, Ar-H), 7.88-7.92 (2H, m, Ar-H); ôc (75 MHz) 26.8 (CH2CH2CH=CH2), 30.1 
(CH2CH2CH=CH2), 40.9 (NCH2CH2S0 2Ph), 49.6 (NCH2CH2N), 52.1 (NCH2CH2N), 54.4 
(NCH2CH2S02Ph), 115.4 (CH=CH2), 127.7 129.3 and 133.9 (Ar-CH), 137.1 (CH=CH2),
139.3 (Ar-C), 165.4 (N-C=N); m/z 291 [(M-H)+, 23%], 198 (3), 165 (2), 151 (100), 137
(8), 123 (76), 109 (17), 97 (9), 94 (10), 82 (13), 77 (88).
8-Phenyl-l,2^4>6,7-hexahydroimidazo[l,2-a]pyridm-7-oiie (2.2.12)
HN
sec-Butyllithium (4.43 cm3 of a 1.1M solution in hexanes, 4.87 mmol) was injected to a 
solution methyl 3-(2-benzylimidazolin-1 -yl)propenoate (0.60 g, 2.48 mmol) in dry THF (25 
cm3) at -78°C under nitrogen. The yellow suspension that was produced was stirred at - 
78°C for 1 h and was allowed to warm up to 20°C where it was stirred for further 1 h. The 
reaction was quenched with water (25 cm3) and the organic layer was extracted with 
diethyl ether (3 x 50 cm3). The combined organic extracts were washed successively with 
saturated aq. NaHCOg (100 cm3), water (100 cm3) and brine (100 cm3), dried and 
concentrated. The crude product was purified by column chromatography on silica gel 
(1:99—>4:96 v/v isopropylamine:ethyl acetate) to give the title compound as a white solid 
(0.18 g, 34%), m.p 139-141 °C (Found: M+ 214.1103. C13Hl4N20  requires: Af 214.1106); v 
max (KBrVcm"1 3111 (NH), 2975,2868,1563, 1548, 1532, 1505,1479, 1441, 1319, 1301, 
1279, 1101; ôh (300 MHz) 2.56 (2H, t, J  7.1, NCH2CH2CO), 3.28 (2H, t, J  7.1, 
NCH2CH2CO), 3.40 (2H, m, NCH2CH2N), 3.48 (2H, m, NC/f2CH2N), 4.85 (1H, br s, NH), 
7.00-7.28 (5H, m, Ar-H); ôc (75 MHz) 35.4 (NCH2CH2CO), 43.1 (NCH2CH2N), 45.2
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(NCH2CH2CO), 50.6 (NCH2CH2N), 94.5 (PhC=CN), 125.8, 128.4 and 130.6 (Ar-CH),
135.0 (Ar-C), 164.6 (PhOCN), 185.7 (CO); m/z 214 (M+, 100%), 185 (92), 171 (6), 157 
(18), 129 (35), 115 (15), 103 (24), 89 (16), 77 (19), 63 (9).
2-Benzyl-l-(3-hydroxypropyl)-2-imidazoline (2.2.13)
/ \
J J )Ph pPh
OH
A solution of methyl 3-(2-benzylimidazolin-l-yl)propenoate (5.20 g, 21.13 mmol) in dry 
THF (150 cm3) was added via cannula to a solution of LiAULt (38.42 cm3 of a 1.1M 
solution in THF, 42.27 mmol) in THF (100 cm3) at -78°C under nitrogen. The resulting 
yellow solution was stirred overnight (-78°C to 20°C). The reaction mixture was then 
cooled down to at 0°C and the excess FiAlH^ was destroyed by addition of ethyl acetate 
(50 cm3). The solvent was removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (1:2:97—>5:20:75 v/v 
isopropylamine:methanol:ethyl acetate) to give the title compound as a yellow oil (2.52 g,
55%) (Found: (M-H)+ 217.1339. C13H18N2O requires: M-H 217.1341); (filmycm"1
NCH2CH2CH2OH), 3.27 (2H, t, J  9.4, NCH2CH2N), 3.41 (2H, t, y  5.9, NCHjCHjCFfeOH),
MHz) 31.0 (NCH2CH2CH2OH), 34.5 (P h o t), 43.1 (N Œ 2CH2N), 50.0 
(NCH2CH2CH2OH), 51.9 (NCH2CH2N), 59.2 (NCH2CH2CH2OH), 126.8, 128.5 and 128.6 
(Ar-CH), 136.1 (Ar-C), 166.1 (N-C=N); m/z 218 (M+, 10%), 201 (4), 187 (43), 173 (35), 
159 (10), 131 (7), 117 (9), 101 (20), 91 (100), 77 (7), 65 (21), 56 (54).
3187 (OH), 2934, 2864, 1600 (O N ), 1496, 1455, 1280, 1169, 1063, 723; 5h  (300 MHz) 
1.54-1.57 (2H, m, NCH2CH2CH2OH), 2.43 (1H, br s, OH), 3.09 (2H, t, J  6.7,
3.57 (2H, s, PhCFfe), 3.66 (2H, t, J  9.4, NC//2CH2N) 7.16-7.28 (5H, m, Ar-H); 5c (75
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General method for the synthesis of l,2,3,5-tetrahydroimidazo[l,2-a]pyridin-5-one
(2.2.19) and (2.2.20)
nQmh 0<YX)Et ___________ „
.1/
HN
The p-ketoester (2 equiv.) was injected into a solution of the 2-substituted 2-imidazoline (1 
equiv.) in toluene (30 cm3) and the solution was heated to reflux using a Dean-Stark trap 
for 12 h. The toluene was then removed under reduced pressure and the crude product was 
purified by column chromatography on silica gel (98:1:1 >85:10:5 v/v ethyl 
acetate:methanol:isopropylamine) to give the l,2,3,5-tetrahydroimidazo[l,2-a]pyridin-5- 
one.
7-Methyl-8-(prop-2-enyl)-l,2,3,5-tetrahydroiimdazo[l,2-a]pyridm-5-one (2.2.19a)
/ \
N>x JMH HN
The compound was synthesised by the general method, from 2-(but-3-enyl)-2-imidazoline 
(0.20 g, 1.61 mmol) and ethyl acetoacetate (0.41 cm3, 3.22 mmol) in toluene (20 cm3). The 
title compound was obtained as yellow solid (0.14 g, 44%), m.p 147-149°C, (Found: M 
190.1102. C11H14N2O requires: M190.1106; vmax (KBr)/cm"' 3215 (NH), 3006,2977,1657 
(NCO), 1545,1467,1421,1399,1288,1202,1106,994,909,809; SH (400 MHz) 2.09 (3H, 
s, CH,), 3.04-3.06 (2H, m, Cfl2CH=CH2), 3.71 (2H, t, /  8.6, NCH2CH2N), 4.20 (2H, t, J  
8.6, NCH2CH2N), 4.66 (1H, br s, NH), 4.98-5.08 (2H, m, CH2CH=CH2), 5.77 (1H, s, 
C ^C C H :), 5.76-5.86 (1H, m, C /^C H 2); 5c (75 MHz) 19.8 (CH3), 30.3 (CH2CH=CH2),
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43.0 (NCH2CH2N), 44.7 (NCH2CH2N), 94.0 (CH2O C N ), 107.4 (CH=CCH3), 115.3 
(CH=CH2), 135.4 (CH=CH2) 150.6 (NCOCH=œH3), 153.4.4 (NC=CCH2), 160.6 (NCO); 
m/z 190 (M*. 81%), 175 (16), 163 (100), 147 (9), 135 (12), 121 (8), 91 (11), 77 (13).
7-Phenyl-8-(prop-2-enyl)-l,2,3,5-tetrahydroimidazo[l,2-a]pyridm-5-onc (2.2.19b)
HN
Ph
The compound was synthesised by the general method, from 2-(but-3-enyl)-2-imidazoline 
(0.20 g, 1.61 mmol) and ethyl benzoylacetate (0.55 cm3, 3.22 mmol) in toluene (20 cm3). 
The title compound was obtained as a yellow solid (0.35, 86%), m.p. 152-154°C (Found: 
M* 252.1267. Ci6H16N20  requires: M  252.1263); Xmm/mn 343 (E^/m ol.dm  3 34980); vml,  
(KBr)/cm"' 3170 (NH), 2981,2924,1656 (NCO), 1547,1475, 1417, 1375, 1181, 781, 708; 
8h (300 MHz) 2.87-291 (2H, m, C1T2CH=CH2), 3.70 (2H, t, J  8.6, NCJf2CH2N), 4.20 (2H, 
t, J  8.6, NCH2CH2N), 4.75 (1H, br s, NH), 4.91-5.04 (2H, m, CH=CH2), 5.77 (1H, s, 
Ctf=CPh), 5.55-5.81 (1H, m, C ffC H 2), 7.15-7.21 (2H, m, Ar-H), 7.24-7.33 (3H, m, Ar- 
H); 5c (75 MHz) 31.1 (CH2=CHCH2), 42.9 (NCH2CH2N), 44.6 (NCH2CH2N), 92.7 
(CH2C=CN), 107.2 (CH=CPh), 115.5 (CH=CH2), 127.8, 127.9 and 128.1 (Ar-CH), 136.1 
(CH=CH2), 139,3 (A r-C ), 151.4  (CH=CPh), 157,2 (NC=CCH2), 160.2 (NCO); m/z 252 
(M% 100%), 225 (59), 197 (10), 152 (14), 127 (19), 115 (15), 102 (11), 77 (18).
7-Phenyl-8-phenylmethyl-1^^5-tetrahydroimidazo[l,2-fl]pyridin-5-one (2.2.19c)
n
N <s/N H
r
HN.
Ph PhPh
The compound was synthesised by the general method, from 2-phenylethyl-2-imidazoline 
(0.10 g, 0.57 mmol) and ethyl benzoylacetate (0.20 cm3, 1.14 mmol) in toluene (20 cm3). 
The title compound was obtained after purification as a white solid (0.13 g, 75%), m.p 210- 
212°C (Found: M+ 302.1423. CioHigNzO requires: M  302.1419); vmax (film)/cm"‘ 3246 
(NH), 1667 (NCO), 1546, 1526, 1468, 1415, 1289, 1237, 699; 8H (400 MHz) 3.60 (2H, s, 
PhCtf2), 3.64 (2H, t, J  8.3, NCiftCHzN), 4.23 (2H, t, J  8.3, NCH2CH2N), 4.38 (1H, br s, 
NH), 5.89 (1H, s, NCOC//=CPh), 7.08-7.36 (10H, m, Ar-H); 8c (100 MHz) 32.4 (PhCH2), 
42.9 (NCH2CH2N), 44.6 (NCH2CH2N), 93.9 (PhCH2C=CN), 107.3 (NCOCH=CPh), 
126.4, 127.7, 127.7, 127.9, 128.2 and 128.8 (Ar-CH), 139.2 and 139.5 (Ar-C), 151.45 
(NCOCH=CPh), 157.4 (NC=CCH2Ph), 160.3 (NCO); m/z 302 (M+, 13%), 273 (2), 225
(14), 202 (2), 167 (2), 154 (2), 140 (2), 127 (5), 105 (5), 91 (19), 77 (19).
6-Methyl-7-phenyl-l,2^3,5-tetrahydroimidazo[l^-<i]pyridin-5-one (2.2.19d)
/  \  
N .\ .NH HN
PhPh
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (0.90 
g, 5.62 mmol) and ethyl acetoacetate (1.43 cm3, 11.25 mmol). The title compound was 
obtained after purification as a white solid (0.72 g, 56%), m.p. 161-163°C (Found: M+ 
226.1107. C14H14N2O requires: M 226.1106); (KBr)/cm  ^ 3145 (NH), 1657 (NCO), 
1559, 1519, 1493, 1439, 1296, 702; 5» (400 MHz) 1.95 (3H, s, CH3), 3.66 (2H, t, J  8.2,
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NŒf2CH2N), 4.23 (2H, t, J  8.2, NCH2C%N), 4.48 (1H, br s, NH), 5.82 (1H, s, CH=C), 
7.21-7.41 (5H, m, Ar-H); 8c (100 MHz) 20.5 (CH,), 42.8 (NCH2CH2N), 44.7 
(NCH2CH2N), 99.7 (PhC=C), 107.0 (NCOCH=CCH,), 127.3, 129.1 and 130.5 (Ar-CH),
135.2 (Ar-C), 151.2 (NCOCH=C(CH,)), 152.4 (NC=CPh), 160.5 (CO); m/z 226(M+, 
100%), 198 (29), 182 (5), 169 (5), 153 (5), 128 (11), 115 (12), 103 (4), 91 (5), 83 (7), 57 
(5).
7,8-Diphenyl-l,2,3,5-tctrahydroimidazo[l,2-ti]pyridin-5-one (2.2.19e)
n
N y NH _________ ^
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (1.10 
g, 6.25 mmol) and ethyl benzoylacetate (2.16 cm3, 12.50 mmol) in toluene (62 cm3). The 
title compound was obtained as a yellow solid (1.05 g, 58%), m.p 279-281 °C (Found: M+ 
288.1259. C19H16N2O requires: Af 288.1263); v™, (KBr)/cm ' 3234 (NH), 1646 (NCO), 
1586, 1531, 1500, 1487, 1469, 1420, 1282, 768, 699; 8h (400 MHz) 3.69 (2H, t, J  8.3, 
NCH2CH2N), 4.20 (2H, t, J  8.3, NCH2CH2N), 4.98 (1H, br s, NH), 5.95 (1H, s, 
COC/^CPh), 7.05-7.28 (10H, m, Ar-H); 8c  (100 MHz) 42.8 and 44.9 (NCH2), 98.3 
(PhC=CN), 107.4 (NCOCH=CPh), 126.7, 127.8, 128.0, 128.6, 128.9, and 130.6 (Ar-CH),
135.3 and 139.0 (Ar-C), 151.0 (NCOCH=CPh), 155.5 (NOCPh), 160.5 (NCO); m/z 288 
(M+, 6%), 242 (2), 223 (3), 210 (3), 190 (4), 162 (4), 120 (16), 91 (24), 57 (18).
HN
Phf
Ph
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10-Phenylmethyl-l,2,3,5,6,7,8,9-octahydroiinidazo[l,2-6]isoqumolm-5-oiie (2.2.20a)
HN.
Ph
The compound was synthesised by the general method, from 2-phenylethyl-2-imidazoline 
(0.10 g, 0.57 mmol) and ethyl 2-cyclohexanone carboxylate (0.18 cm3, 1.15 mmol) in 
toluene (20 cm3). The title compound was obtained as a white solid (0.12 g, 75%), m.p 
231-233°C (Found: C, 76.49; H, 7.18; N, 9.78%; M+ 280.1575 CisHzoNzO-O.lEfeO 
requires: C, 76.65; H, 7.16; N, 9.93%; M  280.1576); Vm« (frlm)/cm ' 3240 (NH), 2927, 
1652 (NCO), 1533, 1494, 1481, 1290, 1228, 740; 8h (400 MHz) 1.65-1.70 (4H, m, 
CHzCfliCHiCHa), 2.42 (2H, t, J  4.8, CH2CH2CH2CH2), 2.53 (2H, t, J  4.8, 
CH2CH2CH2CJÎ2), 3.57 (2H, t, /8 .3 , NCH2CH2N), 3.68 (2H, s, PhC%), 4.20 (2H, t, J8 .3 , 
NCH2CH2N), 4.30 (1H, br s, NH), 7.10-7.30 (5H, m, Ar-H); 8c (100 MHz) 22.2,22.5,23.5 
and 26.9 (CH2), 31.2 (PhCH2), 42.7 (NCH2CH2N), 44.8 (NCH2CH2N), 94.2 
(PhCH2C=CN), 115.4 (NCOC=C), 126.3, 127.6 and 128.7 (Ar-CH), 139.6 (Ar-C), 147.6 
(NCOC=C), 149.2 (NC=CCH2Ph), 160.2 (NCO); m/z 280 (M*. 100%), 265 (26), 251 (29), 
236 (5), 203 (29), 189 (10), 175 (6), 152 (3), 115 (5), 91 (14), 69 (15).
196
10-[(2-Phenyl)phenylmethyl]-l,23>5>6,7,8,9-octahydroimidazo[l,2-6]isoqumoliii-5-one
(2.2.20b)
HN
PhPh
The compound was synthesised by the general method, from 2-[(2-phenyl)phenylethyl]-2- 
imidazoline (0.50 g, 2.00 mmol) and ethyl 2-cyclohexanone carboxylate (0.64 cm3, 4.00 
mmol) in toluene (20 cm3). The title compound was obtained after purification as a white 
solid (0.63 g, 88%), m.p 251-253°C (Found: C, 79.88; H, 6.70; N, 7.78%; M+ 356.1889. 
C24H24N2O O.I5H2O requires: C, 80.28; H, 6.77; N, 7.80%; Af 356.1889); Vmax (film)/cin1 
3208 (NH), 2928, 1657 (NCO), 1533, 1494, 1476, 1450, 1288, 1230, 1154, 751; Ôh (300 
MHz) 1.61-1.66 (4H, m, CHzCi^Ci^CHz), 2.25 (2H, t, J4 .8 , CJ^CHzC^CHz), 2.49 (2H, 
t, J 4.8, CH2CH2CH2CH2), 3.51 (2H, t, J8 .3 , NCH2CH2N), 3.59 (2H, s, ArC/f2), 3.86 (1H, 
br s, NH), 4.17 (2H, t, J  8.3, N O ^O ^N ), 7.18-7.46 (9H, m, Ar-H); 5c (75 MHz) 22.2,
22.5, 23.4 and 26.8 (CH2), 29.6 (ArCH2), 42.7 (NCH2CH2N), 44.8 (NCH2CH2N), 94.4 
(ArCH2C=CN), 115.6 (NCOC=C), 126.3, 127.2, 127.4, 127.9, 128.3, 129.1 and 136.7, 
(Ar-CH), 139.6, 141.4 and 142.2 (Ar-C), 147.6 (NCOC=C), 149.2 (NC=CCH2Ar), 160.2 
(NCO); mlz 356 (M+, 100%), 355 (28), 341 (11), 327 (7), 313 (4), 277 (4), 251 (3), 215 (4), 
203 (71), 189 (20), 175 (15), 165 (33), 152 (21), 128 (5), 115 (6), 91 (6), 77 (16) 44 (23).
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10-Phenyl-1^3>5>6,7A9-octahydroiimdazo[l,2-A]isoqumolin-5-one (2.2.20c)
n
N ^ N H HN
Ph
The compound was synthesised by the general method, from 2-benzyl-2-imidazoline (5.00 
g, 31.25 mmol) and ethyl 2-cyclohexanonecarboxylate (9.98 cm3, 62.50 mmol) in toluene 
(150 cm3). The title compound was obtained as a yellow solid (5.48 g, 66%), m.p 223- 
235°C (Found: C, 76.50; H, 6.81; N, 10.50%; M* 266.1417. CnHigNjO requires: C, 76.66;
H, 6.81; N, 10.50%; M  266.1419); vm„, (filmycm1 3127 (NH), 2935, 1650 (NCO), 1563, 
1523, 1491, 1436, 1096, 698; 8h (400 MHz) 1.56-1.62 (2H, m, CH2CH2CH2CH2),1.67-
I.72 (2H, m, CH2CH2C/72CH2), 2.22 ( 2H, t, 74.8, C%CH2CH2CH2), 2.53 (2H, t, 74.8, 
CH2CH2CH2CH2), 3.59 (2H, t, 7  8.3, NC//2CH2N), 4.11 (1H, hr s, NH), 4.22 (2H, t, 7  8.3, 
NCH2CH2N), 7.19-7.30 (5H, m, Ar-H); 5c (100 MHz) 22.3,22.5,23.4 and 28.5 (CH2) 42.7 
(NCH2CH2N), 44.9 (NCH2CH2N), 98.9 (PhC=CN), 114.9 (NCOC=C), 127.3, 128.9 and
130.8 (Ar-CH), 135.2 (Ar-C), 146.8 (N C O O Q , 148.3 (NOCPh), 160.3 (NCO); mlz 266 
(M+, 52%), 251 (14), 237 (28), 206 (11), 191 (19), 149 (71), 115 (12), 105 (13), 91 (53), 77 
(15).
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2-(But-3-enyl)-l-(3-oxo)but-l-enyl)-2-imidazoline (2.3.4)
N<x /NH
3-Butyn-2-one (0.47 cm3, 5.33 mmol) was injected into a solution of 2-(but-3-enyl)-2- 
imidazoline (0.63 g, 5.08 mmol) in dry methanol (50 cm3) at 20°C under nitrogen. The 
reaction mixture was stirred at 20°C for 14 h. The methanol was then removed under 
reduced pressure and the residue was purified by column chromatography on silica gel 
(0.25:99.75—>2:98 v/v isopropylamine:ethyl acetate) to give the title compound as a yellow 
oil (0.81 g, 83%) (Found: (M-H)+ 191.1184. C n H ^ O  requires: M-H 191.1184); v™, 
(filmycm"1 2950, 1642, 1572, 1479, 1405, 1354, 1257, 1201, 1005, 964, 927; 8h (400 
MHz) 2.20 (3H, s, COCH3), 2.47-2.52 (4H, m, C%C%CH=CH2), 3.57 (2H, t, J  9.2, 
NCH2CH2N), 3.95 (2H, t, 7  9.2, NCH2CH2N), 5.00-5.15 (2H, m, CH=C%), 5.30 (1H, d, J
13.2, NCH=CHCOMe), 5.85-5.94 (1H, m, CH=CH2), 7.75 (1H, d, J  13.2, 
NC//=CIICOMe); 8c (100 MHz) 26.6 (CH2CH2C H C H 2), 28.7 (COCH3), 29.5 
(CH2CH2CH=CH2), 46.3 (NCH2CH2N), 53.3 (NCH2CH2N), 103.6 (NCH=CHCOMe),
116.0 (CH=CH2), 136.5 (CH=CH2), 137.7 (NCH=CHCOMe), 160.2 (N=C-N), 196.6 
(COMe); m/z 192 (M*, 27%) 177 (6), 149 (89), 135 (6), 121 (17), 111 (80), 96 (78), 83 
(48), 68 (44), 55 (100), 43 (100).
2-Benzyl-l-(3-oxobut-l-€nyl)-2-imidazoline (23.7)
n
.NH
Phy
3-Butyn-2-one (1.45 cm3, 18.75 mmol) was injected into a solution of 2-benzyl-2- 
imidazoline (2.50 g, 15.62 mmol) in dry methanol (20 cm3) at 0°C. The reaction mixture
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was stirred at 0°C for 30 min and at 20°C for 4 h. The methanol was then removed under 
reduced pressure and the crude product was purified by column chromatography on silica 
gel (0.25:99.75—>2-98 v/v isopropylaminerethyl acetate) to give the title compound as a 
yellow solid (2.56 g, 72%), m.p. 104-106°C (Found: C, 71.43; H, 7.09; N, 11.93%; M+ 
228.1263. C14H16N2O O.4H2O requires: C, 71.39; H, 6.79; N, 11.89%; M 228.1262); vmax 
(KBrycm"1 2995, 2919, 1606, 1457, 1360, 1249, 1167, 1001, 942; 8h  (400 MHz) 2.10 
(3H, s, COCH3), 3.56 (2H, 1,79.3, NCH2CH2N), 3.88 (2H, s, PhC%), 4.02 (2H, 1,79.3, 
NCH2CH2N), 5.20 (1H, d, 713.2, NCH=CHCOMe), 7.20-7.35 (5H, m, Ar-H), 7.67 (1H, d,
713.2, NCH=CHCOMe); 8c (100 MHz) 28.2 (COCH3), 34.3 (PhCH2), 46.6 (NCH2CH2N),
53.7 (NCH2CH2N), 104.5 (NCH=CHCOMe), 127.7, 128.7 and 129.1 (Ar-CH), 134.3 (Ar- 
C), 138.6 (NCH=CHCOMe), 159.7 (N=C-N), 196.7 (COMe); m/z 228 (M+, 29%), 213 (3), 
185 (12), 171 (5), 159 (2), 117 (8), 111 (98), 96 (100), 91 (52), 83 (42), 70 (22).
2-Benzyl-l-(3-hydroxybut-l-enyl)-2-imidazoline (23.11)
A solution of 2-benzyl-l-(3-(oxo)but-l-enyl)-2-imidazoline (.48 g, 2.10 mmol) in THF (21 
cm3) was added via cannula to LiAlH^ (2.10 cm3 of a 1M solution in THF, 2.10 mmol) at - 
78°C under nitrogen. The resulting yellow solution was stirred at -78°C for 1 h and was 
then allowed to warm up to 20°C. The reaction was quenched with ethyl acetate (5 cm3) 
and stirred the mixture for 30 min. The solvent was removed under reduced pressure and 
the crude product was purified by column chromatography on silica gel (2:98 v/v 
isopropylamine:ethyl acetate) to give the title compound as a thick yellow oil (0.36 g, 75%) 
(Found: M+ 230.1419. CmH^NjO requires: M  320.1419); v™, (filmj/cm"1 3294 (OH), 
2966, 2874, 1661, 1617, 1617, 1456, 1417, 1280, 1144, 1010, 927, 725; 8» (400 MHz;
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CDClj) 1.21 (3H, d, J 6.2, CH3), 2.78 (1H, br s, OH), 3.46 (2H, t, J  10.0 NCH2), 3.68 (2H, 
s, PhCtiz), 3.82 (2H, t, J  10.0, NCH2), 4.17-4.23 (1H, m, CH3CflOH), 4.53-4.59 (1H, dd, J
7.5 and 13.1, NCH=Cfl), 6.56 (1H, d, J  13.1, N CffCH ), 7.20-7.35 (5H, m, Ar-H); 8c (100 
MHz) 24.2 (CH3), 34.0 (PhCH2), 46.5 and 53.2 (NCH2), 67.2 (CH3CHOH), 109.4 
(NCH=CH),), 126.1 (NCH=CH), 127.1, 128.4 and 128.9 (Ar-CH), 134.9 (Ar-C), 160.3 (N- 
C=N); m/z 230 (M+, 7%), 211 (45), 197 (5), 171 (7), 159 (18), 131 (5), 115 (6), 103 (5), 98 
(18), 91 (49), 77 (7), 67 (11).
General method for the synthesis of methyl 3-{2-alkylimidazolin-l-yl)propenoates
n  n  ?°2Me n
N j NH ------------» N ^ N ^ c02M e
Methyl propenoate was injected to a solution of the 2-alkyl-2-imidazoline in dry methanol 
at 20 °C under nitrogen. The resulting yellow solution was stirred overnight at 20 °C. 
Methanol was removed under reduced pressure and the crude product was purified by 
column chromatography on silica gel (3:7—>10:0 v/v ethyl acetate:hexane) to give the 
products.
Z  and E  Methyl 3-(2-benzylimidazolin-l-ynl)propenoate (23.14)
/—\ r~\ 9°=“' r~\
N ^ N H  ------------.
Ph PVT Ph"
These compounds were prepared by the general method, from 2-benzyl-2-imidazoline 
(2.00 g, 12.48 mmol) and methyl propynoate (1.10 cm3, 18.67 mmol) in methanol (62 
cm3). The title compounds were obtained after purification in a 2:1 ratio Z:E isomers (1.95 
g, 65%). Data for Z  isomer: (Found: C, 66.49; H, 6.73; N, 10.74%; M+ 244.1212.
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C m H ^ O tO .W ) requires: C, 66.84; H, 6.36, N, 11.14%; Af244.1212); (film)/cm" 
1 2948, 1704 (CO), 1610 (C=N), 1357, 1268, 1153, 1011, 921, 718; 8h (400 MHz) 3.62 
(3H, s, CO2CH3), 3.81 (2H, s, PhC%), 3.97 (2H, t, J  8.8, NC%CHzN), 4.04 (2H, t, J  8.8, 
NCH2CH2N), 4.65 (1H, d, J  10.0, NCH=CHC02Me), 4.57 (1H, d, J  10.0, 
NCff=CHC02Me), 7.20-7.34 (5H, m, Ar-H); 5c (100 MHz) 34.5 (PhCH2), 49.4 
(NCH2CH2N), 50.9 (C02CH3), 54.1 (NCH2CH2N), 90.9 (NCH=CHC02Me), 127.2, 128.7,
128.9 (Ar-CH), 134.2 (Ar-C), 136.0 (NCH=CHC02Me), 160.5 (N=C-N), 165.9 (C 02Me); 
m/z 244 (M+, 52%), 229 (3), 213 (20), 185 (84), 171 (64), 159 (8), 128 (34), 117 (16), 105 
(20), 91 (100), 77 (19). Data for the £-isomer: m.p 74-76°C, (Found: C, 67.51; H, 6.59; N,
11.24%; M+ 244.1212. Ci4Hi«N2O2 0.2H2O requires: C, 67.81; H, 6.45; N, 11.30%; M  
244.1212); V™, (filmycm-1 2935,1693 (CO), 1607 (C=N), 1408,1315,1261,1192,1170, 
718; 6h (400 MHz) 3.57 (2H, t, J  8.8, NCff2CH2N), 3.68 (3H, s, C 02CH3), 3.94 (2H, s, 
PhCffc), 3.97 (2H, t, J 8.8, NCff2CH2N), 4.82 (1H, d, J  13.2, NCH=CflC02Me), 7.20-7.34 
(5H, m, Ar-H), 7.78 (1H, d, J  13.2, NCH=CHC02Me); Sc (100 MHz) 34.0 (PhCH2), 46.3 
(NCH2CH2N), 51.1 (C02CH3), 53.2 (NCH2CH2N), 93.2 (NCH=CHC0 2Me), 127.4, 128.9 
and 129.1 (Ar-CH), 134.1 (Ar-C), 139.1 (NCH=CHC02Me), 159.5 (N=C-N), 168.6 
(C02Me); m/z 244 (M+, 36%), 213 (25), 185 (50), 171 (30), 159 (10), 128 (40), 117 (20), 
105 (17), 91 (100), 77 (26).
Z  and E  Methyl 3-[2-(furylethylimidazolin-l-yl]propenoate (2.3.15)
These compounds were prepared by the general method, from 2-[2-(2-furyl)ethyl]-2- 
imidazoline (0.21 g, 1.28 mmol) and methyl propynoate (0.17 cm3, 1.92 mmol) in 
methanol (1.2 cm3). The title compounds were obtained as white solids (0.19 g, 60%). Data
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for Z-isomer: m.p. 58-60°C (Found: C, 62.70; H, 6.54; N, 11.14%; M+ 248.1160. 
C13H18N2O3 requires: C, 62.89; H, 6.50, N,11.28%; M 248.1160); v™* (KBr)/cm"' 2949, 
1699 (CO), 1611 (C=N), 1474 , 1378, 1335, 1213, 1173, 997, 924; Sh (400 MHz) 2.69 
(2H, t, 77.8, CHzCT^Furyl), 2.99 (2H, t, 77.8. C/^CHzFuryl), 3.59 (3H, s, CO2CH3), 3.83 
(2H, t, J  9.0, NCH2CH2N), 3.93 (2H, t, J  9.0, NC^CHzN), 4.67 (1H, d, J  10.0, 
NCH=C7/C02Me), 5.98 (1H, d, J  2.9, Furyl-4H), 6.21 (1H, dd, J  1.9 and 2.9, Furyl-3H), 
6.52 (1H, d, J  10.0, NC//=CHC02Me), 7.24 (1H, d, 71.9, Furyl-2H); 5c (100 MHz) 24.5 
(OfeOfeFuryl), 26.6 (OfcOfeFuryl), 49.4 (NCH2CH2N), 50.9 (CO2CH3), 54.0 
(NCH2CH2N), 90.9 (NCH=CHC02Me), 105.6, 110.2 and 141.3 (Furyl-CH), 135.6 
(NCH=CHC02Me), 153.9 (Furyl-C), 160.9 (N=C-N), 165.9 (C02Me); m/z 248 (M+, 25%), 
233 (6), 217 (10), 189 (100), 161 (10), 135 (10), 121 (10), 109 (36), 96 (24), 81 (32), 68
(9). Data for E-isomer: m.p. 96-98 °C (Found: C, 62.74; H, 6.54; N, 11.01%; M+ 
248.1160. C13HU1N2O3 requires: C, 62.89; H, 6.50, N,11.28%; M  248.1160); \ tmx 
(KBrycm"1 2958, 1693 (CO), 1634 (C=N), 1315, 1286, 1217, 1168, 793, 740; 5» (400 
MHz) 2.66 (2H, t, 7  7.8, CHzCT&Furyl), 3.01 (2H, t, 7  7.8, CT^CHzFuryl), 3.48 (2H, t, 7
9.0, NCH2CH2N), 3.65 (3H, s, CO2CH3), 3.87 (2H, t, 79.0, NCH2CH2N), 4.79 (1H, d, 7
13.2, NCH=CflC02Me), 6.00 (1H, d, 73.1, Furyl-4H), 6.21 (1H, dd, 72.0  and 3.1, Furyl- 
3H), 7.25 (1H, d, 72.0, Furyl-2H), 7.65 (1H, d, 713.2, NC//=CHC02Me); 5c (100 MHz)
24.5 (CH2CH2Furyl), 26.2 (CH2CH2Furyl), 46.6 (NCH2CH2N), 51.4 (C02CH3), 53.3 
(NCH2CH2N), 93.6 (NCH=CHC02Me), 105.9, 110.5 and 141.6 (Furyl-CH), 138.8 
(NCH=CHC02Me), 154.1 (Furyl-C), 160.1 (N=C-N), 168.9 (C02Me); m/z 248 (M+, 23%), 
233 (5), 217 (9), 205 (5), 189 (100), 175 (2), 161 (8), 135 (6), 121 (8), 109 (36), 96 (21), 81 
(27), 68 (8).
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Z  and E  methyl 3-[2-(hepta-3,5-dienyl imidazolm-l-yl]propenoate (2.316a-b)
j—  ^ Ç02Me j y
V N^  ^  NV N^ D O , Me
The compounds were synthesised from 2-(hepta-3,5-dienyl)-2-imidazoline (0.31 g, 1.93 
mmol) and methyl propenoate (0.30 cm3, 2.89 mmol) in methanol (10 cm3) using the 
general method. The title compound was obtained after purification as 2:1 mixture of 
propenoate Z:E isomers as yellow oils (each a 3:1 mixture of E,E:E,Z isomers) (0.24 g, 
50%); Data for propenoate Z-isomer (Found: C, 66.95; H, 8.10; N, 11.03%; M+ 248.1534. 
C14H20N2O2 O.IH2O requires C, 67.21; H, 8.08; N, 11.20%; M 248.1525); v™» (filmycm"1 
2949, 1707 (CO), 1653, 1610 (C=N), 1364, 1160, 994, 922; data for heptadienyl E:E 
isomer 5h (400 MHz) 1.73 (3H, d, 7  6.8, CH3), 2.37-2.45 (4H, m, CH=CHC%C%), 3.66 
(3H, s, CO2CH3), 3.88 (2H, t, J  8.8, NC//2CH2N), 3.98 (2H, t, J  8.8, NCH2Gtf2N), 4.74 
(1H, d, J  10.0, NCH=CflC02Me), 5.56-5.66 (2H, m, CH3Cfl=CHCH=C7/CH2), 6.00-6.10 
(2H, m, CII3CII=C//C/^CH), 6.61 (1H, d, J  10.0, NCS=CHC02Me); 5c (100 MHz) 18.1 
(CH3), 27.9 (CH=CHCH2CH2), 28.8 (CH=CHCH2CH2), 49.4 (NCH2CH2N), 50.9 
(C02CH3), 54.1 (NCH2CH2N), 90.6 (NCH=CHC02Me), 128.2, 129.2, 131.2 and 131.6 
(CH), 135.9 (NCH=CHC02Me), 161.3 (N=C-N), 166.1 (C02Me); data for heptadienyl-£.Z 
isomer 5% (400 MHz) 1.11 (3H, d .76 .8 , CftCH ), 2.37-2.45 (4H, m, CH2CH2), 3.66 (3H, 
s, C 02CH3), 3.88 (2H, t, 7  8.8, NC7/2CH2N), 3.98 (2H, t, 7  8.8, NCH2C //2N), 4.74 (1H, d, 
J  10.0, NCH-C7fC02Me), 5.01 (1H, dd, 71.7 and 10.2, CH3CH=CHC//=CH), 5.14 (1H, d, 
J  1.7 and 17.1, CH3CH=CHCH=CHCH2), 5.61-5.66 (1H, m, CH3CH=CHCH=CflCH2),
6.25 6.32 (1H, m, CH3Ctf=CHCH-CHCH2), 6.61 (1H, d, J  10.3, NC7f=CHC02Mc); Sc 
(100 MHz) 20.0 (CH3), 33.8 (CH2CH2), 34.9 (CH2CH2), 49.4 (NCH2CH2N), 50.9 
(C02CH3), 54.1 (NCH2CH2N), 90.6 (NCH=CHC02Me), 116.1, 129.9, 136.9 and 138.5 
(CH), 136.0 (NCH=CHC02Me), 161.3 (N C -N ), 166.1 (C02Me); m/z 248 (M*, 56%), 233
204
(30), 217 (10), 205 (6), 189 (100), 161 (12), 135 (22), 120 (26), 109 (45), 96 (26), 79 (36), 
67 (37), 53 (52).
Data for propenote E-isomer (Found: M+ 248.1523. C14H20N2O2 requires: Af 248.1525); v 
max (f ilm y c m "1 2950,1703 (CO), 1615 (C=N), 1410,1315,1256,1197,1163,994; data for 
heptadienyl-£,E isomer Sh (400 MHz) 1.73 (3H, d, J  6.8, CH3), 2.41-2.51 (4H, m, 
CH2CH2), 3.53 (2H, t, J  9.0, NCH2CH2N), 3.72 (3H, s, CO2CH3), 3.93 (2H, t, J  9.0, 
NCH2CH2N), 4.85 (1H, d, J  13.2, NCH=CflC02Me), 5.58-5.69 (2H, m,
CH3C//=CHCH=C/fCH2), 5.98-6.10 (2H, m, CH3CH=CflCff=CHCH2), 7.74 (1H, d, J
13.2, NC/f=CHC02Me); Sc (100 MHz) 18.5 (CH3), 27.3 (CH2CH2), 28.5 (CH2CH2), 46.2 
(NCH2CH2N), 50.9 (C 02CH3), 53.1 (NCH2CH2N), 92.9 (NCH=CHC02Me), 128.2, 129.0,
131.6 and 131.7 (CH), 138.9 (NCH=CHC02Me), 160.1 (N=C-N), 168.7 (C02Me); m/z 248 
(M% 28%), 233 (22), 217 (9), 205 (6), 189 (100), 175 (16), 161 (10), 149 (14), 134 (17), 
121 (15), 109 (32), 96 (23), 79 (26), 67 (16); Data for heptadienyl E.Z-isomer 8C (400 
MHz) 1.13 (3H, d, J  6.8, CH,), 2.40-2.51 (4H, m, CH2CH2), 3.53 (2H, t, J  9.0, 
NCFf2CH2N), 3.66 (3H, s, C 02CH3), 3.95 (2H, t, J9 .0 , NCH2C/f2N), 4.74 (1H, d, J  10.2, 
NCH=CflC02Me), 5.01 (1H, dd, J  1.7 and 9.8, CH3CH=CHCff=CHCH2), 5.14 (1H, d, J
1.7 and 17.1, CH3CH=CHCH=CHCH2), 5.65-5.70 (1H, m, CH3Cfl=CHCH=CHCH2), 
6.24-6.31 (1H, m, CH3CH=CHCH=CflCH2), 6.61 (1H, d, J  10.2, NC//=CHC02Me); Sc 
(100 MHz) 20.2 (CH,), 27.9 (CH2CH2), 28.8 (CH2CH2), 49.3 (NCH2CH2N), 51.1 
(C02CH3), 54.1 (NCH2CH2N), 90.6 (NCH=CHC02Me), 116.1, 131.1, 135.9 and 138.3 
(CH), 138.8 (NCH=CHC02Me), 160.1 (N=C-N), 168.7 (C02Me).
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General method for the synthesis of l-alkyl-2-benzyl-2-imidazolines
sec-Butyllithium (1.3M solution in hexanes, 1.2 mol equiv.) was injected dropwise to a 
solution of 2-benzyl-2-imidazoline in dry THF/TMEDA (25:1 v/v) at -78 C.The yellow 
solution that was produced was stirred at -78°C for 20 minutes, the alkyl halide (1.2 equiv) 
was injected rapidly and the reaction mixture was stirred overnight (-78°C to 20°C). The 
reaction was quenched with water (100 cm3) and the organic layer was extracted with 
diethyl ether (3 x 50 cm3). The combined organic extracts were washed successively with 
water (100 cm3) and brine (100 cm3), dried and concentrated. The crude product was 
purified by column chromatogaphy on silica gel (0:100—>2:98 v/v isopropylamine : ethyl 
acetate) to give the 1 -alkyl-2-benzyl-2-imidazoline.
2-Benzyl-l-(prop-2-enyl)-2-imidazoline (23.19)
n  n
N<s /N H  / NX / ^
Ph Ph'
Prepared by the general method from 2-benzyl-2-imidazoline (2.00 g, 12.5 mmol), sec- 
butyllithium (10.57 cm3 of a 1.3M solution in hexanes, 13.75 mmol), and 1,3-dibropropane 
(1.39 cm3, 13.75 mmol) to give the title compound as a yellow oil (1.2 g, 48%) (Found: 
(M-H)+ 199.1234. C13HI6N2 requires: M-H 199.1235); (filmycm"1 2933, 2865, 1644, 
1611, 1417, 1211, 1074, 917; 8* (300 MHz) 3.28 (2H, t, J  9.8, NCH2CH2N), 3.63-3.68 
(4H, m, PhCif2 and NCH2CH=CH2) 3.74 (2H, t, J  9.8, NCH2ŒT2N), 5.07-5.14 (2H, m, 
NCH2CH=CH2), 5.52-5.62 (1H, m, NCH2CH=CH2), 7.19-7.34 (5H, m, Ar-H); 8c (75 
MHz) 34.6 (PhCH2), 49.3,50.0 and 52.3 (NCH2), 117.1 (NCH2CH=CH2), 126.7,128.6 and
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128.7 (Ar-CH), 133.7 (NCH2CH=CH2), 136.0 (Ar-C), 165.3 (N=C-N); mlz 200 (M+, 4%), 
199 (9), 185 (6), 171 (2), 157 (2), 136 (2), 123 (4), 91 (100), 83 (61), 68 (38), 56 (23).
2-(2-Phenylhepta-34-dienyl)-l-(prop-2-enyl)-2-iiiiidazoline (2.3.20)
r \
N<x /N
Ph Ph'
n-Butyllithium (1.24 cm3 of a 1.1M solution in hexanes, 1.36 mmol) was injected to a 
stirred solution of 2-benzyl-1 -(prop-2-enyl)- -2-imidazoline (0.249 g, 1.24 mmol) in dry 
THF (12 cm3) at 2ÛÙC under nitrogen. The yellow suspension that was formed was stirred 
at 20°C for 50 min. The reaction mixture was cooled to 0°C and 1 -bromohexa-2,4-diene 
(0.22 g, 1.36 mmol) was injected to it as a solution in THF (3 cm3). The reaction mixture 
was stirred at 0°C for 15 min and at 20°C overnight. The reaction was quenched with water 
(20 cm3) and the organic layer was extracted with diethyl ether (3 x 20 cm3). The combined 
organic extracts were washed with brine (50 cm3) and water (50 cm3), dried and 
concentrated. The crude product was purified by column chromatography on silica gel 
(0:100—>3:97 v/v isopropylamine:ethyl acetate) to give the title compound as a yellow oil 
(0.30 g, 49%) (Found: M+ 280.1937. C19H24N2 requires: M  280.1939); vmM (filmycm1 
3018, 2932, 2859, 1610, 1455, 1416, 1213, 991, 702; 8» (300 MHz) 1.69 (3H, d, J  6.2, 
CH,), 2.48-2.55 (1H, m, PhCHCHfl), 2.82-2.92 (1H, m, PhCHCHH), 3.14-3.30 (2H, m, 
NCH2CH2N), 3.40-3.48 (2H, m, NC//2CH=CH2 ), 3.58-3.62 (1H, m, PhCHCH2), 3.72- 
3.82 (2H, m, NCH2CH2N), 5.00-5.07 (2H, m, NCH2CH=C/f2), 5.40-5.57 (3H, m, 
CHjC/7=CH-CH=CHCH2 and NC,H2Ctf=CH2), 5.93-6.01 (2H, m, CH3CH=CH-
C//=CHCH2), 7.20-7.33 (5H, m, Ar-H); 8c (75 MHz) 18.0 (CH3), 38.7 (PhCHCH2), 44.9 
(PhCHCH2), 48.9 (NCH2CH2N), 50.1 (NCH2CH=CH2), 52.3 (NCH2CH2N), 117.0 
(NCH2CH=CH2), 126.9 (Ar-CH), 127.5 (CH), 128.0 and 128.6 (Ar-CH), 129.3, 131.6,
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132.0, 133.9 (CH), 140.6 (Ar-C), 167.1 (N=C-N); mlz 280 (M+, 85%), 265 (32), 251 (26), 
239 (58), 225 (28), 211 (17), 197 (39), 183 (13), 157 (36), 130 (20), 121 (17), 103 (21), 91 
(18), 81 (80), 65 (19).
2-Benzyl-l-(hexa-2,4-dienyl)-2-imidazoline (23.22)
r \
JMH
Ph"
This compound was prepared by the general method, using n-Butyllithium (8.25 cm3 of a 
2.5M solution in hexanes, 20.62 mmol), 2-benzyl-2-imidazoline (3.00 g, 18.75 mmol) and
l-bromohexa-2,4-diene (3.32 g, 20.62 mmol). The title compound was obtained as a yellow 
oil (2.45 g, 54%) (Found: (M-H)* 239.1546. Cjs^oNr requires M-H 239.1548); vmax 
(filmycm"1 3022, 2932, 2860, 1623, 1495, 1455, 1436, 1262, 1179, 991, 722; 8h (300 
MHz) 1.74 (3H, d, J  6.4, C //3CH), 3.32 (2H, t, J  10.0, NCHiCHzN), 3.61-3.63 (3H, m, 
NCH2CH=CHCH=CHCH3 and PhC%), 3.69 (2H, t, J  10.0, NCH2C7f2N), 5.18-5.35 (1H, 
m, CH), 5.59-5.70 (1H, m, CH), 5.96-6.06 (2H. m, 2 x CH), 7.20-7.33 (5H, m, Ar-H); 8c 
(75 MHz) 18.1 (CH3), 34.7 (PhCH2), 48.5 (NCH2CH2N), 50.0 (NCH2CH=CH), 52.3 
(NCH2CH2N), 125.7 (CH), 126.7, 128.5 and 128.6 (Ar-CH), 129.9, 130.5, 132.8 (CH),
136.1 (ArC), 165.3 (N=C-N); m/z 240 (M+, 19%), 225 (12), 211 (8), 197 (3), 185 (14), 171 
(8), 159 (29), 131 (8), 117 (8), 91 (85), 81 (100), 65 (24).
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l-(Hexa-2,4-dienyl)-2-(2-phenyl)but-3-enyl)-2-imidazoline (2J.23)
PI
w-Butyllithium (2.19 cm3 of a 1.1M solution in hexanes, 2.41 mmol) was injected to a 
stirred solution of 2-benzyl-1 -(hexa-2,4-dienyl)-2-imidazoline (0.57 g, 2.41 mmol) in dry 
THF (22 cm3) at 20°C under nitrogen. The yellow suspension that was formed was stirred 
at 20°C for 50 min. The reaction mixture was cooled to 0°C and 3-bromoprop-l-ene (0.21 
cm3, 2.41 mmol) was injected to it. The reaction mixture was stirred at 0°C for 15 min and 
at 20°C overnight. The reaction was quenched with water (50 cm3) and the organic layer 
was extracted with diethyl ether (3 x 50 cm3). The combined organic extracts were washed 
successively with brine (50 cm3) and water (50 cm3), dried and concentrated. The crude 
product was purified by column chromatography on silica gel (0:100—>3:97 v/v 
isopropylamine:ethyl acetate) to give the title compound as a yellow oil (0.30 g, 49%) 
(Found: (M-H)+ 279.1860. O ^ H ^  requires 279.1861); Vmax (film ycm 1 3022, 2932, 
1640,1455,1437,1251,1207, 991, 702; 8h (300 MHz) 1.72 (3H, d, J6 .2 , CH3), 2.50-2.57 
(1H, m, PhCHCHH), 2.82-2.89 (1H, m, PhCHCHH), 3.13-3.32 (2H, m, NCH2CH2N), 
3.42-3.49 (2H, dd 6.4 and 13.5, NCH2CH), 3.59-3.67 (1H, dd, J6 .0  and 15.6, PhCHCH2), 
3.69-3.79 (2H, m, NCH2CH2N), 4.91-5.01 (2H, m, CH2CH=CH2), 5.02-5.14 (1H, m, CH), 
5.58-5.79 (2H, m, 2 x CH), 5.91-5.96 (2H. m, 2 x CH), 7.21-7.33 (5H, m, Ar-H); 5c (75 
MHz) 18.0 (CH3), 39.8 (PhCHCH2), 48.1 (NCH2CH2N), 50.1 (NCH2CH=CH), 52.3 
(NCH2CH2N), 116.2 (CH=CH2), 125.9 (CH), 126.9, 128.0 and 128.6 (Ar-CH), 129.7,
130.5, 132.7 and 136.6 (CH), 140.5 (Ar-C), 167.1 (N-C N); mlz 240 (M+, 24%), 265 (13), 
251 (13), 239 (9), 225 (13), 211 (16), 199 (84), 171 (11), 157 (30), 130 (20), 116 (24), 103
(12), 91 (31), 77 (39), 65 (15), 53 (50).
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2-Benzyl-l-(2-furylmethyl)-2-imidazoline (23.26) and 2-[l-phenyl-2-(2-furyl)ethyl]-l- 
(2-furylmethyl)-2-lmidazolinc (23.27)
This compound was prepared by the general method, using 2-benzyl-2-imidazoline (5.00 g,
31.25 mmol), sec-butyllithum (26.43 cm3 of a 1.3M solution in hexanes, 34.37 mmol) and 
furfuryl chloride (4.00 g, 34.37 mmol). The title compound was obtained as a yellow liquid 
(4.52 g, 60%) (Found: C, 73.87; H, 6.84; N, 11.54%; M+ 240.1266. C ,5H16N2O'0.2H2O 
requires: C, 73.85; H, 6.72; N„ 11.48%; M  240.1263); (filmycm1 2935, 2865, 1617, 
1496, 1456, 1432, 1265, 1147, 1010, 722; 5» (300 MHz) 3.25 (2H, t, J9 .5 , NCH2), 3.70 
(2H, t, J  9.5, NCH2), .3.75 (2H, s, PhCtf2), 4.14 (2H, s, NCH2Furyl), 5.82 (1H, d, J  2.0, 
Furyl-3H), 6.05 (1H, dd, 72.0 and 3.3, Furyl-4H), 7.21-7.33 (1H, Furyl-5H and 5H, m. Ar­
il); 8c (75 MHz) 34.5 (PhCH2), 43.2 (NCH2Furyl), 49.7 (NCH2), 52.3 (NCH2), 107.8,
110.1 (Furyl-C), 126.6, 128.5 and 128.6 (Ar-CH), 135.9 (Ar-C), 142.1 (Furyl-CH), 150.6 
(Furyl-C), 165.0 (N=C-N); mlz 240 (M+, 39%), 223 (2), 211 (28), 197 (6), 185 (4), 171 (3), 
157 (18), 131 (6), 121 (7), 117 (7), 102 (5), 91 (83), 81 (100), 65 (21); and 2-[l-phenyl-2- 
(2-furyl)ethyl]-1 -(2-furylmethyl)-2-imidazoline as a pale yellow oil (0.92 g, 9%), (Found: 
C, 74.82; H, 6.27; N, 8.85%; M+ 320.1529. C2oH2oN20  requires: C, 74.98; H, 6.28; N, 
8.74%; M 320.1525); V™» (filmycm-1 2933, 2864, 1613, 1505, 1456, 1426, 1178, 1148, 
1012, 736; 8» (300 MHz) 3.05-3.13 (1H, dd, J  8.7 and 15.0, PhCHCHHFur), 3.18-3.29 
(2H, m, NCH2CH2N), 3.47-3.54 (1H, dd,76.2 and 15.0 PhCHCHHFur), 3.67-3.81 (2H, m, 
NCH2), 3.90 (1H, d, 716.0, NCflHFuiyl), 4.05 (1H, dd, 7  6.2 and 8.7, PhCflCH2Furyl), 
4.24 (1H, d, 7  16.1 NCHHFuryl), 5.80 (1H, d, 7  3.1, Fmyl-3H), 5.91 (1H, d, 7  3.3 
NCH2Furyl-3H), 6.18 (1H, dd, 72.0  and 3.1, CHCH2Furyl-4H), 6.25 (1H, dd, 7  2.0 and 
3.3, NCH2Fuiyl-4H), 7.21-7.33 (2H, m Furyl-5H and 5H, m, Ar-H); 8c (75 MHz) 34.1
n
N ^ /N H
Phf
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(PhCHCH2), 43.0 (PhCHCH2), 43.2 (NCHjFuryl), 50.1 and 52.4 (NCH2), 106.7, 107.6,
110.1 and 110.2 (Furyl-CH), 127.9, and 128.6 (Ar-CH), 140.8 (Ar-C), 140.8 and 142.2 
(Furyl-CH), 150.8 and 153.6 (Furyl-C), 166.6 (N=C-N); m/z 320 (M+, 29%), 291 (14), 122 
(3), 263 (1), 239 (540, 211 (8), 195 (6), 171 (3), 158 (2), 141 (7), 128 (9), 115 (9), 103
(11), 91 (12), 81 (100).
2-Benzyl-l-(penta-2,4-dienyl)-2-iinidazolme (2.3.32)
n  n
K x /N H  _____________  M x /N x
Ph'
Prepared by the general method, from 2-benzyl-2-imidazoline (0.72 g, 4.51 mmol), n- 
butyllithium (1.98 cm3 of a 1.3M solution in hexanes 4.96 mmol) and l -bromopenta-2,4- 
diene (0.73 g, 4.96 mmol). The title compound was obtained as a yellow oil (0.58 g, 57%) 
vmax (filmycm"1 3023,2930,1624, 1495,1456,1264,1175,722; Sh (300 MHz) 3.29 (2H, t,
9.9, NCH2), 3.61-3.64 (4H, m, NCff2CH=CH and PhCff2), 3.74 (2H, t, .7 9.9, 
NCH2Cff2N), 5.05-5.23 (2H, m, CR=CH2), 5.37-5.47 (1H, m, CH), 5.97-6.12 (1H. m, 
CH), 6.18-6.32 (1H, m, CH), 7.20-7.35 (5H, m, Ar-H); Sc (100 MHz) 34.7 (PhCH2), 48.4 
and 52.3 (NCH2CH2N), 50.1 (NCH2CH=CH), 117.5 (CH=CH2), 126.7, 128.5 and 128.6 
(Ar-CH), 129.2,133.1 and 135.9 (CH), 136.0 (Ar-C), 165.2 (N=C-N); m/z 226 (M+, 28%), 
211 (18), 197 (7), 184 (16), 171 (9), 159 (36), 148 (7), 135 (13), 121 (7), 108 (12), 96 (43), 
91(91).
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2-(l-Phenylseleneno)but-3-cnyl)-l-(propeii-2-enyl)-2-imidazoline (23.35)
n
N<s /N H NK ,N
PhSe'
sec-Butyllithium (1.72 cm3of a l.OM solution in cyclohexane, 1.72 mmol) was added 
dropwise to a solution of 2-(phenylselenenobut-3-enyl)-2-imidazoline (0.48 g, 1.72 mmol) 
in dry THF (17 cm3) at 20°C under nitrogen. The resulting yellow solution was stirred for 
45 min. 3-Bromoprop-1 -ene (0.15 cm3, 1.72 mmol) was injected and the reaction mixture 
was stirred overnight at 20°C. Water (20 cm3) was added and the organic layer was extracte 
with diethyl ether (3 x 50 cm3). The combined organic extracts were washed successively 
with water (50 cm3) and brine (50 cm3), dried and concentrated. The crude product was 
purified by column chromatography on silica gel (0:100—>2:98 v/v isopropylamine:ethyl 
acetate) to give the title compound as a yellow oil (0.13 g, 23%) and 0.24 g, of starting 
material, 47% yield based on recovered starting material, (Found: NT*" 320.0792. 
CiôHzoNzSe requires: M  320.0792); (filmycm-1 2931, 2860, 1641, 1603, 1477, 1437, 
1416, 1248, 1205, 1001, 918, 740; Ôh (400 MHz) 2.62-2.70 (1H, m, PhSeCHCiffl), 2.87- 
2.97 (1H, m PhSeCHCHfl), 3.23-3.35 (2H, m, NCH2CH2N), 3.55-3.64 (1H, m, PhSeCtf), 
3.67-3.74 ( 2H, m, N O ^C i^N ), 3.77-3.88 (2H, m, NC#2CH=CH2), 5.06-5.24 (4H, m, 2 x 
CH=Ctf2), 5.70-5.82 (1H, m, CH2Ctf=CH2), 5.83-5.90 (1H, m, NCH2C#=CH2), 7.28-7.33 
(3H, m, Ar-H), 7.62 (2H, m, Ar-H); ôc (100 MHz) 37.4 (PhSeCH), 38.0 (PhSeCHCH2),
49.3 (NCH2CH2N), 50.1 (NCH2CH=CH2), 51.9 (NCH2CH2N), 117.1 (CH=CH2), 117.2 
(CH=CH2), 128.5, 128.7 and 128.9 (Ar-CH), 131.5 (Ar-C), 133.9 (CH=CH2), 136.2 
(CH=CH2), 165.6 (N=C-N); mlz 320 (M+, 11%), 279 (2), 239 (57), 225 (3), 211 (3), 197
(12), 163 (100), 149 (13), 135 (6), 121 (36), 107 (5), 93 (8), 82 (9), 77 (17).
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2-Phenylselenenomethyl-2-imidazoline (2336)
n
N^ N" B oc _____________   N ^ /N H
PhSe PhSe'
Trifluoroacetic acid (3 cm3) was added to l-terf-butyloxycarbonyl-2- 
phenylselenenomethyl-2-imidazoline (2.10 g, 6.19 mmol) and the resulting solution was 
stirred at 20°C for 30 min. The trifluoroacetic acid was removed under reduced pressure 
and the imidazoline salt was dissolved in dichloromethane. (20 cm3). The solution was then 
washed with aq. NaOH (10% w/v; 50 cm3) and the organic layer was dried and 
concentrated. The crude product was then purified by column chromatography on silica gel 
(1:99—>4:96 v/v isopropylamine:ethyl acetate) to give the title compound as a white solid 
(1.15 g, 77 %), m.p. 42-44°C (Found: M+ 240.0154. CioH^NaSe requires: Af 240.0166); 
Vmax (KBrycm1 3177, 2932, 2868, 1601, 1577, 1496, 1477, 1438, 1292, 1267, 740; 5» 
(400 MHz) 3.55 (4H, s, NCH2CH2N), 3.64 (2H, s, PhSeCff2), 4.20 (1H, br s, NH), 7.26- 
7.29 (3H, m, Ar-H), 7.52-7.54 (2H, m, Ar-H), 8c (100 MHz) 24.2 (PhSeCH2), 50.8 
(NCH2CH2N), 127.9, 129.4, 132.9 and 134.7 (Ar-C), 165.3 (N=C-N); m/z 240 (M+, 25%), 
239 (34), 179 (100), 132 (8), 117 (11), 104 (5), 91 (18), 81 (13), 77 (30), 54 (41).
2-(l-Phenylseleneno)but-3-enyl)-l-(prop-2-enyl)-2-imidazoline (2335)
/  \  n
N<v .NH
PhSe
zz-Butyllithium (3.23 cm3 of a 2.5 M solution in hexanes, 8.08 mmol) was injected to a 
solution of 2-phenylselenenomethyl-2-imidazoline (0.92 g, 3.85 mmol) in dry THF (38 
cm3) at -78°C under nitrogen. The yellow suspension produced was stirred at -78°C for 20
213
SePh
min. 3-Bromopropene (0.70 cm3, 8.08 mmol) was injected rapidly to the reaction mixture 
and was stirred overnight (-78°C to 20°C). Water (50 cm3) was added to it and the organic 
layer was extracted with diethyl ether (3 x 50 cm3). The combined organic extracts were 
washed successively with water (50 cm3) and brine (50 cm3), dried and concentrated. The 
crude product was purified by column chromatography on silica gel ( 0:100—>2:98 v/v 
isopropylamine:ethyl acetate) to give the title compound as a yellow oil (0.61 g, 50%). Data 
identical to those reported earlier.
2-(Buta-l^-dienyl)-l-(propeii-2-enyl)-2-imidazoline (2.3.34b)
NU .N
A solution of m-chloroperbenzoic acid (0 24 g, 1.36 mmol) (58%) in dry dichloromethane 
(5 cm3) was added via a cannula to a solution of 2-(l-phenylselenenobut-3-enyl)-1- 
(propen-2-enyl)-2-imidazoline (0.20 g, 0.62 mmol) in dry dichloromethane (15 cm3), at 0° 
C under nitrogen. The reaction mixture was stirred at 0°C for 1 h and at20°C for a further 
Ih. The solvent was removrd under reduced pressure and the crude product was purified by 
column chromatography on silica gel (0:100—>3:997 isopropylamine:ethyl acetate) to give 
the title compound as a yellow oil (0.10 g, 100%) (Found: C, 71.35; H, 8.45; N, 17.12%, 
(M-H)+ 161.1079. C10H14N2 requires: C, 71.63; H, 8.71; N, 16.71%; M-H 161.1076),
2933, 2859, 1645, 1603, 1582, 1429, 1402, 1285, 1266, 1221, 1009, 918; Sh 
(400 MHz) 3.35 (2H, t J  10.0 NCH2), 3.75-3.80 (4H, m, NCH2 and NCH2CH=CH2), 5.17- 
5.23 (2H, m, NCH2CH=C//2), 5.30-5.5.34 (IH ,m , CHCH=CHH), 5.46 (IH, d /1 7 .1 , CH- 
CH=CHH), 5.74-5.82 (IH, m, NCH2Cfl=CH2), 6.03 (IH, d, J  15.6, C/f=CH-CH=CH2),
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6.38-6.47 (IH, m, CH-C//=CH2), 7.11-7.18 (IH, d d / 10.7 and 15.6, CH=Ctf-CH=CH2); 8 
c (100 MHz) 50.0 (NCH2CH2N), 50.7 (NCH2CH=CH2), 52.4 (NCH2CH2N), 117.1 
(NCH2CH=CH2), 118.9 (CH-CH=CH2), 122.3, 133.8, 135.8 and 139.0 (CH), 163.3 (N=C- 
N); m/z 162 (M+, 58%), 159 (6), 147 (7), 135 (6), 121 (24), 107 (7), 93 (68), 80 (10), 66 
(26), 54 (17).
Methyl (£)-3-(2-benzylimidazolin-l-yl)pent-2-enoate (2.4.1a)
Prepared by the general method from 2-benzyl-2-imidazoline (0.30 g, 1.88 mmol) and ethyl
NCEt=CHC02Me), 7.15-7.34 (SH, m, Ar-H); 8c (75 MHz) 11.1 (CH3CH2), 29.1 
(CH3CH2). 34.8 (PhCH2), 51.2 (CO2CH3), 50.2 and 53.0 (NCH2), 106.2
(NCEt=CHC02Me), 126.7, 128.3 and 129.1 (Ar-CH), 136.4 (Ar-C), 156.7
(NC(Et)=CHC0 2Me), 163.4 (N=C-N), 166.1 (C02Me); m/z 272 (M+, 13%), 257 (4), 241
2-pentynoate (0.30 cm3, 2.25 mmol) to give the title compound as a yellow oil (0.08 g, 
15%). (Found: C, 68.27; H, 7.59; N, 10.10%; MH+ 273.1605. C16H20N2O2 0.5H2O 
requires: C, 68.32; H, 7.47, N, 9.96%; M S 273.1603); Vmax (filmycm' 1 2973,2947,2874,
1708 (CO), 1620 (C-N), 1456,14166,1384, 1268,1224,1169,1006, 714; %  (300 MHz) 
0.72 (3H, t, J7 .4 , CfljCHj), 2.03 (2H, q , / 7.4, CH3CH2), 3.55 (2H, s, PhC%), 3.63 (2H, t,
J  9.6, NCH2CH2N), 3.73 (3H, s, C 02CH3), 3.83 (2H, t, J  9.6, NCH2CH2N), 5.45 (IH, s,
(3), 213 (38), 199 (9), 184 (1), 156 (12), 140 (2), 130 (7), 124 (39), 116 (25), 96 (43), 91
(100), 68 (25).
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Methyl (j5)-3-(2-benzylimidazoliii-lyl)-3-phenylpropenoate (2.4.1b)
n  V 
P h
Prepared by the general method from 2-benzyl-2-imidazoline (0.46 g, 2.87 mmol) and ethyl 
phenyl propynoate (0.71 cm3, 4.31 mmol) to give the title compound as a yellow oil (0.48 
g, 52%) (Found: C, 74.13; H, 6.39; N, 8.57%; M+ 320.1525. C20H20N2O2 0.2H2O requires: 
C, 74.13; H, 6.30, N, 8.64%; M  320.1525); vm„  (filmycm' 1 2948, 2872,1708 (CO), 1600, 
1574, 1406, 1276, 1153,1007, 777; Sh (300 MHz) 3.40 (2H, s, PhCifc), 3.62 (2H, t, J  9.6, 
NŒf2CH2N), 3.79 (3H, s, C 02CH3), 3.93 (2H, t, J  9.6, NC7f2CH2N), 5.75 (IH, s, 
NCPh=CHC02Me), 7.12-7.43 (10H, m, Ar-H); Sc (100 MHz) 35.2 (PhCH2), 51.2 
(C02CH3), 52.1 (NCH2CH2N), 53.6 (NCH2CH2N), 106.5 (NCPh=CHC02Me), 126.6,
128.1 128.3, 128.6, 129.4 and 130.6 (Ar-CH), 136.0 and 1369 (Ar-C), 152.8 
(NCPh=CHC02Me), 163.4 (N=C-N), 165.4 (C02Me); m/z 320 (M+, 20%), 305 (2), 289 
(6), 261 (65), 247 (18), 229 (2), 204 (25), 191 (2), 174 (14), 158 (12), 144 (57), 57), 130 
(34), 115 (27), 103 (42), 91 (100), 77 (41), 65 (24).
bK .NH
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General method for the synthesis of diethyl 2-(alkylimidazolin-l-yl)-l,4- 
butenedionate
N<S/NH
J C 02Et
:02Et
Diethyl acetylene dicarboxylate (1.2 mol equiv.) was injected to a solution of 2-alkyl-2- 
imidazoline (1 equiv.) in dry dichloromethane (1M in imidazoline) at 0°C. The reaction was 
allowed to warm up to 20°C and was stirred for 8 h. The dichloromethane was removed 
and the crude product was chromatograped on silica gel eluting with 3:7 v/v ethyl 
acetaterhexane to give the title compound.
Diethyl (E)-2-(2-benzylimidazolin-l-yl)-l,4-butenedionate (2.4.8)
Prepared by the general method from 2-benzyl-2-imidazoline (2.00 g, 12.5 mmol) and ethyl
a f C 0 2Et), 7.18-77.34 (5H, m, Ar-H); ôc (75 MHz) 13.5 and 14.2 (CH3CH2), 34.7 
(PhCH2), 50.1 and 52.0 (NCH2), 62.0 and 62.7 (CH3CH2), 96.9 [NCC02Et^CHC02Et],
126.9, 128.4 and 129.1 (Ar-CH), 134.9 (Ar-C), 144.2 |^C(CO2Et)=CHCO2Etj, 158.8 (N-
C02Et
acetylene dicarboxylate (2.40 cm3, 15.00 mmol) to give compound (2.4.9) (see later) and 
the title compound as as an orange gum, (1.42 g, 34%) vmax (film)/cm 2982, 1739 
(C02Et), 1704 (C02Et), 1577, 1416, 1366, 1161,1021, 756; %  (300 MHz) 1.23-1.33 (6H, 
m, 2 x C//3CH2), 3.64 (2H, t, 9.6, NCH2CH2N), 3.69 (2H, s, PhC#2), 3.84 (2H, t, J  9.6, 
NC//2CH2N), 4.14 (2H, q, J  7.2, CH3CH2 ), 4.30 (2H, q, J  7.2, CH3CH2 ), 5.05 (IH, s.
C=N), 164.4 andl66.2 (C02Et); mlz 331 (MH+, 2%), 303 (1), 289 (2), 257 (23), 238 (16),
229 (7), 213 (47), 200 (10), 183 (7), 162 (9), 140 (32), 126 (28), 91 (100).
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Diethyl (E) and (2) 2-[2-(2-phenyl)phenylethylimidazolin-l-yl]-l,4-butenoate (2.4.13)
and (2.4.14)
NK .NH
r \
N<V N v|=??>H'C 02Et 
J  C02Et
Prepared by the general method, from 2-[2-(2-phenyl)phenylethyl]-2-imidazoline (0.47 g, 
1.88 mmol) and ethyl acetylene dicarboxylate (0.36 cm3, 2.22 mmol) to give the E-isomer 
of the title compound as a yellow gum, which was recrystalised from hexane/ethyl acetate, 
as a white crystalline solid (0.43 g, 54%), m.p. 85-87°C (Found: C, 71.20; H, 6.70; N, 
6.64%; (M-H)+ 419.1974. C25H28N20 4 requires: C, 71.41; H, 6.71; N, 6.64%; M-H 
419.1971 ); Vmu (filmycm' 1 2981,1741 and 1703 (C02Et), 1641, 1575,1479,1197,1156, 
1046, 752; 8» (300 MHz) 1.19 (3H, t, 7  7.2, Ctf3CH2), 1.26 (3H, t, J  7.2, Ctf3CH2), 2.41 
(2H, t, J  8.0, CH2CH2Ar), 3.00 (2H, t, J  8.0, CH2CH2Ar), 3.56 (2H, t, J  9.0, NCH2), 3.79 
(2H, t, 79.0, NCH2), 4.12 (2H, q, 77.2, CH3CH2), 4.20 (2H, q, 77.2, CH3CH2), 4.91 (1H, 
s, CHC02Et), 7.18-7.43 (9H, m, Ar-H); 5c (75 MHz) 13.4 and 14.2 (CH3CH2), 29.4 
(ArCH2CH2), 30.1 (ArCH2CH2), 49.8 and 51.9 (NCH2), 60.0 and 62.6 (CH3CH2), 96.0 
[NC(C02Et)=CHC02Et], 126.3, 127.0, 127.6, 128.3, 129.1, 130.3, 138.3 (Ar-CH), 141.4 
and 141.9 (Ar-C), 144.4 [NC(C02Et)=CHC02Me], 159.1 (N-C=N), 164.4 and 166.4 
(C02Et); m/z 421 [(MH)+, 2%], 375 (3), 347 (100), 319 (21), 273 (9), 213 (6), 191 (5), 178
(15), 165 (72), 152 (33), 139 (7), 126 (6), 94 (7), 68 (15); and the Z-isomer of the title 
compound as a thick yellow oil (0,12 g, 15%) (Found: M+ 420,2052, C2sH2gN204 requires: 
Af 420.2049); v™, (film) 2981, 2939, 1729, 1610, 1480, 1368, 1259, 1172, 1033, 753; 5» 
(300 MHz) 1.24-2.31 (6H, m 2 x CH3), 2.12 (2H, t, 78.3, CH2CH2Ar), 2.88 (2H, t, 78.3, 
C#2CH2Ar), 3.62 (2H, t, 7  9.9, NCH2), 3.81 (2H, t, 7  9.9, NCH2), 4.14 (2H, q, 7  7.2,
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CHgCHz), 4.20 (2H, q, 7  7.2, CH3CH2), 6.30 (CH), 7.14-7.40 (9H, m, Ar-H); 5c 14.1 and 
14.2 (CH3), 29.8 and 30.6 (CH2CH2Ar), 51.5 and 53.7 (NCH2), 60.9 and 62.3 (CH3CH2), 
118.5 (CH), 126.1, 126.9, 127.6, 128.2, 129.0, 129.4, 130.2, (Ar-CH), 138.4, 141.5 and
141.8 (Ar-C), 140.0 (NOCH), 163.4 (N-C=N), 163.9 and 164.0 (CO); m/z 420 (M+, 2%), 
391 (1), 375 (2), 364 (1), 34 (100), 319 (20), 275 (6), 249 (5), 238 (2), 178 (7), 165 (29), 
152 (12), 128 (3), 115 (2), 91 (5).
Diethyl (£>-2-[2-(but-3-enyl)imidazolm-l-yI]-l,4-butenedionate (2.4.16)
NNH
Prepared by the general method from 2-(but-3-enyl)-2-imidazoline (0.83 g, 6.69 mmol) and 
ethyl acetylene dicarboxylate (1.28 cm3, 8.03 mmol) to give the title compound as a yellow 
oil (0.34 g, 17%) (Found: C, 60.24; H, 7.46; N, 9.03%; M+ 294.1574. C,5H22N2O4-0.3H2O 
requires: C, 60.08; H, 7.54, N, 9.35%; M 294.1579), vmax (filniVum*1 2983, 1737 (C02El), 
1694 (C02Et), 1639 (C=N), 1577, 1421, 1372, 1337, 1160, 1096, 1027, 915, 800; 8» (300 
MHz) 1.27 (3H, t, J  7.2, CH3CH2), 1.38 (3H, t, J  7.3, C//3CH2), 2.42 (4H, m, 
C//2C//2CH=CH2), 3.62 (2H, t, J  8.9, NC772CH2N), 3.86 (2H, t, J  8.9, NC/72CH2N), 4.12 
(2H, q, J  7.2, CH3C7/2), 4.35 (2H, q, J  7.3, CH3CH2), 5.02 (1H, s, CflC02Et), 5.02-5.15 
(2H, m, CH=C//2), 5.78-5.88 (1H, m, Œf=CH2); 8ç  (75 MHz) 13.7 and 14.3 (CH3CH2),
25.4 (CH2CH2CH=CH2), 30.1 (CH2CH2CH=CH2), 50.0 and 51.9 (NCH2), 60.1 and 62.8 
(CH3CH2), 96.2 [NC(C02Et)=CHC02Et], 115.5 (CH=CH2), 136.9 (CH=CH2), 144.5 
[NC(C02Et)-CHC02Et], 159.3 (N O N ), 164.5 and 166.4 (C02Et); m/z 294 (M+, 7%), 
265 (3), 249 (9), 221 (100), 193 (45), 175 (8), 147 (18), 126 (24), 98 (18), 82 (14).
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General method for the synthesis of 5-ethoxycarbonylmethyIene-l,2,3,6-tetrahydro-
5fl-pyrrolo[l^-a]imidazol-6-one
Diethyl acetylene dicarboxylate (1.2 mol equiv.) was injected to a solution of 2-alkyl-2- 
imidazoline (1 equiv.) in dry dichloromethane (1M solution) at 0°C. The reaction was 
allowed to warm up to 20°C and was stirred for 8 h. The dichloromethane was removed 
and the crude product was chromatographed on silica gel (3:7-10:0 v/v ethyl acetate:hexane 
to give the title compound.
(2)-5-Ethoxycarbonylniethylene-7-phenyl-l,2,3,6-tetrahydro-5/7-pyrrolo[l,2-a] 
imidazol-6-one (2.4.9)
Prepared by the general method from 2-benzyl-2-imidazoline (2.00 g, 12.5 mmol) and ethyl 
acetylenedicarboxylate (2.40 cm3, 15.00 mmol) to give the Z-isomer of the title compound 
as an orange solid that precipitated out of solution and was recrystallised from methanol
701; ÔH [300 MHz; (CD3)SO] 1.21 (3H, t, J7.2, (% (% ) , 4.00 (2H, t, /7 .5 , N C /^C ^N ),
C02Et
O
(1.50 g, 42%), m.p. 230-232"C (Found: C, 67.55; H, 5.64; N, 9.84%; M* 284.1155. 
Cl6H16N20 3 requires: C, 67.59; H, 5.67, N, 9.85%; M  284.1161); Vmm (KBrVcm' 1 3291
(NH), 2984, 1712 (C02Et), 1655,1603, 1559, 1515, 1482, 1447, 1307, 1189, 1154, 1105,
4.10-4.17 (4H, m, CH3Cff2 and NCH2CH2N), 5.48 (1H, s, C7fC02Et), 7.05 (1H, t , ./ 7.5,
Ar-H), 7.28 (2H, t, J  7.5, Ar-H), 7.69 (2H, d, J  7.5, Ar-H); 5c [75 MHz; (CD3)SO] 14.1
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(CH3CH2), 44.8 and 48.0 (NCH2), 59.8 (CH3CH2), 88.4 (PhOCN), 90.9 (CHC02Et), 
123.7, 124.2 and 128.1 (Ar-CH), 132.5 (Ar-C), 144.0 (NC=CHC02Et), 165.4 (NC=CPh),
168.8 (C02Et), 180.8 (CO); m/z 284 (M+, 47%), 238 (42), 211 (28), 183 (32), 168 (9), 154 
(27), 143 (27), 128 (48), 115 (88), 103 (31), 89 (100), 77 (48), 63 (35).
(Z) and (J5)-5-Ethoxycarbonylmethylene-7-phenyl-l^^,6-tetrahydro-5flr-pyrrolo[1,2- 
fl]imidazol-6-one (2.4.9) and (2.4.10)
COgEt
PI
HN.
Ph
A solution of diethyl l-[(l-carboxylate)prop-l-enoate]-2-(phenylmethyl)-2-iniidazoline 
(1,20 gi 3,63 mmol) in THF (30 cm3) was added to a solution of potasium fcr/ butoxide 
(0.81 g, 7.27 mmol). The orange solution produced was stirred at 20 C for 12 h and the 
solvent was removed. The crude product was purified by column chromatography on silica 
gel (0:3:7—>5:95:0 methanol:ethyl acetate:hexane) to give the Z-and E-isomers of the tit/e 
compound in a 5:1 ratio as an orange and yellow solids (0.69 g, 67%); Data for E-isomer 
(less polar material) yellow solid, m.p. 172-174 C (Found: M+ 284.1161. C ^ H i^O g  
requires: M284.1161); v™* (KBr) 3436 (NH), 1636, 1610, 1543, 1495, 1233, 1216, 1186, 
780; Ôh (300 MHz) 1.36 (3H, t, J7.2, CH3), 3.49 (2H, t, /7 .2 , NCH2), 4.25 (2H, q ,J7 .2 , 
(% ( % ) ,  4.43 (2H, t, J7.2, NCH2), 5.06, (1H, s, CH), 7.26 (1H, t, J7 .8 , Ar-H), 7.39 (2H, 
t ,/7 .8 , Ar-H), 8.22 (2H, d, /7 .8 , Ar-H), 13.82 (1H, hr s, NH); 5c (100 MHz) 14.2 (CH3),
41.1 and 41.5 (NCH2CH2N), 61.1 (NC=CPh), 61.7 (CH3CH2), 88.4, (NC=CH), 127.1,
127.4, 128.3, (Ar-CH), 130.8 (Ar-C), 148.7 (NC=CH), 159.3 (NC=CPh), 164.2 (C02Et), 
172.7 (CO); m/z 284 (M+, 17%), 238 (100), 209 (15), 181 (10), 167 (1), 153 (5), 143 (6), 
128 (6), 115 (17), 103 (4), 89 (7), 77 (4); data for Z isomer as reported earlier.
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(Z)- and (£)-5-Methoxycarbonylmethylene-7-phenyl-l,2^,6-tetrahydro-5ff- 
pyrrolo[l,2-a] imidazol-6-one (2.4.11) and (2.4.12)
Prepared by the general method from 2-benzyl-2-imidazoline (3.05 g, 19.06 mmol) and 
dimethyl acetylene dicarboxylate (2.81 cm3, 22.87 mmol) to give the the Z-isomer of the 
tit/e compound as an orange precipitate that was recrystallised from methanol, (1.24 g, 
24%), m.p 236-238°C (Found: C, 66.17; H, 5.14; N, 10.25%; M* 270.1002. CuH^NzOs 
requires: C, 66.66; H, 5.22; N, 10.36%; M 270.1004); vmal (KBr)/cm"1 3255, (NH), 1717, 
(COzMe), 1674, 1604, 1562 (CO), 1514, 1309, 1189, 1169, 1154, 1105; 8h [300 MHz; 
(CD3)SO] 3.66 (3H, s, CH3), 4.00 (2H, t, J  7.2, NCffcCHjN), 4.13 (2H, t, J  7.2, 
NCH2C//2N), 5.49 (1H, s, CflC02Me), 7.05 (1H, t, 7  7.5, Ar-H), 7.28 (2H, t, J  7.5, Ar-H), 
7.67 (2H, d, J  7.5, Ar-H), 9.58 (1H, hr s, NH); 5c [75 MHz; (CD3)SO] 44.8 and 47.9 
(NCH2), 51.2 (CH3), 88.4 (PhOCN), 90.6 (CHC02Me), 123.7, 124.2 and 128.1 (Ar-CH),
132.4 (Ar-C), 144.1 (NC=CHC02Me), 165.8 (NCCPh), 168.2 (C02Me), 180.8 (CO); m/z 
270 (M+, 86%), 238 (100), 209 (29), 181 (26), 168 (4), 153 (14), 143 (17), 129 (10), 115 
(34), 103 (12), 89 (38), 77 (19); and the E isomer of the title compound was recrystallised 
out of the reaction mixture from methanol/hexane as an orange solid (1.70 g, 33%), m.p. 
161-163 C (Found: M+ 270.1020. Ci;HwN20 3 requires: M  270.1004); v™» (KBr) 3251 
(NH), 1716, 1614, 1550, 1511, 1494, 1443, 1421, 1233, 1218, 1183, 797, 776; 8» (300 
MHz) 3.38 (2H, t, 77.2, NCH2), 3.78 (3H, s, CH3), 4.36 (2H, t,77.2, NCH2), 4.98, (1H, s, 
CH), 7.26 (1H, t, 7  7.6, Ar-H), 7.39 (2H, t, 7  7.6, Ar-H), 8.22 (2H, d, 7  7.6, Ar-H), 13.72 
(1H, br s, NH); 5c (100 MHz) 41.3 (NCH2CH2N), 51.9 (CH3), 61.2 (NC=CPh), 87.8, 
(NC=CH), 127.1, 127.4 and 128.3 (Ar-CH), 130.8 (Ar-C), 148.6 (NC=CH), 159.3
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(NC=CPh), 163.9 (C02Et), 172.7 (CO); mlz 270 (M+, 25%), 238 (100), 209 (6), 181 (5), 
153 (7), 143 (9), 128 (6), 115 (17), 91 (13), 77 (2).
(Z)-5-Ethoxycarbonylmethylene-7-[(2-phenyl)phenylmethyl]-l,2,3,6-tetrahydro-5/i- 
pyrrolo[l,2-fl]imidazol-6-one (2.4.15)
N<x
COoEt
C02Et
C02Et
HN
A solution of diethyl l-[(l-carboxylate)prop-l-enoate]-2-(2-pheny)phenylmethyl)-2- 
imidazoline (68 mg, 0.16 mmol) in THF (3 cm3) was added to a solution of potasium tert- 
butoxide (35 mg, 0.31 mmol) in THF (3 cm3). The resulting yellow solution was stirred at 
20°C for 12h, the solvent was removed under reduced pressure and the residue was 
chromatographed on silica gel (0:3:7—>5:95:0 methanol:ethyl acctatc:hexanc) to give the 
title compound as a yellow oil (32 mg, 54%), (Found: M+ 374.1627. C23H22N2O3 requires: 
M  374.1630); (fihnycm1 3404 (NH), 1712 (C02Et), 1659 (CO), 1568, 1480, 1369, 
1163; 8h (300 MHz) 1.27 (3H, t, /7 .1 , C^CH ;), 3.55 (2H, s, CH2Ai \  3.63 (2H, t, J7 .4 , 
NCH2), 4.09 (2H, t,J7 .4 , NCH2), 4.14 (2H, q ,J7 .1 , CH3CÆ2), 5.77 (1H, s, CH), 7.20-7.47 
(9H, m, Ar-H); ôc (75 MHz) 14.2 (CH3CH2), 25.0 (ArCH2), 45.3 and 47.3 (NCH2), 60.2 
(CH3CH2), 88.1 (PhC=CN), 93.9 [NC(C0 2Et)=CHC02Et], 126.4, 127.1, 127.9, 128.3, 
129.5, 130.3, 137.6 (Ar-CH), 141.2 and 141.8 (Ar-C), 143.6 [NC(C0 2Et)=CHC02Et],
166.5 (NCCPh), 169.4 (C02Et), 184.4 (CO); mlz 374 (M+, 17%), 345 (3), 328 (2), 317
(2), 299 (9), 271 (22), 247 (2), 221 (2), 203 (11), 189 (8), 178 (16), 165 (100), 152 (66), 
128 (9), 115 (13), 94 (8), 7 (42).
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(Z)-5-Ethoxycarboiiylmethylene-7-{prop-2-enyl)-l,2,3,6-tetrahydro-5//-pyrrolo[l,2-fl]
imidazol-6-one (2.4.17)
HN.
Prepared by the general method from 2-(but-3-enyl)-2-imidazoline (0.83 g, 6.69 mmol) and 
ethyl acetylene dicarboxylate (1.28 cm3, 8.03 mmol) to give the title compound as a yellow 
solid (0.10 g, 6%), m.p 162-164°C (Found: C, 60.36; H, 6.40; N, 10.30%; MH+ 249.1239. 
C,3H,6N2O3 0.5H2O requires: C, 60.70; H, 6.61, N, 10.89%; MH 249.1235); 
(KBrycm"1 3391 (NH), 3317,2981,1714 (C02Et), 1658 (CO), 1554,1494,1321,1150; 8h 
(300 MHz) 1.29 (3H, t, J  7.1, C/73CH2), 2.97 (2H, d, J  6.4, Cff2CH=CH2), 3.94 (2H, t, J
7.4, NCH2CH2N), 4.14-4.26 (4H, m, CH3CH2 and NCH2C/f2N), 5.01-5.13 (2H, m, 
CH=C«2), 5.78-5.88 (1H, m, Cti=CH2), 5.83 (1H, s, C7/C02Et); ôc (75 MHz) 14.3 
(CH3CH2), 25.4 (CH2CH=CH2), 45.4 and 47.6 (NCH2), 60.2 (CH3CH2), 85.9 (PhC=CN),
93.9 [NC(C02Et)=CHC02Et], 115.1 (CH=CH2), 136.6 (CH=CH2), 144.1
(NC(C02Et>CHC02Et), 166.5 (NC=CPh), 168.8 (C02Et), 181.3 (CO); mlz 248 (M+, 
15%), 219 (4), 202 (10), 191 (13), 173 (15), 161 (14), 147 (17), 135 (5), 121 (8), 105 (12), 
84 (62).
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5-Ethoxycarbonylmethyl-7-phenyl-l,2^,6-pentahydro-5Zi-pyrrolo[l,2-fl]iinidazol-6-
one (2.4.21)
HN
Ph
HN
A solution of 5-ethoxycarbonylmethylene-7-phenyl-l ,2,3,6-tetrahydro-5//-pyrrolo[ 1,2-a] 
imidazol-6-one (0.80 g, 2.81 mmol) in methanol (28 cm3) containing 10% Pd/C (0.03 g, 
0.28 mmol) was stirred under an atmosphere of hydrogen for 24 h. The catalyst was filtered 
and the residue was recrystallised from hexane/methanol to give the title compound as 
white crystals (0.56 g, 69%), m.p. 119-121°C (Found: C, 67.00; H, 6.29; N, 9.70%; M+ 
286.1317. QeHigNîO, requires: C, 67.12; H, 6.34, N, 9.78%; M  286.1317); vm„  
(KBrycm"1 3282 (NH), 1724 (C02Et), 1607,1548,1516,1305, 1160, 1189; Sh (300 MHz) 
1.27 (3H, t, J  7.1, CH3CH2), 2.33-2.43 (1H, dd, J  10.6 and 17.2, CHHC02Et), 3.02-3.08 
(1H, dd, J  2.6 and 17.2, C*CH2C02Et), 3.13-3.22 (1H, dd, J  8.2 and 17.2, 
CHCflHC02Et), 3.59-3.70 (1H, m, NCHfl), 3.74-3.93 (3H, m, NCflH, and NCH2), 4.21 
(2H, q, J  7.2, CH3C//2), 6.54 (1H, br s, NH), 7.01 (1H, t, J  7.3, Ar-H), 7.22 (2H, t, J  7.3, 
Ar-H), 7.55 (2H, d, J7 .3 , Ar-H); 5c (75 MHz) 14.2 (CH3CH2), 36.4 (NCHCH2), 46.5 and
47.2 (NCH2), 60.8 (CH3CH2), 62.5 (NCH), 92.2 (PhC=CN), 12.2, 124.9 and 128.5 (Ar- 
CH), 132.9 (Ar-C), 172.2 (NC=CPh), 174.6 (C02Et), 193.0 (CO); m/z 286 (M+, 73%), 257
(3), 241 (8), 213 (100), 199 (13), 185 (36), 171 (7), 156 (5), 143 (7), 128 (6), 115 (20), 103 
(6), 89 (22).
225
5-Ethoxycarbonylmethyl-7-phenyl-l,23,4,6,-pentahydro-5Zi-pyrr<)lo[l,2-a]imidazol-
6-one (2.4.20)
HN{J^ C02Me
I   ^ uUgivie
HN.
A solution of 5-methoxycarbonylmethylene-7-phenyl-1,2,3,6,-tetrahydro-5H-pyrrolo[ 1 ,2-ût] 
imidazol-6-one (0.76 g, 2.81 mmol) in methanol (28 cm3) was stirred in the presence of 
10% Pd/C ( 0.03 g, 0.028 mmol) under an atmosphere of hydrogen for 12 hours. The 
catalyst was filtred and the methanol was removed under reduced pressure. The yellow 
gum that was produced was recrystallised from hexane/methanol to give the title 
compound as a white solid (0.70 g, 92%), m.p. 171-174 C (Found: M 272.1160. 
C15H16N2O3 requires: Af 272.1161); 3257 (NH), 1729 (C02Me), 1607 (CO), 1549,
1516, 1477,1442,1381,1306,1197,1167, 762; 5» (300 MHz, CD3OD) 2.44-2.52 (1H, dd, 
<7 9.8 and 16.7, C#HC02Me), 2.96-3.03 (1H, dd, J  3.2 and 16.7, C#CH2C02Me), 3.23- 
3.34 (1H, dd, J9 .8  and 18.3, CH#C02Me), 3.61-3.69 (1H, m, NCflHCH2N), 3.71 (3H, s, 
CH3), 3.74-3.95 (1H, m, NCHHC^N), 7.06 (1H, t, 7  7.4, Ar-H), 7.29 (2H, t, 7  7.4, Ar-H), 
7.56 (2H, d, J  7.4, Ar-H); Sc (100 MHz; CD3OD) 36.8 (CH2C02Me), 47.8 and 48.1 
(NCH2CH2N), 52.4 (CH3), 63.5 (CH), 93.9 (NC=CPh), 125.5, 126.4, 129.3, (Ar-CH),
133.9 (Ar-C), 173.6 (NC=CPh), 176.1 (C02Et), 194.2 (CO); m/z 272 (M+, 72%), 241 (6), 
238 (3), 225 (2), 213 (100), 199 (10), 185 (26), 171 (7), 157 (5), 142 (8), 128 (9), 115 (18), 
96 (9), 91 (14), 89 (14).
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Appendix
2-(2-Oxo-(3-phenyl)ethylidene)imidazolidme (2.131b)
Empirical formula C16H20N2O3
Formula weight 288.34
Temperature 150 (2) K
Wavelength 0.71073 Â
Crystal system Orthorhombic
Space group Pbca
Unit cell dimensions a = 10.6561 (2) Â a  = 90 
b = 15.5737 (3) Â p = 90 
c = 17.8997(3)Â y =90
Volume 2970.54 (9) A3
Z 8
Density (calculated) 1.289 M g/m 3
Absorption coefficient 0.090 mm"'
F (000) 1232
Crystal Bipyramid; colourless
Crystal size 0.20 x 0.20 x 0.20 mm3
6 range for data collection 2.58-26.00
Index ranges -\2< h<  13, -19< A:< 19, -22 </<22,
Reflections collected 23802
Independent reflections 2910 [Bint = 0.0565]
Completeness to 0 = 27.47 99.9%
Max. and min. transmission 0.9823 and 0.9823
Refinement method Full-matrix least-squares on F 2
Data / restraints / parameters 2910/0/270
Goodness-of-fit on F 2 1.048
Final R indices [I>2g(I)] Rl = 0.0356, wR2 = 0.0893
R indices (all data) R l=  0.0467, wR2 = 0.0947
Largest diff. Peak and hole 0.168 and-0.211 e A"3
Bond lengths [Â] and angles [°] for 2-(2-oxo-3-phenyl)ethylidene)imidazoline 
(2.1.31b)
01-CS
0 2 - 0 2  
0 3 - 0 2  
0 3 - 0 3  
N1-C12 
N1-C3 
N l-O  
N2-C3 
N2-C2 
N2-H2N 
C1-C2 
O -H IA  
C1-H1B 
C2-H2A 
C2-H2B 
C3-C4 
C4-C5 
C4-H4 
C5-C6 
C6-C11 
Cft-C7 
C7-C8 
C7-H7 
C8-C9 
C8-H8 
C9-C10 
C9-H9 
00-01
0 0-H IO
0 1 -H I1  
0 3 - 0 4  
0 3 - 0 6  
0 3 - 0 5  
C14-H14A 
C14-H14B 
CI4-H14C 
0 5 —H15A 
0 5 —H15B 
Cl J—H15C 
C16-H16A 
C16-H16B 
C16-H16C
0 2 - 0 3 - 0 3  
C12-N1-C3 
0 2 —Nl-Cl 
C3-N1-C1 
C3-N2-C2 
C3-N2-H2N 
C2-N2-H2N 
N1-C1-C2 
N l-O -H IA  
C 2-0-H 1A  
N1-C1-H1B 
C2-C1-H1B 
H1A-C1-H1B 
N2-C2-C1 
N2-C2-H2A 
C1-C2-H2A
1.2576(14)
1.2050(14)
1.3333(14)
1.4889(14)
1.3852(15)
1.3916(15)
1.4781(15)
1.3339(15)
1.4474(17)
0.885(16)
1.5254(19)
0.957(14)
0.983(15)
0.962(16)
0.992(15)
1.3856(16)
1.4162(17)
0.962(13)
1.5072(16)
1.3929(17)
1,3938(17)
1.3828(18)
0.955(14)
1.3855(18)
0.934(15)
1.3831(19)
0.980(14)
1.3873(18)
0.972(15)
0.942(15)
1.5133(19)
1.5138(18)
1.5176(17)
1.013(16)
0.999(16)
0.985(17)
0.993(17)
0.955(18)
1.006(17)
0.988(16)
1.002(16)
1.002(16)
120.70(9)
126.09(9)
123.32(10)
110.50(9) 
113.88(11) 
116.0(10) 
128.3(10) 
103.04(10) 
110.4(8) 
111.9(8) 
110.1(8) 
113.1(8) 
108.2(12) 
102.72(10)
110.7(8)
N2-C2-H2B
C1-C2-H2B
H2A-C2-H2B
N2-C3-C4
N2-C3-N1
C4-C3-N1
C3-C4-C5
C3-C4-H4
C5-C4-H4
01-C5—C4
01-C5-C6 
C4-C5-C6 
Cl 1-C6-C7 
Cl 1-C6—C5 
C7-C6-C5 
C8-C7-C6 
C8-C7-H7 
C6-C7-H7 
C7-C8-C9 
C7-C8-H8 
C9-C8-H8 
C10-C9-C8 
C10-C9-H9 
C8-C9-H9 
C9-C10-C11 
C9-C10-H10 
C11-C10-H10 
C10-C11-C6 
C10-C11-H11 
C6-CI1-H11
02-C 12-03
02-C12-N1
03-C12—NI 
03-C13—C14 
03-C13-C16 
C14-C13-C16 
03-C13-C15 
C14-CI3-C15 
C16-C13-C15 
C13-C14-H14A 
C13-C14-H14B 
H14A-C14-H14B 
C13-C14-H14C 
H14A-C14-H14C 
H14B-C14-H14C 
CI3-C15-H15A 
C13-C15-H15B 
H15A-C15-H15B 
C13-C15-H15C 
HI5A-C15-H15C 
H15B-C15-H15C 
C13-C16-H16A 
C13-C16-H16B 
H16A-C16-H16B 
CI3—C16-H16C 
H16A-C16-H16C 
II16D-C16 1116C
110.9(9) 
110.7(8) 
110.4(12) 
124.34(11) 
107.86(10) 
127.79(10) 
120.23(10) 
117.4(8) 
122.3(8) 
124,08(11) 
117.08(10) 
118.84(10) 
118.34(11) 
123.51(11) 
118.14(10) 
121.06(11) 
121. 1(8 ) 
117.8(8)
119.97(12) 
119.0(9) 
121.1(9) 
119.73(12) 
119.5(8) 
120.7(8) 
120.24(12) 
120.9(9) 
118.8(9) 
120.66( 12) 
121.2(9) 
118.1(9) 
127.01(11) 
124.42(11) 
108.56(9) 
101.91(10) 
109.79(10) 
111.33(11) 
109.84(10) 
111.04(11) 
112.43(12) 
110.3(9) 
106.7(9) 
111. 1( 12)
110.9(10)
107.1(13)
110.8(13)
112.3(9)
112.5(10)
109.8(13)
107.5(9)
109.3(13)
105.1(14)
110.9(9)
107.8(8)
107.2(12)
111.6(9)
110.7(12)
108.5(12)
111.2(9)
Bond length [Â]and angle [°] for the hydrogen bond
D —H-.-A rf(H-A) <*(£>—A) ^(£>HA)
N2—H2M-01 0.885(16) 1.939(15) 2.6264(14) 133.3(13)
10-Phenyl-l,2^,5,6,7,8,9-octahydroiinidazo[l,2-A]isoquinoliii-5-oiie (2.2.20c)
Empirical formula C17H18N2O
Formula weight 266.33
Temperature 150 (2) K
Wavelength 0.71073 Â
Crystal system Triclinic
Space group, P-l
Unit cell dimensions a = 8.831 (2) Â a  = 90.34 
b = 11.534 (2) Â P = 92.49 
c = 13.182 (3) Â y = 90.79
Volume 13441.3 (5) Â3
Z 4
Density (calculated) 1.319 M g /m 3
Absorption coefficient 0.083 mm'1
F (000) 568
Crystal size 0.5 x 0.2 x 0.1 mm
6 range for data collection 1.77 to 24
Index ranges -\0< h<  10, -13 < k <13, -15 < /<  15
Reflections collected / unique 21333 / 4182 [R(int) = 0.1113]
Completeness to 0 = 24.00 99.5%
Refinement method Full-matrix least squares on F 2
Data / restraints / parameters 4182/0/378
Goodness-of-fit on F1 1.213
Final R indices [/>2o(7)] Rl = 0.0661, wR2 = 0.1715
R indices (all data) Rl = 0.0906, wR2 — 0.1873
Largest diff. Peak and hole 0.282 and-0.341 e Â"3
Bond lengths [Â] and angles [°] for lO-phenyl-1,2,3,5,6,7,8,9-
octahydroimidazo [l,2-A]isoquinoliii-5-one (2.2.20c)
0 ( 1 ) - C ( 1 3 )
N ( l ) - C ( 3 )
N ( 2 ) - C ( 3 )
N ( 2 ) - C ( l )
N ( 3 ) - C (19) 
N ( 4 ) - C ( 3 0 )
C ( 1 ) - C ( 2)
C ( 4 ) - C (11)
C ( 5 ) - C (10)
C ( 6 ) - C ( 7 )
C(8)-C(9)
C ( l l ) - C ( 1 2 )  
C ( 1 2 ) - C ( 1 3 )
C ( 1 4 ) - C ( 1 5 )
C ( 1 6 ) - C ( 1 7 )
C ( 2 0 ) - C ( 2 1 )
C ( 2 1 ) - C ( 2 2 )
C ( 2 2 ) - C ( 2 3 )  
C ( 2 4 ) - C ( 2 5 )
C ( 2 6 ) - C (27)
C ( 2 8 ) - C (34)
C ( 2 9 ) - C (31)
C ( 3 1 ) - C ( 3 2 1)
C ( 3 3 ) - C (3 4)
C ( 3 3 ' ) - C (34)
C ( 3 ) - N ( l ) - C < 2 )
C (3) -N( 2)  -C (1)
C ( 2 0 ) - H ( 3 ) - C (19) 
C ( 2 0 ) - N ( 4 ) - C ( 1 8 )  
N(2)  -C (1) -C (2)
N ( 2 ) - C ( 3 ) - C (4)
C( 4 ) - C ( 3 ) - N (1)
C (3) -C (4) -C (5)
C ( 1 0 ) - C ( 5 ) -C (6)
C( 6)  -C (5) -C (4)
C ( 8 ) - C ( 7 ) - C (6)
C ( 1 0 ) - C ( 9 ) - C ( 8 )
C (12)  -C  (1 1 ) -C  (4) 
C ( 4 ) - C ( l l ) - C ( 1 7 )
C ( 1 1 ) - C ( 1 2 ) - C (14) 
0 ( 1 ) - C ( 1 3 ) - N ( 2 )  
N ( 2 ) - C ( 1 3 ) - C ( 1 2 )
C ( 1 6 ) - C ( 1 5 ) -C( 1 4)
C ( l l ) - C ( 1 7 ) - C ( 1 6 )
N ( 3 ) - C ( 1 9 ) - C ( 1 8 )
N ( 4 ) - C ( 2 0 ) - N (3)
C ( 2 0 ) - C ( 2 1 ) - C ( 2 8 )
C ( 2 8 ) - C ( 2 1 ) - C ( 2 2 )
C ( 2 7 ) - C ( 2 2 ) - C ( 2 1 )
C ( 2 4 ) - C ( 2 3 ) - C ( 2 2 )
C ( 2 4 ) - C ( 2 5 ) - C ( 2 6 )
C ( 2 2 ) - C ( 2 7 ) - C ( 2 6 )  
C ( 2 9 ) - C ( 2 8 ) - C ( 3 4 )  
C ( 2 8 ) - C ( 2 9 ) - C ( 3 0 )  
C ( 3 0 ) - C ( 2 9 ) - C ( 3 1 )
0 ( 2 ) - C ( 3 0 ) - C (29)
C ( 2 9 ) - C ( 3 1 ) - C ( 3 2 )
C ( 3 2 ) - C ( 3 1 ) - C ( 3 2 1) 
C ( 3 2 ) - C ( 3 3 ) - C ( 3 4 )  
C ( 3 4 ) - C ( 3 3 1) - C( 32  ' ) 
C ( 3 3 ) - C ( 3 4 ) - C ( 3 3 ' )
1 . 2 5 2 ( 3 )  0 ( 2 ) - C ( 3 0 )  1 . 2 5 5 ( 3 )
1 . 3 9 0 ( 3 )  N ( l ) - C (2) 1 . 4 6 7 ( 3 )
1 . 3 6 0 ( 3 )  N ( 2 ) - C ( 1 3 )  1 . 3 8 5 ( 3 )
1 . 4 6 9 ( 3 )  N ( 3 ) - C ( 2 0 )  1 . 3 9 3 ( 3 )
1 . 4 7 0 ( 3 )  N ( 4 ) - C ( 2 0 )  1 . 3 5 7 ( 3 )
1 . 3 8 8 ( 3 )  N ( 4 ) - C ( 1 8 )  1 . 4 6 6 ( 3 )
1 . 5 3 8 ( 3 )  C ( 3 ) - C (4) 1 . 3 7 1 ( 4 )
1 . 4 3 8 ( 4 )  C ( 4 ) - C (5) 1 . 4 9 5 ( 3 )
1 . 3 8 9 ( 4 )  C ( 5 H C ( 6 )  1 . 3 9 2 ( 4 )
1 . 3 9 0 ( 4 )  C ( 7 ) - C (8) 1 . 3 7 8 ( 4 )
1 . 3 8 6 ( 4 )  C ( 9 ) - C ( 10 )  1 . 3 8 1 ( 4 )
1 . 3 7 7 ( 3 )  C ( 1 1 ) - C( 1 7 )  1 . 5 0 5 ( 4 )
1 . 4 2 7 ( 4 )  C ( 1 2 ) - C ( 1 4 )  1 . 5 1 6 ( 3 )
1 . 5 1 5 ( 4 )  C ( 1 5 ) - C (16)  1 . 5 0 8 ( 4 )
1 . 5 3 3 ( 4 )  C ( 1 8 ) - C (19) 1 . 5 3 2 ( 4 )
1 . 3 6 5 ( 4 )  C ( 2 1 ) - C ( 2 8 )  1 . 4 3 8 ( 4 )
1 . 4 9 9 ( 3 )  C ( 2 2 ) - C (27)  1 . 3 8 5 ( 4 )
1 . 3 9 3 ( 4 )  C ( 2 3 ) - C (24) 1 . 3 9 2 ( 4 )
1 . 3 7 5 ( 4 )  C ( 2 5 ) - C (26) 1 . 3 8 3 ( 4 )
1 . 3 8 4 ( 4 )  C ( 2 8 ) - C (29)  1 . 3 7 9 ( 3 )
1 . 5 1 0 ( 4 )  C ( 2 9 ) - C ( 3 0 )  1 . 4 2 4 ( 4 )
1 . 5 1 3 ( 4 )  C ( 3 1 ) - C (32) 1 . 5 2 2 ( 5 )
1 . 5 5 9 ( 1 3 ) C ( 3 2 ) - C (33)  1 . 4 8 6 ( 7 )
1 . 5 1 8 ( 6 )  C ( 3 2 ' ) - C ( 3 3 1) 1 . 6 0 ( 2 )
1 . 4 6 6 ( 1 4 )
1 0 8 . 4 ( 2 )  C ( 3 ) - N ( 2 ) - C ( 1 3 )  1 2 4 . 1 ( 2 )
1 1 1 . 6 ( 2 )  C ( 1 3 ) - N ( 2 ) - C (1) 1 2 4 . 3 ( 2 )
1 0 8 . 8 ( 2 )  C ( 2 0 ) - N ( 4 ) - C ( 3 0 )  1 2 3 . 9 ( 2 )
1 1 2 . 0 ( 2 )  C ( 3 0 ) - N ( 4 ) - C ( 1 8 )  1 2 4 . 0 ( 2 )
1 0 1 . 7 ( 2 )  N ( l ) - C ( 2 ) - C (1) 1 0 3 . 6 ( 2 )
1 2 1 . 8 ( 2 )  N ( 2 ) - C ( 3 ) - N ( l ) -  1 0 9 . 3 ( 2 )
1 2 8 . 9 ( 2 )  C ( 3 ) - C ( 4 ) - C (11)  1 1 6 . 6 ( 2 )
1 1 9 . 5 ( 2 )  C ( 1 1 ) - C ( 4 ) - C (5) 1 2 3 . 9 ( 2 )
1 1 7 . 7 ( 2 )  C ( 1 0 ) - C ( 5 ) - C (4) 1 2 1 . 3 ( 2 )
1 2 1 . 0 ( 2 )  C ( 7 ) - C ( 6 ) - C ( 5 )  1 2 1 . 0 ( 3 )
1 2 0 . 4 ( 3 )  C ( 7 ) - C ( 8 ) - C (9) 1 1 9 . 2 ( 2 )
1 2 0 . 2 ( 3 )  C ( 9 ) - C ( 1 0 ) - C ( 5 )  1 2 1 . 4 ( 2 )
1 2 1 . 0 ( 2 )  C ( 1 2 ) - C ( l l ) - C ( 1 7 )  1 2 0 . 3 ( 2 )
1 1 8 . 7 ( 2 )  C ( 1 1 ) - C ( 1 2 ) - C (13)  1 2 1 . 3 ( 2 )
1 2 3 . 4 ( 2 )  C ( 1 3 ) - C ( 1 2 ) - C (14) 1 1 5 . 2 ( 2 )
1 1 9 . 1 ( 2 )  O ( 1 ) - C ( 1 3 ) - C (12)  1 2 5 . 7 ( 2 )
1 1 5 . 2 ( 2 )  C ( 1 5 ) - C ( 1 4 ) - C ( 1 2 )  1 1 3 . 8 ( 2 )
1 1 1 . 7 ( 2 )  C ( 1 5 ) - C ( 1 6 ) - C (17) 1 1 0 . 8 ( 2 )
1 1 2 . 4 ( 2 )  N ( 4 ) - C ( 1 8 ) - C (19) 1 0 2 . 4 ( 2 )
1 0 4 . 1 ( 2 )  N ( 4 ) - C ( 2 0 ) - C ( 2 1 )  1 2 2 . 1 ( 2 )
1 0 9 . 3 ( 2 )  C ( 2 1 ) - C ( 2 0 ) - N ( 3 )  1 2 8 . 6 ( 2 )
1 1 6 . 5 ( 2 )  C ( 2 0 ) - C ( 2 1 ) - C ( 2 2 )  1 1 9 . 6 ( 2 )
1 2 4 . 0 ( 2 )  C ( 2 7 ) - C ( 2 2 ) - C ( 2 3 )  1 1 8 . 2 ( 2 )
1 2 0 . 9 ( 2 )  C ( 2 3 ) - C ( 2 2 ) - C ( 2 1 )  1 2 0 . 9 ( 2 )
1 2 0 . 5 ( 3 )  C ( 2 5 ) - C ( 2 4 ) - C ( 2 3 )  1 2 0 . 4 ( 3 )
1 1 9 . 6 ( 3 )  C ( 2 5 ) - C ( 2 6 ) - C (27)  1 2 0 . 0 ( 3 )
1 2 1 . 3 ( 3 )  C ( 2 9 ) - C ( 2 8 ) - C ( 2 1 )  1 2 1 . 1 ( 2 )
1 1 9 . 9 ( 2 )  C ( 2 1 ) - C ( 2 8 ) - C ( 3 4 )  1 1 8 . 9 ( 2 )
1 2 1 . 0 ( 2 )  C ( 2 8 ) - C ( 2 9 ) - C (31)  1 2 3 . 3 ( 2 )
1 1 5 . 6 ( 2 )  0 ( 2 ) - C ( 3 0 ) - N ( 4 )  1 1 9 . 0 ( 2 )
1 2 5 . 6 ( 2 )  N ( 4 ) - C ( 3 0 ) - C (2 9)  1 1 5 . 3 ( 2 )
1 1 4 . 6 ( 2 )  C ( 2 9 ) - C ( 3 1 ) - C ( 3 2 ' )  1 0 9 . 7 ( 5 )
3 1 . 2 ( 5 )  C ( 3 3 ) - C ( 3 2 ) - C ( 3 1 )  1 1 2 . 3 ( 4 )
1 1 3 . 4 ( 6 )  C ( 3 1 ) - C ( 3 2 ' ) - C ( 3 3 ' )  1 0 4 . 3 ( 1 1 )
1 0 8 . 3 ( 1 3 ) C ( 3 3 ) - C ( 3 4 ) - C ( 2 8 )  1 1 3 . 9 ( 3 )
2 8 . 4 ( 7 )  C ( 2 8 ) - C ( 3 4 ) - C ( 3 3 ' )  1 1 4 . 7 ( 6 )
(Z)-5-Ethoxycarbonylmethyleiie-7-phenyl-l,2,3,6-tetrahydro-5//-pyrrolo[l,2-a]
lmidazol-6-one (2.4.9)
Empirical formula C16H16N2O3
Formula weight 284.32
Temperature 150 (2) K
Wavelength 0.71073 A
Crystal system Orthorhombic
Space group Pbca
Unit cell dimensions a = 7.1760 (10) A a  = 90 
b =  17.805 (4) A p = 90 
c -  20.947 (4) A y = 90
Volume 2676.4 (9) A3
Z 8
Density (calculated) 1.411 M g/m 3
Absorption coefficient 0.099 mm'1
F  (000) 1200
Crystal Needle; orange
Crystal size 0.4 x 0.25 x 0.25 mm3
6 range for data collection 1.94-27.47
Index ranges -7 < A < 9, -19 < k < 23, -27</<27,
Reflections collected 16412
Independent reflections 3062 [Rût = 0.1168]
Completeness to 6 = 27.47 99.9%
Absorption correction Semi-impirical from equivalents
Max. and min. transmission 1.0 and 0.935
Refinement method Full-matrix least-squares on F1
Data / restraints / parameters 3062/0/191
Goodness-of-fit on F1 0.815
Final R indices [Z>2a(J)] f l l=  0.0576, wfl2 = 0.1218
R indices (all data) f l l=  0.1387, wfl2 = 0.1595
Largest diff. Peak and hole 0.246 and-0.260 e A"3
Bond lengths [Â] and angles [°] for (Z)-5-Ethoxycarbonylmethylene-7-phenyl- 
l^^,6-tetrahydro-5fl-pyrrolo[l^-a]imidazol-6-one (2.4.9)
01-C I2
02-C 14
03-C14  
03-C1S 
Nl-Cfi 
N1-C9 
N2-C11 
N2-C8 
N2-C10 
C1-C2 
C1-C6 
C2-C3 
C3-C4 
C4-C5 
C5-C6 
C6-C7 
C7-C8 
C7-C12 
C9-C10 
C11-C13 
C11-C12 
C13-C14 
C15-C16
C14-03-C15
C8-N1-C9
Cl 1-N2-C8
C11-N2-C10
C8-N2-C10
C2-C1-C6
C3-C2-CI
C4-C3-C2
C3-C4-C5
C4-C5-C6
C1-C6-C5
C1-C6-C7
C5-C6-C7
C8-C7-C12
C8-C7-C6
C12 C7-C6
N1-C8-N2
N1-C8-C7
N2-C8-C7
N1-C9-C10
N2-C10-C9
C13-C11-N2
C13-C11-C12
N2-C11-CI2
01-C12-C7
01-C12-C11 
C7-CI2-C11 
Cl 1-C13-C14
02-C 14-03
02-C14-C13
03-C14-C13 
03-C15-C16
1.241(3)
1.217(3)
1.332(3)
1.455(3)
1.322(3) 
1.4680) 
1.3790) 
1.383(3) 
1.470(3) 
1.390(3) 
1J910) 
1.383(4) 
1.378(4) 
1.3820) 
1.407(3) 
1.464(3) 
1.394(3) 
1.4230) 
1.530(3) 
1.3410) 
1.5340) 
1.4570) 
1.497(4)
117.42(19)
112.2(2)
109.40)
138.60) 
111.27(19) 
121.00 ) 
120.5(3) 
119.3(2) 
120.8(2) 
120.80)
117.70)
122.60)
119.70) 
105.0(2) 
127.0(2) 
128.00) 
109.4(2) 
137.4(2)
113.20) 
103.86(19) 
10235(19)
134.90)
120.40)
104.70) 
130.50)
121.70) 
107.8(2)
130.90)
123.20) 
123.10) 
113.7(2)
106.90)
(£)-Diethyl 2-[2-(2-phenyl)phenylethylimidazolm-l-yl]-l,4-butenoate (2.4.13)
Empirical formula C2 5H28N 2O4
Formula weight 420.49
Temperature 298 (2) K
Wavelength 0.71073 Â
Crystal system Triclinic
Space group P-\
Unit cell dimensions a=11.0117 (5)Â<x = 65.331 (3) 
b = 10.6661 (8 ) Â P = 65.329 (4) 
c = 12.2753 (9) Â y = 62.908 (3)
Volume 1119.42 (13) Â3
Z 2
Density (calculated) 1.248 M g /m 3
Absorption coefficient 0.085 mm" 1
F  (0 0 0 ) 448
Crystal Colourless plates
Crystal size 0 . 1 0  x 0 . 1 0  x 0 . 0 2  mm3
6  range for data collection 3.26-23.25
Index ranges -11 <h<  12,-11 <k<  1 1 , -1 3 < /< 1 3
Reflections collected 8067
Independent reflections 3169 [Rmt = 0.0767]
Completeness to 8  = 23.25 98.4 %
Absorption correction Empirical, SORTAV
Max. and min. transmission 0.9983 and 0.9916
Refinement method Full-matrix least-squares on F1
Data / restraints / parameters 3169/0/283
Goodness-of-fit on 0.931
Final R indices [/>2a(7)] R1 = 0.0558, wR2 -  0.1103
R indices (all data) RI = 0.1396, wR2 -  0.1373
Extinction coefficient 0.013 (3)
Largest diff. Peak and hole 0.217 and-0.207 e A"3
Bond lengths [Â] and angles [°] for (£)-Diethyl 2-[2-(2-
phenyl)phenylethyllmidazolin-l-yl]-l,4-butenoate (2.4.13)
O1-C20 1.351(4) CI4-C15 1.497(4)
01-C21 1.446(4) 0 4 - 0 3 1.519(4)
N1-C18 1.373(4) 0 3 - 0 2 1.522(4)
N1-C15 1.417(4) C7-C8 1.395(5)
N1-C17 1.466(4) C 7 -0 2 1.403(4)
04-C23 1.202(4) C19-C20 1.457(5)
03-C23 1.331(4) 0 2 - 0 1 1.388(5)
03-C24 1.470(4) C1-C2 1.385(5)
N2-C15 1.261(4) C ll-O O 1.384(5)
N2-C16 1.473(4) C10-C9 1.371(5)
O2-C20 1.199(4) C8-C9 1.372(5)
C6-C1 1.387(5) C21-C22 1.500(5)
C6-C5 1.394(5) C5-C4 1.378(5)
C6-C7 1.489(5) C2-C3 1.369(6)
C18-C19 1.350(4) C3-C4 1.358(6)
C18-C23 1.499(5) C24-C25 1.432(5)
C17-C16 1.531(4)
C20-O1-C21 117.0(3) N2-C15-N1 114.9(3)
C18-N1-C15 132.4(3) N2-C15-C14 122.5(3)
C18-N1-C17 119.8(2) N1-C15-C14 122.6(3)
C15-N1-C17 107.5(3) C2-C1-C6 120.4(4)
C23-03-C24 119.3(3) N2-C1 6 -0 7 106.2(3)
C15-N2-C16 108.8(3) 0 0 - 0 1 - 0 2 121.8(4)
C1-C6-C5 117.5(4) € 9 - 0 0 - 0 1 119.4(4)
C1-C6-C7 122.3(4) C9-C8-C7 121.5(4)
C5-C6-C7 120.1(4) O2-C20-O1 123.2(3)
C19-C18-N1 121.8(3) O2-C20-C19 127.5(3)
C19-C18-C23 119.5(3) O1-C20-C19 109.3(3)
N1-C18-C23 118.7(3) 01-C21-C22 106.4(3)
N1-C17-C16 102.2(2) C4-C5-C6 121.1(4)
C15-C14-C13 112.1(3) C3-C2-C1 121.0(4)
C14-C13-C12 114.7(3) C4-C3-C2 119.3(4)
C8-C7-C12 118.8(3) C10-C9-C8 120.0(4)
C8-C7-C6 117,6(3) C3-C4-C5 120.7(5)
C12-C7-C6 123.6(3) 04-C23-03 125.5(4)
C18-C19-C20 123.5(3) 04-C23-C18 124.0(4)
C11-C12-C7 118.5(3) 03-C23-C18 110.5(4)
C11-C12-C13 120.3(3) C25-C24-03 110.9(3)
C7-C12-C13 121.2(3)
